US20170258825A1 - Amine polymers for use as bile acid sequestrants - Google Patents
Amine polymers for use as bile acid sequestrants Download PDFInfo
- Publication number
- US20170258825A1 US20170258825A1 US15/601,291 US201715601291A US2017258825A1 US 20170258825 A1 US20170258825 A1 US 20170258825A1 US 201715601291 A US201715601291 A US 201715601291A US 2017258825 A1 US2017258825 A1 US 2017258825A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- alkylene
- polymer
- amine
- ium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 590
- 150000001412 amines Chemical class 0.000 title claims abstract description 425
- 229920000080 bile acid sequestrant Polymers 0.000 title claims description 10
- 229940096699 bile acid sequestrants Drugs 0.000 title description 6
- 239000003613 bile acid Substances 0.000 claims abstract description 186
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 96
- 239000003833 bile salt Substances 0.000 claims abstract description 50
- 229940093761 bile salts Drugs 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 17
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 3
- 208000003251 Pruritus Diseases 0.000 claims abstract 2
- 125000002947 alkylene group Chemical group 0.000 claims description 413
- 239000000178 monomer Substances 0.000 claims description 289
- -1 decylene, undecylene Chemical group 0.000 claims description 272
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 170
- 238000004132 cross linking Methods 0.000 claims description 137
- 238000006243 chemical reaction Methods 0.000 claims description 104
- 238000003556 assay Methods 0.000 claims description 99
- 150000001408 amides Chemical class 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 98
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 80
- 125000003118 aryl group Chemical group 0.000 claims description 78
- 239000011324 bead Substances 0.000 claims description 78
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 78
- 125000000524 functional group Chemical group 0.000 claims description 72
- 239000003446 ligand Substances 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 71
- 150000002148 esters Chemical class 0.000 claims description 67
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 65
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 62
- 239000002245 particle Substances 0.000 claims description 54
- 238000003786 synthesis reaction Methods 0.000 claims description 52
- 230000015572 biosynthetic process Effects 0.000 claims description 51
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 51
- 210000003608 fece Anatomy 0.000 claims description 50
- 238000000338 in vitro Methods 0.000 claims description 45
- 241001465754 Metazoa Species 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 125000000732 arylene group Chemical group 0.000 claims description 37
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 33
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims description 30
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 claims description 29
- 125000001931 aliphatic group Chemical group 0.000 claims description 29
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 27
- 238000006116 polymerization reaction Methods 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 27
- 230000002496 gastric effect Effects 0.000 claims description 23
- 229910019142 PO4 Inorganic materials 0.000 claims description 22
- 239000007795 chemical reaction product Substances 0.000 claims description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 22
- 230000008961 swelling Effects 0.000 claims description 22
- 239000010452 phosphate Substances 0.000 claims description 21
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 20
- 239000007853 buffer solution Substances 0.000 claims description 20
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 20
- 230000002411 adverse Effects 0.000 claims description 18
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims description 17
- 229920002905 Colesevelam Polymers 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 17
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 15
- 230000003247 decreasing effect Effects 0.000 claims description 15
- 238000001727 in vivo Methods 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- AFFLGGQVNFXPEV-UHFFFAOYSA-N 1-decene Chemical group CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 claims description 14
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 13
- RZTDESRVPFKCBH-UHFFFAOYSA-N 1-methyl-4-(4-methylphenyl)benzene Chemical group C1=CC(C)=CC=C1C1=CC=C(C)C=C1 RZTDESRVPFKCBH-UHFFFAOYSA-N 0.000 claims description 12
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- CRSBERNSMYQZNG-UHFFFAOYSA-N 1-dodecene Chemical group CCCCCCCCCCC=C CRSBERNSMYQZNG-UHFFFAOYSA-N 0.000 claims description 11
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 claims description 10
- 235000021068 Western diet Nutrition 0.000 claims description 10
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 9
- 229960000674 colesevelam hydrochloride Drugs 0.000 claims description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- JXGAANHBGJSIPY-UHFFFAOYSA-N n,n,n',n'-tetrakis(3-aminopropyl)dodecane-1,12-diamine Chemical compound NCCCN(CCCN)CCCCCCCCCCCCN(CCCN)CCCN JXGAANHBGJSIPY-UHFFFAOYSA-N 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- 229960001152 colesevelam Drugs 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- PMWXGSWIOOVHEQ-UHFFFAOYSA-N pyridine-2,6-dicarbaldehyde Chemical group O=CC1=CC=CC(C=O)=N1 PMWXGSWIOOVHEQ-UHFFFAOYSA-N 0.000 claims description 8
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 claims description 8
- 229960003693 sevelamer Drugs 0.000 claims description 8
- JWOTWWORMYMZCR-UHFFFAOYSA-N 1-methyl-4-[3-(1-methylpiperidin-4-yl)propyl]piperidine Chemical compound C1CN(C)CCC1CCCC1CCN(C)CC1 JWOTWWORMYMZCR-UHFFFAOYSA-N 0.000 claims description 7
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims description 7
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims description 7
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 229920006037 cross link polymer Polymers 0.000 claims description 7
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001165 hydrophobic group Chemical group 0.000 claims description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 7
- 150000003141 primary amines Chemical class 0.000 claims description 7
- IFDLXKQSUOWIBO-UHFFFAOYSA-N 1,3-dichloropropan-1-ol Chemical compound OC(Cl)CCCl IFDLXKQSUOWIBO-UHFFFAOYSA-N 0.000 claims description 6
- 238000008214 LDL Cholesterol Methods 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 5
- 241000699673 Mesocricetus auratus Species 0.000 claims description 5
- 229940100389 Sulfonylurea Drugs 0.000 claims description 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 5
- 229940125753 fibrate Drugs 0.000 claims description 5
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 5
- 125000005188 oxoalkyl group Chemical group 0.000 claims description 5
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 5
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 5
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 4
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 4
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 4
- 229940086609 Lipase inhibitor Drugs 0.000 claims description 4
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims description 4
- 102000034527 Retinoid X Receptors Human genes 0.000 claims description 4
- 108010038912 Retinoid X Receptors Proteins 0.000 claims description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 4
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 4
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 150000003335 secondary amines Chemical group 0.000 claims description 4
- 239000013049 sediment Substances 0.000 claims description 4
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 4
- PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical compound NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 claims description 3
- ZILVNHNSYBNLSZ-UHFFFAOYSA-N 2-(diaminomethylideneamino)guanidine Chemical compound NC(N)=NNC(N)=N ZILVNHNSYBNLSZ-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 3
- 208000026600 Idiopathic malabsorption due to bile acid synthesis defects Diseases 0.000 claims description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 3
- 229960000815 ezetimibe Drugs 0.000 claims description 3
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 108091005995 glycated hemoglobin Proteins 0.000 claims description 3
- 230000002641 glycemic effect Effects 0.000 claims description 3
- 238000012623 in vivo measurement Methods 0.000 claims description 3
- 229960004844 lovastatin Drugs 0.000 claims description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 2
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 claims description 2
- KDHWOCLBMVSZPG-UHFFFAOYSA-O 3-(1h-imidazol-3-ium-3-yl)propan-1-amine Chemical compound [NH3+]CCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-O 0.000 claims description 2
- DZIHTWJGPDVSGE-UHFFFAOYSA-N 4-[(4-aminocyclohexyl)methyl]cyclohexan-1-amine Chemical compound C1CC(N)CCC1CC1CCC(N)CC1 DZIHTWJGPDVSGE-UHFFFAOYSA-N 0.000 claims description 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims description 2
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000018619 Apolipoproteins A Human genes 0.000 claims description 2
- 108010027004 Apolipoproteins A Proteins 0.000 claims description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
- 102100038495 Bile acid receptor Human genes 0.000 claims description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 2
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 claims description 2
- 239000004593 Epoxy Chemical group 0.000 claims description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 2
- 108010011459 Exenatide Proteins 0.000 claims description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 2
- 102000051325 Glucagon Human genes 0.000 claims description 2
- 108060003199 Glucagon Proteins 0.000 claims description 2
- HNSCCNJWTJUGNQ-UHFFFAOYSA-N Glyclopyramide Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)NC(=O)NN1CCCC1 HNSCCNJWTJUGNQ-UHFFFAOYSA-N 0.000 claims description 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 2
- 108010019598 Liraglutide Proteins 0.000 claims description 2
- 229940123898 Phospholipase A2 inhibitor Drugs 0.000 claims description 2
- 229940122075 Potassium channel antagonist Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 2
- 229940123934 Reductase inhibitor Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 claims description 2
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 claims description 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001466 acetohexamide Drugs 0.000 claims description 2
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004733 albiglutide Drugs 0.000 claims description 2
- 239000003288 aldose reductase inhibitor Substances 0.000 claims description 2
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical group C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims description 2
- 229960001667 alogliptin Drugs 0.000 claims description 2
- 229960005370 atorvastatin Drugs 0.000 claims description 2
- 229960004111 buformin Drugs 0.000 claims description 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims description 2
- 229960005110 cerivastatin Drugs 0.000 claims description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 2
- 229960001761 chlorpropamide Drugs 0.000 claims description 2
- 230000001906 cholesterol absorption Effects 0.000 claims description 2
- 229960002174 ciprofibrate Drugs 0.000 claims description 2
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 claims description 2
- 229960001214 clofibrate Drugs 0.000 claims description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- YQLZOAVZWJBZSY-UHFFFAOYSA-N decane-1,10-diamine Chemical compound NCCCCCCCCCCN YQLZOAVZWJBZSY-UHFFFAOYSA-N 0.000 claims description 2
- QFTYSVGGYOXFRQ-UHFFFAOYSA-N dodecane-1,12-diamine Chemical compound NCCCCCCCCCCCCN QFTYSVGGYOXFRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001519 exenatide Drugs 0.000 claims description 2
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims description 2
- 229960002297 fenofibrate Drugs 0.000 claims description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003765 fluvastatin Drugs 0.000 claims description 2
- 229960003627 gemfibrozil Drugs 0.000 claims description 2
- 229960004580 glibenclamide Drugs 0.000 claims description 2
- 229960000346 gliclazide Drugs 0.000 claims description 2
- 229960004346 glimepiride Drugs 0.000 claims description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 2
- 229960001381 glipizide Drugs 0.000 claims description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 2
- 229960003468 gliquidone Drugs 0.000 claims description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
- 229960004666 glucagon Drugs 0.000 claims description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims description 2
- 229950002888 glyclopyramide Drugs 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 229960002397 linagliptin Drugs 0.000 claims description 2
- 229960002701 liraglutide Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 2
- 229950009116 mevastatin Drugs 0.000 claims description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960003243 phenformin Drugs 0.000 claims description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 2
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims description 2
- 229960005095 pioglitazone Drugs 0.000 claims description 2
- 229960002797 pitavastatin Drugs 0.000 claims description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 2
- 239000003450 potassium channel blocker Substances 0.000 claims description 2
- 229960002965 pravastatin Drugs 0.000 claims description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 2
- 108700027806 rGLP-1 Proteins 0.000 claims description 2
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 claims description 2
- 229950010764 rivoglitazone Drugs 0.000 claims description 2
- 229960004586 rosiglitazone Drugs 0.000 claims description 2
- 229960000672 rosuvastatin Drugs 0.000 claims description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 2
- 229960004937 saxagliptin Drugs 0.000 claims description 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 2
- 108010033693 saxagliptin Proteins 0.000 claims description 2
- 229960002855 simvastatin Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 2
- 229960004034 sitagliptin Drugs 0.000 claims description 2
- 239000005495 thyroid hormone Substances 0.000 claims description 2
- 229940036555 thyroid hormone Drugs 0.000 claims description 2
- 229960002277 tolazamide Drugs 0.000 claims description 2
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims description 2
- 229960005371 tolbutamide Drugs 0.000 claims description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001641 troglitazone Drugs 0.000 claims description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims description 2
- 229960001254 vildagliptin Drugs 0.000 claims description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims 8
- 229940123464 Thiazolidinedione Drugs 0.000 claims 3
- 229940123208 Biguanide Drugs 0.000 claims 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 238000004062 sedimentation Methods 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 17
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 14
- 206010012735 Diarrhoea Diseases 0.000 abstract description 4
- 206010069703 Bile acid malabsorption Diseases 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 172
- 239000000243 solution Substances 0.000 description 83
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 79
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 48
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 47
- 239000002904 solvent Substances 0.000 description 47
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 45
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 45
- 239000000499 gel Substances 0.000 description 40
- 239000000047 product Substances 0.000 description 40
- 239000004971 Cross linker Substances 0.000 description 38
- 239000007787 solid Substances 0.000 description 38
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 230000014759 maintenance of location Effects 0.000 description 32
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 30
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 30
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 29
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 29
- 239000004380 Cholic acid Substances 0.000 description 29
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 29
- 235000019416 cholic acid Nutrition 0.000 description 29
- 229960002471 cholic acid Drugs 0.000 description 29
- 239000000523 sample Substances 0.000 description 27
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 25
- LYBWJVKFJAIODE-UHFFFAOYSA-N n,n,n',n'-tetrakis(3-aminopropyl)butane-1,4-diamine Chemical group NCCCN(CCCN)CCCCN(CCCN)CCCN LYBWJVKFJAIODE-UHFFFAOYSA-N 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 125000003277 amino group Chemical group 0.000 description 18
- 241000699800 Cricetinae Species 0.000 description 17
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 17
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 17
- 235000021317 phosphate Nutrition 0.000 description 17
- 150000003839 salts Chemical group 0.000 description 17
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 16
- 229960003964 deoxycholic acid Drugs 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 229960004198 guanidine Drugs 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 108010007979 Glycocholic Acid Proteins 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 13
- 239000011521 glass Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 238000011553 hamster model Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 210000000813 small intestine Anatomy 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 230000002550 fecal effect Effects 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 10
- GTQHJCOHNAFHRE-UHFFFAOYSA-N 1,10-dibromodecane Chemical compound BrCCCCCCCCCCBr GTQHJCOHNAFHRE-UHFFFAOYSA-N 0.000 description 9
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 9
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 210000000941 bile Anatomy 0.000 description 9
- 230000029142 excretion Effects 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 8
- PUNFIBHMZSHFKF-KTKRTIGZSA-N (z)-henicos-12-ene-1,2,3-triol Chemical compound CCCCCCCC\C=C/CCCCCCCCC(O)C(O)CO PUNFIBHMZSHFKF-KTKRTIGZSA-N 0.000 description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000005642 Oleic acid Substances 0.000 description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 229960004132 diethyl ether Drugs 0.000 description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 8
- 238000004949 mass spectrometry Methods 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- 239000012085 test solution Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 229920000768 polyamine Polymers 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 6
- JOJYXCWFUKMQDO-UHFFFAOYSA-N 2-n,2-n,6-n,6-n-tetrakis(3-aminopropyl)pyridine-2,6-dicarboxamide Chemical compound NCCCN(CCCN)C(=O)C1=CC=CC(C(=O)N(CCCN)CCCN)=N1 JOJYXCWFUKMQDO-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- IVGCCEVCWCEGAS-UHFFFAOYSA-N n,n,n',n'-tetrakis(3-aminopropyl)decane-1,10-diamine Chemical compound NCCCN(CCCN)CCCCCCCCCCN(CCCN)CCCN IVGCCEVCWCEGAS-UHFFFAOYSA-N 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- CPJXMXQYRHNIFU-HNNXBMFYSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-3-(1h-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)OC(C)(C)C)ON1C(=O)CCC1=O CPJXMXQYRHNIFU-HNNXBMFYSA-N 0.000 description 4
- HFVIYAZBVIGNAN-UHFFFAOYSA-N 1,1-dibromodecane Chemical group CCCCCCCCCC(Br)Br HFVIYAZBVIGNAN-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000007992 BES buffer Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 4
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 229960000789 guanidine hydrochloride Drugs 0.000 description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 150000004693 imidazolium salts Chemical group 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- PSCKKBLWXBASKY-UHFFFAOYSA-N n,n,n',n'-tetrakis(3-aminopropyl)butanediamide Chemical compound NCCCN(CCCN)C(=O)CCC(=O)N(CCCN)CCCN PSCKKBLWXBASKY-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 235000021195 test diet Nutrition 0.000 description 4
- NFHKUKSZBFAZCF-UHFFFAOYSA-N (4-tert-butyl-2,6-dimethylphenyl)methylhydrazine Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CNN NFHKUKSZBFAZCF-UHFFFAOYSA-N 0.000 description 3
- VQGJEJWEEVDLKZ-UHFFFAOYSA-N 1,3-bis(3-iodopropyl)imidazol-1-ium Chemical compound ICCCN1C=C[N+](CCCI)=C1 VQGJEJWEEVDLKZ-UHFFFAOYSA-N 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
- AZUCPFMKPGFGTB-UHFFFAOYSA-N 2,2-diiodopropane Chemical compound CC(C)(I)I AZUCPFMKPGFGTB-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010064190 Cholestatic pruritus Diseases 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-O Thiophenium Chemical compound [SH+]1C=CC=C1 YTPLMLYBLZKORZ-UHFFFAOYSA-O 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 239000012805 animal sample Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- KCCPOIYPAKWIND-UHFFFAOYSA-N n'-(3-aminopropyl)-n'-[3-[bis(3-aminopropyl)amino]propyl]propane-1,3-diamine Chemical compound NCCCN(CCCN)CCCN(CCCN)CCCN KCCPOIYPAKWIND-UHFFFAOYSA-N 0.000 description 3
- BDYZNNPAFGNSJM-UHFFFAOYSA-N n'-(3-aminopropyl)-n'-[[3-[[bis(3-aminopropyl)amino]methyl]phenyl]methyl]propane-1,3-diamine Chemical compound NCCCN(CCCN)CC1=CC=CC(CN(CCCN)CCCN)=C1 BDYZNNPAFGNSJM-UHFFFAOYSA-N 0.000 description 3
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 3
- UTHPZNNIVCFCFB-UHFFFAOYSA-N n-[2-(5-chloropentanoylamino)ethyl]-4-nonoxybenzamide Chemical compound CCCCCCCCCOC1=CC=C(C(=O)NCCNC(=O)CCCCCl)C=C1 UTHPZNNIVCFCFB-UHFFFAOYSA-N 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000003352 sequestering agent Substances 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- BSVZCOFBNKXLMI-UHFFFAOYSA-N tert-butyl n-[2-[(4-nonoxybenzoyl)amino]ethyl]carbamate Chemical compound CCCCCCCCCOC1=CC=C(C(=O)NCCNC(=O)OC(C)(C)C)C=C1 BSVZCOFBNKXLMI-UHFFFAOYSA-N 0.000 description 3
- 150000003512 tertiary amines Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- ZJJATABWMGVVRZ-UHFFFAOYSA-N 1,12-dibromododecane Chemical compound BrCCCCCCCCCCCCBr ZJJATABWMGVVRZ-UHFFFAOYSA-N 0.000 description 2
- JXEWXOGOVZEUSK-UHFFFAOYSA-N 11-[4-[3-[1-(11-hydroxyundecyl)-1-methylpiperidin-1-ium-4-yl]propyl]-1-methylpiperidin-1-ium-1-yl]undecan-1-ol Chemical compound C1C[N+](C)(CCCCCCCCCCCO)CCC1CCCC1CC[N+](C)(CCCCCCCCCCCO)CC1 JXEWXOGOVZEUSK-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- VWUCIBOKNZGWLX-UHFFFAOYSA-N 1h-imidazol-1-ium;bromide Chemical compound [Br-].C1=C[NH+]=CN1 VWUCIBOKNZGWLX-UHFFFAOYSA-N 0.000 description 2
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 2
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- SZHCRCQYMFGDFD-UHFFFAOYSA-N 3-[4-[bis(2-cyanoethyl)amino]butyl-(2-cyanoethyl)amino]propanenitrile Chemical compound N#CCCN(CCC#N)CCCCN(CCC#N)CCC#N SZHCRCQYMFGDFD-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical compound OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 description 2
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 2
- YGIQRZYCGUKJRF-UHFFFAOYSA-N 4-nonoxybenzoyl chloride Chemical compound CCCCCCCCCOC1=CC=C(C(Cl)=O)C=C1 YGIQRZYCGUKJRF-UHFFFAOYSA-N 0.000 description 2
- SVNNWKWHLOJLOK-UHFFFAOYSA-N 5-chloropentanoyl chloride Chemical compound ClCCCCC(Cl)=O SVNNWKWHLOJLOK-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 2
- 101710153349 Fibroblast growth factor 19 Proteins 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 2
- 102100036673 Sterol O-acyltransferase 2 Human genes 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012482 calibration solution Substances 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000011243 crosslinked material Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- JMLPVHXESHXUSV-UHFFFAOYSA-N dodecane-1,1-diamine Chemical compound CCCCCCCCCCCC(N)N JMLPVHXESHXUSV-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 2
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- GIQVCEDBESSIJN-UHFFFAOYSA-N n'-(3-aminopropyl)-n'-[3-[3-[3-[bis(3-aminopropyl)amino]propyl]imidazol-3-ium-1-yl]propyl]propane-1,3-diamine Chemical compound NCCCN(CCCN)CCCN1C=C[N+](CCCN(CCCN)CCCN)=C1 GIQVCEDBESSIJN-UHFFFAOYSA-N 0.000 description 2
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 2
- DROHBDGJGFKBMH-UHFFFAOYSA-N n,n,n',n'-tetrakis(3-aminopropyl)hexanediamide Chemical compound NCCCN(CCCN)C(=O)CCCCC(=O)N(CCCN)CCCN DROHBDGJGFKBMH-UHFFFAOYSA-N 0.000 description 2
- QLWLXMPJNRAPOS-UHFFFAOYSA-N n,n,n',n'-tetrakis(3-aminopropyl)octane-1,8-diamine Chemical compound NCCCN(CCCN)CCCCCCCCN(CCCN)CCCN QLWLXMPJNRAPOS-UHFFFAOYSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 229960003912 probucol Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 2
- VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- ITAWMPSVROAMOE-UHFFFAOYSA-N sodium;imidazol-3-ide Chemical compound [Na+].C1=C[N-]C=N1 ITAWMPSVROAMOE-UHFFFAOYSA-N 0.000 description 2
- 239000004059 squalene synthase inhibitor Substances 0.000 description 2
- 238000007155 step growth polymerization reaction Methods 0.000 description 2
- 108010016093 sterol O-acyltransferase 1 Proteins 0.000 description 2
- 108010016092 sterol O-acyltransferase 2 Proteins 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000010557 suspension polymerization reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 2
- LXMTWOFEQAQMTJ-UHFFFAOYSA-N tert-butyl n-[3-[3-[3-[3-[bis[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]amino]propyl]imidazol-1-ium-1-yl]propyl-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]amino]propyl]carbamate;iodide Chemical compound [I-].CC(C)(C)OC(=O)NCCCN(CCCNC(=O)OC(C)(C)C)CCCN1C=C[N+](CCCN(CCCNC(=O)OC(C)(C)C)CCCNC(=O)OC(C)(C)C)=C1 LXMTWOFEQAQMTJ-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical group O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- SBHCLVQMTBWHCD-METXMMQOSA-N (2e,4e,6e,8e,10e)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O SBHCLVQMTBWHCD-METXMMQOSA-N 0.000 description 1
- LIEMBEWXEZJEEZ-INEUFUBQSA-N (2r,3r)-4-(6-aminopurin-9-yl)-2,3-dihydroxybutanoic acid Chemical compound NC1=NC=NC2=C1N=CN2C[C@@H](O)[C@@H](O)C(O)=O LIEMBEWXEZJEEZ-INEUFUBQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- UQIPVSBPFZSWGD-ILYVXUQDSA-N (8r,9s,13s,14s,16r)-16-chloro-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound C1C[C@]2(C)C(=O)[C@H](Cl)C[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 UQIPVSBPFZSWGD-ILYVXUQDSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- KAJZGRFYZKWYDX-VQHVLOKHSA-N (e)-3-methyl-4-phenylbut-3-enamide Chemical compound NC(=O)CC(/C)=C/C1=CC=CC=C1 KAJZGRFYZKWYDX-VQHVLOKHSA-N 0.000 description 1
- QFDISQIDKZUABE-UHFFFAOYSA-N 1,1'-bipiperidine Chemical compound C1CCCCN1N1CCCCC1 QFDISQIDKZUABE-UHFFFAOYSA-N 0.000 description 1
- LCUQJELQVHGIJS-UHFFFAOYSA-N 1,1-dibromododecane Chemical compound CCCCCCCCCCCC(Br)Br LCUQJELQVHGIJS-UHFFFAOYSA-N 0.000 description 1
- ATWLRNODAYAMQS-UHFFFAOYSA-N 1,1-dibromopropane Chemical compound CCC(Br)Br ATWLRNODAYAMQS-UHFFFAOYSA-N 0.000 description 1
- VPHVPFMFWODQFL-UHFFFAOYSA-M 1,3-bis(3-iodopropyl)imidazol-1-ium;iodide Chemical compound [I-].ICCCN1C=C[N+](CCCI)=C1 VPHVPFMFWODQFL-UHFFFAOYSA-M 0.000 description 1
- GRJWOKACBGZOKT-UHFFFAOYSA-N 1,3-bis(chloromethyl)benzene Chemical compound ClCC1=CC=CC(CCl)=C1 GRJWOKACBGZOKT-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- 229940051269 1,3-dichloro-2-propanol Drugs 0.000 description 1
- DEWLEGDTCGBNGU-UHFFFAOYSA-N 1,3-dichloropropan-2-ol Chemical compound ClCC(O)CCl DEWLEGDTCGBNGU-UHFFFAOYSA-N 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- DXJDIECQHYENDF-UHFFFAOYSA-M 1-(1-bromodecyl)pyridin-1-ium;bromide Chemical compound [Br-].CCCCCCCCCC(Br)[N+]1=CC=CC=C1 DXJDIECQHYENDF-UHFFFAOYSA-M 0.000 description 1
- LNVIMNGCZQSEGF-UHFFFAOYSA-M 1-(1-bromopropyl)-3-methylimidazol-3-ium bromide Chemical compound [Br-].CCC(Br)[n+]1ccn(C)c1 LNVIMNGCZQSEGF-UHFFFAOYSA-M 0.000 description 1
- WUVDOBAWWVOQJG-UHFFFAOYSA-N 1-(11-bromoundecyl)-4-[3-[1-(11-bromoundecyl)-1-methylpiperidin-1-ium-4-yl]propyl]-1-methylpiperidin-1-ium Chemical compound C1C[N+](C)(CCCCCCCCCCCBr)CCC1CCCC1CC[N+](C)(CCCCCCCCCCCBr)CC1 WUVDOBAWWVOQJG-UHFFFAOYSA-N 0.000 description 1
- CEJNFBKBBBJFPP-UHFFFAOYSA-N 1-(3-iodopropyl)thiolan-1-ium Chemical compound ICCC[S+]1CCCC1 CEJNFBKBBBJFPP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- HSXGVUKUWYPECQ-UHFFFAOYSA-N 1-piperazin-1-ylpiperazine Chemical compound C1CNCCN1N1CCNCC1 HSXGVUKUWYPECQ-UHFFFAOYSA-N 0.000 description 1
- QGRRJTQMMXJUNP-UHFFFAOYSA-N 1-pyrrolidin-1-ylpyrrolidine Chemical compound C1CCCN1N1CCCC1 QGRRJTQMMXJUNP-UHFFFAOYSA-N 0.000 description 1
- XFGANBYCJWQYBI-UHFFFAOYSA-N 11-bromoundecan-1-ol Chemical compound OCCCCCCCCCCCBr XFGANBYCJWQYBI-UHFFFAOYSA-N 0.000 description 1
- YNCPXBIZAPNQIJ-UHFFFAOYSA-N 1h-imidazole;sodium Chemical compound [Na].C1=CNC=N1 YNCPXBIZAPNQIJ-UHFFFAOYSA-N 0.000 description 1
- MNZPFYUUDBYKMD-UHFFFAOYSA-N 2,3,4,5,6-pentachlorophenol;hydrochloride Chemical class Cl.OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl MNZPFYUUDBYKMD-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- JDTUPLBMGDDPJS-UHFFFAOYSA-N 2-methoxy-2-phenylethanol Chemical compound COC(CO)C1=CC=CC=C1 JDTUPLBMGDDPJS-UHFFFAOYSA-N 0.000 description 1
- SBAJRGRUGUQKAF-UHFFFAOYSA-N 3-(2-cyanoethylamino)propanenitrile Chemical compound N#CCCNCCC#N SBAJRGRUGUQKAF-UHFFFAOYSA-N 0.000 description 1
- UBRUDPATYDECDH-UHFFFAOYSA-N 3-(3-bromopropyl)-1,3-benzothiazol-3-ium Chemical compound C1=CC=C2[N+](CCCBr)=CSC2=C1 UBRUDPATYDECDH-UHFFFAOYSA-N 0.000 description 1
- ALJCVONBFKPPDX-UHFFFAOYSA-N 3-(3-iodopropyl)-1,3-thiazol-3-ium Chemical compound ICCC[N+]=1C=CSC=1 ALJCVONBFKPPDX-UHFFFAOYSA-N 0.000 description 1
- SKVDRZPETVYLIY-UHFFFAOYSA-N 3-(3-iodopropyl)-2-methyl-1,3-thiazol-3-ium Chemical compound CC=1SC=C[N+]=1CCCI SKVDRZPETVYLIY-UHFFFAOYSA-N 0.000 description 1
- BOQWOOLSORMISR-UHFFFAOYSA-N 4-morpholin-4-ylmorpholine Chemical compound C1COCCN1N1CCOCC1 BOQWOOLSORMISR-UHFFFAOYSA-N 0.000 description 1
- BOZLUAUKDKKZHJ-UHFFFAOYSA-N 4-nonoxybenzoic acid Chemical compound CCCCCCCCCOC1=CC=C(C(O)=O)C=C1 BOZLUAUKDKKZHJ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- RAOOXEKSFHZFSQ-UHFFFAOYSA-N 5-chloro-n-[2-(1h-indol-3-yl)ethyl]pentanamide Chemical compound C1=CC=C2C(CCNC(=O)CCCCCl)=CNC2=C1 RAOOXEKSFHZFSQ-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 1
- 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001393 Crofelemer Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- LIEMBEWXEZJEEZ-UHFFFAOYSA-N D-threo-Leutysin Natural products NC1=NC=NC2=C1N=CN2CC(O)C(O)C(O)=O LIEMBEWXEZJEEZ-UHFFFAOYSA-N 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- RGLLOUBXMOGLDQ-IVEVATEUSA-N Furazabol Chemical compound C([C@@H]1CC2)C3=NON=C3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 RGLLOUBXMOGLDQ-IVEVATEUSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- DEQCBCDALCTPET-UHFFFAOYSA-N N,N,N',N'-tetrakis(3-aminopropyl)hexanediamide tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NCCCN(CCCN)C(=O)CCCCC(=O)N(CCCN)CCCN DEQCBCDALCTPET-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 1
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229940123185 Squalene epoxidase inhibitor Drugs 0.000 description 1
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- PNAMDJVUJCJOIX-IUNFJCKHSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-IUNFJCKHSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- OUHCZCFQVONTOC-UHFFFAOYSA-N [3-acetyloxy-2,2-bis(acetyloxymethyl)propyl] acetate Chemical compound CC(=O)OCC(COC(C)=O)(COC(C)=O)COC(C)=O OUHCZCFQVONTOC-UHFFFAOYSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- LPQVLIUFLWUMHG-UHFFFAOYSA-N acetyl 2-aminoacetate Chemical compound CC(=O)OC(=O)CN LPQVLIUFLWUMHG-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- DFDGRKNOFOJBAJ-UHFFFAOYSA-N acifran Chemical compound C=1C=CC=CC=1C1(C)OC(C(O)=O)=CC1=O DFDGRKNOFOJBAJ-UHFFFAOYSA-N 0.000 description 1
- 229950000146 acifran Drugs 0.000 description 1
- 229940023032 activated charcoal Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JSWZEAMFRNKZNL-UHFFFAOYSA-N alosetron Chemical compound N1C=NC(CN2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JSWZEAMFRNKZNL-UHFFFAOYSA-N 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000010539 anionic addition polymerization reaction Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- FMTFZYKYVZBISL-HUVRVWIJSA-N azacosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](N(C)CCCN(C)C)[C@@]1(C)CC2 FMTFZYKYVZBISL-HUVRVWIJSA-N 0.000 description 1
- 229950005866 azacosterol Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 229960001264 benfluorex Drugs 0.000 description 1
- 229950008586 benzalamide Drugs 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CJAVTWRYCDNHSM-UHFFFAOYSA-N benzoic acid 2-[1-[3-(trifluoromethyl)phenyl]propan-2-ylamino]ethyl ester Chemical compound C=1C=CC=CC=1C(=O)OCCNC(C)CC1=CC=CC(C(F)(F)F)=C1 CJAVTWRYCDNHSM-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- OTBHHUPVCYLGQO-UHFFFAOYSA-N bis(3-aminopropyl)amine Chemical compound NCCCNCCCN OTBHHUPVCYLGQO-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000012662 bulk polymerization Methods 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010538 cationic polymerization reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- 229940009025 chenodeoxycholate Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 description 1
- 229960002099 cilansetron Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940047615 crofelemer Drugs 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- OWEZJUPKTBEISC-UHFFFAOYSA-N decane-1,1-diamine Chemical compound CCCCCCCCCC(N)N OWEZJUPKTBEISC-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 dicycloverine Drugs 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000012674 dispersion polymerization Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229950010710 furazabol Drugs 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- XBSQTYHEGZTYJE-OETIFKLTSA-N glycolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 XBSQTYHEGZTYJE-OETIFKLTSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-O hydron;1,3-oxazole Chemical compound C1=COC=[NH+]1 ZCQWOFVYLHDMMC-UHFFFAOYSA-O 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical compound [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-O isoquinolin-2-ium Chemical compound C1=[NH+]C=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-O 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 229960001961 meglutol Drugs 0.000 description 1
- 229950008446 melinamide Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000012703 microemulsion polymerization Methods 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- OOVXZFCPCSVSEM-NADOGSGZSA-N mytatrienediol Chemical compound C1C[C@]2(C)[C@@H](O)[C@@](C)(O)C[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 OOVXZFCPCSVSEM-NADOGSGZSA-N 0.000 description 1
- FGIXKMMIIPMYFG-UHFFFAOYSA-N n'-(3-aminopropyl)-n'-[[4-[[bis(3-aminopropyl)amino]methyl]phenyl]methyl]propane-1,3-diamine Chemical compound NCCCN(CCCN)CC1=CC=C(CN(CCCN)CCCN)C=C1 FGIXKMMIIPMYFG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012673 precipitation polymerization Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- GWHOGODUVLQCEB-UHFFFAOYSA-N pyridine-2,6-dicarbonyl chloride Chemical compound ClC(=O)C1=CC=CC(C(Cl)=O)=N1 GWHOGODUVLQCEB-UHFFFAOYSA-N 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940074790 simvastatin and ezetimibe Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HFQQZARZPUDIFP-UHFFFAOYSA-M sodium;2-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O HFQQZARZPUDIFP-UHFFFAOYSA-M 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- SVXZTCUBEFUKRQ-UHFFFAOYSA-N sultosilic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1=CC=C(O)C(S(O)(=O)=O)=C1 SVXZTCUBEFUKRQ-UHFFFAOYSA-N 0.000 description 1
- 229950001820 sultosilic acid Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- QBYUNVOYXHFVKC-GBURMNQMSA-N taurolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 QBYUNVOYXHFVKC-GBURMNQMSA-N 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- RXUZRBQIVIUOLJ-UHFFFAOYSA-N tert-butyl n-[3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propylamino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNCCCNC(=O)OC(C)(C)C RXUZRBQIVIUOLJ-UHFFFAOYSA-N 0.000 description 1
- RUUUELDYQOTSQW-UHFFFAOYSA-N tert-butyl-[2-[(4-nonoxybenzoyl)amino]ethyl]carbamic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCCCCCCCCOC1=CC=C(C(=O)NCCN(C(O)=O)C(C)(C)C)C=C1 RUUUELDYQOTSQW-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- WRCITXQNXAIKLR-UHFFFAOYSA-N tiadenol Chemical compound OCCSCCCCCCCCCCSCCO WRCITXQNXAIKLR-UHFFFAOYSA-N 0.000 description 1
- 229960000822 tiadenol Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- AISMNBXOJRHCIA-UHFFFAOYSA-N trimethylazanium;bromide Chemical compound Br.CN(C)C AISMNBXOJRHCIA-UHFFFAOYSA-N 0.000 description 1
- SYHDSBBKRLVLFF-UHFFFAOYSA-N triparanol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC(C)=CC=1)CC1=CC=C(Cl)C=C1 SYHDSBBKRLVLFF-UHFFFAOYSA-N 0.000 description 1
- 229950005498 triparanol Drugs 0.000 description 1
- 229940014499 ursodeoxycholate Drugs 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-M ursodeoxycholate Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-M 0.000 description 1
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- IYEPZNKOJZOGJG-UHFFFAOYSA-N xenbucin Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1C1=CC=CC=C1 IYEPZNKOJZOGJG-UHFFFAOYSA-N 0.000 description 1
- 229950005298 xenbucin Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
- C08G73/0213—Preparatory process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0206—Polyalkylene(poly)amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/024—Polyamines containing oxygen in the form of ether bonds in the main chain
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0246—Polyamines containing other atoms than carbon, hydrogen, nitrogen or oxygen in the main chain
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0246—Polyamines containing other atoms than carbon, hydrogen, nitrogen or oxygen in the main chain
- C08G73/0253—Polyamines containing sulfur in the main chain
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/0273—Polyamines containing heterocyclic moieties in the main chain
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/028—Polyamidoamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
- C08L79/02—Polyamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
Definitions
- the present invention generally relates to amine polymers useful to bind bile acids in the gastrointestinal tract of a patient in need of bile acid removal. These polymers and pharmaceutical compositions thereof are useful to lower cholesterol, particularly, non-high density lipoprotein (non-HDL), or more particularly, low-density lipoprotein (LDL) cholesterol, in patients in need thereof.
- non-HDL non-high density lipoprotein
- LDL low-density lipoprotein
- Cholesterol is used by the body as a structural component of cell membranes. In addition, it is a basic building block for the production of many hormones, adrenal steroids, vitamin D and bile acids. Elevated levels of cholesterol carried in particles of low density lipoprotein cholesterol (LDL-C), or less specifically, cholesterol not carried in particles of high-density cholesterol (non HDL-C) are associated with an increased risk of coronary heart disease. A direct link between high blood cholesterol and cardiovascular disease (CVD) has been confirmed for both non-statin and statin trials, consistent with a direct relationship between LDL-C lowering and CVD reduction. These studies as well as many others have led to recommendations by health authorities for lowering elevated total cholesterol and LDL-C levels.
- LDL-C low density lipoprotein cholesterol
- CVD cardiovascular disease
- Bile acids are amphipathic detergents with micelle-forming properties that are synthesized in the liver from cholesterol and solubilize lipids to aid in their uptake from the gastrointestinal lumen.
- Common bile acids found in man include unconjugated bile acids (for example cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid) and conjugated bile acids (for example taurocholic acid, glycocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, glycolithocholic acid, and taurolithocholic acid).
- unconjugated bile acids for example cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid
- conjugated bile acids for example taurocholic acid, glycocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid,
- the bile acids are predominantly deprotonated and are in their salt form. The majority of bile acids are reabsorbed, primarily by active transport in the distal ileum, with elimination in the feces being the primary route of cholesterol excretion.
- a bile acid sequestrant can bind bile acids to prevent reabsorption of the bile acids and cause more of the bile acids to be excreted in the stool.
- the sequestrant reduces the amount of bile acids reabsorbed by the intestine and subsequently transported to the liver.
- hepatic cholesterol 7-alpha-hydroxylase is upregulated. This results in additional conversion of cholesterol into bile acids, thereby restoring the bile acid pool.
- Upregulation of cholesterol conversion to bile acids also involves a cascade of signaling that results in up-regulation of liver LDL-receptors and consequent lowering of serum LDL-C levels, amongst other effects.
- bile acid sequestrants do not reduce the serum LDL-cholesterol concentration enough without requiring the patient to take either large amounts of the sequestrant or another drug that is combined with the sequestrant (e.g., statins). These reduce patient compliance and tolerance. Thus, bile acid sequestrants capable of more effectively removing bile salts from the gastrointestinal tract with equal or lower doses are needed.
- the present invention provides an amine polymer that is effective for binding and removing bile salts from the gastrointestinal tract.
- One aspect of the invention is an amine polymer that comprises repeat units derived from polymerization of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1.1, and the amine polymer has a binding affinity for bile acids of at least 0.46 mmol/g when measured using an in vitro A assay.
- Another aspect is an amine polymer comprising the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer, wherein units of the polymer have the structure of formula 1
- R 10 is derived from the crosslinking monomer and is C 2 to C 16 alkylene, —NH—C(NH)—NH—, —NH—C(NH 2 + )—NH—, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy;
- R 30 is derived from the amine monomer and is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, a cycloalkyl, an aryl, or a heterocyclo functional group; each R 20 is independently C 2
- a further aspect is an amine polymer that comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of formula 1 wherein R 10 is derived from the crosslinking monomer and is C 2 to C 16 alkylene, —NH—C(NH)—NH—, —NH—C(NH 2 + )—NH—, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy; R 30 is derived from the amine monomer and is C 2 to C 6 alkylene; each R 20 is independently C 2 to C 6 alkylene or C 2 to C 6 alkylene wherein one or more of the —CH 2 —
- an amine polymer that comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of formula 1 wherein R 10 is derived from the crosslinking monomer and is C 8 to C 16 alkylene, or C 8 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; R 30 is derived from the amine monomer and is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo
- Yet another aspect of the another aspect is an amine polymer that comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of formula 1 wherein R 10 is derived from the crosslinking monomer and is C 2 to C 6 alkylene, or C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy;
- R 30 is derived from the amine monomer and is C 8 to C 16 alkylene, arylene, diformylheterocyclo, or C 8 to C 16 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide,
- a further aspect of the invention is an amine polymer that comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the polymer is insoluble in water, at least some of said amine secondary nitrogen atoms are part of a crosslinked polymer network, and the crosslinking monomer is a hydrophobic group having a calculated log P (c Log P) of greater than 4; and the crosslinking monomer is a compound having the formula X-R 1 -X, wherein each X is independently a leaving group, and R 1 is C 8 to C 50 alkylene or C 8 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
- Yet a further aspect of the invention is an amine polymer that comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the polymer is insoluble in water, at least some of said amine secondary nitrogen atoms are part of a crosslinked polymer network, and the amine monomer has at least one segment that is a C 8 to C 16 alkylene, arylene, or C 8 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, and the segment has a calculated log P (c Log P) of greater than 4; and the crosslinking monomer is a compound having the formula X-R 1 -X, wherein each X is independently a leaving group, and R 1 is C 2 to C 6 alkylene, or C
- Another aspect is an amine polymer that comprises repeat units derived from polymerization of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1, and wherein: the polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and the polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using a B assay.
- an amine polymer comprising units of the polymer having nodes of positive charge separated by aliphatic segments, wherein the nodes of positive charge have a charge density of at least 19.0 mEq/g and a molecular weight of at least 200.0 g/mol and at least one aliphatic segment is bonded to each node of positive charge, the at least one aliphatic segment having a calculated log P (c Log P) greater than 4 and wherein each of the nodes of positive charge does not contain an aliphatic segment having a calculated log P (c Log P) greater than 4.
- a further aspect is an amine polymer comprising units of the polymer having nodes of positive charge separated by aliphatic segments, wherein the nodes of positive charge have a charge density greater than 17.3 mEq/g and the structure of formula A
- each R 20 being independently C 3 to C 8 alkylene or C 3 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group; and wherein at least one aliphatic segment is bonded to each node of positive charge, each aliphatic segment having a calculated log P (c Log P) greater than 4.
- Yet another aspect is an amine polymer comprising units of the polymer having the structure of formula 1 wherein R 10 is C 2 to C 16 alkylene, arylene, —NH—C(NH)—NH—, —NH—C(NH 2 + )—NH—, dimethylbiphenyl, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy;
- R 30 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a
- Another aspect is an amine polymer that comprises repeat units derived from polymerization of an amine monomer and a crosslinking monomer, wherein the amine monomer is an amine of formula 2 having the structure:
- each R 2 is independently C 2 to C 8 alkylene or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with at least one amide functional group
- R 3 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group
- the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R 1 -X, or a combination thereof, wherein each X is independently a leaving group, R 1 is C 8 to C 16 alkylene, or C 5 to C o5 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced
- Yet another aspect is an amine polymer derived from polymerization of an amine monomer and a crosslinking monomer wherein the amine monomer is an amine of formula 3 having the structure:
- each R 21 is independently C 2 to C 8 wherein one or more of the —CH 2 — groups of the alkylene group is replaced with at least one sulfur atom
- R 31 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group
- the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R 1 -X, or a combination thereof, wherein each X is independently a leaving group
- R 1 is C 2 to C 16 alkylene, arylene, dimethylbiphenyl, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an
- a further aspect is an amine polymer that comprises repeat units derived from polymerization of an amine monomer of formula 2 and a crosslinking monomer, wherein each R 2 is independently C 2 to C 8 alkylene or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group; and R 3 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and a portion of the nitrogen atoms of the amine polymer are substituted with a ligand selected from aminoalkyl, aryl, arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl
- R 46 is C 6 to C 16 alkylene
- R 47 is 1,y-bis(1-methylpiperidin-4-yl)C y alkylene
- R 48 is C 6 to C 16 alkyl
- m is an integer from 3 to 12
- x is an integer from 1 to 12
- y is an integer from 1 to 14
- z is an integer from 1 to 16.
- Another aspect of the invention is an amine of formula 6 having the structure:
- each R 25 is independently C 2 to C 8 alkylene or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with at least one amide functional group
- R 35 is C 8 to C 16 alkylene, or C 8 to C 16 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
- Yet a further aspect is an amine polymer useful as a bile acid sequestrant, wherein, in a buffer solution at 37° C. containing less than 2.6 mM taurocholic acid, the amine polymer binds more of the acid than sevelamer and in a buffer solution at 37° C. containing more than 5.0 mM taurocholic acid the amine polymer binds more bile acid that colesevelam.
- FIG. 1A is a graph of the unbound taurocholic acid concentration versus the bound taurocholic acid concentration for various bile acid binders at taurocholic acid concentrations up to 20 mM.
- FIG. 1B is the same graph as FIG. 1A at taurocholic acid concentrations up to 5 mM.
- FIG. 2A is a graph of the unbound glycodeoxycholic acid concentration versus the bound taurocholic acid concentration for various bile acid binders at glycodeoxycholic acid concentrations up to 20 mM.
- FIG. 2B is the same graph as FIG. 2A at glycodeoxycholic acid concentrations up to 5 mM.
- the present invention is an amine polymer useful for binding bile salts, pharmaceutical compositions comprising the amine polymer, and methods of treating hypercholesterolemia, diabetes or other conditions that might benefit from bile acid sequestration in the gastrointestinal tract and/or increased fecal excretion of bile acids and/or bile acid metabolites, by administering the amine polymer to an animal subject in need thereof.
- the amine polymers exhibit increased affinity and/or capacity for binding bile salts and/or their retention as compared to commercial bile acid sequestrants.
- the polymers have a combination of hydrogen bonding and electrostatic properties, charged nitrogen atoms, hydrophobicity and/or polymer architecture to provide such increased affinity and/or capacity for bile salts.
- bile acid and “bile salt” are used interchangeably herein and those of skill in the art will understand that a bile acid will be present in salt form and, to a lesser degree, in the protonated form in the gastrointestinal tract.
- the amine polymer can comprise repeat units derived from polymerization of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1.1, and the amine polymer has a binding affinity for bile acids of at least 0.46 mmol/g when measured using an in vitro A assay.
- the amine polymer can comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer, wherein units of the polymer have the structure of formula 1:
- R 10 is derived from the crosslinking monomer and is C 2 to C 16 alkylene, —NH—C(NH)—NH—, —NH—C(NH 2 + )—NH—, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy;
- R 30 is derived from the amine monomer and is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, a cycloalkyl, an aryl, or a heterocyclo functional group; each R 20 is independently C 2
- the amine polymer can also comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of formula 1 wherein R 10 is derived from the crosslinking monomer and is C 2 to C 16 alkylene, —NH—C(NH)—NH—, —NH—C(NH 2 + )—NH—, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy; R 30 is derived from the amine monomer and is C 2 to C 6 alkylene; each R 20 is independently C 2 to C 6 alkylene or C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the
- the amine polymer can comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of formula 1 wherein R 10 is derived from the crosslinking monomer and is C 8 to C 16 alkylene, or C 8 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; R 30 is derived from the amine monomer and is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group
- the amine polymer can also comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of formula 1 wherein R 10 is derived from the crosslinking monomer and is C 2 to C 6 alkylene, or C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy;
- R 30 is derived from the amine monomer and is C 8 to C 16 alkylene, arylene, diformylheterocyclo, or C 8 to C 16 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an
- the amine polymers described herein can have a binding affinity for bile acids of at least 0.46 mmol/g when measured in vitro using an in vitro A assay.
- the amine polymers described herein can also have a molar ratio of the amine monomer to the crosslinking monomer in the range of from 1:3 to about 1:1.1.
- the primary and secondary amine atoms can have a calculated ratio from 1:1 to about 1:5.
- the amine polymer can also comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the polymer is insoluble in water, at least some of said amine secondary nitrogen atoms are part of a crosslinked polymer network, and the crosslinking monomer is a compound having the formula X-R 1 -X, wherein each X is independently a leaving group, and R 1 is C 8 to C 50 alkylene, or C 8 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group and the calculated log P (c Log P) of the crosslinking monomer is greater than 4.
- the amine polymer can also comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the polymer is insoluble in water, at least some of said amine secondary nitrogen atoms are part of a crosslinked polymer network, and the amine monomer has at least one segment that is a C 8 to C 16 alkylene, arylene, or C 8 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, and a calculated log P (c Log P) of the at least one segment of the amine monomer is greater than 4; and the crosslinking monomer is a compound having the formula X-R 1 -X, wherein each X is independently a leaving group, and R 1 is C 2 to C 6 alkylene, or
- the amine polymer can comprise repeat units derived from polymerization of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1.1, and wherein: the polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and the polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using a B assay.
- the amine polymer can comprise units of the polymer having the structure of formula 1 wherein R 10 is C 2 to C 16 alkylene, arylene, —NH—C(NH)—NH—, —NH—C(NH 2 + )—NH—, dimethylbiphenyl, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy;
- R 30 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloal
- the amine polymer comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer and R 10 is derived from the crosslinking monomer and R 30 is derived from the amine monomer.
- the amine polymer binds phosphate in vitro in an amount of less than 0.2 mmol/gram of polymer when measured using a B assay.
- Some of the amine polymers having units of the polymer of Formula 1 can have an R 30 of ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, decylene, undecylene, dodecylene, 1,4-phenylenedimethyl, 1,6-dioxohexane-1,6-diyl, or 2,6-diformylpyridine.
- R 30 is C 3 to C 12 alkylene; particularly, R 30 is butylene; also R 30 can be decylene or dodecylene.
- each R 20 can independently be C 2 to C 6 alkylene; each R 20 can independently be C 2 to C 4 alkylene; particularly, each R 20 can be propylene.
- the amine polymer comprises units of the polymer having nodes of positive charge separated by aliphatic segments.
- the nodes of positive charge have a charge density of at least 19.0 mEq/g and a molecular weight of at least 200.0 g/mol and at least one aliphatic segment is bonded to each node of positive charge, the at least one aliphatic segment having a calculated log P (c Log P) greater than 4 and wherein each of the nodes of positive charge does not contain an aliphatic segment having a calculated log P (c Log P) greater than 4.
- the amine polymer comprises units of the polymer having nodes of positive charge separated by aliphatic segments, wherein the nodes of positive charge have a charge density greater than 17.3 mEq/g and the structure of formula A
- each R 20 is independently C 3 to C 8 alkylene or C 3 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group; and wherein at least one aliphatic segment is bonded to each node of positive charge, each aliphatic segment having a calculated log P (c Log P) greater than 4.
- the aliphatic segments separating the nodes of positive charge can be a C 8 to C 16 alkylene, or C 8 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
- the polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and the polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using the B assay.
- the polymer binds phosphate in vitro in an amount of less than 0.2 mmol/gram of polymer when measured using the B assay. Also, in some of the polymers, each of the nodes of positive charge does not contain an aliphatic segment having a calculated log P (c Log P) greater than 4.
- An amine polymer can also comprise repeat units derived from polymerization of an amine monomer and a crosslinking monomer, wherein the amine monomer is an amine of formula 2 having the structure:
- each R 2 is independently C 2 to C 8 alkylene or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with at least one amide functional group
- R 3 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group
- the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R 1 -X, or a combination thereof, wherein each X is independently a leaving group, R 1 is C 8 to C 16 alkylene, or C 5 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an
- R 1 is C 8 to C 16 alkylene, or C 5 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
- amine polymers described herein above are derived from an amine monomer which is an amine of formula 2 wherein each R 2 is independently C 2 to C 8 alkylene or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group, and R 3 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
- the crosslinking monomer used in deriving the polymers is guanidine, a guanidinium salt, a compound having the formula X-R 1 -X, or a combination thereof, wherein each X is independently a leaving group, R 1 is C 8 to C 16 alkylene, dimethylbiphenyl, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with a phenyl, piperidinium or imidazolium functional group.
- R 1 is C 8 to C 16 alkylene, dimethylbiphenyl, or C 2 to C 50 alkylene wherein one or two of the —CH 2 — groups of the alkylene group is replaced with one or two phenyl, piperidinium or imidazolium functional groups.
- each R 2 is independently C 2 to C 8 alkylene or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group
- R 3 is C 8 to C 16 alkylene, arylene, diformylheterocyclo, or C 8 to C 16 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group
- a crosslinking monomer which is a compound having the formula X-R 1 -X, wherein each X is independently a leaving group
- R 1 is C 2 to C 6 alkylene or C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group
- the amine polymers derived from an amine monomer of Formula 2 can have an R 3 of ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, decylene, undecylene, dodecylene, 1,4-phenylenedimethyl, 1,6-dioxohexane-1,6-diyl, or 2,6-diformylpyridine.
- R 3 is C 3 to C 12 alkylene; particularly, R 3 is butylene; also R 3 can be decylene or dodecylene.
- each R 2 can independently be C 2 to C 6 alkylene; each R 2 can independently be C 2 to C 4 alkylene; particularly, each R 2 can be propylene.
- the amine polymer can have the general structure of formula 5
- Formula 5 represents a crosslink within the polymer network, which may form.
- the crosslink can be represented in Formula 5 as a tetrasubstituted nitrogen (quaternized) to generate a formula containing N(R 20 )(R 10 ) 3 or the crosslink can be represented in Formula 1 as N(R 20 )(R 10 )(R 10 ).
- the amine polymer can be derived from polymerization of an amine monomer and a crosslinking monomer wherein the amine monomer is an amine of formula 3 having the structure:
- each R 21 is independently C 2 to C 8 wherein one or more of the —CH 2 — groups of the alkylene group is replaced with at least one sulfur atom
- R 31 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group
- the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R 1 -X, or a combination thereof, wherein each X is independently a leaving group
- R 1 is C 2 to C 16 alkylene, arylene, dimethylbiphenyl, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an
- each R 21 is m-sulfidoC m alkyl, m is an integer from 1 to 6 and R 31 is C 3 to C 8 alkylene.
- R 31 is C 3 to C 12 alkylene; particularly, R 31 is butylene; also R 31 can be decylene or dodecylene.
- an amine of formula 6 has the structure:
- each R 25 is independently C 2 to C 8 alkylene or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with at least one amide functional group
- R 35 is C 8 to C 16 alkylene, or C 8 to C 16 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
- each R 25 is independently C 3 to C 6 alkylene; particularly propylene.
- R 35 is C 10 to C 14 alkylene; particularly decylene or dodecylene.
- the amine of Formula 6 can be used as an amine monomer in the polymerization reaction to form some of the amine polymers described herein.
- amine polymers described herein can undergo a post polymerization reaction, which comprises reaction of the amine polymer with at least one additional crosslinking monomer or a ligand.
- the reaction can proceed with both the crosslinking monomers present (e.g., by using cross linking monomers with different reactivity rates) or the amine monomer can react with one crosslinking monomer and then react with the second crosslinking monomer (e.g., the cross linking monomers are added sequentially to the reactor or the polymer is recovered prior to reaction with the second cross linking monomer).
- These reactions with two or more different crosslinking monomers can provide improved yield or improved physical characteristics.
- the crosslinking monomer and the ligand can be added simultaneously or sequentially as well.
- the amine monomer is other than a dendrimer wherein a dendrimer has a hyperbranched fractal-like structure that emanates from a central core and consists of a large number of terminal groups with a definite geometrical growth (Peppas et al., “Dendrimers and star polymers for pharmaceutical and medical applications,” Proceed. Intern. Symp. Control. Rel. Bioact. Mater, 20:143-144 (1993)).
- the crosslinking monomer can be guanidine, a guanidinium salt, a compound having the formula X-R 1 -X, or a combination thereof, wherein each X is independently a leaving group, and R 1 is C 2 to C 16 alkylene, arylene, dimethylbiphenyl, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy.
- the crosslinking monomer is X-R 1 -X wherein each X is independently a leaving group, and R 1 is C 8 to C 16 alkylene, or C 8 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with a heterocyclo functional group.
- the crosslinking monomer is X-R 1 -X wherein each X is independently a leaving group, and R 1 is C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with a heterocyclo functional group, or one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy.
- the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R 1 -X, or a combination thereof, wherein each X is independently a leaving group, R 1 is C 8 to C 16 alkylene, dimethylbiphenyl, or C 2 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with one or two phenyl, piperidinium or imidazolium functional groups.
- the functional groups can be p-xylene, 1,3-bis(m-haloC m alkyl)-1H-imidazol-3-ium, 4,4′-(C x alkane-1,x-diyl)bis(1-(m-haloC m alkyl)-1-methylpiperidinium), or 1-(q-haloC q alkyl)-3-(m-(3-(p-haloC p alkyl)-1H-imidazol-3-ium-1-yl)C m alkyl)-1H-imidazol-3-ium, wherein m is an integer from 2 to 14, p is an integer from 2 to 14, q is an
- X is independently a leaving group
- R 1 is C 8 to C 50 alkylene or C 8 to C 50 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with a heterocyclo functional group.
- the crosslinking monomer is guanidine, guanidinium hydrohalide, 1,3-bis(3-halopropyl)-1H-imidazol-3-ium, 4,4′-(propane-1,3-diyl)bis(1-(10-halodecyl)-1-methylpiperidinium), 1-(12-halododecyl)-3-(12-(3-(12-halododecyl)-1H-imidazol-3-ium-1-yl)dodecyl)-1H-imidazol-3-ium, or 1-(10-halodecyl-3-(10-(3-(10-halodecyl)-1H-imidazol-3-ium-1-yl)decyl)-1H-imidazol-3-ium.
- the crosslinking monomer is guanidine, a compound having the formula X-R 1 -X wherein R 1 is C 8 to C 16 alkylene, or a combination thereof, and the polymer comprises a comonomer, the comonomer being C m alkane-1,m-diyldiamine, alkylenedicycloalkanamine, (m-aminoC m alkyl)heterocycle, 3-(m-aminoC m alkyl)-1H-imidazol-3-ium, or a combination thereof, wherein m is an integer from 2 to 16, and each X is independently a leaving group, such as hexane-1,6-diyldiamine, heptane-1,7-diylamine, octane-1,8-diyldiamine, nonane-1,9-diylamine, decane-1,10-diyldiamine,
- R 1 is C 8 to C 14 alkylene; particularly, R 1 is decylene or dodecylene.
- R 1 is C 2 to C 6 alkylene or C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy; particularly, R 1 is —CH 2 —CH(OH)—CH 2 —, and the polymer comprises the comonomer.
- X is halo, epoxy, diaziridino, mesylate, sulfate, phosphate, aldehyde, ketone, or a combination thereof.
- Leaving groups are well known and can be selected from those known in the art, such as those in Larock, Comprehensive Organic Transformations (VCH 1989), e.g., p. 397 et seq.
- the amine polymers can comprise a comonomer, the comonomer being C m alkane-1,m-diyldiamine, alkylenedicycloalkanamine, (m-aminoC m alkyl)heterocycle, 3-(m-aminoC m alkyl)-1H-imidazol-3-ium, or a combination thereof, wherein m is an integer from 2 to 16, and each X is independently a leaving group.
- R 1 is C 8 to C 14 alkylene or C 8 to C 12 alkylene, such as decylene or dodecylene.
- R 1 is a C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy, and more preferably a C 2 to C 4 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy, such as —CH 2 —CH(OH)—CH 2 —.
- R 10 can be C 8 to C 14 alkylene or C 8 to C 12 alkylene, such as decylene or dodecylene.
- R 10 is a C 2 to C 6 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy, and more preferably a C 2 to C 4 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is substituted with hydroxy, such as —CH 2 —CH(OH)—CH 2 —.
- the various embodiments reflect that the amine polymer has nodes of positive charge separated by aliphatic segments.
- the aliphatic segments are preferably hydrophobic.
- the hydrophobicity is combined with sufficient positive charge for efficient and effective affinity and retention of bile salts.
- the combination provides an unexpected improvement in bile acid binding affinity, binding capacity, retention and removal as compared to (i) conventional bile acid binders having hydrophilic crosslinkers that prevent the collapsing of the polymer network due to the absorption of hydrophobic elements, such as bile acids and fatty acids present in the GI and (ii) conventional bile acid binders with insufficient charge density in proximity to the hydrophobic elements.
- a node of positive charge is generally a collection of three or more nitrogen atoms is defined by an appropriate combination of charge density, molecular weight and/or structure.
- the charge density of a node is generally greater than 16.5 mEq/g, greater than 17.3 mEq/g, greater than 19 mEq/g, and even more specifically greater than 22 mEq/g.
- Charge density is calculated in accordance with formulas known to those of skill in the art assuming a 100% degree of ionization of the nitrogen atoms for purposes of the calculation.
- the formula used herein is that the charge density in mEq/g units is equal to the number of nitrogen atoms in the node multiplied by one over the molecular weight of the node multiplied by one thousand or (# N atoms) ⁇ (1/molecular weight) ⁇ (1000).
- the formula weight of the node of positive charge is calculated for the neutral amine by adding hydrogen atoms to each nitrogen atom of the node until each nitrogen atom has three bonds.
- the nodes of positive charge can have a molecular weight of greater than 50 mol/g, greater than 100 mol/g, greater than 125 mol/g or greater than 200 mol/g.
- the charge density and molecular weight for various nodes are detailed in Table 1.
- a node of positive charge preferably has the structure of formula A
- each R 20 is independently C 3 to C 8 alkylene or C 3 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group.
- the nodes of positive charge are separated by hydrophobic aliphatic segments.
- the hydrophobicity of an aliphatic segment is expressed by the calculated log P, as discussed herein.
- the amine polymer can also comprise repeat units derived from polymerization of an amine monomer of formula 2 and a crosslinking monomer, wherein the amine monomer of formula 2 has the structure:
- each R 2 is independently C 2 to C 8 alkylene or C 2 to C 8 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide functional group; and R 3 is C 2 to C 12 alkylene, arylene, diformylheterocyclo, or C 2 to C 12 alkylene wherein one or more of the —CH 2 — groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and a portion of the nitrogen atoms of the amine polymer are substituted with a ligand selected from aminoalkyl, aryl, arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo, heterocyloalkyl, (trialkylammonio)alkyl, 2-
- R 46 is C 6 to C 16 alkylene
- R 47 is 1,y-bis(1-methylpiperidin-4-yl)C y alkylene
- R 48 is C 6 to C 16 alkyl
- m is an integer from 3 to 12
- x is an integer from 1 to 12
- y is an integer from 1 to 14
- z is an integer from 1 to 16.
- the amine polymers described herein can also have a portion of the nitrogen atoms of the amine polymer substituted with a ligand post-polymerization of alkyl, aminoalkyl, aryl, arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo, heterocycloalkyl, (trialkylammonio)alkyl, 2-(protected amino)-m-(heterocyclo)-1-oxoC m alkyl, 2-(protected amino)-1-oxoC m alkyl, 2-(protected amino)-3-methyl-1-oxoC m alkyl, 2-(protected amino)-4-methyl-1-oxoC m alkyl, 2-(protected amino)-1-oxo-m-arylC m alkyl, 2-(protected amino)-m-(alkylthio)-1-ox
- R 46 is C 6 to C 16 alkylene
- R 47 is 1,y-bis(1-methylpiperidin-4-yl)C y alkylene
- R 48 is C 6 to C 16 alkyl
- m is an integer from 3 to 12
- x is an integer from 1 to 12
- y is an integer from 1 to 14
- z is an integer from 1 to 16.
- the ligand is arylalkyl selected from naphthalen-2-ylalkyl or naphthalen-1-ylalkyl; heterocycloalkyl selected from m-(1-methylpyrrolidinium-1-yl)C m alkyl, m-(2-(1H-indol-3-yl)ethylamino)-m-oxoC m alkyl, m-(2-methylthiazol-3-ium-3-yl)C m alkyl, m-(benzo[d]thiazol-3-ium-3-yl)C m alkyl, m-(pyridinium-1-yl)C m alkyl, m-(tetrahydro-1H-thiophenium-1-yl)C m alkyl, z-(1,2-dialkyl-1H-imidazol-3-ium-3-yl)C z alkyl, m-(2,3-dialkyl-1
- the ligand is derived from an amino acid.
- Such ligands include, but are not limited to, 2-(protected amino)-m-(heterocyclo)-1-oxoC m alkyl, m-amino-2-(protected amino)-1,m-dioxoC m alkyl, m-amino-2-(protected amino)-1-oxoC m alkyl, 2-(protected amino)-1-oxoC m alkyl, 2-(protected amino)-m-(alkylthio)-1-oxoC m alkyl, 2-(protected amino)-m-(hydroxyphenyl)-1-oxoC m alkyl, 2-(protected amino)-1-oxo-m-phenylC m alkyl, 2-(protected amino)-m-(1H-imidazol-4-yl)-1-oxoC m alkyl, 2-(protected amino
- amine polymers described herein have a portion of the nitrogen atoms of the amine polymer substituted with a ligand of 2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-1-oxopropyl, 5-(2-(4-(nonyloxy)benzamido)ethylamino)-5-oxopentyl, (4,5-dihydro-1H-imidazolyl, 10-(pyridinium-1-yl)decyl, 2-(1H-indol-3-yl)ethyl, 5-(2-(1H-indol-3-yl)ethylamino)-5-oxopentyl, 2-amino-3-(1H-indol-2-yl)-1-oxopropyl, 3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl, 10-(1,2-dimethyl-1H-imidazol
- R 46 is decylene
- R 47 is 1,3-bis(1-methylpiperidin-4-yl)propane
- R 48 is decyl
- amine polymers described herein have a portion of the nitrogen atoms of the amine polymer substituted with a ligand of 2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-1-oxopropyl, 5-(2-(4-(nonyloxy)benzamido)ethylamino)-5-oxopentyl, (4,5-dihydro-1H-imidazolyl, 10-(pyridinium-1-yl)decyl, 2-(1H-indol-3-yl)ethyl, 54241H-indol-3-yl)ethylamino)-5-oxopentyl, 2-amino-3-(1H-indol-2-yl)-1-oxopropyl, 3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl, 10-(1,2-dimethyl-1H-imidazol)
- R 46 is decylene
- R 47 is 1,3-bis(1-methylpiperidin-4-yl)propane
- R 48 is decyl
- the protecting group is independently —C(O)OR 49 , —C(O)R 50 , wherein R 49 is alkyl or aryl, and R 50 is amino, hydrogen, alkyl, or haloalkyl.
- Protecting groups are well known in the art, and those known in the art may be used.
- the amine polymers having a portion of the nitrogen atoms of the amine polymer substituted with a ligand can have about 5 mole % to about 60 mole % ligand based on the moles of amine monomer, about 5 mole % to about 50 mole % ligand based on the moles of amine monomer, or about 10 mole % to about 30 mole % ligand based on the moles of amine monomer.
- the ratio of primary, secondary, and tertiary amines can be calculated by assuming complete reaction between the amine monomer and the crosslinking monomer and comparing the number of moles of the amine monomer and the crosslinking monomer along with the number of possible reaction sites on the crosslinking monomer.
- the amine polymer is N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (BTA)
- BTA N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine
- the amine has two tertiary amines and four primary amines before reacting with a crosslinking monomer.
- the crosslinking monomer is dibromodecane and the mole ratio of BTA to dibromodecane is 1 to 1, two of the primary amine atoms will react with the crosslinking monomer to convert two of the primary amines to two secondary amines.
- the ratio of the primary to secondary to tertiary amines is 1 to 1 to 1.
- the amine polymers of the invention can bind various bile acids such that the concentration of bound taurocholic acid is greater than 1.5 mmol/g polymer and the concentration of unbound taurocholic acid is less than 1.0 mmol/g polymer when the polymer is placed in a buffer solution having a 2.5 mM taurocholic acid concentration at 37° C. and the concentration of bound taurocholic acid is greater than 5.0 mmol/g polymer and the concentration of unbound taurocholic acid is greater than 4.0 mmol/g polymer when the polymer is placed in a buffer solution having a taurocholic acid concentration of at least 10 mM at 37° C.
- the amine polymers of the invention can bind bile acids such that the concentration of bound glycodeoxycholate is greater than 1.0 mmol/g polymer and the concentration of unbound glycodeoxycholate is less than 0.1 mmol/g polymer when the polymer is placed in a buffer solution having a 1.25 mM glycodeoxycholate concentration at 37° C. and the concentration of bound glycodeoxycholate is greater than 6.0 mmol/g polymer and the concentration of unbound glycodeoxycholate is greater than 2.0 mmol/g polymer when the polymer is placed in a buffer solution having a glycodeoxycholate concentration of at least 10 mM at 37° C.
- the amine polymer can be useful as a bile acid sequestrant, wherein, in a buffer solution at 37° C. containing less than 2.6 mM taurocholic acid, the amine polymer binds more of the acid than sevelamer and in a buffer solution at 37° C. containing more than 5.0 mM taurocholic acid the amine polymer binds more bile acid that colesevelam.
- the amine polymer can have the structure of any one of the amine polymers disclosed herein.
- the amine polymer is derived from the polymerization of an amine monomer and a crosslinking monomer wherein the amine monomer comprises N,N,N′,N′-tetrakis(3-aminopropyl)-1,12-diaminododecane and the crosslinking monomer comprises 1,3-dichloropropanol.
- the invention herein uses a combination of positive charge density and hydrophobicity to achieve unexpected bile acid binding affinity, binding capacity, retention and removal.
- the charge density comes from a concentration of positively charged nitrogen atoms that are separated by a hydrophobic segment. Hydrophobicity is expressed by the calculated log P, as discussed herein.
- the present invention has a unique combination of high binding affinity at low concentrations of bile acids and high binding capacity for bile acids at high concentrations of bile acids.
- the polymers of the present invention bound more bile acid than sevelamer, and in a buffer solution containing more than 5.0 mM taurocholic acid, the polymers of the present invention bound more bile acid than colesevelam. Even more specifically, at 37° C., in a buffer solution containing less than 2.0 mM taurocholic acid, the polymers of the present invention bound more bile acid than sevelamer, and in a buffer solution containing more than 7.0 mM taurocholic acid, the polymers of the present invention bound more bile acid than colesevelam.
- the polymers of the present invention bound more bile acid than sevelamer, and in a buffer solution containing more than 10.0 mM taurocholic acid, the polymers of the present invention bound more bile acid than colesevelam.
- the Langmuir equation known to those of skill in the art can be used in a linear regression analysis to determine equilibrium binding constants that reflect the greater affinity than sevelamer and the greater binding capacity than colesevelam.
- FIGS. 1 and 2 show graphs of the data from Example 50 plotted as the unbound bile acid in mmol bile acid per g polymer on the x-axis and bound bile acid in mmol bile acid per g polymer on the y-axis.
- the trend of the bile acid binding shows that the polymer of Sample 99 binds more bile acid than the commercial bile acid sequestrants with the exception of colesevelam at low bile acid concentrations (i.e., less than 2.5 mM) and binds more bile acid than all the commercial bile acid sequestrants except sevelamer at high bile acid concentrations (i.e., greater than 5.0 mM).
- the calculated log P (c Log P) of at least one of R 10 or R 30 of Formula 1 of the amine polymers can be greater than 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, or 8.
- the calculated log P (c Log P)(Clog P) is determined by drawing the structure of the crosslinker without the leaving groups in Chemdraw Ultra 11.0 (CambridgeSoft, Cambridge Mass.) and replacing the leaving groups with hydrogen, and selecting the chemical properties tool to calculate the c Log P. For example, for the crosslinker 1,10-dibromodecane, one would enter the structure of decane into Chemdraw and select “show chemical properties” from the “view” toolbar to calculate its c Log P as 5.984. If the crosslinker is a ring structure that opens during crosslinking, such as epichlorohydrin, the c Log P is determined by drawing the ring-opened structure as shown below for epichlorohydrin:
- One method for preparing the amine polymers described herein is to contact an amine monomer having six, seven or eight possible reaction sites or an amine monomer of Formulae 2 or 3 with a crosslinking monomer.
- the amine monomer and crosslinking monomer can be contacted in the presence of a solvent; the solvent is preferably a polar aprotic solvent (e.g., dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAC), tetrahydrofuran (THF), methyltetrahydrofuran, dimethylsulfoxide), 1,4-dioxane, 2-pyrrolidinone, or 1-methyl-2-pyrrolidinone.
- a polar aprotic solvent e.g., dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAC), tetrahydrofuran (THF), methyltetrahydr
- Polar protic solvents can also be used (e.g. methanol, ethanol, isopropyl alcohol, butanol, pentanol, or ethylene glycol).
- the reaction mixture is heated to from about 40° C. to about 120° C. or at about 60° C. to 70° C. for about 12 to 24 hours.
- the polymer gel product is washed with a basic solution, followed by water, and then lyophilized until dry.
- Monomers of the amine as defined in formulas 2 and/or 3 can be prepared using methods known to those of skill in the art, with specific examples of such syntheses in the examples below.
- the desired core (R 3 ) is prepared or commercially available and converted into a tetranitrile using known synthetic routes.
- an alkyl tetranitrile is prepared by the addition of acrylonitrile to an alkyldiamine via a Michael-type reaction.
- An alkyl tetranitrile can also be prepared by the addition of a dihaloalkyl to 3,3′-iminodipropionitrile.
- Another approach of preparing an alkyl tetranitrile is via the synthesis of the primary amine protected form of bis(3-aminopropyl)amine, (e.g., bis(3-(t-butoxycarbonylamino)propyl)amine or bis((3-benzyloxycarbonylamino)propyl)amine) followed by the addition of the dihaloalkane, and subsequent deprotection (see for example, Protective Groups in Organic Synthesis by Theodore Greene, Wiley-Interscience, 1999). Thereafter, the alkyl tetranitrile intermediate is then hydrogenated. Hydrogenation can be accomplished using a variety of techniques including Raney-nickel and/or Raney-cobalt catalysts followed by washing.
- a general hydrogenation procedure with Raney cobalt would combine the alkyl tetranitrile with hydrogen at a pressure from 100 to 5000 psi (e.g., about 1300-1500 psi) with or without NH 3 (e.g., about 40 psi NH 3 ) at a temperature of 50 to 120° C. (e.g., about 100° C.) in a solvent (e.g., water, methanol, ethanol, toluene, etc.) with adequate stirring and reaction time.
- a solvent e.g., water, methanol, ethanol, toluene, etc.
- the amine polymers of the invention have various chemical, structural and physical properties that contribute to their capacity for binding bile acids and/or their affinity for binding bile acids preferentially over fatty acids, phosphates and/or other compounds present in the gastrointestinal tract.
- the amine polymer can be administered in the form of a salt, or as a partial salt, or as salt free base.
- the “salt” has nitrogen atoms or groups in all or some of the repeat units that are protonated to create a positively charged nitrogen atom associated with a negatively charged counterion.
- the anionic counterions can be selected to minimize adverse effects on the patient.
- Suitable counterions include Cl ⁇ , Br ⁇ , CH 3 OSO 3 ⁇ , HSO 4 ⁇ , SO 4 2 ⁇ , nitrate, HCO 3 ⁇ , CO 3 2 ⁇ , acetate, lactate, phosphate, hydrophosphate, fumarate, malate, pyruvate, malonate, benzoate, glucuronate, oxalate, acetylglycinate, succinate, propionate, butyrate, ascorbate, citrate, tartrate, maleate, folate, an amino acid derivative, a nucleotide, a lipid, a phospholipid, or a combination thereof.
- the counterions can be the same as, or different from, each other.
- the reaction product can contain two different types of counterions.
- the nitrogen atoms will be in a salt form, with the percent of nitrogen atoms in a salt form being dictated by certain properties, such as flowability, storage time, and weight.
- the amine polymer is analyzed using assay A.
- the A assay combines the polymer to be analyzed in a desired concentration with a solution that mimics certain conditions present in the lower small intestine as described in Protocol 1 in the examples. After a period of time, the polymers are recovered by centrifugation and the supernatants are sampled, filtered to remove any remaining particulates and assayed for ion concentrations by liquid chromatography (LC).
- LC liquid chromatography
- the in vitro bile salt binding affinity for the amine polymers of this invention is from about 0.34 to about 0.75 mmol/gram polymer, particularly from about 0.46 to about 0.75 mmol/gram polymer, and more particularly, from about 0.55 to about 0.75 mmol/gram polymer when measured in the Assay A solution. Further, in some embodiments, the in vitro bile salt binding affinity for the amine polymers of this invention is greater than 0.55 mmol/gram polymer, greater than 0.60 mmol/gram polymer, or greater than 0.65 mmol/gram polymer.
- the concentration of phosphate ions was also determined on a strong anion exchange column by liquid chromatography using a basic mobile phase in order to measure the phosphate binding affinity.
- the polymers of the invention bind phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer, particularly less than 0.2 mmol/gram of polymer, more particularly up to about 0.15 mmol/gram polymer, and even more particularly, up to about 0.10 mmol/gram polymer when measured using a B assay.
- the amine polymer is analyzed using Assay B.
- Assay B the polymer to be analyzed is combined in a desired concentration with a solution that mimics certain conditions present in the upper small intestine as described in Protocol 2 in the examples. The same general procedure as described above was used to calculate the amount of each component bound.
- the in vitro bile salt binding capacity under the conditions of the B assay in Protocol 2 results in a maximum of about 3.7 mmol/gram polymer.
- the in vitro bile salt binding capacity for the amine polymers is from about 0.28 to about 3.7 mmol/gram polymer, particularly from about 2.22 to about 3.7 mmol/gram polymer, and more particularly from about 3 to about 3.7 mmol/gram polymer when measured in the assay B solution.
- the amine polymer is analyzed in a hamster model.
- the hamster model provides a complex and relevant measure of the polymer's binding capacity for bile acids, its binding affinity for bile acids over other anions, and its ability to retain bound bile acids and to increase the excretion of bile acids and bile acids metabolites from the gastrointestinal tract into the feces.
- Golden Syrian hamsters may be used as they have a similar bile acid profile to that of humans.
- feces from the last three days of the treatment period are collected, pooled, lyophilized, and then homogenized by grinding in a mortar and pestle.
- the feces samples are then extracted for fecal bile salt analysis.
- a baseline treatment period is conducted where all groups of animals are placed in metabolic cages as described above and fed only on western diet without added test article. Feces are collected as described above and the effect of the amine polymer on bile salt fecal excretion is determined by comparing baseline versus treatment periods. Otherwise, the effect of amine polymers on bile salt fecal excretion is determined by comparing untreated versus test groups.
- Hamster fecal bile salts are analyzed as described in the examples.
- the amine polymers can have a calculated in vivo binding capacity at least 25%, 50%, 75%, 100%, 125%, 150%, 175% or 200% greater than colesevelam hydrochloride when measured at a dosage of 0.5% of the total feed intake in male Golden Syrian hamsters fed a Western diet.
- the amine polymers can have a calculated in vivo bile salt binding capacity of at least about 0.35 mmol bile salt/gram of polymer when measured in humans.
- the amine polymers can have an in vivo binding capacity in a human of at least 0.35 mmol bile salt per gram of polymer, at least 0.4 mmol bile salt per gram of polymer, at least 0.5 mmol bile salt per gram of polymer, at least 0.6 mmol bile salt per gram of polymer, or more.
- Polymers of the invention are crosslinked materials, meaning that they do not generally dissolve in solvents however they can swell with solvents or absorb the solvent.
- swelling ratio refers to the number of grams of solvent taken up by one gram of crosslinked polymer when equilibrated in an aqueous environment. The swelling ratio is sensitive to the polymer solvent interaction parameter as described in Flory Huggins (Flory P. J. “Principles of Polymer Chemistry, Cornell Ithica Pub. 1953). When more than one measurement of swelling is taken for a given polymer, the mean of the measurements is taken to be the swelling ratio.
- the counterion content of the polymer can affect the swelling ratio, in the examples listed below, a chloride counterion is used, and the chloride content is stated.
- the counterion content can be as much as 25 wt. % of the total weight of the polymer and as little as ⁇ 1% of the total weight of the polymer.
- the amine polymers can be particles having a mean diameter from about 10 microns to about 200 microns.
- the amine polymer particles are substantially spherical beads. These beads can have a mean diameter from about 10 microns to about 200 microns.
- the term “substantially” means generally rounded particles having an average aspect ratio of about 1.0 to about 2.0. Aspect ratio is the ratio of the largest linear dimension of a particle to the smallest linear dimension of the particle. Aspect ratios may be easily determined by those of ordinary skill in the art. This definition includes spherical particles, which by definition have an aspect ratio of 1.0.
- the particles have an average aspect ratio of about 1.0, 1.2, 1.4, 1.6, 1.8 or 2.0.
- the particles may be round or elliptical when observed at a magnification wherein the field of view is at least twice the diameter of the particle.
- the substantially spherical beads can be prepared using methods known to a person skilled in the art.
- a preferred mode of synthesis is a heterogeneous process.
- Such processes are also referred to as polymerization in dispersed media and include direct or inverse suspension, emulsion, precipitation, dispersion or micro emulsion polymerization, reaction in aerosol or using bulk polymerization methods.
- the continuous phase can be selected from apolar solvents such as silicone, toluene, benzene, hydrocarbon solvents or oils, halogenated solvents, supercritical carbon dioxide, and the like.
- the discrete phase for the inverse suspension system comprises solubilizing the monomer and crosslinker in water; this can be achieved by the addition of an acid such as hydrochloric acid to form the amine salt, which renders the organic amine substantially more water soluble and dispersing the amine solution in a water-immiscible solvent to form an emulsion.
- an acid such as hydrochloric acid
- water can be used as the continuous phase, although salt brines are also useful to “salt out” the monomer and crosslinker into the discrete phase, as described in U.S. Pat. No. 5,414,068.
- the monomers can be dispersed either neat or as a solution in the continuous phase using a cosolvent.
- the crosslinking monomer can be added to the reaction in a semicontinuous fashion (staged addition) allowing the polymerization reaction to occur. Isolation of the beads can be carried out by filtration, washing and drying. Size can be further controlled or modified by reduction processes such as extrusion and grinding.
- the yield and efficiency of the reaction of crosslinker and amine monomer can be increased by the addition of a Dean-Stark process to a suspension polymerization reaction.
- a Dean-Stark process water is removed, which concentrates the reaction mixture (e.g., amine and crosslinker).
- the concentrating process allows any reactive chain ends on the growing network to react, driving the reaction to completion.
- the temperature also rises as the water is removed. Increased efficiency in the reaction may allow for the use of lower amounts of crosslinker and may produce a product having higher purity.
- the ratio of the crosslinker to amine monomer can change depending on the process conditions (e.g., salting out or Dean-Stark conditions), monomer purity and the desired physical properties (e.g., swelling ratio, particle size, etc.).
- the mole ratio of the amine monomer (e.g., of formula 2 or formula 3) to the crosslinking monomer is from about 1:1 to about 1:5; preferably, from about 1:1 to about 1:3 and more specifically from about 1:1.1 to about 1:3.
- the crosslinked amine polymer particle is generally a reaction product of a reaction mixture that is subjected to reaction conditions.
- the reaction mixture may also generally contain components that are not chemically incorporated into the product.
- the reaction mixture typically comprises monomers.
- the reactions are conducted such that a polymer network is generated, which is insoluble but can be solvated into a gel.
- the interpenetrating solvent is water
- the insoluble material is described as a hydrogel.
- the reaction is carried either in solution, in bulk (i.e. using the neat monomers and crosslinking compounds) or in dispersed media.
- the reaction may start with the introduction of for example, temperature change or irradiation.
- amine polymers can be prepared by chain growth or step growth. Step growth polymerization involves the polymerization of monomers that contain unsaturated functional groups, including radical polymerization, cationic polymerization and anionic polymerization.
- Step growth polymerization involves the reaction of bifunctional or polyfunctional monomers that grow via, dimers, trimers to longer oligomers.
- a polyfunctional amine containing monomer When using a polyfunctional amine containing monomer, the growth results in a branched polymer.
- Network formation occurs when the polymer chains react with each other. Parameters that effect the network formation reaction include temperature, solvent choice, the concentrations of monomers and crosslinkers, and the ratio of the monomer to the crosslinking monomer.
- desirable solvents have a high dielectric constant and include the following, but are not limited to, water, methanol, (and alcoholic solvents), N, N-dimethylformamide, methylpyrrolidone, dimethylsulfoxide, tetrahydrofuran, methyltetrahydrofuran and acetonitrile.
- a base maybe desired in some cases.
- Polymerization reactions to prepare the amine polymers include preparing an aqueous solution of the amine monomer, optionally with a surfactant, and adding an organic phase containing an organic solvent and optionally, a surfactant, to the aqueous phase.
- the crosslinker then can be added in a batch or a semi-continuous fashion. For example, the crosslinker can be added to the polymerization all at once or can be added slowly over a period of time.
- the amine polymer particles have a mean diameter of from about 10 ⁇ m to about 200 ⁇ m. Specific ranges are where the amine polymer particles have a mean diameter of from about 20 ⁇ m to about 200 ⁇ m, from about 20 ⁇ m to about 150 ⁇ m, or from about 20 ⁇ m to about 125 ⁇ m. Other ranges include from about 35 ⁇ m to about 150 ⁇ m, from about 35 ⁇ m to about 125 ⁇ m, from about 50 ⁇ m to about 125 ⁇ m, or from about 50 ⁇ m to about 100 ⁇ m.
- Particle sizes, including mean diameters, distributions, etc. can be determined using techniques known to those of skill in the art. For example, U.S. Pharmacopeia (USP) ⁇ 429> discloses methods for determining particle sizes.
- Various amine polymer particles also have less than about 4 volume percent of the particles that have a diameter of less than about 10 ⁇ m; particularly, less than about 2 volume percent of the particles that have a diameter of less than about 10 ⁇ m; more particularly, less than about 1 volume percent of the particles that have a diameter of less than about 10 ⁇ m; and even more particularly, less than about 0.5 volume percent of the particles that have a diameter of less than about 10 ⁇ m.
- specific ranges are less than about 4 volume percent of the particles that have a diameter of less than about 20 ⁇ m; less than about 2 volume percent of the particles that have a diameter of less than about 20 ⁇ m; less than about 1 volume percent of the particles that have a diameter of less than about 20 ⁇ m; less than about 0.5 volume percent of the particles that have a diameter of less than about 20 ⁇ m; less than about 2 volume percent of the particles that have a diameter of less than about 30 ⁇ m; less than about 1 volume percent of the particles that have a diameter of less than about 30 ⁇ m; less than about 1 volume percent of the particles that have a diameter of less than about 30 ⁇ m; less than about 1 volume percent of the particles that have a diameter of less than about 40 ⁇ m; or less than about 0.5 volume percent of the particles that have a diameter of less than about 40 ⁇ m.
- the amine polymer has a particle size distribution wherein not more than about 5 volume % of the particles have a diameter less than about 30 ⁇ m (i.e., D(0.05) ⁇ 30 ⁇ m), not more than about 5 volume % of the particles have a diameter greater than about 250 ⁇ m (i.e., D(0.05)>250 ⁇ m), and at least about 50 volume % of the particles have a diameter in the range from about 70 to about 150 ⁇ m.
- the particle distribution of the amine polymer can be described as the span.
- the span of the particle distribution is defined as (D(0.9) ⁇ D(0.1))/D(0.5), where D(0.9) is the value wherein 90% of the particles have a diameter below that value, D(0.1) is the value wherein 10% of the particles have a diameter below that value, and D(0.5) is the value wherein 50% of the particles have a diameter above that value and 50% of the particles have a diameter below that value as measured by laser diffraction.
- the span of the particle distribution is typically from about 0.5 to about 1, from about 0.5 to about 0.95, from about 0.5 to about 0.90, or from about 0.5 to about 0.85.
- Particle size distributions can be measured using Niro Method No. A 8 d (revised September 2005), available from GEA Niro, Denmark, using the Malvern Mastersizer.
- a once-a-day dose is substantially equivalent to a twice-a-day dose, which is also substantially equivalent to a three-times-a-day dose.
- the once per day or twice per day administration of a daily amount of the polymer or the composition has a bile acid removal that is not statistically significantly different from the removal of the same polymer or composition at the same daily amount administered three times per day.
- the invention is directed to methods of removing bile acids from an animal subject by administering an amine polymer or a pharmaceutical composition comprising an amine polymer, wherein less than 25% of subjects taking the polymer or composition once per day experience mild or moderate gastrointestinal adverse events at a dose of 6.0 grams/day or less.
- Gastrointestinal adverse events may include flatulence, diarrhea, abdominal pain, constipation, stomatitis, nausea and/or vomiting.
- the polymer or composition is administered twice a day and less than 25% of subjects taking the polymer or composition twice per day experience mild or moderate gastrointestinal adverse events. In some instances, the subjects taking the polymer or composition once per day or twice per day experience no severe gastrointestinal adverse events.
- the amine polymers or pharmaceutical compositions of the present invention have about 50% or more tolerability as compared to the same polymer or composition of the same daily amount administered three times a day. For example, for every two patients in which administration of the polymer three times a day is well tolerated, there is at least one patient in which administration of the polymer once a day or twice a day is well tolerated.
- well tolerated means there is no apparent dose response relationship for gastrointestinal adverse events.
- well tolerated means that the following gastrointestinal adverse effects are not reported from a statistically significant number of subjects, including those effects selected from the group consisting of flatulence, diarrhea, abdominal pain, constipation, stomatitis, nausea and vomiting.
- the present invention provides a method of removing bile acids from the gastrointestinal tract of an animal subject in need thereof, comprising administering an effective amount of an amine polymer or a composition comprising an amine polymer, wherein the polymer or composition is as well tolerated as administering substantially the same amount of the same polymer or composition three times per day.
- the subject is experiencing hypercholesteremia and thus the method treats hypercholesteremia. In other instances, the method lowers serum cholesterol.
- the tolerability of the polymer or composition comprising the polymers results from physical properties that the amine polymers may possess, including a viscosity when hydrated and sedimented of from about 10,000 Pa ⁇ s to about 2,500,000 Pa ⁇ s, from about 10,000 Pa ⁇ s to about 2,000,000 Pa ⁇ s, from about 10,000 Pa ⁇ s to about 1,500,000 Pa ⁇ s, from about 10,000 Pa ⁇ s to about 1,000,000 Pa ⁇ s, from about 10,000 Pa ⁇ s to about 500,000 Pa ⁇ s, or from about 10,000 Pa ⁇ s to about 250,000 Pa ⁇ s, from about 30,000 Pa ⁇ s to about 3,000,000 Pa ⁇ s, from about 30,000 Pa ⁇ s to about 2,000,000 Pa ⁇ s, or from about 30,000 Pa ⁇ s to about 1,000,000 Pa ⁇ s, the viscosity being measured at a shear rate of 0.01 sec ⁇ 1 .
- This viscosity is measured using a wet polymer prepared by mixing the polymer thoroughly with a slight excess of simulated intestinal fluid (per USP ⁇ 26>), allowing the mixture to sediment for 3 days at 37° C., and decanting free liquid from the sedimented wet polymer.
- the steady state shear viscosity of this wet polymer can be determined using a Bohlin VOR Rheometer (available from Malvern Instruments Ltd., Malvern, U.K.) or equivalent with a parallel plate geometry (upper plate of 15 mm diameter and lower plate of 30 mm diameter, and gap between plates of 1 mm) and the temperature maintained at 3TC.
- the amine polymers may further have a hydrated and sedimented yield stress of from about 150 Pa to about 4000 Pa, from about 150 Pa to about 3000 Pa, from about 150 Pa to about 2500 Pa, from about 150 Pa to about 1500 Pa, from about 150 Pa to about 1000 Pa, from about 150 Pa to about 750 Pa, or from about 150 Pa to about 500 Pa, from about 200 Pa to about 4000 Pa, from about 200 Pa to about 2500 Pa, from about 200 Pa to about 1000 Pa, or from about 200 Pa to about 750 Pa.
- Dynamic stress sweep measurements i.e., yield stress
- This rheometer also has a parallel plate geometry (upper plate of 15 mm diameter, lower plate of 30 mm diameter, and gap between plates of 1 mm) and the temperature is maintained at 37° C.
- a constant frequency of 1 Hz with two integration periods can be used while the shear stress is increased from 1 to 10 4 Pa.
- Amine polymers used in this invention may also have desirable compressibility and bulk density when in the form of a dry powder.
- Some of the particles of the amine polymers in the dry form have a bulk density of from about 0.8 g/cm 3 to about 1.5 g/cm 3 , from about 0.82 g/cm 3 to about 1.5 g/cm 3 , from about 0.84 g/cm 3 to about 1.5 g/cm 3 , from about 0.86 g/cm 3 to about 1.5 g/cm 3 , from about 0.8 g/cm 3 to about 1.2 g/cm 3 , or from about 0.86 g/cm 3 to about 1.2 g/cm 3 .
- the bulk density affects the volume of amine polymer needed for administration to a patient. For example, a higher bulk density means that a lower volume will provide the same number of grams of amine polymer. This lower volume can improve patient compliance by allowing the patient to perceive they are taking a smaller amount due to the smaller volume.
- a powder composed of the particles of the amine polymer in dry form has a compressibility index of from about 3 to about 30, from about 3 to about 25, from about 3 to about 20, from about 3 to about 15, from about 3 to about 13, from about 5 to about 25, from about 5 to about 20, or from about 5 to about 15.
- the compressibility index is defined as 100*(TD ⁇ BD)/TD, wherein BD and TD are the bulk density and tap density, respectively. Bulk density (BD) and tapped density (TD) are used to calculate a compressibility index (CI). Standardized procedures for this measurement are specified as USP ⁇ 616>.
- a quantity of the powder is weighed into a graduated cylinder. The mass M and initial (loosely packed) volume V o are recorded.
- the cylinder is then placed on an apparatus which raises and then drops the cylinder, from a height of 3 mm ⁇ 10%, at a rate of 250 times (taps) per minute.
- the volume is measured after 500 taps and then again after an additional 750 taps (1250 total). If the difference in volumes after 500 and 1250 taps is less than 2%, then the final volume is recorded as V f and the experiment is complete. Otherwise, tapping is repeated in increments of 1250 taps at a time, until the volume change before and after tapping is less than 2%.
- the following quantities are calculated from the data:
- the powder form of the amine polymers settles into its smallest volume more easily than polymers conventionally used to treat hypercholesteremia. This makes the difference between the bulk density and the tap density (measured powder density after tapping a set number of times) from about 3% to about 30%, from about 3% to about 25%, from about 3% to about 20%, from about 3% to about 15%, from about 3% to about 10%, from about 5% to about 35%, from about 5% to about 30%, or from about 5% to about 20% of the bulk density.
- the polymers and pharmaceutical compositions described herein retain a significant amount of the bound bile salts throughout the small intestine, and specifically, the bile salts bound by the polymer are not released prior to entry into the colon or excretion of the polymer in the feces.
- the term “significant amount” as used herein is not intended to mean that the entire amount of the bound bile salt are retained prior to fecal excretion or entry in to the colon.
- a sufficient amount of the bound bile salts are retained, such that a therapeutic and/or prophylactic benefit is obtained.
- the bile acids may then be released from the polymer but may still substantially be excreted either intact or as metabolites in the feces and thus for purposes of this invention have been sufficiently retained.
- Retention of bile acids may be measured by measuring the amounts of bile acids in the feces or in colonic aspirates or extracts above baseline levels (i.e., above the amount of bile acids retained in the feces when no polymer is administered to the animal subject).
- Particular amounts of bound bile salts that can be retained range from about 5% to about 100% above baseline levels.
- the polymer or pharmaceutical composition should retain at least about 5% of the bound bile salts, more particularly at least about 10%, even more particularly at least about 25% and most particularly at least about 50% of the bound bile salts above baseline levels.
- Retention of bile acids by the polymer can be calculated either directly by in vitro methods or indirectly by in vivo methods.
- the period of retention is generally during the time that the polymer or composition is being used therapeutically or prophylactically.
- the retention period is the time of residence of the polymer or composition in the gastrointestinal or the average residence time of the polymer or composition in the small intestine.
- Bile acids may be characterized by their site of synthesis and modification; primary bile acids (for example cholic acid and chenodeoxycholic acid) are synthesized in hepatocytes from cholesterol and secondary or tertiary bile acids (for example deoxycholic acid and lithocholic acid) are the products of bacterial dehydroxylation in the terminal ileum and colon.
- Primary bile acids may be deconjugated and/or dehydroxylated to convert them to secondary or tertiary bile acids; for example deoxycholate (from cholate) and lithocholate (from chenodeoxycholate).
- a change in the ratio of excreted bile acids towards primary or unmetabolized bile acids is a measure of in vivo retention of bile acids by polymers.
- the amine polymers in an in vivo measurement, can produce on average at least 11% primary bile acids in the feces based on total bile acids in the feces. In various embodiments, the amine polymers bind at least 15% or at least 20% primary bile acids in the feces based on the total bile acids in the feces.
- the amine polymers are not significantly absorbed from the gastrointestinal tract. Depending upon the size distribution of the amine polymer particles, clinically insignificant amounts of the polymers may be absorbed. More specifically, about 90% or more of the polymer is not absorbed, about 95% or more is not absorbed, even more specifically about 97% or more is not absorbed, and most specifically about 98% or more of the polymer is not absorbed.
- the amine polymers can be used to remove bile salts from an animal subject by administering an effective amount of the polymer to an animal subject in need thereof.
- the bile salts can be bound and retained by the amine polymer and then removed from the gastrointestinal tract in the feces.
- the amine polymers can be used to reduce serum LDL-cholesterol, or serum non-HDL-cholesterol, in an animal subject.
- the mean serum LDL can be decreased by at least 15%, at least 20%, at least 25%, at least 30% or more after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events.
- the daily dose of the amine polymer is about 6.0 g/day, 5.0 g/day, 4.0 g/day, 3.0, 2.5, or 2.0 g/day or less.
- the amine polymers can be administered to improve glycemic control in a human subject with Type II diabetes mellitus.
- glycated hemoglobin Hb A1c
- the daily dose of the amine polymer is about 6.0 g/day, 5.0 g/day, 4.0 g/day, 3.0, 2.5, or 2.0 g/day or less.
- the fasting plasma glucose can be decreased by at least 14 mg/dL (0.8 mmol/L), at least 16 mg/dL (0.9 mmol/L), at least 18 mg/dL (1 mmol/L), at least 20 mg/dL (1.1 mmol/L) or more after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events.
- the daily dose of the amine polymer is about 6.0 g/day, 5.0 g/day, 4.0 g/day, 3.0, 2.5, or 2.0 g/day or less.
- the amine polymers can be used to ameliorate, treat or slow progression of Alzheimer's disease.
- the amine polymers can also be used to treat non-alcoholic statohepatitis, cholestatic pruritus, irritable bowel syndrome with diarrhea (IBS-D), idiopathic bile acid malabsorption, genetic or congenital Fibroblast Growth Factor 19 (FGF19) deficiency or a combination thereof.
- IBS-D irritable bowel syndrome with diarrhea
- FGF19 Fibroblast Growth Factor 19
- amine polymers When used to treat cholestatic pruritus, they can be used in combination with an oral or topical antipruritic containing, for example, an antihistamine, a corticosteroid, a local anesthetic, a counterirritant, an opioid, an opioid receptor antagonist, or other therapies including but not limited to crotamiton, doxepin, mirtazapine, capsaicin, tacrolimus, linoleic acid, gabapentin, activated charcoal, thalidomide, naltrexone, erythropoietin, nicergoline, naltrexone, nalmefene, butorphanol, naloxone, rifampin, ondansetron, ursodeoxycholate, S-adenosyl-L-methionine, serotonin-selective reuptake inhibitors, phenobarbital, dronabinol, phototherapy,
- the amine polymers When used to treat IBS-D, they can be used in combination with antidiarrheals such as opiates, opioid or opioid analogs including loperamide, codeine, diphenoxylate, serotonin receptor antagonists such as alosetron, ramosetron and cilansetron, serotonin-selective reuptake inhibitors, tricyclic antidepressants such as amitriptyline and desipramine or drugs reducing the levels of serotonin (5-HT), antispasmodic drugs including anticholinergics such as hyoscyamine or dicyclomine, chloride secretion blockers such as crofelemer and probiotics.
- antidiarrheals such as opiates, opioid or opioid analogs including loperamide, codeine, diphenoxylate, serotonin receptor antagonists such as alosetron, ramosetron and cilansetron, serotonin-selective reuptake
- an animal subject can be a human or other mammal in need of either bile salt removal, reduction of serum LDL-cholesterol, or non HDL-cholesterol concentration, increase in HDL-C or improved glycemic control.
- the methods, polymers and compositions described herein are suitable for removal of bile salts from an animal subject wherein the subject is in need of such bile salt removal.
- patients experiencing hypercholesterolemia or hyperlipidemia benefit from such bile salt removal.
- the methods described herein are applicable to these patients regardless of the underlying condition that is causing the high serum cholesterol levels or need for bile acid removal.
- the amine polymers can be administered once, twice, or three times a day. If the amine polymer is administered once a day, it may be administered just before, with, or just after the largest meal of the day. Also, if administered once a day, it may be administered in connection with the largest, on average during a twenty-four hour period, release of bile acids from the gall bladder, which is typically in the morning. Further, it is preferred that the amine polymer is administered at least 3 hours before or after any agents that might have an adverse interaction with the amine polymers.
- the dosage regimen to treat hypercholesterolemia, atherosclerosis, diabetes, Alzheimer's disease, non-alcoholic steatohepatits, cholestatic pruritus, IBS-D, idiopathic bile acid malabsorption or reduce plasma cholesterol with the combination therapy and pharmaceutical compositions of the present invention can be selected using a variety of factors. These include the type, age, weight, sex, diet, and medical condition of the patient, the severity of the disease, the route of administration, pharmacological consideration such as the activity, efficacy, pharmacokinetics and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, and whether the amine polymer is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely.
- Initial treatment of a patient suffering from a hyperlipidemic condition can begin with the dosages indicated above. Treatment should generally be continued as necessary over a period of several weeks to several months or years until the condition has been controlled or eliminated.
- Patients undergoing treatment with the amine polymers disclosed herein can be routinely monitored by, for example, measuring serum LDL and total cholesterol levels by any of the methods well known in the art, to determine the effectiveness of the combination therapy. Repeated analysis of such data permits modification of the treatment regimen during therapy so that optimal effective amounts of each type of agent are administered at any point in time, and so that the duration of treatment can be determined as well.
- the treatment regimen/dosing schedule can be rationally modified over the course of therapy so that the lowest amount of amine polymer and optionally, combination treatment, is administered and so that administration is continued only so long as is necessary to successfully treat the hyperlipidemic condition such as hypercholesterolemia and atherosclerosis.
- the amine polymers or pharmaceutical compositions may be administered in combination with other therapeutic agents.
- therapeutic agents that can be co-administered with the compounds of the invention will depend, in part, on the condition being treated.
- various agents can be co-administered with the amine polymer, including agents used in reducing serum LDL-cholesterol or non-HDL-cholesterol, which comprise a hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor, a fibrate, a cholesterol absorption inhibitor, niacin (i.e.
- HMG CoA hydroxymethyl-glutaryl-coenzyme A
- the HMG CoA reductase inhibitor comprises a statin, such as atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or a combination thereof.
- the cholesterol absorption inhibitor can comprise ezetimibe.
- the fibrate can be benzafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate, or a combination thereof.
- the intestinal lipase inhibitor can comprise orlisatat.
- the amine polymers or pharmaceutical compositions may be administered in combination with a HMG CoA reductase inhibitor and niacin (e.g., lovastatin and niacin), or a HMG CoA reductase inhibitor and a cholesterol absorption inhibitor (e.g., simvastatin and ezetimibe), or a HMG CoA reductase inhibitor and an intestinal lipase inhibitor.
- agents can be co-administered with the amine polymer, including agents used in preventing or treating diabetes, obesity or other dyslipidemias, such as a sulfonylurea, a biguanidine, a glitazone, a thiazolidindione, an activator of peroxisome poliferator-activated receptors (PPARs), an alpha-glucosidase inhibitor, a potassium channel antagonist, an aldose reductase inhibitor, a glucagon antagonist, a retinoid X receptor (RXR) antagonist, a farnesoid X receptor (FXR) agonist, a FXR antagonist, glucagon-like peptide-1 (GLP-1), a GLP-1 analog, a dipeptidyl peptidase IV (DPP-IV) inhibitor, amylin, an amylin analog, an SGLT2 inhibitor, insulin, an insulin secretagogue, a thyroid hormone, a thyroid hormone
- the biguanidine can be metformin, buformin, phenformin, or a combination thereof.
- the thiazolidindione can be pioglitazone, rivoglitazone, rosiglitazone, troglitazone, or a combination thereof.
- the sulfonylurea can be acetohexamide, chlorpropamide, tolbutamide, tolazamide, glipizide, gliclazide, glibenclamide, gliquidone, glyclopyramide, glimepiride, or a combination thereof.
- the DPP-IV inhibitor can be alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin, or a combination thereof.
- the GLP-1 analog can be exenatide, liraglutide, albiglutide, or a combination thereof.
- the alpha glucosidase inhibitor can be acarbose, miglitol or voglibose.
- dyslipidemia is taken to mean a deviation in at least one of total serum cholesterol, LDL-cholesterol, non-HDL cholesterol, HDL-cholesterol or triglyceride from that considered normal by the National Cholesterol Education Program or other suitable bodies.
- agents can be co-administered with the amine polymer, including an anti-platelet agent, a beta-blocker, a renin-angiotensin-aldosterone system (RAAS) inhibitor, a RAAS modulator (e.g., angiotensin converting enzyme inhibitors, renin inhibitors, angiotensin receptor blockers, aldosterone antagonists or sodium channel blockers, including amiloride, triamterene, trimethoprim, and pentamidine) or a combination thereof
- RAAS renin-angiotensin-aldosterone system
- RAAS modulator e.g., angiotensin converting enzyme inhibitors, renin inhibitors, angiotensin receptor blockers, aldosterone antagonists or sodium channel blockers, including amiloride, triamterene, trimethoprim, and pentamidine
- the amine polymers can also be administered with other cholesterol-lowering agents such as acifran, azacosterol, benfluorex, ⁇ -benzalbutyramide, carnitine, chondroitin sulfate, clomestrone, detaxtran, dextran sulfate sodium, 5,8,11,14,17-eicosapentaenoic acid, eritadenine, furazabol, meglutol, melinamide, mytatrienediol, ornithine, ⁇ -oryzanol, pantethine, pentaerythritol tetraacetate, ⁇ -phenybutyramide, priozadil, probucol, ⁇ -sitosterol, sultosilic acid, piperazine salt, tiadenol, triparanol, xenbucin, or a combination thereof
- cholesterol-lowering agents such as acifran, azacosterol, benfluor
- agents that can be advantageously used for treatment in combination with the amine polymers are a squalene epoxidase inhibitor, a squalene synthetase inhibitor (or squalene synthase inhibitor), an acyl-coenzyme A, cholesterol acyltransferase (ACAT) inhibitor (including selective inhibitors of ACAT-1 or ACAT-2, as well as dual inhibitors of ACAT-1 and ACAT-2), a microsomal triglyceride transfer protein (MTP) inhibitor, probucol, a cholesterol absorption inhibitor (e.g., ezetimibe and 1-(4-fluorophenyl)-3(R)-3(S)-(4-fluorophenyl)-3-hydroxypropyl), 4(S)-4-hydroxyphenol (-2-azetidinone) described in U.S.
- ACAT cholesterol acyltransferase
- MTP microsomal triglyceride transfer protein
- a LDL receptor inducer e.g., a platelet aggregation inhibitor (e.g., a glycoprotein IIb/IIa fibrinogen receptor antagonist), aspirin, vitamin B 6 (or pyridoxine), vitamin B 12 (or cyanocobalamin), a water-soluble pharmaceutical salt or ester of folic acid (e.g., sodium salt and the methylglucamine salt), an anti-oxidant vitamin (e.g., vitamin C and E and beta-carotene), or a combination thereof
- a platelet aggregation inhibitor e.g., a glycoprotein IIb/IIa fibrinogen receptor antagonist
- aspirin e.g., aspirin
- vitamin B 6 or pyridoxine
- vitamin B 12 or cyanocobalamin
- a water-soluble pharmaceutical salt or ester of folic acid e.g., sodium salt and the methylglucamine salt
- an anti-oxidant vitamin e.g., vitamin C and E and beta
- therapeutic benefit includes achieving a therapeutic benefit.
- therapeutic benefit includes eradication, amelioration, or prevention of the underlying disorder being treated.
- therapeutic benefit includes eradication or amelioration of the underlying hypercholesterolemia.
- a therapeutic benefit is achieved with the eradication, amelioration, or prevention of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder.
- the amine polymer or composition of the invention may be administered to a patient at risk of developing hypercholesterolemia or diabetes or to a patient reporting one or more of the physiological symptoms of hypercholesterolemia or diabetes, even though a diagnosis of hypercholesterolemia or diabetes may not have been made.
- compositions of the present invention include compositions wherein the amine polymers are present in an effective amount, i.e., in an amount effective to achieve therapeutic or prophylactic benefit.
- the actual amount effective for a particular application will depend on the patient (e.g., age, weight, etc.), the condition being treated, and the route of administration. Determination of an effective amount is well within the capabilities of those skilled in the art, especially in light of the disclosure herein.
- the effective amount for use in humans can be estimated from animal models. For example, a dose for humans can be formulated to achieve gastrointestinal concentrations that have been found to be effective in animals.
- the human patient takes about 0.5 g to about 10 g per day, preferably about 0.5 g to about 5 g per day, more preferably, about 0.5 g to about 3 g per day, about 0.5 g to about 2.5 g per day, and most preferably about 0.5 g to about 2.0 g per day.
- the polymers and compositions described herein can be used as food products and/or food additives. They can be added to foods prior to consumption or during packaging.
- the amine polymers or pharmaceutically acceptable salts thereof, or compositions described herein, can be delivered to the patient using a wide variety of routes or modes of administration.
- the most preferred routes for administration are oral, intestinal, or rectal. Rectal routes of administration are known to those of skill in the art.
- Intestinal routes of administration generally refer to administration directly into a segment of the gastrointestinal tract, e.g., through a gastrointestinal tube or through a stoma.
- the most preferred route for administration is oral.
- the polymers may be administered per se or in the form of a pharmaceutical composition wherein the active compound(s) is in admixture or mixture with one or more pharmaceutically acceptable excipients.
- Pharmaceutical compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable excipients comprising carriers, diluents, and auxiliaries which facilitate processing of the active compounds into preparations which can be used physiologically. Proper composition is dependent upon the route of administration chosen.
- the polymers or compositions of the invention can be formulated readily by combining the polymer or composition with pharmaceutically acceptable excipients well known in the art.
- excipients enable the compositions of the invention to be formulated as powders, tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, wafers, and the like, for oral ingestion by a patient to be treated.
- Pharmaceutical preparations for oral use can be obtained as a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose or sucrose; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone (PVP); and various flavoring agents known in the art.
- disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- the amine polymer composition can comprise one or more fat-soluble vitamins such as vitamin A, D, E, K, or a combination thereof.
- An amount of the fat-soluble vitamin can be added to the composition sufficient to deliver about the daily dietary intake level (i.e., the Reference Daily Intake (RDI)), which is currently 3000 IU, 400 IU, 30 IU, 80 ⁇ g, respectively, for vitamin A, D, E, and K.
- RDI Reference Daily Intake
- the active ingredient e.g., polymer
- the active ingredient constitutes over about 20%, more particularly over about 50%, even more particularly over about 75%, and most particularly more than about 90% by weight of the oral dosage form, the remainder comprising suitable excipient(s).
- the amine polymers or pharmaceutical compositions can be administered in the form of a chewable or mouth-disintegrating tablet, a liquid, a powder, a powder contained within a sachet, a soft gelatin capsule, or a hard gelatin capsule.
- the polymers of the invention are provided as pharmaceutical compositions in the form of liquid compositions.
- the pharmaceutical composition contains an amine polymer dispersed in a suitable liquid excipient. Suitable liquid excipients are known in the art; see, e.g., Remington's Pharmaceutical Sciences.
- An effective amount of the polymers of the invention can be administered to the animal subject in less than four unit doses per day, such as in less than four tablets per day.
- the “dosage unit” or “unit dose” is a tablet, capsule or other oral dosage form containing an amount of the amine polymer.
- the polymer is generally administered in 4, 3, 2 or 1 unit doses in a 24-hour period, which provides a daily dose of the polymer to the subject under treatment.
- an “alkyl” group as described herein alone or as part of another group is an optionally substituted linear saturated monovalent hydrocarbon radical containing from one to twenty carbon atoms and preferably one to twelve carbon atoms, or an optionally substituted branched saturated monovalent hydrocarbon radical containing three to twenty carbon atoms, and preferably three to eight carbon atoms.
- unsubstituted alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, s-pentyl, t-pentyl, and the like.
- amide as used herein represents a bivalent (i.e., difunctional) amido linkage (i.e.,
- aryl as used herein alone or as part of another group denotes an optionally substituted monovalent aromatic hydrocarbon radical, preferably a monovalent monocyclic or bicyclic group containing from 6 to 12 carbons in the ring portion, such as phenyl, biphenyl, naphthyl, substituted phenyl, substituted biphenyl or substituted naphthyl. Phenyl and substituted phenyl are the more preferred aryl groups.
- aryl also includes heteroaryl.
- cycloalkyl denotes optionally an optionally substituted cyclic saturated monovalent bridged or non-bridged hydrocarbon radical containing from three to eight carbon atoms in one ring and up to 20 carbon atoms in a multiple ring group.
- exemplary unsubstituted cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, and the like.
- alkylene denotes a bivalent alkyl group such as methylene (—CH 2 —) or ethylene (—CH 2 CH 2 —), and arylene denotes a bivalent aryl group such as o-phenylene, m-phenylene, or p-phenylene.
- alkylene denotes an optionally substituted linear saturated bivalent hydrocarbon radical.
- ether as used herein represents a bivalent (i.e., difunctional) ether linkage (i.e., —O—).
- ester as used herein represents a bivalent (i.e., difunctional) ester linkage (i.e., —C(O)O—).
- heteroaryl denotes an optionally substituted monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms in protonated or unprotonated form, where one or more, preferably one, two, or three, ring atoms are heteroatoms independently selected from N, O, and S, and the remaining ring atoms are carbon.
- heteroaryl moieties include benzofuranyl, benzo[d]thiazolyl, benzo[d]thiazolium, isoquinolinyl, isoquinolinium, quinolinyl, quinolinium, thiophenyl, imidazolyl, imidazolium, oxazolyl, oxazolium, furanyl, thiazolyl, thiazolium, pyridinyl, pyridinium, furyl, thienyl, pyridyl, pyrrolyl, pyrrolidinium, indolyl, indolinium, and the like.
- heterocyclo denotes a saturated or unsaturated monovalent monocyclic group of 4 to 8 ring atoms in protonated or unprotonated form, in which one or two ring atoms are heteroatom(s), independently selected from N, O, and S, and the remaining ring atoms are carbon atoms. Additionally, the heterocyclic ring may be fused to a phenyl or heteroaryl ring, provided that the entire heterocyclic ring is not completely aromatic.
- Exemplary heterocyclo groups include the heteroaryl groups described above, pyrrolidino, pyrrolidinium, piperidino, piperidinium, morpholino, morpholinium, piperazino, piperazinium, and the like.
- hydrocarbon as used herein describes a compound or radical consisting exclusively of the elements carbon and hydrogen.
- substituted as in “substituted aryl,” “substituted alkyl,” and the like, means that in the group in question (i.e., the alkyl, aryl or other group that follows the term), at least one hydrogen atom bound to a carbon atom is replaced with one or more substituent groups such as hydroxy (—OH), alkylthio, phosphino, amido (—CON(R A )(R B ), wherein R A and R B are independently hydrogen, alkyl, or aryl), amino (—N(R A )(R B ), wherein R A and R B are independently hydrogen, alkyl, or aryl), halo (fluoro, chloro, bromo, or iodo), silyl, nitro (—NO 2 ), an ether (—OR A wherein R A is alkyl or aryl), an ester (—OC(O)R A wherein R A is alkyl or aryl), keto (
- substituted introduces a list of possible substituted groups, it is intended that the term apply to every member of that group. That is, the phrase “optionally substituted alkyl or aryl” is to be interpreted as “optionally substituted alkyl or optionally substituted aryl.”
- Protocol 1 Conditions Mimicking the Lower Small Intestine (A Assay).
- Amine polymers were measured in conditions mimicking those found in the lower small intestine (Northfield, T C and McColl, I (1973) “Postprandial concentrations of free and conjugated bile salts down the length of the normal human small intestine”, Gut 14: 513-518, Borgstrom, B, et al. (1957) “Studies of intestinal digestion and absorption in the human”, J Clin Invest 36: 1521-1536.)
- test solution 50 mM N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 50 mM sodium BES, 6.5 mM sodium phosphate, 0.93 mM sodium glycocholate, 0.93 mM sodium glycodeoxycholate, 150 mM sodium chloride, pH 7.0.
- BES N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid
- 50 mM sodium BES 50 mM sodium BES
- 6.5 mM sodium phosphate 0.93 mM sodium glycocholate
- 0.93 mM sodium glycodeoxycholate 150 mM sodium chloride, pH 7.0.
- the test solution was stored at ⁇ 20° C. Before use the test solution was thawed in a 37° C. water bath, stirred vigorously on a stir plate for greater than 20 minutes, and filtered through a Nalgene 0.45 micron cellulose nitrate filter unit.
- Amine polymers to be analyzed were freeze-dried a minimum of 18 hours and were accurately dispensed into 16 ⁇ 100 mm borosilicate test tubes, with each tube containing between 23 and 28 mg of test sample. The precise weight was noted and the above solution was added using a 10 mL disposable pipette, so that the polymer concentration was 2.5 mg/mL.
- the tubes were covered with a sheet of Teflon, clamped and tumbled end-over-end (30-40 revolutions per minute) inside an atmospheric chamber at 37° C. for three hours.
- the polymers were recovered by centrifugation at 500 ⁇ g for 10 minutes and the supernatants were sampled, filtered through a 96 well 0.45 micron Whatman Unifilter 800 by centrifugation at 1000 ⁇ g for 10 minutes to remove any remaining particulates. Filtrates were transferred to either glass IC vials with rubber septa or 96 well polypropylene deep well sample plates.
- GC glycocholate
- GDC glycodeoxycholate
- 50 ⁇ L of the sample solution was injected onto a HPLC system, equipped with Phenomenex Luna C8 (2) column (100 ⁇ , 5 ⁇ m, 50 ⁇ 2.00 mm), and a UV detector.
- the signal of GC and GDC was detected at a wavelength of 205 nm from the UV detector.
- Calibration solutions comprised of GC and GDC standards of different concentrations were also injected onto the same HPLC system.
- the calibration curve of each component was then constructed by plotting the peak area vs. concentration. Based on the peak area of the GC and GDC found in the sample and the corresponding calibration curve, the concentration of each component in the sample was calculated in mM.
- the concentration of phosphate was also determined by injection of 20 uL of filtrate onto strong anion exchange columns (Dionex AG11-HC 50 ⁇ 4 mm ID and Dionex AS11-HC 250 ⁇ 4 mm ID) using a Waters Alliance 2795 Separation Module equipped with a 6 column switching valve installed inside a column oven and a Dionex Conductivity Detector CD25 (with DS3 flow cell and ASRS Ultra 11 4 mm Suppressor).
- the mobile phase was 30 mM KOH buffer with a 1 mL/min flow rate and a run time of 15 minutes per sample.
- Phosphate standards of different concentrations were also injected onto the same system and the calibration curve was then constructed by plotting the peak area vs. concentration. Based on the peak area found in the sample and the corresponding calibration curve, the concentration of phosphate in the sample was calculated in mM.
- Protocol 2 Conditions Mimicking the Upper Small Intestine (Assay B).
- test polymers The bile salt binding performance of test polymers was evaluated at a polymer concentration of 2.5 mg/mL in the manner described in Protocol 1 above, with the exception that the following test solution was used: 50 mM N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 50 mM sodium BES, 6.5 mM sodium phosphate, 4.6 mM sodium glycocholate, 4.6 mM sodium glycodeoxycholate, 1.2 mM oleyl glycerol, 9 mM oleic acid, 150 mM sodium chloride, pH 7.0.
- BES N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid
- test solution 50 mM sodium BES, 6.5 mM sodium phosphate, 4.6 mM sodium glycocholate, 4.6 mM sodium glycodeoxycholate, 1.2 mM oleyl glycerol, 9 mM
- Freeze-dried polymer was precisely dispensed into the 16 ⁇ 100 mm borosilicate test tubes, with each tube containing between 28 and 33 mg of test sample. In certain cases, the concentration of polymer was adjusted from 2.5 mg/mL to 1 mg/mL. Otherwise the procedure was identical to that described in Protocol 1 above, except filtrates submitted for analytical analysis were only dispensed into glass IC vials.
- GC glycocholate
- GDC glycodeoxycholate
- OG oleyl glycerol
- OA oleic acid
- Calibration solutions comprised of GC, GDC, OG and OA standards of different concentrations were also injected onto the same HPLC system.
- the calibration curve of each component was then constructed by plotting the peak area vs. concentration. Based on the peak area of the GC, GDC, OG or OA found in the sample and the corresponding calibration curve, the concentration of each component in the sample is calculated in mM.
- a baseline treatment period was conducted where all groups of animals were placed in metabolic cages as described above and fed only on western diet without added test article. Feces were collected as described above and the effect of amine polymer on bile salt fecal excretion was determined by comparing baseline versus treatment periods. Otherwise, the effect of amine polymer on bile salt fecal excretion was determined by comparing untreated versus test groups.
- Example 1 N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C 4 BTA) Polymers with Dihaloalkane Crosslinkers
- Example 3 N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C 4 BTA) Polymers with Epichlorohydrin (ECH)—Comparative Example
- Example 4 N,N,N′,N′-tetrakis(3-aminopropyl)-1,12-dodecanediamine (C 12 BTA) Polymers with 1,3-bis(3-iodopropyl)-1H-imidazol-3-ium
- N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine materials were conducted using parallel synthesis.
- N,N,N′,N′-tetrakis(3-aminopropyl)-1,12-dodecanediamine was dispensed into a 40 mL glass vial.
- 1,3-bis(3-iodopropyl)-1H-imidazol-3-ium and N-methylpyrrolidone (NMP) was added to the vial.
- the vial was capped and heated for 17 hours at 58° C.
- Crosslinkers were dispensed as 40 wt. % in dimethyl sulfoxide (DMSO). Solvent was added to each vial to make the final solid content concentration at 40 wt. %. Vials were equipped with magnetic stirrer, capped and heated for 17 hours at 70° C. Most vials contained a solid plug of polymer. The polymer was swollen and ground in dimethyl formamide (DMF), washed with aqueous hydrochloric acid (1 M), water, saturated solution sodium bicarbonate (NaHCO 3 ) three times, water (two times) and lyophilized until dry.
- DMF dimethyl formamide
- NaHCO 3 saturated solution sodium bicarbonate
- Example 7 N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C 4 BTA) Terpolymers with 1-(3-aminopropyl)imidazole (API) as Comonomer, and 1,10-dibromodecane (DBD), as Crosslinking Monomer
- Example 8 N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C 4 BTA) with Guanidine Hydrochloride as a Crosslinking Monomer
- Synthesis of polymers with guanidine hydrochloride as a crosslinker consisted of three components: N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine monomer (C 4 BTA), guanidine hydrochloride, and a comonomer. All the reactions were carried out using an appropriate size round bottom flask with a nitrogen inlet port and hot plates equipped with silicon oil baths.
- N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine monomer was dispensed into a round bottom flask with a nitrogen inlet port. Then guanidine hydrochloride and comonomer (if present) were added to the flask. The reaction flasks were capped using a rubber septum and nitrogen flow was introduced from the nitrogen inlet port. The reaction flask were then heated for 18 hours at 120° C. and then for 4 hours at 180° C.
- the polymer formed was swollen and ground in 1M hydrochloric acid solution and then washed with ethanol (two times), water, 3M sodium hydroxide (two times) and water (three times) and lyophilized until dry. Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below.
- Example 9 Synthesis of Polymers of N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C 4 BTA) and with Dihalo Bis Piperidinium as Crosslinkers and Ligands
- Synthesis of polymers with dihalobis piperidinium as crosslinkers consisted of two components: N,N,N′,N′-tetrakis(3-aminopropyl)-1,10-dacanediamine monomer (C 10 BTA) or N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C 4 BTA) and dihalobis piperidinium (TMBMP-DBD).
- the reactions were carried out using a 250 mL size round bottom flask with a nitrogen inlet port and hot plates equipped with silicon oil baths.
- a BTA monomer was dissolved in methanol to make a 50 wt. % solution and then dispensed into a round bottom flask. Then TMBMP-DBD or TMBMP-DBDD was added to the flask as a 50 wt. % solution in methanol.
- the reaction flasks were capped using a rubber septum and nitrogen flow was introduced from the nitrogen inlet port. The reaction flasks were then heated for 18 hours at 55° C.
- the polymers formed with C 4 BTA were swollen and ground in methanol and washed with methanol (two times), 1M hydrochloric acid, and water (three times) and lyophilized until dry.
- the polymers formed with C 10 BTA were swollen and ground in methanol and washed with methanol (two times), 0.5M hydrochloric acid, water, 0.5M sodium bicarbonate (two times) and water (three times) and lyophilized until dry. Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below.
- Polymer synthesized with BTA and dihalobis piperidinium crosslinker were further modified by reacting with alkyl halides to attach a pendant alkyl ligand to the scaffold.
- polymer scaffold was first soaked in methanol in a 250 mL round bottom flask and then different amount of alkyl halide ligand (as listed in table below) was added to the flask. The reactions were carried out at 55° C. for 18 hours. The polymer were then washed with methanol (2 times), 1 M hydrochloric acid, 1 M sodium chloride (2 times), and water (3 times) and lyophilized until dry. Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below.
- Example 13 N,N,N′,N′-tetrakis(3-aminopropyl)-1,3-propanediamine (C 3 BTA), N,N,N′,N′-tetrakis (3-aminopropyl)-1,8-octaneanediamine (C 8 BTA), N,N,N′,N′-tetrakis(3-aminopropyl)-1,10-decanediamine (C 10 BTA) and N,N,N′,N′-tetrakis (3-aminopropyl)-1,12-dodecanediamine (C 12 BTA) Gel Synthesis
- Cross-linker wt DMSO B assay A assay Hamster Bile Acids Sample # mole ratio monomer (mg) (R 1 ) (mg) (mg) (mmol/g) (mmol/g) (mmol/g) in feces* 17-A1 1:0.5 C 8 BTA 300.0 C 10 alkylene 120.8 631.2 17-A2 1:0.5 C 10 BTA 300.0 C 10 alkylene 112.3 618.5 17-A3 1:0.5 C 12 BTA 300.0 C 10 alkylene 105.0 607.5 17-B1 1:1 C 8 BTA 300.0 C 10 alkylene 241.6 812.4 3.33 17-B2 1:1 C 10 BTA 300.0 C 10 alkylene 224.7 787.0 3.22 17-B3 1:1 C 12 BTA 300.0 C 10 alkylene 210.0 764.9 3.32 17-C1 1:1.6 C 8 BTA 300.0 C 10 al
- the selected monomer was dispensed into 8 mL glass vials. Solutions of the crosslinking monomer of formula X-R 1 -X wherein X is halo such as chloro or bromo and R 1 is a hydrocarbon chain as listed in the table below was dispensed as 40 wt. % in dimethyl sulfoxide (DMSO). Solvents and K 2 CO 3 were added to each vial. The vials were equipped with magnetic stirrer, capped and heated for 17 hours at 60° C. Most vials contained a solid plug of polymer. The polymer was swollen and ground in methanol, washed with aqueous hydrochloric acid (1 M), water, sodium hydroxide (0.01 M, three times), water (two times) and lyophilized until dry.
- DMSO dimethyl sulfoxide
- Example 15 N 1 ,N 1 ′-(1,3-phenylenebis(methylene))bis(N 1 -(3-aminopropyl)propane-1,3-diamine)
- Example 16 N 2 ,N 2 ,N 6 ,N 6 -tetrakis(3-aminopropyl)pyridine-2,6-dicarboxamide
- Example 17 N 1 ,N 1 ,N 6 ,N 6 -tetrakis(3-aminopropyl)adipamide
- Example 18 N 1 ,N 1 ,N 4 ,N 4 -tetrakis(3-aminopropyl)succinamide
- the product form a precipitate oil.
- the hexanes were removed and the precipitate was stirred/washed with the following solvents to remove excess dibromoalkane; ethylacetate and diethyl ether.
- the white precipitate was placed in a vacuum oven to remove excess organic solvent.
- Step 1 (Recipe for BTA modified with ligand).
- C 4 BTA N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine
- NMP N-methylpyrrolidone
- the vials were sealed and the mixture was stirred at 80° C., stirring at 500 RPM for 18 hours, then cooled to room temperature. Attachment of the ligand to C 4 BTA was confirmed using MS.
- the amounts of the C 4 BTA, NMP, and Boc-Trp-OSu use are listed in the table below.
- Step 2 Crosslinking the modified BTA monomer.
- the C 4 BTA-ligand mixture was subsequently treated with neat 1,10-dibromodecane (DBD) or epichlorohydrin (ECH).
- DBD 1,10-dibromodecane
- EH epichlorohydrin
- the reactions were sealed and heated at 80° C. for 18 hours with stirring at 500 RPM until the reaction mixture gelled. Samples that gelled were washed with methanol (2 ⁇ ), 1M NaOH solution, water (3 ⁇ ), then lyophilized dry.
- the amounts for the reactants are listed in the table below.
- the scaffold was prepared by mixing C 4 BTA neat with a 50 wt. % 1,10-dibromodecane (DBD) in N-methylpyrrolidone (NMP). Additional NMP was added to give a total concentration of crosslinker and C 4 BTA equal to 37.5 wt. %.
- the mixture was heated at 70° C. stirring at 400 RPM until the mixture formed a gel.
- the gel was continued to be heated for a total of 22 hours before cooling.
- the solid was ground in methanol, washed with methanol, 1M NaCl, MeOH, water (3 ⁇ ), then lyophilized dry to give tacky particles.
- the scaffold was portioned out into a 4 ⁇ 6 library plate with 8 mL vials. To this was added a 20 wt. % solution of ligand (thiazolium) in NMP. The vials were filled with NMP to achieve a total volume of 2.5 mL. The mixture was stirred at 80° C. for 18 hours, stirring at 500 RPM. Reactions were cooled, washed with methanol, 1M NaOH, and water, then lyophilized dry. The amounts used for the reactions follow.
- Example 30 C 3 Methyl Imidazole Ligand: Synthesis of 1-methyl-3-(1-bromopropyl) imidazolium bromide ligand
- Dibromoalkane (0.3 mol) was placed into a 3-necked flask that was fitted with an overhead stirrer. Acetone was added such that the resulting solution was 3 M. Methyl imidazole (0.03 mol) was dissolved in acetone to result in a 2M solution. This was added to the flask and the reaction was stirred overnight at 45-50° C. The next day, the acetone was vacuumed off and the product was purified by column chromatography using 500 g of silica gel and 90:10 CH 2 Cl 2 :MeOH. The yield was in the range of 60-70% of materials that ranged from a clear oil to a white sold. The product was identified by 1 H NMR and mass spectrometry.
- Dibromoalkane (0.3 mol) was placed into a 3-necked flask that was fitted with an overhead stirrer. Acetone was added such that the resulting solution was 3M. A 1-methylpyrrolidine solution (0.03 mol) was dissolved in acetone to result in a 2M solution. This was added to the flask and the reaction was stirred overnight at 55° C.
- the isolation method depended on the form of the product, for example, when the product precipitated out of solution, the solid was filtered and washed with acetone and when the product was an oil, the acetone was vacuumed off and the product was purified either by column chromatography using 500 g of silica gel and CH 2 Cl 2 :MeOH. The yield was in the range of 60-70% of materials that ranged from a clear oil to a white sold. The product was identified by 1 H NMR and mass spectrometry.
- the desired polyamine scaffold gel was dissolved in water and neutralized with an equimolar solution of NaOH. An appropriate amount of a solution of 1,3-dialkylimidazolium bromide in methanol was added to the polyamine solution. The mixture was heated to 75° C. for 24 hours. After cooling to room temperature the modified polyamine gel was washed by exposing the gel to a methanol wash (2 ⁇ ), 0.5 M HCl wash and water wash (2 ⁇ ). In each wash, the gel was stirred for 30 minutes, exposed to the washing solvent, and centrifuged; the supernatant liquid was decanted and the wash solvent was added to the gel. After the final water wash, the gel was placed into a lyophilizer to remove the water. The gel was isolated as a white fluffy material.
- Step A 1. 4-(nonyloxy)benzoyl chloride. To a suspension of 4-(nonyloxy)benzoic acid (6.02 g, 0.0228 mol) in 100 mL of dichloromethane was added DMF (0.176 mL, 0.00228 mol), followed by thionyl chloride (2.5 mL, 0.0342 mol). The reaction was stirred at room temperature for 2 hours and became a clear solution. The solvent was removed under reduced pressure. The residue was dried under high vacuum overnight. The product (6.54 gram) was obtained as a brown oil which was used for next step directly.
- Step B tert-butyl 2-(4-(nonyloxy)benzamido)ethylcarbamate.
- a solution of tert-butyl-2-aminoethylcarbamate (3.65 g, 0.0228 mol) and diisopropylethylamine (4.76 mL, 0.0274 mol) in 100 mL of dichloromethane was cooled to 4° C. in an ice bath.
- 4-(Nonyloxy)benzoyl chloride (6.54 g, 0.0228 mol) was dissolved in 50 mL of dichloromethane and was added to tert-butyl-2-aminoethylcarbamate solution dropwise.
- Step C tert-butyl 2-(4-(nonyloxy)benzamido)ethylcarbamate.
- tert-butyl-2-(4-(nonyloxy)benzamido)ethylcarbamate 9.1 g, 0.0224 mol
- trifluoroacetic acid 17.25 mL, 0.224 mol
- the reaction was stirred at room temperature for 16 hours.
- Solvent was removed under reduced pressure.
- Toluene (100 mL) was added to the residue to form a heteroazeotrope.
- Solvent and remaining trifluoroacetic acid were removed under reduced pressure.
- the residue was dried under high vacuum until no further weight change (2 days). The product was obtained as a trifluoroacetate salt, which was used directly for next step.
- Step D N-(2-(5-chloropentanamido)ethyl)-4-(nonyloxy)benzamide.
- a solution of tert-butyl-2-(4-(nonyloxy)benzamido)ethylcarbamate trifluoroacetate salt from previous step and diisopropylethylamine (11.7 mL, 0.0672 mol) in 150 mL of dichloromethane was cooled to 4° C. in an ice bath.
- 5-Chloro-valeroyl chloride (2.88 mL, 0.0224 mol) was dissolved in 50 mL of dichloromethane and was added to the above solution dropwise. The internal temperature remained at or below 4° C. during the addition.
- This synthesis can be used to make other amino acid-based ligands by substituting the appropriate amine reactant for 2-(1H-indol-3-yl)ethanamine (e.g., use of 3-methylbutan-1-amine to make a Leu-based ligand).
- Dibromodecane (12.10 g, 0.039 mol) was dispensed with methanol (13 mL) and N,N-dimethylformamide (13 mL) into a round bottom flask (100 mL) under nitrogen with a mechanical stirrer and reflux condenser. Diaminohexane (4.55 g, 0.039 mol) was added to the flask and the mixture was brought to reflux while stirring. After 35 minutes gelation occurred and mechanical stirring was stopped. The resulting gel was cured at 85° C. for 17 hours.
- the polymer formed was swollen and ground in water (two times, 80 mL), methanol (two times, 80 mL), water (two times, 80 mL), ethanol (once, 500 mL), water (once, 100 mL), HCl (1M, 80 mL) ethanol (500 mL) and water (100 mL) and lyophilized until dry.
- Bile acid Bile acid Bile acid Bile acid binding binding binding affinity capacity retention A assay B assay Hamster Sample # (mmol/g) (mmol/g) (mmol/g) 46-A1 0.52 2.60 6.22 4.6
- Example 36 N,N,N′,N′-Tetrakis(3-aminopropyl)-1,12-diaminododecane (C 12 BTA), N,N,N′,N′-Tetrakis(3-aminopropyl)-1,10-diaminodecane (C 10 BTA), N,N,N′,N′-Tetrakis(3-aminopropyl)-1,8-diaminooctane (C 8 BTA), N,N,N′,N′-Tetrakis(3-aminopropyl)-1,4-diaminobutane (C 4 BTA) beads synthesis with 1,3-dichloropropanol (DCP)
- C 12 BTA-DCP, C 10 BTA-DCP, C 8 BTA-DCP, C 4 BTA-DCP beads were conducted in a Semi-Continuous Parallel Polymerization Reactor (SCPPR).
- SCPPR Semi-Continuous Parallel Polymerization Reactor
- C 4 BTA, C 8 BTA, C 10 BTA, and C 12 BTA monomers were dispensed into 11 mL glass tubes and cooled to 5° C. in an ice bath and water was added.
- Hydrochloric acid HCl, 37 wt. % in water
- DDS Dodecylbenzenesulfonic acid sodium salt
- Example 37 C 12 BTA-DCP, C 10 BTA-DCP, C 8 BTA-DCP, C 4 BTA-DCP Beads Synthesis for In Vivo Study
- Heptanes 21.59 mL
- Span 80 solution 20.32 mL, 15 wt. % in heptanes
- the final mixture was stirred at 220 rpm with an overhead stirrer and heated in oil bath at 75° C.
- the internal temperature of the reaction was at 70° C.
- a Dean-Stark treatment was performed to remove the water using the azeotrope of heptanes and water (at 80° C.).
- the reaction was ended after the mixture temperature reached 100° C. or when all the water in the reaction mixture was collected.
- the reaction mixture was cooled to ambient temperature, stirring was stopped, and the organic layer was decanted.
- the beads were washed with 150 mL isopropyl alcohol, followed by one wash with HCl (150 ml, 1.0 M), one wash with water, two washes with NH 4 OH (150 mL, 10 wt. % in water), one wash saturated aqueous NaCl solution, and three washes with water.
- the beads were lyophilized for 48 hours.
- the final product was isolated in 80% yield (4.9 g).
- Various synthesis experiments are detailed below.
- sample 51-D1 Acid loading of sample 51-D1.
- the isolated dry bead prepared from 51-D1 (example 37) was placed into a flask. Using 1 M HCl solution in water, an appropriate amount of HCl was added to the bead such that the resulting beads contained 5, 10, 15 and 20 weight percent of chloride. The chloride content in the bead was later confirmed by elemental analysis and found to be 5, 9, 12, and 19 wt. % respectively.
- the sample ID's for these compounds were given 79-A1, 79-A2, 79-A3 and 79-A4 respectively.
- Example 38 C 12 BTA, C 10 BTA, C 8 BTA, C 4 BTA Beads Synthesis with 1,1′-(dodecane-1,12-diyl)bis(3-bromopropyl)-1H-imidazol-3-ium (C 12 Core, C 3 Bisimidazolium) Crosslinker
- C 12 BTA-C 12 core, C 3 bisimidazolium, C 10 BTA-C 12 core, C 3 bisimidazolium, and C 4 BTA-C 12 core, C 3 bisimidazolium beads were conducted in a SCPPR.
- C 4 BTA, C 8 BTA, C 10 BTA, and C 12 BTA monomers were dispensed into 11 mL glass tubes and cooled to 5° C. in an ice bath and water was added.
- Hydrochloric acid (HCl, 37 wt. % in water) was added slowly to this solution followed by mixing for 2 minutes.
- DDS (15 wt. % in water) and a solution of the designated crosslinking monomer (40 wt.
- Example 39 C 12 BTA-C 12 Core, C 3 Bisimidazolium and C 4 BTA-C 12 Core, C 3 Bisimidazolium Beads for In Vivo Study
- % in water of formula X-R 1 -X (wherein X is halo such as chloro or bromo and R 1 is C 12 core, C 3 bisimidazolium), heptanes (82.74 mL), and Span 80 solution (77.82 ml, 15 wt. % in heptanes) was added to the mixture.
- the final mixture was stirred at 220 rpm with an overhead stirrer and heated in oil bath at 75° C.
- the internal temperature of the reaction was at 70° C.
- a Dean-Stark treatment was performed to remove the water using the azeotrope of heptanes and water at 80° C. This was achieved by increasing the temperature of the oil bath.
- the endpoint of the process was when the temperature of the mixture reached 100° C. or when all the water in the reaction mixture was collected.
- the reaction mixture was cooled to ambient temperature, stirring was stopped, and the organic layer was decanted.
- the beads were washed with 150 mL isopropyl alcohol, followed by one wash with HCl (150 mL, 1.0 M), one wash with water, one wash with saturated aqueous NaCl solution, and three washes with water.
- the beads were lyophilized for 48 hours.
- the final product was isolated in 80% yield (4.9 g).
- Aqueous Layer Monomer Crosslinker Organic layer BTA Solvent Acid Surfactant C 12 core/C 3 solvent Surfactant BTA wt water HCl DDS bisimidazolium heptanes span 80 Polymer Sample # Core (mg) (mg) (mg) (mg) (mg) (mg) (mg) (mg) (mg) Product 82-D3 C 4 100 853 11.53 50.3 356 2560 204.8 Bead 74-A1 C 4 2000 17069 231 1006 7139 51207 4097 Beads 75-A1 C 4 3000 25603 346 1509 10709 76810 6145 Beads 76-A1 C 4 6000 51207 692 3019 21418 153620 12290 Beads 77-A1 C 12 3794 26189 323 1118 10000 78566 6285 Beads 77-A2 C 12 3794 26189 323 1118 10000 78566 6285 Beads 78-
- Example 40 Hydrophobic Post Polymerization of Beads Prepared with C 4 BTA and C 12 Core, C 3 Bisimidazolium Crosslinker for In Vivo Study
- the external oil was ramped to 75° C. in 1 hour.
- the internal temperature of the reaction was at 72-75° C.
- a Dean-Stark treatment was performed to remove the acetonitrile and water at 80° C. This was achieved by increasing the temperature of the oil bath to 95° C.
- the end point of the process end point was when the temperature of the mixture reached 95° C. or when all the water in the reaction mixture was collected.
- the reaction mixture was cooled to ambient temperature, stirring was stopped, and the organic layer was removed by vacuum.
- the beads were washed with 500 mL ethanol twice and collected by filtration. The beads were vacuum dried for 24 hours before the post polymerization.
- the final product was isolated in a 67% yield (25 g).
- a Dean-Stark treatment was performed to remove the water using the azeotrope of heptanes and water (at 80° C.); achieved by increasing the temperature of the oil bath to 95° C. The end point of the process was when the temperature of the mixture reached 100° C. or when all the water in the reaction mixture was collected.
- the reaction mixture was cooled to ambient temperature, stirring was stopped, and the organic layer was decanted.
- the beads were washed with two washes with ethanol, two washes with 0.5 M HCl solution, one wash with saturated aqueous NaCl solution, and two washes with water. The beads were vacuum-dried for 48 hours.
- An Argonaut Advantage Series 3400 Process Chemistry workstation equipped with over head stirrer, reflux condenser, nitrogen inlet port, and Julabo FP88 refrigeration unit was used to prepare prepolymer solution.
- 50 g (166.63 mmol) of 1, 10-dibromodecane and 50 g ethanol were added.
- the mixture was heated to 50° C. at 300 rpm to make sure that 1,10-dibromodecane was completely dissolved in ethanol.
- 32.965 g (104.14 mmol) of C 4 BTA and 32.96 g of ethanol were added to make a 50 wt. % solution of C 4 BTA in ethanol.
- the resulting prepolymer solution was then filtered to remove any unreacted 1,10-dibromodecane.
- the solution was then stored in a 250 mL pyrex glass bottle with cap before next utilization.
- the percent solid content of the solution was determined by thermogravimetric analysis and was found to be 58 wt. % of prepolymer in water.
- Bead synthesis was performed in a 250 mL Argonaut Advantage Series 3400 Process Chemistry workstation equipped with an over head stirrer, a reflux condenser, a nitrogen inlet port, and a Julabo FP88 refrigeration unit.
- Mineral oil was used as a continuous phase with 10 wt. % Span 80 as a surfactant.
- 30 g (21.5 mmol) of prepolymer solution (58 wt. % in water) was added.
- the reaction flask was stirred at 300 rpm and was heated to 50° C.
- the stirring was stopped and 101.17 mL of mineral oil solution containing 10 wt. % Span 80 was added to the reaction mixture.
- the stirring was resumed at 300 rpm, the reaction temperature was increased to 60° C. and the reaction was allowed to continue for 17 hours under inert nitrogen atmosphere.
- the reaction was cooled to room temperature with the help of refrigeration unit.
- the beads were then vacuum dried for 48 hours to remove water.
- the final product weight was 5.2 gm.
- Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below.
- Example 45 Solution Polymerization of N,N,N′,N′-(3-aminopropyl)-diaminododecane-2-methyl-1, 3-bis(oxiran-2-ylmethyl)-1H-imidazol-3-ium gel
- Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below.
- Bile acid binding Bile acid binding Bile acid capacity affinity retention B assay A assay Hamster Swelling Sample # (mmol/g) (mmol/g) (mmol/g) (g/g) 91-A1 3.07 0.58 0.40 10.68 91-A2 2.98 0.61 0.43 6.1
- the resulting mixture was stirred for an extra 5 minutes before the addition of heptanes (95.7 mL) and sorbitan oleate (Span 80) solution (90.0 mL, 15 wt. % in heptanes).
- the final mixture was stirred at ⁇ 160 rpm with an overhead stirrer.
- the external oil was ramped to 75° C. in 1 hour.
- a Dean-Stark treatment was performed to remove the acetonitrile and water at 80° C. This was achieved by increasing the temperature of the oil bath to 105° C.
- the process end point was identified by the temperature of the mixture reaching 95° C. or until all the water in the reaction mixture was collected.
- the resulting mixture was stirred for an extra 5 minutes before the addition of heptanes (46.8 mL) and sorbitan oleate (Span 80) solution (44.0 mL, 15 wt. % in heptanes).
- the final mixture was stirred at 150-200 rpm with an overhead stirrer.
- the external oil was ramped to 75° C. in 1 hour.
- a Dean-Stark treatment was performed to remove the acetonitrile and water at 80° C. This was achieved by increasing the temperature of the oil bath to 105° C.
- the process end point was identified by the temperature of the mixture reaching 95° C. or until all the water in the reaction mixture was collected.
- a 150 mL three-neck flask equipped with overhead stirrer, condenser was charged with tris(3-aminopropylamine) (0.63 g 3.35 mmole), water (8.86 mL), acetonitrile (6.05 mL), and dodecylbenzenesulfonic acid sodium salt solution (3.56 mL, 15 wt. % in water). The mixture was stirred for 5 minutes. After homogeneous solution was obtained, TMBMP-DBD (5.60 g, 6.68 mmol) was added.
- the resulting mixture was stirred for an extra 5 minutes before the addition of heptanes (28.5 mL) and sorbitan oleate (Span 80) solution (26.8 mL, 15 wt. % in heptanes).
- the final mixture was stirred at ⁇ 180 rpm with an overhead stirrer.
- the external oil was ramped to 75° C. in 1 hour.
- a Dean-Stark treatment was performed to remove the acetonitrile and water at 80° C. This was achieved by increasing the temperature of the oil bath to 105° C.
- the process end point was identified by the temperature of the mixture reaching 95° C. or until all the water in the reaction mixture was collected.
- the reaction mixture was allowed to cool to ambient temperature, stirring was stopped and the organic layer was removed by vacuum.
- the beads were washed with hexane twice, ethanol twice, 0.5M HCl solution three times, saturated NaCl solution once, and water three times. The beads were then vacuum-dried for 24 hours.
- Example 50 Preparation and Bile Acid Binding Study of N,N,N′,N′-tetrakis(3-aminopropyl)-1,12-diaminododecane Crosslinked with 1.4 mol 1,3-dichloropropanol (Sample 99; S 99)
- Sample 99 was subsequently washed to remove excess solvents and impurities as outlined in the table below.
- the beads were further exposed to HCl to reach a final content of 10.04 wt. % chloride by elemental analysis.
- Bile acid binding capacity, affinity, and retention for Sample 99 were determined via the A assay, B assay and hamster model and results are reported in the table below, along with swelling ratio and bead size.
- a simple buffer was made consisting of 100 mM BES (N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid) and 150 mM NaCl at a final pH of 7.0 in 4 L batches. Briefly, 42.65 g of BES (acid), 47.04 g of BES (Na-salt) and 35.06 g of NaCl were dissolved in MilliQ pure water. The volume was adjusted to 4 L and the pH was noted.
- BES N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid
- a single bile acid was added to 300 ml of BES buffer to a concentration of 20 mM.
- the solution was allowed to mix 3-6 hours and then subsequently diluted in a series of two fold dilutions.
- the final dilution set therefore, contained matrices at 0, 0.31, 0.62, 1.25, 2.5, 5, 10, and 20 mM bile acid.
- the bile acid and the amount weighed into the BES buffer are listed in the table below.
- Bile Acid Abbreviation Amount added (g) Cholate CA 2.58 Glycocholate GC 2.925 Taurocholate TC 3.226 Glycodeoxycholate GDC 2.829 Taurodeoxycholate TDC 3.13
- Polymer samples were dispensed in duplicate into 16 ⁇ 100 mm glass tubes, with each tube containing accurately weighed 8 to 12 mg of dried sample. Binding matrices as described above were dispensed into the sample tubes to give a final concentration of 1 mg test sample per mL of buffer. Control tubes with buffer only were also prepared. The samples were incubated at 37° C. for three hours to reach bile acid binding equilibrium while rotating on a rotisserie platform. Following incubation, the samples were centrifuged at 500 ⁇ g for 30 minutes to pellet the bile acid binding polymer. The supernatant was collected and transferred to a 0.45 micron Whatman 96-well uniplate to remove small particles prior to analysis. The filtrate was used to determine bile acid concentration as described below. Samples were diluted with BES buffer as needed for a final anticipated concentration of less than 2 mM.
- Binding capacity was calculated as (Cstart ⁇ Ceq)/1, where Cstart (mM) is the starting concentration of bile acid in the binding matrix, Ceq (mM) is the concentration of bile acid remaining in the sample at equilibrium after exposure to polymer, and 1 corresponds to the concentration of the bile acid binder (mg/ml).
- the units for the bound bile acid (e.g., TDC Bnd) and the unbound bile acid (e.g., TDC Unbd) are mmol bile acid/g binder. All assays were run in duplicate with values reported as an average, +/ ⁇ SD.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like.
Description
- The present invention generally relates to amine polymers useful to bind bile acids in the gastrointestinal tract of a patient in need of bile acid removal. These polymers and pharmaceutical compositions thereof are useful to lower cholesterol, particularly, non-high density lipoprotein (non-HDL), or more particularly, low-density lipoprotein (LDL) cholesterol, in patients in need thereof.
- Cholesterol is used by the body as a structural component of cell membranes. In addition, it is a basic building block for the production of many hormones, adrenal steroids, vitamin D and bile acids. Elevated levels of cholesterol carried in particles of low density lipoprotein cholesterol (LDL-C), or less specifically, cholesterol not carried in particles of high-density cholesterol (non HDL-C) are associated with an increased risk of coronary heart disease. A direct link between high blood cholesterol and cardiovascular disease (CVD) has been confirmed for both non-statin and statin trials, consistent with a direct relationship between LDL-C lowering and CVD reduction. These studies as well as many others have led to recommendations by health authorities for lowering elevated total cholesterol and LDL-C levels.
- Bile acids are amphipathic detergents with micelle-forming properties that are synthesized in the liver from cholesterol and solubilize lipids to aid in their uptake from the gastrointestinal lumen. Common bile acids found in man include unconjugated bile acids (for example cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid) and conjugated bile acids (for example taurocholic acid, glycocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, glycolithocholic acid, and taurolithocholic acid). After a meal, bile acids are released by the gall bladder. At ileal pH, the bile acids are predominantly deprotonated and are in their salt form. The majority of bile acids are reabsorbed, primarily by active transport in the distal ileum, with elimination in the feces being the primary route of cholesterol excretion.
- A bile acid sequestrant can bind bile acids to prevent reabsorption of the bile acids and cause more of the bile acids to be excreted in the stool. The sequestrant reduces the amount of bile acids reabsorbed by the intestine and subsequently transported to the liver. To compensate for this disruption in enterohepatic circulation and consequent reduction of the endogenous bile acid pool, hepatic cholesterol 7-alpha-hydroxylase is upregulated. This results in additional conversion of cholesterol into bile acids, thereby restoring the bile acid pool. Upregulation of cholesterol conversion to bile acids also involves a cascade of signaling that results in up-regulation of liver LDL-receptors and consequent lowering of serum LDL-C levels, amongst other effects.
- Existing bile acid sequestrants do not reduce the serum LDL-cholesterol concentration enough without requiring the patient to take either large amounts of the sequestrant or another drug that is combined with the sequestrant (e.g., statins). These reduce patient compliance and tolerance. Thus, bile acid sequestrants capable of more effectively removing bile salts from the gastrointestinal tract with equal or lower doses are needed.
- The present invention provides an amine polymer that is effective for binding and removing bile salts from the gastrointestinal tract.
- One aspect of the invention is an amine polymer that comprises repeat units derived from polymerization of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1.1, and the amine polymer has a binding affinity for bile acids of at least 0.46 mmol/g when measured using an in vitro A assay.
- Another aspect is an amine polymer comprising the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer, wherein units of the polymer have the structure of
formula 1 - wherein R10 is derived from the crosslinking monomer and is C2 to C16 alkylene, —NH—C(NH)—NH—, —NH—C(NH2 +)—NH—, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy; R30 is derived from the amine monomer and is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, a cycloalkyl, an aryl, or a heterocyclo functional group; each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and at least one of R10 or R30 is a hydrophobic group having a calculated log P (c Log P) of greater than 4.
- A further aspect is an amine polymer that comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of
formula 1 wherein R10 is derived from the crosslinking monomer and is C2 to C16 alkylene, —NH—C(NH)—NH—, —NH—C(NH2 +)—NH—, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy; R30 is derived from the amine monomer and is C2 to C6 alkylene; each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and R10 is a hydrophobic group having a calculated log P (c Log P) of greater than 4. - Yet another aspect is an amine polymer that comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of
formula 1 wherein R10 is derived from the crosslinking monomer and is C8 to C16 alkylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; R30 is derived from the amine monomer and is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group. - Yet another aspect of the another aspect is an amine polymer that comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of
formula 1 wherein R10 is derived from the crosslinking monomer and is C2 to C6 alkylene, or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy; R30 is derived from the amine monomer and is C8 to C16 alkylene, arylene, diformylheterocyclo, or C8 to C16 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy; and each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group. - A further aspect of the invention is an amine polymer that comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the polymer is insoluble in water, at least some of said amine secondary nitrogen atoms are part of a crosslinked polymer network, and the crosslinking monomer is a hydrophobic group having a calculated log P (c Log P) of greater than 4; and the crosslinking monomer is a compound having the formula X-R1-X, wherein each X is independently a leaving group, and R1 is C8 to C50 alkylene or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
- Yet a further aspect of the invention is an amine polymer that comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the polymer is insoluble in water, at least some of said amine secondary nitrogen atoms are part of a crosslinked polymer network, and the amine monomer has at least one segment that is a C8 to C16 alkylene, arylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, and the segment has a calculated log P (c Log P) of greater than 4; and the crosslinking monomer is a compound having the formula X-R1-X, wherein each X is independently a leaving group, and R1 is C2 to C6 alkylene, or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
- Another aspect is an amine polymer that comprises repeat units derived from polymerization of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1, and wherein: the polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and the polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using a B assay.
- Yet another aspect is an amine polymer comprising units of the polymer having nodes of positive charge separated by aliphatic segments, wherein the nodes of positive charge have a charge density of at least 19.0 mEq/g and a molecular weight of at least 200.0 g/mol and at least one aliphatic segment is bonded to each node of positive charge, the at least one aliphatic segment having a calculated log P (c Log P) greater than 4 and wherein each of the nodes of positive charge does not contain an aliphatic segment having a calculated log P (c Log P) greater than 4.
- A further aspect is an amine polymer comprising units of the polymer having nodes of positive charge separated by aliphatic segments, wherein the nodes of positive charge have a charge density greater than 17.3 mEq/g and the structure of formula A
- each R20 being independently C3 to C8 alkylene or C3 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and wherein at least one aliphatic segment is bonded to each node of positive charge, each aliphatic segment having a calculated log P (c Log P) greater than 4.
- Yet another aspect is an amine polymer comprising units of the polymer having the structure of formula 1 wherein R10 is C2 to C16 alkylene, arylene, —NH—C(NH)—NH—, —NH—C(NH2 +)—NH—, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy; R30 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and each R20 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; the polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and the polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using a B assay.
- Another aspect is an amine polymer that comprises repeat units derived from polymerization of an amine monomer and a crosslinking monomer, wherein the amine monomer is an amine of formula 2 having the structure:
- wherein each R2 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with at least one amide functional group, and R3 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, R1 is C8 to C16 alkylene, or C5 to Co5 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
- Yet another aspect is an amine polymer derived from polymerization of an amine monomer and a crosslinking monomer wherein the amine monomer is an amine of formula 3 having the structure:
- wherein each R21 is independently C2 to C8 wherein one or more of the —CH2— groups of the alkylene group is replaced with at least one sulfur atom, and R31 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, and R1 is C2 to C16 alkylene, arylene, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
- A further aspect is an amine polymer that comprises repeat units derived from polymerization of an amine monomer of formula 2 and a crosslinking monomer, wherein each R2 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and R3 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and a portion of the nitrogen atoms of the amine polymer are substituted with a ligand selected from aminoalkyl, aryl, arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo, heterocyloalkyl, (trialkylammonio)alkyl, 2-(protected amino)-m-(heterocyclo)-1-oxoCmalkyl, 2-(protected amino)-1-oxoCmalkyl, 2-(protected amino)-3-methyl-1-oxoCmalkyl, 2-(protected amino)-4-methyl-1-oxoCmalkyl, 2-(protected amino)-1-oxo-m-arylCmalkyl, 2-(protected amino)-m-(alkylthio)-1-oxoCmalkyl, 2-(protected amino)-m-(aryl)-1-oxoCmalkyl, 2-(protected amino)-m-carboxy-1-oxoCmalkyl, 2-(protected amino)-m-guanidino-1-oxoCmalkyl, 2-(protected amino)-(m-1)-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-mercapto-1-oxoCmalkyl, m-(alkylamino)-m-oxoCmalkyl, m-(alkylheterocyclo)Cmalkyl, m-amino-2-(protected amino)-1-oxoCmalkyl, m-amino-2-(protected amino)-1,m-dioxoCmalkyl, m-(x-aminoCxalkyl)heterocycloCmalkyl, (m-1)-amino-m-(heterocyclo)-1-oxoCmalkyl, m-(arylalkylamino)-m-oxoCmalkyl, m-(x-(alkylthio)Cxalkylamino)-m-oxoCmalkyl, m-(x-aminoCxalkylamino)-m-oxoCmalkyl, m-(x-amino-x-oxoCxalkylamino)-m-oxoCmalkyl, m-(x-carboxyCxalkylamino)-m-oxoCmalkyl, m-(heterocycloalkylamino)-m-oxoCmalkyl, m-(x-hydroxyCxalkylamino)-m-oxoCmalkyl, m-((x-1)-hydroxyCxalkylamino)-m-oxoCmalkyl, m-(x-mercaptoCxalkylamino)-m-oxoCmalkyl, m-(x-trialkylammonioCxalkyl)heterocycloCmalkyl, m-(x-(2-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, m-(x-(3-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, m-(x-(4-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, a ligand of formula 4
-
*-R46-R47-R48 (4) - or a combination thereof, wherein R46 is C6 to C16 alkylene, R47 is 1,y-bis(1-methylpiperidin-4-yl)Cyalkylene, R48 is C6 to C16 alkyl, m is an integer from 3 to 12, x is an integer from 1 to 12, y is an integer from 1 to 14, and z is an integer from 1 to 16.
- Another aspect of the invention is an amine of formula 6 having the structure:
- wherein each R25 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with at least one amide functional group, and R35 is C8 to C16 alkylene, or C8 to C16 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
- Yet a further aspect is an amine polymer useful as a bile acid sequestrant, wherein, in a buffer solution at 37° C. containing less than 2.6 mM taurocholic acid, the amine polymer binds more of the acid than sevelamer and in a buffer solution at 37° C. containing more than 5.0 mM taurocholic acid the amine polymer binds more bile acid that colesevelam.
- Other objects and features will be in part apparent and in part pointed out hereinafter.
-
FIG. 1A is a graph of the unbound taurocholic acid concentration versus the bound taurocholic acid concentration for various bile acid binders at taurocholic acid concentrations up to 20 mM. -
FIG. 1B is the same graph asFIG. 1A at taurocholic acid concentrations up to 5 mM. -
FIG. 2A is a graph of the unbound glycodeoxycholic acid concentration versus the bound taurocholic acid concentration for various bile acid binders at glycodeoxycholic acid concentrations up to 20 mM. -
FIG. 2B is the same graph asFIG. 2A at glycodeoxycholic acid concentrations up to 5 mM. - The present invention is an amine polymer useful for binding bile salts, pharmaceutical compositions comprising the amine polymer, and methods of treating hypercholesterolemia, diabetes or other conditions that might benefit from bile acid sequestration in the gastrointestinal tract and/or increased fecal excretion of bile acids and/or bile acid metabolites, by administering the amine polymer to an animal subject in need thereof. The amine polymers exhibit increased affinity and/or capacity for binding bile salts and/or their retention as compared to commercial bile acid sequestrants. The polymers have a combination of hydrogen bonding and electrostatic properties, charged nitrogen atoms, hydrophobicity and/or polymer architecture to provide such increased affinity and/or capacity for bile salts. The terms “bile acid” and “bile salt” are used interchangeably herein and those of skill in the art will understand that a bile acid will be present in salt form and, to a lesser degree, in the protonated form in the gastrointestinal tract.
- The amine polymer can comprise repeat units derived from polymerization of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1.1, and the amine polymer has a binding affinity for bile acids of at least 0.46 mmol/g when measured using an in vitro A assay.
- Also, the amine polymer can comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer, wherein units of the polymer have the structure of formula 1:
- wherein R10 is derived from the crosslinking monomer and is C2 to C16 alkylene, —NH—C(NH)—NH—, —NH—C(NH2 +)—NH—, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy; R30 is derived from the amine monomer and is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, a cycloalkyl, an aryl, or a heterocyclo functional group; each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and at least one of R10 or R30 is a hydrophobic group having a calculated log P (c Log P) of greater than 4.
- The amine polymer can also comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of
formula 1 wherein R10 is derived from the crosslinking monomer and is C2 to C16 alkylene, —NH—C(NH)—NH—, —NH—C(NH2 +)—NH—, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy; R30 is derived from the amine monomer and is C2 to C6 alkylene; each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and R10 is a hydrophobic group having a calculated log P (c Log P) of greater than 4. - Additionally, the amine polymer can comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of
formula 1 wherein R10 is derived from the crosslinking monomer and is C8 to C16 alkylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; R30 is derived from the amine monomer and is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group. - The amine polymer can also comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the general structure of
formula 1 wherein R10 is derived from the crosslinking monomer and is C2 to C6 alkylene, or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy; R30 is derived from the amine monomer and is C8 to C16 alkylene, arylene, diformylheterocyclo, or C8 to C16 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group. - The amine polymers described herein can have a binding affinity for bile acids of at least 0.46 mmol/g when measured in vitro using an in vitro A assay. The amine polymers described herein can also have a molar ratio of the amine monomer to the crosslinking monomer in the range of from 1:3 to about 1:1.1. For the amine polymers having a structure of
formula 1, the primary and secondary amine atoms can have a calculated ratio from 1:1 to about 1:5. - The amine polymer can also comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the polymer is insoluble in water, at least some of said amine secondary nitrogen atoms are part of a crosslinked polymer network, and the crosslinking monomer is a compound having the formula X-R1-X, wherein each X is independently a leaving group, and R1 is C8 to C50 alkylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group and the calculated log P (c Log P) of the crosslinking monomer is greater than 4.
- The amine polymer can also comprise the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the polymer is insoluble in water, at least some of said amine secondary nitrogen atoms are part of a crosslinked polymer network, and the amine monomer has at least one segment that is a C8 to C16 alkylene, arylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, and a calculated log P (c Log P) of the at least one segment of the amine monomer is greater than 4; and the crosslinking monomer is a compound having the formula X-R1-X, wherein each X is independently a leaving group, and R1 is C2 to C6 alkylene, or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
- Further, the amine polymer can comprise repeat units derived from polymerization of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1.1, and wherein: the polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and the polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using a B assay.
- The amine polymer can comprise units of the polymer having the structure of formula 1 wherein R10 is C2 to C16 alkylene, arylene, —NH—C(NH)—NH—, —NH—C(NH2 +)—NH—, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy; R30 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and each R20 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; the polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and the polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using a B assay. In some instances, the amine polymer comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer and R10 is derived from the crosslinking monomer and R30 is derived from the amine monomer. In some cases, the amine polymer binds phosphate in vitro in an amount of less than 0.2 mmol/gram of polymer when measured using a B assay.
- Some of the amine polymers having units of the polymer of
Formula 1 can have an R30 of ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, decylene, undecylene, dodecylene, 1,4-phenylenedimethyl, 1,6-dioxohexane-1,6-diyl, or 2,6-diformylpyridine. Further, in some amine polymers having units of the polymer ofFormula 1, R30 is C3 to C12 alkylene; particularly, R30 is butylene; also R30 can be decylene or dodecylene. Further for amine polymers having units of the polymer ofFormula 1, each R20 can independently be C2 to C6 alkylene; each R20 can independently be C2 to C4 alkylene; particularly, each R20 can be propylene. - Also, the amine polymer comprises units of the polymer having nodes of positive charge separated by aliphatic segments. The nodes of positive charge have a charge density of at least 19.0 mEq/g and a molecular weight of at least 200.0 g/mol and at least one aliphatic segment is bonded to each node of positive charge, the at least one aliphatic segment having a calculated log P (c Log P) greater than 4 and wherein each of the nodes of positive charge does not contain an aliphatic segment having a calculated log P (c Log P) greater than 4.
- In some instances, the amine polymer comprises units of the polymer having nodes of positive charge separated by aliphatic segments, wherein the nodes of positive charge have a charge density greater than 17.3 mEq/g and the structure of formula A
- wherein each R20 is independently C3 to C8 alkylene or C3 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and wherein at least one aliphatic segment is bonded to each node of positive charge, each aliphatic segment having a calculated log P (c Log P) greater than 4. The aliphatic segments separating the nodes of positive charge can be a C8 to C16 alkylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group. For some of the polymers, the polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and the polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using the B assay. In some cases, the polymer binds phosphate in vitro in an amount of less than 0.2 mmol/gram of polymer when measured using the B assay. Also, in some of the polymers, each of the nodes of positive charge does not contain an aliphatic segment having a calculated log P (c Log P) greater than 4.
- An amine polymer can also comprise repeat units derived from polymerization of an amine monomer and a crosslinking monomer, wherein the amine monomer is an amine of formula 2 having the structure:
- wherein each R2 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with at least one amide functional group, and R3 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, R1 is C8 to C16 alkylene, or C5 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy. In some instances, R1 is C8 to C16 alkylene, or C5 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
- Some of the amine polymers described herein above are derived from an amine monomer which is an amine of formula 2 wherein each R2 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group, and R3 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group. In some instances, the crosslinking monomer used in deriving the polymers is guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, R1 is C8 to C16 alkylene, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with a phenyl, piperidinium or imidazolium functional group. In some cases, R1 is C8 to C16 alkylene, dimethylbiphenyl, or C2 to C50 alkylene wherein one or two of the —CH2— groups of the alkylene group is replaced with one or two phenyl, piperidinium or imidazolium functional groups.
- Others of the amine polymers described herein are derived from the polymerization of an amine of formula 2 wherein each R2 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group, and R3 is C8 to C16 alkylene, arylene, diformylheterocyclo, or C8 to C16 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and a crosslinking monomer which is a compound having the formula X-R1-X, wherein each X is independently a leaving group, R1 is C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
- The amine polymers derived from an amine monomer of Formula 2 can have an R3 of ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, decylene, undecylene, dodecylene, 1,4-phenylenedimethyl, 1,6-dioxohexane-1,6-diyl, or 2,6-diformylpyridine. Further, in some amine polymers derived from an amine monomer of Formula 2, R3 is C3 to C12 alkylene; particularly, R3 is butylene; also R3 can be decylene or dodecylene. Further for amine polymers derived from an amine monomer of Formula 2, each R2 can independently be C2 to C6 alkylene; each R2 can independently be C2 to C4 alkylene; particularly, each R2 can be propylene.
- In some embodiments, the amine polymer can have the general structure of formula 5
- wherein R10, R20, and R30 have the definitions above in connection with
formula 1. Formula 5 represents a crosslink within the polymer network, which may form. In some instances, the crosslink can be represented in Formula 5 as a tetrasubstituted nitrogen (quaternized) to generate a formula containing N(R20)(R10)3 or the crosslink can be represented inFormula 1 as N(R20)(R10)(R10). - Additionally, the amine polymer can be derived from polymerization of an amine monomer and a crosslinking monomer wherein the amine monomer is an amine of formula 3 having the structure:
- wherein each R21 is independently C2 to C8 wherein one or more of the —CH2— groups of the alkylene group is replaced with at least one sulfur atom, and R31 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, and R1 is C2 to C16 alkylene, arylene, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy. In some instances, each R21 is m-sulfidoCmalkyl, m is an integer from 1 to 6 and R31 is C3 to C8 alkylene. In some amine polymers derived from an amine monomer of Formula 3, R31 is C3 to C12 alkylene; particularly, R31 is butylene; also R31 can be decylene or dodecylene.
- Further, an amine of formula 6 has the structure:
- wherein each R25 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with at least one amide functional group, and R35 is C8 to C16 alkylene, or C8 to C16 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group. In some embodiments, each R25 is independently C3 to C6 alkylene; particularly propylene. In various instances, R35 is C10 to C14 alkylene; particularly decylene or dodecylene. The amine of Formula 6 can be used as an amine monomer in the polymerization reaction to form some of the amine polymers described herein.
- Many of the amine polymers described herein can undergo a post polymerization reaction, which comprises reaction of the amine polymer with at least one additional crosslinking monomer or a ligand. When the amine polymers undergo such a post polymerization reaction with two crosslinking monomers, the reaction can proceed with both the crosslinking monomers present (e.g., by using cross linking monomers with different reactivity rates) or the amine monomer can react with one crosslinking monomer and then react with the second crosslinking monomer (e.g., the cross linking monomers are added sequentially to the reactor or the polymer is recovered prior to reaction with the second cross linking monomer). These reactions with two or more different crosslinking monomers can provide improved yield or improved physical characteristics. When these further reactions occur with an additional ligand, the crosslinking monomer and the ligand can be added simultaneously or sequentially as well.
- Further, the amine monomer is other than a dendrimer wherein a dendrimer has a hyperbranched fractal-like structure that emanates from a central core and consists of a large number of terminal groups with a definite geometrical growth (Peppas et al., “Dendrimers and star polymers for pharmaceutical and medical applications,” Proceed. Intern. Symp. Control. Rel. Bioact. Mater, 20:143-144 (1993)).
- In the amine polymers described herein the crosslinking monomer can be guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, and R1 is C2 to C16 alkylene, arylene, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy. In some instances, the crosslinking monomer is X-R1-X wherein each X is independently a leaving group, and R1 is C8 to C16 alkylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with a heterocyclo functional group. In other instances, the crosslinking monomer is X-R1-X wherein each X is independently a leaving group, and R1 is C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy. In other instances, the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, R1 is C8 to C16 alkylene, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with one or two phenyl, piperidinium or imidazolium functional groups.
- For the amine polymers having a crosslinking monomer of formula X-R1-X, where R1 is C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with one or two phenyl, piperidinium or imidazolium functional groups, the functional groups can be p-xylene, 1,3-bis(m-haloCmalkyl)-1H-imidazol-3-ium, 4,4′-(Cxalkane-1,x-diyl)bis(1-(m-haloCmalkyl)-1-methylpiperidinium), or 1-(q-haloCqalkyl)-3-(m-(3-(p-haloCpalkyl)-1H-imidazol-3-ium-1-yl)Cmalkyl)-1H-imidazol-3-ium, wherein m is an integer from 2 to 14, p is an integer from 2 to 14, q is an integer from 2 to 14, and x is an integer from 2 to 8. For some amine polymers where the crosslinking monomer is X-R1-X, X is independently a leaving group, and R1 is C8 to C50 alkylene or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with a heterocyclo functional group.
- In various amine polymers, the crosslinking monomer is guanidine, guanidinium hydrohalide, 1,3-bis(3-halopropyl)-1H-imidazol-3-ium, 4,4′-(propane-1,3-diyl)bis(1-(10-halodecyl)-1-methylpiperidinium), 1-(12-halododecyl)-3-(12-(3-(12-halododecyl)-1H-imidazol-3-ium-1-yl)dodecyl)-1H-imidazol-3-ium, or 1-(10-halodecyl-3-(10-(3-(10-halodecyl)-1H-imidazol-3-ium-1-yl)decyl)-1H-imidazol-3-ium.
- In some of the amine polymers, the crosslinking monomer is guanidine, a compound having the formula X-R1-X wherein R1 is C8 to C16 alkylene, or a combination thereof, and the polymer comprises a comonomer, the comonomer being Cmalkane-1,m-diyldiamine, alkylenedicycloalkanamine, (m-aminoCmalkyl)heterocycle, 3-(m-aminoCmalkyl)-1H-imidazol-3-ium, or a combination thereof, wherein m is an integer from 2 to 16, and each X is independently a leaving group, such as hexane-1,6-diyldiamine, heptane-1,7-diylamine, octane-1,8-diyldiamine, nonane-1,9-diylamine, decane-1,10-diyldiamine, undecane-1,11-diylamine, dodecane-1,12-diyldiamine, 4,4′-methylenedicyclohexanamine, 3-(3-aminopropyl)-1H-imidazol-3-ium, or a combination thereof. In some of the amine polymers, R1 is C8 to C14 alkylene; particularly, R1 is decylene or dodecylene. In other amine polymers, R1 is C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is substituted with hydroxy; particularly, R1 is —CH2—CH(OH)—CH2—, and the polymer comprises the comonomer.
- In the amine polymers where the crosslinking monomer is X-R1-X, X is halo, epoxy, diaziridino, mesylate, sulfate, phosphate, aldehyde, ketone, or a combination thereof. Leaving groups are well known and can be selected from those known in the art, such as those in Larock, Comprehensive Organic Transformations (VCH 1989), e.g., p. 397 et seq.
- The amine polymers can comprise a comonomer, the comonomer being Cmalkane-1,m-diyldiamine, alkylenedicycloalkanamine, (m-aminoCmalkyl)heterocycle, 3-(m-aminoCmalkyl)-1H-imidazol-3-ium, or a combination thereof, wherein m is an integer from 2 to 16, and each X is independently a leaving group.
- In one preferred embodiment, R1 is C8 to C14 alkylene or C8 to C12 alkylene, such as decylene or dodecylene. In another preferred embodiment, R1 is a C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is substituted with hydroxy, and more preferably a C2 to C4 alkylene wherein one or more of the —CH2— groups of the alkylene group is substituted with hydroxy, such as —CH2—CH(OH)—CH2—. In the amine polymers wherein units of the polymer have the structure of
Formula 1, R10 can be C8 to C14 alkylene or C8 to C12 alkylene, such as decylene or dodecylene. In another preferred embodiment, R10 is a C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is substituted with hydroxy, and more preferably a C2 to C4 alkylene wherein one or more of the —CH2— groups of the alkylene group is substituted with hydroxy, such as —CH2—CH(OH)—CH2—. - The various embodiments reflect that the amine polymer has nodes of positive charge separated by aliphatic segments. The aliphatic segments are preferably hydrophobic. The hydrophobicity is combined with sufficient positive charge for efficient and effective affinity and retention of bile salts. The combination provides an unexpected improvement in bile acid binding affinity, binding capacity, retention and removal as compared to (i) conventional bile acid binders having hydrophilic crosslinkers that prevent the collapsing of the polymer network due to the absorption of hydrophobic elements, such as bile acids and fatty acids present in the GI and (ii) conventional bile acid binders with insufficient charge density in proximity to the hydrophobic elements. In various embodiments, a node of positive charge is generally a collection of three or more nitrogen atoms is defined by an appropriate combination of charge density, molecular weight and/or structure. The charge density of a node is generally greater than 16.5 mEq/g, greater than 17.3 mEq/g, greater than 19 mEq/g, and even more specifically greater than 22 mEq/g. Charge density is calculated in accordance with formulas known to those of skill in the art assuming a 100% degree of ionization of the nitrogen atoms for purposes of the calculation. The formula used herein is that the charge density in mEq/g units is equal to the number of nitrogen atoms in the node multiplied by one over the molecular weight of the node multiplied by one thousand or (# N atoms)×(1/molecular weight)×(1000). The formula weight of the node of positive charge is calculated for the neutral amine by adding hydrogen atoms to each nitrogen atom of the node until each nitrogen atom has three bonds. The nodes of positive charge can have a molecular weight of greater than 50 mol/g, greater than 100 mol/g, greater than 125 mol/g or greater than 200 mol/g. For example, the charge density and molecular weight for various nodes are detailed in Table 1.
- A node of positive charge preferably has the structure of formula A
- wherein each R20 is independently C3 to C8 alkylene or C3 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group.
- In some embodiments, the nodes of positive charge are separated by hydrophobic aliphatic segments. The hydrophobicity of an aliphatic segment is expressed by the calculated log P, as discussed herein.
- The amine polymer can also comprise repeat units derived from polymerization of an amine monomer of formula 2 and a crosslinking monomer, wherein the amine monomer of formula 2 has the structure:
- wherein each R2 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and R3 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and a portion of the nitrogen atoms of the amine polymer are substituted with a ligand selected from aminoalkyl, aryl, arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo, heterocyloalkyl, (trialkylammonio)alkyl, 2-(protected amino)-m-(heterocyclo)-1-oxoCmalkyl, 2-(protected amino)-1-oxoCmalkyl, 2-(protected amino)-3-methyl-1-oxoCmalkyl, 2-(protected amino)-4-methyl-1-oxoCmalkyl, 2-(protected amino)-1-oxo-m-arylCmalkyl, 2-(protected amino)-m-(alkylthio)-1-oxoCmalkyl, 2-(protected amino)-m-(aryl)-1-oxoCmalkyl, 2-(protected amino)-m-carboxy-1-oxoCmalkyl, 2-(protected amino)-m-guanidino-1-oxoCmalkyl, 2-(protected amino)-(m-1)-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-mercapto-1-oxoCmalkyl, m-(alkylamino)-m-oxoCmalkyl, m-(alkylheterocyclo)Cmalkyl, m-amino-2-(protected amino)-1-oxoCmalkyl, m-amino-2-(protected amino)-1,m-dioxoCmalkyl, m-(x-aminoCxalkyl)heterocycloCmalkyl, (m-1)-amino-m-(heterocyclo)-1-oxoCmalkyl, m-(arylalkylamino)-m-oxoCmalkyl, m-(x-(alkylthio)Cxalkylamino)-m-oxoCmalkyl, m-(x-aminoCxalkylamino)-m-oxoCmalkyl, m-(x-amino-x-oxoCxalkylamino)-m-oxoCmalkyl, m-(x-carboxyCxalkylamino)-m-oxoCmalkyl, m-(heterocycloalkylamino)-m-oxoCmalkyl, m-(x-hydroxyCxalkylamino)-m-oxoCmalkyl, m-((x-1)-hydroxyCxalkylamino)-m-oxoCmalkyl, m-(x-mercaptoCxalkylamino)-m-oxoCmalkyl, m-(x-trialkylammonioCxalkyl)heterocycloCmalkyl, m-(x-(2-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, m-(x-(3-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, m-(x-(4-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, a ligand of formula 4
-
*-R46-R47-R48 (4) - or a combination thereof, wherein R46 is C6 to C16 alkylene, R47 is 1,y-bis(1-methylpiperidin-4-yl)Cyalkylene, R48 is C6 to C16 alkyl, m is an integer from 3 to 12, x is an integer from 1 to 12, y is an integer from 1 to 14, and z is an integer from 1 to 16.
- The amine polymers described herein can also have a portion of the nitrogen atoms of the amine polymer substituted with a ligand post-polymerization of alkyl, aminoalkyl, aryl, arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo, heterocycloalkyl, (trialkylammonio)alkyl, 2-(protected amino)-m-(heterocyclo)-1-oxoCmalkyl, 2-(protected amino)-1-oxoCmalkyl, 2-(protected amino)-3-methyl-1-oxoCmalkyl, 2-(protected amino)-4-methyl-1-oxoCmalkyl, 2-(protected amino)-1-oxo-m-arylCmalkyl, 2-(protected amino)-m-(alkylthio)-1-oxoCmalkyl, 2-(protected amino)-m-(aryl)-1-oxoCmalkyl, 2-(protected amino)-m-carboxy-1-oxoCmalkyl, 2-(protected amino)-m-guanidino-1-oxoCmalkyl, 2-(protected amino)-(m-1)-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-mercapto-1-oxoCmalkyl, m-(alkylamino)-m-oxoCmalkyl, m-(alkylheterocyclo)Cmalkyl, m-amino-2-(protected amino)-1-oxoCmalkyl, m-amino-2-(protected amino)-1,m-dioxoCmalkyl, m-(x-aminoCxalkyl)heterocycloCmalkyl, (m-1)-amino-m-(heterocyclo)-1-oxoCmalkyl, m-(arylalkylamino)-m-oxoCmalkyl, m-(x-(alkylthio)Cxalkylamino)-m-oxoCmalkyl, m-(x-aminoCxalkylamino)-m-oxoCmalkyl, m-(x-amino-x-oxoCxalkylamino)-m-oxoCmalkyl, m-(x-carboxyCxalkylamino)-m-oxoCmalkyl, m-(heterocycloalkylamino)-m-oxoCmalkyl, m-(x-hydroxyCxalkylamino)-m-oxoCmalkyl, m-((x-1)-hydroxyCxalkylamino)-m-oxoCmalkyl, m-(x-mercaptoCxalkylamino)-m-oxoCmalkyl, m-(x-trialkylammonioCxalkyl)heterocycloCmalkyl, m-(x-(2-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, m-(x-(3-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, m-(x-(4-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, a ligand of formula 4
-
*-R46-R47-R48 (4) - or a combination thereof, wherein R46 is C6 to C16 alkylene, R47 is 1,y-bis(1-methylpiperidin-4-yl)Cyalkylene, R48 is C6 to C16 alkyl, m is an integer from 3 to 12, x is an integer from 1 to 12, y is an integer from 1 to 14, and z is an integer from 1 to 16.
- In some embodiments, the ligand is arylalkyl selected from naphthalen-2-ylalkyl or naphthalen-1-ylalkyl; heterocycloalkyl selected from m-(1-methylpyrrolidinium-1-yl)Cmalkyl, m-(2-(1H-indol-3-yl)ethylamino)-m-oxoCmalkyl, m-(2-methylthiazol-3-ium-3-yl)Cmalkyl, m-(benzo[d]thiazol-3-ium-3-yl)Cmalkyl, m-(pyridinium-1-yl)Cmalkyl, m-(tetrahydro-1H-thiophenium-1-yl)Cmalkyl, z-(1,2-dialkyl-1H-imidazol-3-ium-3-yl)Czalkyl, m-(2,3-dialkyl-1H-imidazol-3-ium-1-yl)Cmalkyl, z-(1-alkyl-1H-imidazol-3-ium-3-yl)Czalkyl, m-(3-alkyl-1H-imidazol-3-ium-1-yl)Cmalkyl, or z-(thiazol-3-ium-3-yl)Czalkyl; 2-(protected amino)-m-(heterocyclo)-1-oxoCmalkyl selected from 2-(protected amino)-m-(1H-indol-3-yl)-1-oxoCm-alkyl or 2-(protected amino)-m-(1H-imidazol-4-yl)-1-oxoCmalkyl; 2-(protected amino)-1-oxo-m-phenylCmalkyl; 2-(protected amino)-m-(hydroxyphenyl)-1-oxoCmalkyl; m-(alkylheterocyclo)Cmalkyl selected from m-(3-alkyl-1H-imidazol-3-ium-1-yl)Cmalkyl, m-(1-alkyl-1H-imidazol-3-ium-3-yl)Cmalkyl, m-(1-alkyl-2-methyl-1H-imidazol-3-ium-3-yl)Cmalkyl, or m-(3-alkyl-2-methyl-1H-imidazol-3-ium-1-yl)Cmalkyl; m-(x-aminoCxalkyl)heterocycloCmalkyl selected from m-(3-(x-aminoCxalkyl)-1H-imidazol-3-ium-1-yl)Cmalkyl or m-(1-(x-aminoCxalkyl)-1H-imidazol-3-ium-3-yl) Cmalkyl; (m-1)-amino-m-(1H-indol-2-yl)-1-oxoCmalkyl; m-(arylalkylamino)-m-oxoCmalkyl selected from m-(hydroxyphenalkylamino)-m-oxoCmalkyl or m-(phenalkylamino)-m-oxo-Cmalkyl; m-(x-(heterocyclo)Cxalkyl)heterocycloCmalkyl selected from m-(1-(x-(1-methyl-1H-imidazol-3-ium-3-yl)Cxalkyl)-1H-imidazol-3-ium-3-yl) Cmalkyl, m-(1-(x-(3-methyl-1H-imidazol-3-ium-1-yl)Cxalkyl)-1H-imidazol-3-ium-3-yl) Cmalkyl, m-(3-(x-(1-methyl-1H-imidazol-3-ium-3-yl)Cxalkyl)-1H-imidazol-3-ium-1-yl) Cmalkyl, or m-(3-(x-(3-methyl-1H-imidazol-3-ium-1-yl)Cxalkyl)-1H-imidazol-3-ium-1-yl) Cmalkyl; m-(x-(1H-imidazol-4-yl)Cxalkylamino)-m-oxoCmalkyl; or m-(x-trialkylammonioCxalkyl)heterocycloCmalkyl selected from m-(3-(x-trialkylammonio)Cxalkyl)-1H-imidazol-3-ium-1-yl)Cmalkyl or m-(1-(x-trialkylammonio)Cxalkyl)-1H-imidazol-3-ium-3-yl)Cmalkyl wherein m is an integer from 3 to 12, x is an integer from 1 to 12, and z is an integer from 1 to 16.
- In some instances, the ligand is derived from an amino acid. Such ligands include, but are not limited to, 2-(protected amino)-m-(heterocyclo)-1-oxoCmalkyl, m-amino-2-(protected amino)-1,m-dioxoCmalkyl, m-amino-2-(protected amino)-1-oxoCmalkyl, 2-(protected amino)-1-oxoCmalkyl, 2-(protected amino)-m-(alkylthio)-1-oxoCmalkyl, 2-(protected amino)-m-(hydroxyphenyl)-1-oxoCmalkyl, 2-(protected amino)-1-oxo-m-phenylCmalkyl, 2-(protected amino)-m-(1H-imidazol-4-yl)-1-oxoCmalkyl, 2-(protected amino)-m-carboxy-1-oxoCmalkyl, 2-(protected amino)-3-methyl-1-oxoCmalkyl, 2-(protected amino)-4-methyl-1-oxoCmalkyl, 2-(protected amino)-m-mercapto-1-oxoCmalkyl, 2-(protected amino)-(m-1)-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-guanidino-1-oxoCmalkyl, m-(x-(alkylthio)Cxalkylamino)-m-oxoCmalkyl, m-(hydroxyphenalkylamino)-m-oxoCmalkyl, m-oxo-m-(phenalkylamino)Cmalkyl, m-(x-(1H-imidazol-4-yl)Cxalkylamino)-m-oxoCmalkyl, m-(x-carboxyCxalkylamino)-m-oxoCmalkyl, m-(alkylamino)-m-oxoCmalkyl, m-(x-mercaptoCxalkylamino)-m-oxoCmalkyl, m-((x-1)-hydroxyCxalkylamino)-m-oxoCmalkyl, m-(x-hydroxyCxalkylamino)-m-oxoCmalkyl, m-(x-aminoCxalkylamino)-m-oxoCmalkyl, or m-(x-amino-x-oxoCxalkylamino)-m-oxoCmalkyl, wherein m is an integer from 3 to 12, and x is an integer from 1 to 12.
- Some of the amine polymers described herein have a portion of the nitrogen atoms of the amine polymer substituted with a ligand of 2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-1-oxopropyl, 5-(2-(4-(nonyloxy)benzamido)ethylamino)-5-oxopentyl, (4,5-dihydro-1H-imidazolyl, 10-(pyridinium-1-yl)decyl, 2-(1H-indol-3-yl)ethyl, 5-(2-(1H-indol-3-yl)ethylamino)-5-oxopentyl, 2-amino-3-(1H-indol-2-yl)-1-oxopropyl, 3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl, 10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl, 10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl, 3-(thiazol-3-ium-3-yl)propyl, 3-aminopropyl, 3-cyclohexylpropyl, 3-phenylpropyl, 3-(trimethylammonio)propyl, 3-(1-methylpyrrolidinium-1-yl)propyl, 3-(2-methylthiazol-3-ium-3-yl)propyl, 3-(benzo[d]thiazol-3-ium-3-yl)propyl, 3-(tetrahydro-1H-thiophenium-1-yl)propyl, 3-(3-methyl-1H-imidazol-3-ium-1-yl)propyl, 3-(1-methyl-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(3-aminopropyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(3-aminopropyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-decyl-1H-imidazol-3-ium-1-yl)propyl, 3-(1-decyl-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(1-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-1-yl)propyl, 4-(3-decyl-1H-imidazol-3-ium-1-yl)butyl, 4-(1-decyl-1H-imidazol-3-ium-3-yl)butyl, 10-(1-decyl-2-methyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-decyl-2-methyl-1H-imidazol-3-ium-1-yl)decyl, 3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl, 3-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)propyl, 10-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)decyl, 10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl, 10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-methyl-1H-imidazol-3-ium-1-yl)decyl, 10-(1-butyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-butyl-1H-imidazol-3-ium-1-yl)decyl, 10-(pyridinium-1-yl)decyl, 10-(1-methylpyrrolidinium-1-yl)decyl, naphthalen-2-ylmethyl, naphthalen-1-ylmethyl, 4-amino-2-(tert-butoxycarbonylamino)-1,4-dioxobutyl, 2-(tert-butoxycarbonylamino)-1-oxoethyl, 2-(tert-butoxycarbonylamino)-4-(methylthio)-1-oxobutyl, 5-(3-(methylthio)propylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)-1-oxopropyl, 5-(4-hydroxyphenethylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-1-oxo-3-phenylpropyl, 5-oxo-5-(phenethylamino)pentyl, 2-tert-butoxycarbonylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl, 5-(2-(1H-imidazol-4-yl)ethylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-3-carboxy-1-oxopropyl, 5-(2-carboxyethylamino)-5-oxopentyl, 2-tert-butoxycarbonylamino)-3-methyl-1-oxobutyl, 5-(isobutylamino)-5-oxopentyl,(3R)-2-(tert-butoxycarbonylamino)-3-methyl-1-oxopentyl,(R)-5-(2-methylbutylamino)-5-oxopentyl, 2-tert-butoxycarbonylamino)-3-mercapto-1-oxopropyl, 5-(2-mercaptoethylamino)-5-oxopentyl,(3R)-2-(tert-butoxycarbonylamino)-3-hydroxy-1-oxobutyl,(R)-5-(2-hydroxypropylamino)-5-oxopentyl, 6-amino-2-(tert-butoxycarbonylamino)-1-oxohexyl, 5-(5-aminopentylamino)-5-oxopentyl, 5-amino-2-(tert-butoxycarbonylamino)-1,5-dioxopentyl, 5-(4-amino-4-oxobutylamino)-5-oxopentyl, 2-tert-butoxycarbonylamino)-5-guanidino-1-oxopentyl, 5-(4-guanidinobutylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-3-hydroxy-1-oxopropyl, 5-(2-hydroxyethylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-4-methyl-1-oxopentyl, 5-(isopentylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-4-carboxy-1-oxobutyl, 5-(3-carboxypropylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-1-oxopropyl, 5-(ethylamino)-5-oxopentyl, a ligand of formula 4
-
*-R46-R47-R48 (4) - or a combination thereof, wherein R46 is decylene, R47 is 1,3-bis(1-methylpiperidin-4-yl)propane, and R48 is decyl.
- Some of the amine polymers described herein have a portion of the nitrogen atoms of the amine polymer substituted with a ligand of 2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-1-oxopropyl, 5-(2-(4-(nonyloxy)benzamido)ethylamino)-5-oxopentyl, (4,5-dihydro-1H-imidazolyl, 10-(pyridinium-1-yl)decyl, 2-(1H-indol-3-yl)ethyl, 54241H-indol-3-yl)ethylamino)-5-oxopentyl, 2-amino-3-(1H-indol-2-yl)-1-oxopropyl, 3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl, 10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl, 10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl, 3-(thiazol-3-ium-3-yl)propyl, 3-aminopropyl, 3-cyclohexylpropyl, 3-phenylpropyl, 3-(trimethylammonio)propyl, 3-(1-methylpyrrolidinium-1-yl)propyl, 3-(2-methylthiazol-3-ium-3-yl)propyl, 3-(benzo[d]thiazol-3-ium-3-yl)propyl, 3-(tetrahydro-1H-thiophenium-1-yl)propyl, 3-(3-methyl-1H-imidazol-3-ium-1-yl)propyl, 3-(1-methyl-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(3-aminopropyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(3-aminopropyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-decyl-1H-imidazol-3-ium-1-yl)propyl, 3-(1-decyl-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(1-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-1-yl)propyl, 4-(3-decyl-1H-imidazol-3-ium-1-yl)butyl, 4-(1-decyl-1H-imidazol-3-ium-3-yl)butyl, 10-(1-decyl-2-methyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-decyl-2-methyl-1H-imidazol-3-ium-1-yl)decyl, 3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl, 3-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)propyl, 10-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)decyl, 10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl, 10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-methyl-1H-imidazol-3-ium-1-yl)decyl, 10-(1-butyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-butyl-1H-imidazol-3-ium-1-yl)decyl, 10-(pyridinium-1-yl)decyl, 10-(1-methylpyrrolidinium-1-yl)decyl, naphthalen-2-ylmethyl, naphthalen-1-ylmethyl, a ligand of formula 4
-
*-R46-R47-R48 (4) - or a combination thereof, wherein R46 is decylene, R47 is 1,3-bis(1-methylpiperidin-4-yl)propane, and R48 is decyl.
- In the above ligands having protected amino groups, the protecting group is independently —C(O)OR49, —C(O)R50, wherein R49 is alkyl or aryl, and R50 is amino, hydrogen, alkyl, or haloalkyl. Protecting groups are well known in the art, and those known in the art may be used.
- The amine polymers having a portion of the nitrogen atoms of the amine polymer substituted with a ligand can have about 5 mole % to about 60 mole % ligand based on the moles of amine monomer, about 5 mole % to about 50 mole % ligand based on the moles of amine monomer, or about 10 mole % to about 30 mole % ligand based on the moles of amine monomer.
- The ratio of primary, secondary, and tertiary amines can be calculated by assuming complete reaction between the amine monomer and the crosslinking monomer and comparing the number of moles of the amine monomer and the crosslinking monomer along with the number of possible reaction sites on the crosslinking monomer. For example, when the amine polymer is N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (BTA), the amine has two tertiary amines and four primary amines before reacting with a crosslinking monomer. If the crosslinking monomer is dibromodecane and the mole ratio of BTA to dibromodecane is 1 to 1, two of the primary amine atoms will react with the crosslinking monomer to convert two of the primary amines to two secondary amines. Thus, the ratio of the primary to secondary to tertiary amines is 1 to 1 to 1.
- Also, the amine polymers of the invention can bind various bile acids such that the concentration of bound taurocholic acid is greater than 1.5 mmol/g polymer and the concentration of unbound taurocholic acid is less than 1.0 mmol/g polymer when the polymer is placed in a buffer solution having a 2.5 mM taurocholic acid concentration at 37° C. and the concentration of bound taurocholic acid is greater than 5.0 mmol/g polymer and the concentration of unbound taurocholic acid is greater than 4.0 mmol/g polymer when the polymer is placed in a buffer solution having a taurocholic acid concentration of at least 10 mM at 37° C. Additionally, the amine polymers of the invention can bind bile acids such that the concentration of bound glycodeoxycholate is greater than 1.0 mmol/g polymer and the concentration of unbound glycodeoxycholate is less than 0.1 mmol/g polymer when the polymer is placed in a buffer solution having a 1.25 mM glycodeoxycholate concentration at 37° C. and the concentration of bound glycodeoxycholate is greater than 6.0 mmol/g polymer and the concentration of unbound glycodeoxycholate is greater than 2.0 mmol/g polymer when the polymer is placed in a buffer solution having a glycodeoxycholate concentration of at least 10 mM at 37° C.
- Further, the amine polymer can be useful as a bile acid sequestrant, wherein, in a buffer solution at 37° C. containing less than 2.6 mM taurocholic acid, the amine polymer binds more of the acid than sevelamer and in a buffer solution at 37° C. containing more than 5.0 mM taurocholic acid the amine polymer binds more bile acid that colesevelam. The amine polymer can have the structure of any one of the amine polymers disclosed herein. Specifically, the amine polymer is derived from the polymerization of an amine monomer and a crosslinking monomer wherein the amine monomer comprises N,N,N′,N′-tetrakis(3-aminopropyl)-1,12-diaminododecane and the crosslinking monomer comprises 1,3-dichloropropanol.
- Without wishing to be bound by any particular theory, the invention herein uses a combination of positive charge density and hydrophobicity to achieve unexpected bile acid binding affinity, binding capacity, retention and removal. The charge density comes from a concentration of positively charged nitrogen atoms that are separated by a hydrophobic segment. Hydrophobicity is expressed by the calculated log P, as discussed herein. Further, as shown in
FIGS. 1 and 2 , the present invention has a unique combination of high binding affinity at low concentrations of bile acids and high binding capacity for bile acids at high concentrations of bile acids. More specifically, at 37° C., in a buffer solution containing less than 2.6 mM taurocholic acid, the polymers of the present invention bound more bile acid than sevelamer, and in a buffer solution containing more than 5.0 mM taurocholic acid, the polymers of the present invention bound more bile acid than colesevelam. Even more specifically, at 37° C., in a buffer solution containing less than 2.0 mM taurocholic acid, the polymers of the present invention bound more bile acid than sevelamer, and in a buffer solution containing more than 7.0 mM taurocholic acid, the polymers of the present invention bound more bile acid than colesevelam. Yet more specifically, at 37° C., in a buffer solution containing less than 1.5 mM taurocholic acid, the polymers of the present invention bound more bile acid than sevelamer, and in a buffer solution containing more than 10.0 mM taurocholic acid, the polymers of the present invention bound more bile acid than colesevelam. In some embodiments, the Langmuir equation known to those of skill in the art can be used in a linear regression analysis to determine equilibrium binding constants that reflect the greater affinity than sevelamer and the greater binding capacity than colesevelam. -
FIGS. 1 and 2 show graphs of the data from Example 50 plotted as the unbound bile acid in mmol bile acid per g polymer on the x-axis and bound bile acid in mmol bile acid per g polymer on the y-axis. With this data graphed in this manner, the trend of the bile acid binding shows that the polymer ofSample 99 binds more bile acid than the commercial bile acid sequestrants with the exception of colesevelam at low bile acid concentrations (i.e., less than 2.5 mM) and binds more bile acid than all the commercial bile acid sequestrants except sevelamer at high bile acid concentrations (i.e., greater than 5.0 mM). - Further, the calculated log P (c Log P) of at least one of R10 or R30 of Formula 1 of the amine polymers can be greater than 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, or 8. The calculated log P (c Log P)(Clog P) is determined by drawing the structure of the crosslinker without the leaving groups in Chemdraw Ultra 11.0 (CambridgeSoft, Cambridge Mass.) and replacing the leaving groups with hydrogen, and selecting the chemical properties tool to calculate the c Log P. For example, for the crosslinker 1,10-dibromodecane, one would enter the structure of decane into Chemdraw and select “show chemical properties” from the “view” toolbar to calculate its c Log P as 5.984. If the crosslinker is a ring structure that opens during crosslinking, such as epichlorohydrin, the c Log P is determined by drawing the ring-opened structure as shown below for epichlorohydrin:
- For example, the calculated log P (c Log P) for various segments is detailed in Table 2.
- One method for preparing the amine polymers described herein is to contact an amine monomer having six, seven or eight possible reaction sites or an amine monomer of Formulae 2 or 3 with a crosslinking monomer. The amine monomer and crosslinking monomer can be contacted in the presence of a solvent; the solvent is preferably a polar aprotic solvent (e.g., dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAC), tetrahydrofuran (THF), methyltetrahydrofuran, dimethylsulfoxide), 1,4-dioxane, 2-pyrrolidinone, or 1-methyl-2-pyrrolidinone. Polar protic solvents can also be used (e.g. methanol, ethanol, isopropyl alcohol, butanol, pentanol, or ethylene glycol). Once the amine monomer and the crosslinking monomer are contacted, the reaction mixture is heated to from about 40° C. to about 120° C. or at about 60° C. to 70° C. for about 12 to 24 hours. After the reaction is complete, the polymer gel product is washed with a basic solution, followed by water, and then lyophilized until dry.
- Monomers of the amine as defined in formulas 2 and/or 3 can be prepared using methods known to those of skill in the art, with specific examples of such syntheses in the examples below. In general, however, the desired core (R3) is prepared or commercially available and converted into a tetranitrile using known synthetic routes. For certain embodiments, an alkyl tetranitrile is prepared by the addition of acrylonitrile to an alkyldiamine via a Michael-type reaction. An alkyl tetranitrile can also be prepared by the addition of a dihaloalkyl to 3,3′-iminodipropionitrile. Another approach of preparing an alkyl tetranitrile is via the synthesis of the primary amine protected form of bis(3-aminopropyl)amine, (e.g., bis(3-(t-butoxycarbonylamino)propyl)amine or bis((3-benzyloxycarbonylamino)propyl)amine) followed by the addition of the dihaloalkane, and subsequent deprotection (see for example, Protective Groups in Organic Synthesis by Theodore Greene, Wiley-Interscience, 1999). Thereafter, the alkyl tetranitrile intermediate is then hydrogenated. Hydrogenation can be accomplished using a variety of techniques including Raney-nickel and/or Raney-cobalt catalysts followed by washing. A general hydrogenation procedure with Raney cobalt would combine the alkyl tetranitrile with hydrogen at a pressure from 100 to 5000 psi (e.g., about 1300-1500 psi) with or without NH3 (e.g., about 40 psi NH3) at a temperature of 50 to 120° C. (e.g., about 100° C.) in a solvent (e.g., water, methanol, ethanol, toluene, etc.) with adequate stirring and reaction time.
- The amine polymers of the invention have various chemical, structural and physical properties that contribute to their capacity for binding bile acids and/or their affinity for binding bile acids preferentially over fatty acids, phosphates and/or other compounds present in the gastrointestinal tract.
- The amine polymer can be administered in the form of a salt, or as a partial salt, or as salt free base. The “salt” has nitrogen atoms or groups in all or some of the repeat units that are protonated to create a positively charged nitrogen atom associated with a negatively charged counterion. The anionic counterions can be selected to minimize adverse effects on the patient. Examples of suitable counterions include Cl−, Br−, CH3OSO3 −, HSO4 −, SO4 2−, nitrate, HCO3 −, CO3 2−, acetate, lactate, phosphate, hydrophosphate, fumarate, malate, pyruvate, malonate, benzoate, glucuronate, oxalate, acetylglycinate, succinate, propionate, butyrate, ascorbate, citrate, tartrate, maleate, folate, an amino acid derivative, a nucleotide, a lipid, a phospholipid, or a combination thereof. The counterions can be the same as, or different from, each other. For example, the reaction product can contain two different types of counterions. In most cases, not all of the nitrogen atoms will be in a salt form, with the percent of nitrogen atoms in a salt form being dictated by certain properties, such as flowability, storage time, and weight.
- To determine the in vitro binding affinity for bile salts under conditions that are intended to mimic in certain respects those conditions found in the lower small intestine, the amine polymer is analyzed using assay A. The A assay combines the polymer to be analyzed in a desired concentration with a solution that mimics certain conditions present in the lower small intestine as described in
Protocol 1 in the examples. After a period of time, the polymers are recovered by centrifugation and the supernatants are sampled, filtered to remove any remaining particulates and assayed for ion concentrations by liquid chromatography (LC). By comparing the equilibrium concentrations of glycocholate (GCeq), glycodeoxycholate (GDCeq), oleyl glycerol (OGeq) and/or oleic acid (OAeq) in the presence of the polymer to their concentrations in test solution in the absence of the polymer, the amount of each component bound under these experimental conditions in mmoles/g polymer is calculated. The in vitro bile salt binding affinity under the conditions of the A assay inProtocol 1 results in a maximum of about 0.75 mmol/gram polymer. Thus, the in vitro bile salt binding affinity for the amine polymers of this invention is from about 0.34 to about 0.75 mmol/gram polymer, particularly from about 0.46 to about 0.75 mmol/gram polymer, and more particularly, from about 0.55 to about 0.75 mmol/gram polymer when measured in the Assay A solution. Further, in some embodiments, the in vitro bile salt binding affinity for the amine polymers of this invention is greater than 0.55 mmol/gram polymer, greater than 0.60 mmol/gram polymer, or greater than 0.65 mmol/gram polymer. - In some cases the concentration of phosphate ions was also determined on a strong anion exchange column by liquid chromatography using a basic mobile phase in order to measure the phosphate binding affinity. The polymers of the invention bind phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer, particularly less than 0.2 mmol/gram of polymer, more particularly up to about 0.15 mmol/gram polymer, and even more particularly, up to about 0.10 mmol/gram polymer when measured using a B assay.
- To determine the in vitro binding capacity for bile salts under conditions that are intended to mimic in certain respects those conditions found in the upper small intestine after a meal, the amine polymer is analyzed using Assay B. In Assay B, the polymer to be analyzed is combined in a desired concentration with a solution that mimics certain conditions present in the upper small intestine as described in Protocol 2 in the examples. The same general procedure as described above was used to calculate the amount of each component bound. The in vitro bile salt binding capacity under the conditions of the B assay in Protocol 2 results in a maximum of about 3.7 mmol/gram polymer. Thus, the in vitro bile salt binding capacity for the amine polymers is from about 0.28 to about 3.7 mmol/gram polymer, particularly from about 2.22 to about 3.7 mmol/gram polymer, and more particularly from about 3 to about 3.7 mmol/gram polymer when measured in the assay B solution.
- To determine the in vivo binding retention for bile salts, the amine polymer is analyzed in a hamster model. The hamster model provides a complex and relevant measure of the polymer's binding capacity for bile acids, its binding affinity for bile acids over other anions, and its ability to retain bound bile acids and to increase the excretion of bile acids and bile acids metabolites from the gastrointestinal tract into the feces. Preferably, Golden Syrian hamsters may be used as they have a similar bile acid profile to that of humans. Male Golden Syrian hamsters are acclimated and then placed on a high-fat, high-sucrose western diet, D12079B (Research Diet, New Brunswick, N.J.) for several days before the study is started. The amine polymers to be analyzed are blended into western diet at the desired dose to prepare the test diets. The hamsters are held in individual metabolic cages allowing the separation and collection of feces. Animals from the test groups are switched to the test diets, while animals from the untreated group are kept on western diet without added amine polymer. Food intake is measured for four consecutive days. For each hamster, feces from the last three days of the treatment period are collected, pooled, lyophilized, and then homogenized by grinding in a mortar and pestle. The feces samples are then extracted for fecal bile salt analysis. In some cases, a baseline treatment period is conducted where all groups of animals are placed in metabolic cages as described above and fed only on western diet without added test article. Feces are collected as described above and the effect of the amine polymer on bile salt fecal excretion is determined by comparing baseline versus treatment periods. Otherwise, the effect of amine polymers on bile salt fecal excretion is determined by comparing untreated versus test groups. Hamster fecal bile salts are analyzed as described in the examples. The amine polymers can have a calculated in vivo binding capacity at least 25%, 50%, 75%, 100%, 125%, 150%, 175% or 200% greater than colesevelam hydrochloride when measured at a dosage of 0.5% of the total feed intake in male Golden Syrian hamsters fed a Western diet.
- The amine polymers can have a calculated in vivo bile salt binding capacity of at least about 0.35 mmol bile salt/gram of polymer when measured in humans. The amine polymers can have an in vivo binding capacity in a human of at least 0.35 mmol bile salt per gram of polymer, at least 0.4 mmol bile salt per gram of polymer, at least 0.5 mmol bile salt per gram of polymer, at least 0.6 mmol bile salt per gram of polymer, or more.
- Polymers of the invention are crosslinked materials, meaning that they do not generally dissolve in solvents however they can swell with solvents or absorb the solvent. As used herein, “swelling ratio” refers to the number of grams of solvent taken up by one gram of crosslinked polymer when equilibrated in an aqueous environment. The swelling ratio is sensitive to the polymer solvent interaction parameter as described in Flory Huggins (Flory P. J. “Principles of Polymer Chemistry, Cornell Ithica Pub. 1953). When more than one measurement of swelling is taken for a given polymer, the mean of the measurements is taken to be the swelling ratio. The swelling ratio in water, or in physiological isotonic buffer, which is representative of the gastrointestinal tract (for example United States Pharmacopeia Simulated Intestinal Fluid or Simulated Gastric Fluid), is typically in the range of about 1 to about 10 g of swelling solution (solvent)/g of polymer, particularly about 2 to 6, and more particularly about 2 to about 4. The counterion content of the polymer can affect the swelling ratio, in the examples listed below, a chloride counterion is used, and the chloride content is stated. The counterion content can be as much as 25 wt. % of the total weight of the polymer and as little as <1% of the total weight of the polymer.
- The amine polymers can be particles having a mean diameter from about 10 microns to about 200 microns. In some of the embodiments, the amine polymer particles are substantially spherical beads. These beads can have a mean diameter from about 10 microns to about 200 microns. As used herein, the term “substantially” means generally rounded particles having an average aspect ratio of about 1.0 to about 2.0. Aspect ratio is the ratio of the largest linear dimension of a particle to the smallest linear dimension of the particle. Aspect ratios may be easily determined by those of ordinary skill in the art. This definition includes spherical particles, which by definition have an aspect ratio of 1.0. In some embodiments, the particles have an average aspect ratio of about 1.0, 1.2, 1.4, 1.6, 1.8 or 2.0. The particles may be round or elliptical when observed at a magnification wherein the field of view is at least twice the diameter of the particle.
- The substantially spherical beads can be prepared using methods known to a person skilled in the art. For example, a preferred mode of synthesis is a heterogeneous process. Such processes are also referred to as polymerization in dispersed media and include direct or inverse suspension, emulsion, precipitation, dispersion or micro emulsion polymerization, reaction in aerosol or using bulk polymerization methods. In inverse suspension, the continuous phase can be selected from apolar solvents such as silicone, toluene, benzene, hydrocarbon solvents or oils, halogenated solvents, supercritical carbon dioxide, and the like. The discrete phase for the inverse suspension system comprises solubilizing the monomer and crosslinker in water; this can be achieved by the addition of an acid such as hydrochloric acid to form the amine salt, which renders the organic amine substantially more water soluble and dispersing the amine solution in a water-immiscible solvent to form an emulsion. With a direct suspension or emulsion process, water can be used as the continuous phase, although salt brines are also useful to “salt out” the monomer and crosslinker into the discrete phase, as described in U.S. Pat. No. 5,414,068. The monomers can be dispersed either neat or as a solution in the continuous phase using a cosolvent. The crosslinking monomer can be added to the reaction in a semicontinuous fashion (staged addition) allowing the polymerization reaction to occur. Isolation of the beads can be carried out by filtration, washing and drying. Size can be further controlled or modified by reduction processes such as extrusion and grinding.
- The yield and efficiency of the reaction of crosslinker and amine monomer can be increased by the addition of a Dean-Stark process to a suspension polymerization reaction. During the Dean-Stark process water is removed, which concentrates the reaction mixture (e.g., amine and crosslinker). Without being limited by any particular theory, the concentrating process allows any reactive chain ends on the growing network to react, driving the reaction to completion. Generally, the temperature also rises as the water is removed. Increased efficiency in the reaction may allow for the use of lower amounts of crosslinker and may produce a product having higher purity.
- Thus, when preparing polymer beads, the ratio of the crosslinker to amine monomer can change depending on the process conditions (e.g., salting out or Dean-Stark conditions), monomer purity and the desired physical properties (e.g., swelling ratio, particle size, etc.). In various embodiments, the mole ratio of the amine monomer (e.g., of formula 2 or formula 3) to the crosslinking monomer is from about 1:1 to about 1:5; preferably, from about 1:1 to about 1:3 and more specifically from about 1:1.1 to about 1:3.
- Polymers can be obtained by methods known to those in the art, examples of which are illustrated in the Examples herein. The crosslinked amine polymer particle is generally a reaction product of a reaction mixture that is subjected to reaction conditions. The reaction mixture may also generally contain components that are not chemically incorporated into the product. The reaction mixture typically comprises monomers.
- In general, the reactions are conducted such that a polymer network is generated, which is insoluble but can be solvated into a gel. When the interpenetrating solvent is water, the insoluble material is described as a hydrogel. The reaction is carried either in solution, in bulk (i.e. using the neat monomers and crosslinking compounds) or in dispersed media. The reaction may start with the introduction of for example, temperature change or irradiation. In general amine polymers can be prepared by chain growth or step growth. Step growth polymerization involves the polymerization of monomers that contain unsaturated functional groups, including radical polymerization, cationic polymerization and anionic polymerization. Step growth polymerization involves the reaction of bifunctional or polyfunctional monomers that grow via, dimers, trimers to longer oligomers. When using a polyfunctional amine containing monomer, the growth results in a branched polymer. Network formation occurs when the polymer chains react with each other. Parameters that effect the network formation reaction include temperature, solvent choice, the concentrations of monomers and crosslinkers, and the ratio of the monomer to the crosslinking monomer. For polyamines such as that formed from an amine monomer and multi functional alkyl bromide crosslinker, desirable solvents have a high dielectric constant and include the following, but are not limited to, water, methanol, (and alcoholic solvents), N, N-dimethylformamide, methylpyrrolidone, dimethylsulfoxide, tetrahydrofuran, methyltetrahydrofuran and acetonitrile. The addition of a base maybe desired in some cases.
- Polymerization reactions to prepare the amine polymers include preparing an aqueous solution of the amine monomer, optionally with a surfactant, and adding an organic phase containing an organic solvent and optionally, a surfactant, to the aqueous phase. The crosslinker then can be added in a batch or a semi-continuous fashion. For example, the crosslinker can be added to the polymerization all at once or can be added slowly over a period of time.
- The amine polymer particles have a mean diameter of from about 10 μm to about 200 μm. Specific ranges are where the amine polymer particles have a mean diameter of from about 20 μm to about 200 μm, from about 20 μm to about 150 μm, or from about 20 μm to about 125 μm. Other ranges include from about 35 μm to about 150 μm, from about 35 μm to about 125 μm, from about 50 μm to about 125 μm, or from about 50 μm to about 100 μm. Particle sizes, including mean diameters, distributions, etc. can be determined using techniques known to those of skill in the art. For example, U.S. Pharmacopeia (USP)<429> discloses methods for determining particle sizes.
- Various amine polymer particles also have less than about 4 volume percent of the particles that have a diameter of less than about 10 μm; particularly, less than about 2 volume percent of the particles that have a diameter of less than about 10 μm; more particularly, less than about 1 volume percent of the particles that have a diameter of less than about 10 μm; and even more particularly, less than about 0.5 volume percent of the particles that have a diameter of less than about 10 μm. In other cases, specific ranges are less than about 4 volume percent of the particles that have a diameter of less than about 20 μm; less than about 2 volume percent of the particles that have a diameter of less than about 20 μm; less than about 1 volume percent of the particles that have a diameter of less than about 20 μm; less than about 0.5 volume percent of the particles that have a diameter of less than about 20 μm; less than about 2 volume percent of the particles that have a diameter of less than about 30 μm; less than about 1 volume percent of the particles that have a diameter of less than about 30 μm; less than about 1 volume percent of the particles that have a diameter of less than about 30 μm; less than about 1 volume percent of the particles that have a diameter of less than about 40 μm; or less than about 0.5 volume percent of the particles that have a diameter of less than about 40 μm. In various embodiments, the amine polymer has a particle size distribution wherein not more than about 5 volume % of the particles have a diameter less than about 30 μm (i.e., D(0.05)<30 μm), not more than about 5 volume % of the particles have a diameter greater than about 250 μm (i.e., D(0.05)>250 μm), and at least about 50 volume % of the particles have a diameter in the range from about 70 to about 150 μm.
- The particle distribution of the amine polymer can be described as the span. The span of the particle distribution is defined as (D(0.9)−D(0.1))/D(0.5), where D(0.9) is the value wherein 90% of the particles have a diameter below that value, D(0.1) is the value wherein 10% of the particles have a diameter below that value, and D(0.5) is the value wherein 50% of the particles have a diameter above that value and 50% of the particles have a diameter below that value as measured by laser diffraction. The span of the particle distribution is typically from about 0.5 to about 1, from about 0.5 to about 0.95, from about 0.5 to about 0.90, or from about 0.5 to about 0.85. Particle size distributions can be measured using Niro Method No. A 8 d (revised September 2005), available from GEA Niro, Denmark, using the Malvern Mastersizer.
- It has now been found that when using the amine polymers and the compositions of the present invention, a once-a-day dose is substantially equivalent to a twice-a-day dose, which is also substantially equivalent to a three-times-a-day dose. Generally, the once per day or twice per day administration of a daily amount of the polymer or the composition has a bile acid removal that is not statistically significantly different from the removal of the same polymer or composition at the same daily amount administered three times per day.
- Additionally, the invention is directed to methods of removing bile acids from an animal subject by administering an amine polymer or a pharmaceutical composition comprising an amine polymer, wherein less than 25% of subjects taking the polymer or composition once per day experience mild or moderate gastrointestinal adverse events at a dose of 6.0 grams/day or less. Gastrointestinal adverse events may include flatulence, diarrhea, abdominal pain, constipation, stomatitis, nausea and/or vomiting. In some aspects, the polymer or composition is administered twice a day and less than 25% of subjects taking the polymer or composition twice per day experience mild or moderate gastrointestinal adverse events. In some instances, the subjects taking the polymer or composition once per day or twice per day experience no severe gastrointestinal adverse events. The amine polymers or pharmaceutical compositions of the present invention have about 50% or more tolerability as compared to the same polymer or composition of the same daily amount administered three times a day. For example, for every two patients in which administration of the polymer three times a day is well tolerated, there is at least one patient in which administration of the polymer once a day or twice a day is well tolerated.
- When administration is well tolerated, there should be little or no significant dose modification or dose discontinuation by the subject. In some embodiments, well tolerated means there is no apparent dose response relationship for gastrointestinal adverse events. In some of these embodiments, well tolerated means that the following gastrointestinal adverse effects are not reported from a statistically significant number of subjects, including those effects selected from the group consisting of flatulence, diarrhea, abdominal pain, constipation, stomatitis, nausea and vomiting.
- In other embodiments, the present invention provides a method of removing bile acids from the gastrointestinal tract of an animal subject in need thereof, comprising administering an effective amount of an amine polymer or a composition comprising an amine polymer, wherein the polymer or composition is as well tolerated as administering substantially the same amount of the same polymer or composition three times per day. In some instances, the subject is experiencing hypercholesteremia and thus the method treats hypercholesteremia. In other instances, the method lowers serum cholesterol.
- Without wanting to be bound by any particular theory, the tolerability of the polymer or composition comprising the polymers results from physical properties that the amine polymers may possess, including a viscosity when hydrated and sedimented of from about 10,000 Pa·s to about 2,500,000 Pa·s, from about 10,000 Pa·s to about 2,000,000 Pa·s, from about 10,000 Pa·s to about 1,500,000 Pa·s, from about 10,000 Pa·s to about 1,000,000 Pa·s, from about 10,000 Pa·s to about 500,000 Pa·s, or from about 10,000 Pa·s to about 250,000 Pa·s, from about 30,000 Pa·s to about 3,000,000 Pa·s, from about 30,000 Pa·s to about 2,000,000 Pa·s, or from about 30,000 Pa·s to about 1,000,000 Pa·s, the viscosity being measured at a shear rate of 0.01 sec−1. This viscosity is measured using a wet polymer prepared by mixing the polymer thoroughly with a slight excess of simulated intestinal fluid (per USP <26>), allowing the mixture to sediment for 3 days at 37° C., and decanting free liquid from the sedimented wet polymer. The steady state shear viscosity of this wet polymer can be determined using a Bohlin VOR Rheometer (available from Malvern Instruments Ltd., Malvern, U.K.) or equivalent with a parallel plate geometry (upper plate of 15 mm diameter and lower plate of 30 mm diameter, and gap between plates of 1 mm) and the temperature maintained at 3TC.
- The amine polymers may further have a hydrated and sedimented yield stress of from about 150 Pa to about 4000 Pa, from about 150 Pa to about 3000 Pa, from about 150 Pa to about 2500 Pa, from about 150 Pa to about 1500 Pa, from about 150 Pa to about 1000 Pa, from about 150 Pa to about 750 Pa, or from about 150 Pa to about 500 Pa, from about 200 Pa to about 4000 Pa, from about 200 Pa to about 2500 Pa, from about 200 Pa to about 1000 Pa, or from about 200 Pa to about 750 Pa. Dynamic stress sweep measurements (i.e., yield stress) can be made using a Reologica STRESSTECH Rheometer (available from Reologica Instruments AB, Lund, Sweden) or equivalent in a manner known to those of skill in the art. This rheometer also has a parallel plate geometry (upper plate of 15 mm diameter, lower plate of 30 mm diameter, and gap between plates of 1 mm) and the temperature is maintained at 37° C. A constant frequency of 1 Hz with two integration periods can be used while the shear stress is increased from 1 to 104 Pa.
- Amine polymers used in this invention may also have desirable compressibility and bulk density when in the form of a dry powder. Some of the particles of the amine polymers in the dry form have a bulk density of from about 0.8 g/cm3 to about 1.5 g/cm3, from about 0.82 g/cm3 to about 1.5 g/cm3, from about 0.84 g/cm3 to about 1.5 g/cm3, from about 0.86 g/cm3 to about 1.5 g/cm3, from about 0.8 g/cm3 to about 1.2 g/cm3, or from about 0.86 g/cm3 to about 1.2 g/cm3. The bulk density affects the volume of amine polymer needed for administration to a patient. For example, a higher bulk density means that a lower volume will provide the same number of grams of amine polymer. This lower volume can improve patient compliance by allowing the patient to perceive they are taking a smaller amount due to the smaller volume.
- A powder composed of the particles of the amine polymer in dry form has a compressibility index of from about 3 to about 30, from about 3 to about 25, from about 3 to about 20, from about 3 to about 15, from about 3 to about 13, from about 5 to about 25, from about 5 to about 20, or from about 5 to about 15. The compressibility index is defined as 100*(TD−BD)/TD, wherein BD and TD are the bulk density and tap density, respectively. Bulk density (BD) and tapped density (TD) are used to calculate a compressibility index (CI). Standardized procedures for this measurement are specified as USP <616>. A quantity of the powder is weighed into a graduated cylinder. The mass M and initial (loosely packed) volume Vo are recorded. The cylinder is then placed on an apparatus which raises and then drops the cylinder, from a height of 3 mm±10%, at a rate of 250 times (taps) per minute. The volume is measured after 500 taps and then again after an additional 750 taps (1250 total). If the difference in volumes after 500 and 1250 taps is less than 2%, then the final volume is recorded as Vf and the experiment is complete. Otherwise, tapping is repeated in increments of 1250 taps at a time, until the volume change before and after tapping is less than 2%. The following quantities are calculated from the data:
-
Bulk Density (BD)=M/V o -
Tapped Density (TD)=M/V f -
Compressibility Index (CI, also called Carr's Index)=100*(TD−BD)/TD. - The powder form of the amine polymers settles into its smallest volume more easily than polymers conventionally used to treat hypercholesteremia. This makes the difference between the bulk density and the tap density (measured powder density after tapping a set number of times) from about 3% to about 30%, from about 3% to about 25%, from about 3% to about 20%, from about 3% to about 15%, from about 3% to about 10%, from about 5% to about 35%, from about 5% to about 30%, or from about 5% to about 20% of the bulk density.
- The polymers and pharmaceutical compositions described herein retain a significant amount of the bound bile salts throughout the small intestine, and specifically, the bile salts bound by the polymer are not released prior to entry into the colon or excretion of the polymer in the feces. The term “significant amount” as used herein is not intended to mean that the entire amount of the bound bile salt are retained prior to fecal excretion or entry in to the colon. A sufficient amount of the bound bile salts are retained, such that a therapeutic and/or prophylactic benefit is obtained. For example, it may be sufficient for a polymer to retain bile acids such that there is a significant increase in the amount of bile acids entering the colon. The bile acids may then be released from the polymer but may still substantially be excreted either intact or as metabolites in the feces and thus for purposes of this invention have been sufficiently retained. Retention of bile acids may be measured by measuring the amounts of bile acids in the feces or in colonic aspirates or extracts above baseline levels (i.e., above the amount of bile acids retained in the feces when no polymer is administered to the animal subject). Particular amounts of bound bile salts that can be retained range from about 5% to about 100% above baseline levels. The polymer or pharmaceutical composition should retain at least about 5% of the bound bile salts, more particularly at least about 10%, even more particularly at least about 25% and most particularly at least about 50% of the bound bile salts above baseline levels. Retention of bile acids by the polymer can be calculated either directly by in vitro methods or indirectly by in vivo methods. The period of retention is generally during the time that the polymer or composition is being used therapeutically or prophylactically. When the polymer or composition is used to bind and remove bile salts from the gastrointestinal tract, the retention period is the time of residence of the polymer or composition in the gastrointestinal or the average residence time of the polymer or composition in the small intestine.
- The polymers and pharmaceutical compositions described herein may result in an increased ratio of primary to secondary bile acids excreted in the feces. Bile acids may be characterized by their site of synthesis and modification; primary bile acids (for example cholic acid and chenodeoxycholic acid) are synthesized in hepatocytes from cholesterol and secondary or tertiary bile acids (for example deoxycholic acid and lithocholic acid) are the products of bacterial dehydroxylation in the terminal ileum and colon. Primary bile acids may be deconjugated and/or dehydroxylated to convert them to secondary or tertiary bile acids; for example deoxycholate (from cholate) and lithocholate (from chenodeoxycholate). A change in the ratio of excreted bile acids towards primary or unmetabolized bile acids is a measure of in vivo retention of bile acids by polymers. The amine polymers, in an in vivo measurement, can produce on average at least 11% primary bile acids in the feces based on total bile acids in the feces. In various embodiments, the amine polymers bind at least 15% or at least 20% primary bile acids in the feces based on the total bile acids in the feces.
- Generally, the amine polymers are not significantly absorbed from the gastrointestinal tract. Depending upon the size distribution of the amine polymer particles, clinically insignificant amounts of the polymers may be absorbed. More specifically, about 90% or more of the polymer is not absorbed, about 95% or more is not absorbed, even more specifically about 97% or more is not absorbed, and most specifically about 98% or more of the polymer is not absorbed.
- The amine polymers can be used to remove bile salts from an animal subject by administering an effective amount of the polymer to an animal subject in need thereof. The bile salts can be bound and retained by the amine polymer and then removed from the gastrointestinal tract in the feces. Further, the amine polymers can be used to reduce serum LDL-cholesterol, or serum non-HDL-cholesterol, in an animal subject. In some instances, the mean serum LDL can be decreased by at least 15%, at least 20%, at least 25%, at least 30% or more after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events. In some instances, the daily dose of the amine polymer is about 6.0 g/day, 5.0 g/day, 4.0 g/day, 3.0, 2.5, or 2.0 g/day or less.
- Further, the amine polymers can be administered to improve glycemic control in a human subject with Type II diabetes mellitus. Preferably, when a human subject with Type II diabetes mellitus is treated, glycated hemoglobin (HbA1c) can be decreased by at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1.0% or more after 18, 26, 52 or more weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events. In some instances, the daily dose of the amine polymer is about 6.0 g/day, 5.0 g/day, 4.0 g/day, 3.0, 2.5, or 2.0 g/day or less. Also, the fasting plasma glucose can be decreased by at least 14 mg/dL (0.8 mmol/L), at least 16 mg/dL (0.9 mmol/L), at least 18 mg/dL (1 mmol/L), at least 20 mg/dL (1.1 mmol/L) or more after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events. In some instances, the daily dose of the amine polymer is about 6.0 g/day, 5.0 g/day, 4.0 g/day, 3.0, 2.5, or 2.0 g/day or less.
- Further, the amine polymers can be used to ameliorate, treat or slow progression of Alzheimer's disease.
- The amine polymers can also be used to treat non-alcoholic statohepatitis, cholestatic pruritus, irritable bowel syndrome with diarrhea (IBS-D), idiopathic bile acid malabsorption, genetic or congenital Fibroblast Growth Factor 19 (FGF19) deficiency or a combination thereof. When the amine polymers are used to treat cholestatic pruritus, they can be used in combination with an oral or topical antipruritic containing, for example, an antihistamine, a corticosteroid, a local anesthetic, a counterirritant, an opioid, an opioid receptor antagonist, or other therapies including but not limited to crotamiton, doxepin, mirtazapine, capsaicin, tacrolimus, linoleic acid, gabapentin, activated charcoal, thalidomide, naltrexone, erythropoietin, nicergoline, naltrexone, nalmefene, butorphanol, naloxone, rifampin, ondansetron, ursodeoxycholate, S-adenosyl-L-methionine, serotonin-selective reuptake inhibitors, phenobarbital, dronabinol, phototherapy, or a combination thereof
- When the amine polymers are used to treat IBS-D, they can be used in combination with antidiarrheals such as opiates, opioid or opioid analogs including loperamide, codeine, diphenoxylate, serotonin receptor antagonists such as alosetron, ramosetron and cilansetron, serotonin-selective reuptake inhibitors, tricyclic antidepressants such as amitriptyline and desipramine or drugs reducing the levels of serotonin (5-HT), antispasmodic drugs including anticholinergics such as hyoscyamine or dicyclomine, chloride secretion blockers such as crofelemer and probiotics.
- As used herein, an animal subject can be a human or other mammal in need of either bile salt removal, reduction of serum LDL-cholesterol, or non HDL-cholesterol concentration, increase in HDL-C or improved glycemic control.
- The methods, polymers and compositions described herein are suitable for removal of bile salts from an animal subject wherein the subject is in need of such bile salt removal. For example, patients experiencing hypercholesterolemia or hyperlipidemia benefit from such bile salt removal. The methods described herein are applicable to these patients regardless of the underlying condition that is causing the high serum cholesterol levels or need for bile acid removal.
- The amine polymers can be administered once, twice, or three times a day. If the amine polymer is administered once a day, it may be administered just before, with, or just after the largest meal of the day. Also, if administered once a day, it may be administered in connection with the largest, on average during a twenty-four hour period, release of bile acids from the gall bladder, which is typically in the morning. Further, it is preferred that the amine polymer is administered at least 3 hours before or after any agents that might have an adverse interaction with the amine polymers.
- The dosage regimen to treat hypercholesterolemia, atherosclerosis, diabetes, Alzheimer's disease, non-alcoholic steatohepatits, cholestatic pruritus, IBS-D, idiopathic bile acid malabsorption or reduce plasma cholesterol with the combination therapy and pharmaceutical compositions of the present invention can be selected using a variety of factors. These include the type, age, weight, sex, diet, and medical condition of the patient, the severity of the disease, the route of administration, pharmacological consideration such as the activity, efficacy, pharmacokinetics and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, and whether the amine polymer is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely.
- Initial treatment of a patient suffering from a hyperlipidemic condition such as hypercholesterolemia and/or atherosclerosis can begin with the dosages indicated above. Treatment should generally be continued as necessary over a period of several weeks to several months or years until the condition has been controlled or eliminated. Patients undergoing treatment with the amine polymers disclosed herein can be routinely monitored by, for example, measuring serum LDL and total cholesterol levels by any of the methods well known in the art, to determine the effectiveness of the combination therapy. Repeated analysis of such data permits modification of the treatment regimen during therapy so that optimal effective amounts of each type of agent are administered at any point in time, and so that the duration of treatment can be determined as well. In this way, the treatment regimen/dosing schedule can be rationally modified over the course of therapy so that the lowest amount of amine polymer and optionally, combination treatment, is administered and so that administration is continued only so long as is necessary to successfully treat the hyperlipidemic condition such as hypercholesterolemia and atherosclerosis.
- If necessary, the amine polymers or pharmaceutical compositions may be administered in combination with other therapeutic agents. The choice of therapeutic agents that can be co-administered with the compounds of the invention will depend, in part, on the condition being treated. For example, various agents can be co-administered with the amine polymer, including agents used in reducing serum LDL-cholesterol or non-HDL-cholesterol, which comprise a hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor, a fibrate, a cholesterol absorption inhibitor, niacin (i.e. nicotinic acid or derivatives thereof), a phytosterol, an intestinal lipase inhibitor, an intestinal or secreted phospholipase A2 inhibitor, inhibitors of the synthesis or normal activity of Apo-B100, agonists of the synthesis or normal activity of ApoA, or any agent that modulates cholesterol absorption or metabolism, or a combination thereof. In some instances, the HMG CoA reductase inhibitor comprises a statin, such as atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or a combination thereof. The cholesterol absorption inhibitor can comprise ezetimibe. The fibrate can be benzafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate, or a combination thereof. The intestinal lipase inhibitor can comprise orlisatat. In some instances, the amine polymers or pharmaceutical compositions may be administered in combination with a HMG CoA reductase inhibitor and niacin (e.g., lovastatin and niacin), or a HMG CoA reductase inhibitor and a cholesterol absorption inhibitor (e.g., simvastatin and ezetimibe), or a HMG CoA reductase inhibitor and an intestinal lipase inhibitor.
- In another example, other agents can be co-administered with the amine polymer, including agents used in preventing or treating diabetes, obesity or other dyslipidemias, such as a sulfonylurea, a biguanidine, a glitazone, a thiazolidindione, an activator of peroxisome poliferator-activated receptors (PPARs), an alpha-glucosidase inhibitor, a potassium channel antagonist, an aldose reductase inhibitor, a glucagon antagonist, a retinoid X receptor (RXR) antagonist, a farnesoid X receptor (FXR) agonist, a FXR antagonist, glucagon-like peptide-1 (GLP-1), a GLP-1 analog, a dipeptidyl peptidase IV (DPP-IV) inhibitor, amylin, an amylin analog, an SGLT2 inhibitor, insulin, an insulin secretagogue, a thyroid hormone, a thyroid hormone analog, an alpha glucosidase inhibitor or a combination thereof. The biguanidine can be metformin, buformin, phenformin, or a combination thereof. The thiazolidindione can be pioglitazone, rivoglitazone, rosiglitazone, troglitazone, or a combination thereof. The sulfonylurea can be acetohexamide, chlorpropamide, tolbutamide, tolazamide, glipizide, gliclazide, glibenclamide, gliquidone, glyclopyramide, glimepiride, or a combination thereof. The DPP-IV inhibitor can be alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin, or a combination thereof. The GLP-1 analog can be exenatide, liraglutide, albiglutide, or a combination thereof. The alpha glucosidase inhibitor can be acarbose, miglitol or voglibose.
- The term dyslipidemia is taken to mean a deviation in at least one of total serum cholesterol, LDL-cholesterol, non-HDL cholesterol, HDL-cholesterol or triglyceride from that considered normal by the National Cholesterol Education Program or other suitable bodies. In another example, other agents can be co-administered with the amine polymer, including an anti-platelet agent, a beta-blocker, a renin-angiotensin-aldosterone system (RAAS) inhibitor, a RAAS modulator (e.g., angiotensin converting enzyme inhibitors, renin inhibitors, angiotensin receptor blockers, aldosterone antagonists or sodium channel blockers, including amiloride, triamterene, trimethoprim, and pentamidine) or a combination thereof
- The amine polymers can also be administered with other cholesterol-lowering agents such as acifran, azacosterol, benfluorex, β-benzalbutyramide, carnitine, chondroitin sulfate, clomestrone, detaxtran, dextran sulfate sodium, 5,8,11,14,17-eicosapentaenoic acid, eritadenine, furazabol, meglutol, melinamide, mytatrienediol, ornithine, γ-oryzanol, pantethine, pentaerythritol tetraacetate, α-phenybutyramide, priozadil, probucol, β-sitosterol, sultosilic acid, piperazine salt, tiadenol, triparanol, xenbucin, or a combination thereof
- Other agents that can be advantageously used for treatment in combination with the amine polymers are a squalene epoxidase inhibitor, a squalene synthetase inhibitor (or squalene synthase inhibitor), an acyl-coenzyme A, cholesterol acyltransferase (ACAT) inhibitor (including selective inhibitors of ACAT-1 or ACAT-2, as well as dual inhibitors of ACAT-1 and ACAT-2), a microsomal triglyceride transfer protein (MTP) inhibitor, probucol, a cholesterol absorption inhibitor (e.g., ezetimibe and 1-(4-fluorophenyl)-3(R)-3(S)-(4-fluorophenyl)-3-hydroxypropyl), 4(S)-4-hydroxyphenol (-2-azetidinone) described in U.S. Pat. Nos. 5,727,115 and 5,846,966), a LDL receptor inducer, a platelet aggregation inhibitor (e.g., a glycoprotein IIb/IIa fibrinogen receptor antagonist), aspirin, vitamin B6 (or pyridoxine), vitamin B12 (or cyanocobalamin), a water-soluble pharmaceutical salt or ester of folic acid (e.g., sodium salt and the methylglucamine salt), an anti-oxidant vitamin (e.g., vitamin C and E and beta-carotene), or a combination thereof
- The term “treating” as used herein includes achieving a therapeutic benefit. By therapeutic benefit is meant eradication, amelioration, or prevention of the underlying disorder being treated. For example, in a hypercholesterolemia patient, therapeutic benefit includes eradication or amelioration of the underlying hypercholesterolemia. Also, a therapeutic benefit is achieved with the eradication, amelioration, or prevention of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. In some treatment regimens, the amine polymer or composition of the invention may be administered to a patient at risk of developing hypercholesterolemia or diabetes or to a patient reporting one or more of the physiological symptoms of hypercholesterolemia or diabetes, even though a diagnosis of hypercholesterolemia or diabetes may not have been made.
- The pharmaceutical compositions of the present invention include compositions wherein the amine polymers are present in an effective amount, i.e., in an amount effective to achieve therapeutic or prophylactic benefit. The actual amount effective for a particular application will depend on the patient (e.g., age, weight, etc.), the condition being treated, and the route of administration. Determination of an effective amount is well within the capabilities of those skilled in the art, especially in light of the disclosure herein. The effective amount for use in humans can be estimated from animal models. For example, a dose for humans can be formulated to achieve gastrointestinal concentrations that have been found to be effective in animals. In various embodiments, the human patient takes about 0.5 g to about 10 g per day, preferably about 0.5 g to about 5 g per day, more preferably, about 0.5 g to about 3 g per day, about 0.5 g to about 2.5 g per day, and most preferably about 0.5 g to about 2.0 g per day.
- The polymers and compositions described herein can be used as food products and/or food additives. They can be added to foods prior to consumption or during packaging.
- The amine polymers or pharmaceutically acceptable salts thereof, or compositions described herein, can be delivered to the patient using a wide variety of routes or modes of administration. The most preferred routes for administration are oral, intestinal, or rectal. Rectal routes of administration are known to those of skill in the art. Intestinal routes of administration generally refer to administration directly into a segment of the gastrointestinal tract, e.g., through a gastrointestinal tube or through a stoma. The most preferred route for administration is oral.
- The polymers (or pharmaceutically acceptable salts thereof) may be administered per se or in the form of a pharmaceutical composition wherein the active compound(s) is in admixture or mixture with one or more pharmaceutically acceptable excipients. Pharmaceutical compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable excipients comprising carriers, diluents, and auxiliaries which facilitate processing of the active compounds into preparations which can be used physiologically. Proper composition is dependent upon the route of administration chosen.
- For oral administration, the polymers or compositions of the invention can be formulated readily by combining the polymer or composition with pharmaceutically acceptable excipients well known in the art. Such excipients enable the compositions of the invention to be formulated as powders, tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, wafers, and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained as a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose or sucrose; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone (PVP); and various flavoring agents known in the art. If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Additionally, the amine polymer composition can comprise one or more fat-soluble vitamins such as vitamin A, D, E, K, or a combination thereof. An amount of the fat-soluble vitamin can be added to the composition sufficient to deliver about the daily dietary intake level (i.e., the Reference Daily Intake (RDI)), which is currently 3000 IU, 400 IU, 30 IU, 80 μg, respectively, for vitamin A, D, E, and K.
- In various embodiments, the active ingredient (e.g., polymer) constitutes over about 20%, more particularly over about 50%, even more particularly over about 75%, and most particularly more than about 90% by weight of the oral dosage form, the remainder comprising suitable excipient(s).
- The amine polymers or pharmaceutical compositions can be administered in the form of a chewable or mouth-disintegrating tablet, a liquid, a powder, a powder contained within a sachet, a soft gelatin capsule, or a hard gelatin capsule. In some embodiments, the polymers of the invention are provided as pharmaceutical compositions in the form of liquid compositions. In various embodiments, the pharmaceutical composition contains an amine polymer dispersed in a suitable liquid excipient. Suitable liquid excipients are known in the art; see, e.g., Remington's Pharmaceutical Sciences.
- An effective amount of the polymers of the invention can be administered to the animal subject in less than four unit doses per day, such as in less than four tablets per day. The “dosage unit” or “unit dose” is a tablet, capsule or other oral dosage form containing an amount of the amine polymer. The polymer is generally administered in 4, 3, 2 or 1 unit doses in a 24-hour period, which provides a daily dose of the polymer to the subject under treatment.
- Unless otherwise indicated, an “alkyl” group as described herein alone or as part of another group is an optionally substituted linear saturated monovalent hydrocarbon radical containing from one to twenty carbon atoms and preferably one to twelve carbon atoms, or an optionally substituted branched saturated monovalent hydrocarbon radical containing three to twenty carbon atoms, and preferably three to eight carbon atoms. Examples of unsubstituted alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, s-pentyl, t-pentyl, and the like.
- The term “amide” as used herein represents a bivalent (i.e., difunctional) amido linkage (i.e.,
- The term “aryl” as used herein alone or as part of another group denotes an optionally substituted monovalent aromatic hydrocarbon radical, preferably a monovalent monocyclic or bicyclic group containing from 6 to 12 carbons in the ring portion, such as phenyl, biphenyl, naphthyl, substituted phenyl, substituted biphenyl or substituted naphthyl. Phenyl and substituted phenyl are the more preferred aryl groups. The term “aryl” also includes heteroaryl.
- The term “cycloalkyl” as used herein denotes optionally an optionally substituted cyclic saturated monovalent bridged or non-bridged hydrocarbon radical containing from three to eight carbon atoms in one ring and up to 20 carbon atoms in a multiple ring group. Exemplary unsubstituted cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, norbornyl, and the like.
- The term “-ene” as used as a suffix as part of another group denotes a bivalent radical in which a hydrogen atom is removed from each of two terminal carbons of the group, or if the group is cyclic, from each of two different carbon atoms in the ring. For example, alkylene denotes a bivalent alkyl group such as methylene (—CH2—) or ethylene (—CH2CH2—), and arylene denotes a bivalent aryl group such as o-phenylene, m-phenylene, or p-phenylene. For clarity, addition of the -ene suffix is not intended to alter the definition of the principal word other than denoting a bivalent radical. Thus, continuing the example above, alkylene denotes an optionally substituted linear saturated bivalent hydrocarbon radical.
- The term “ether” as used herein represents a bivalent (i.e., difunctional) ether linkage (i.e., —O—).
- The term “ester” as used herein represents a bivalent (i.e., difunctional) ester linkage (i.e., —C(O)O—).
- The term “heteroaryl,” as used herein alone or as part of another group, denotes an optionally substituted monovalent monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms in protonated or unprotonated form, where one or more, preferably one, two, or three, ring atoms are heteroatoms independently selected from N, O, and S, and the remaining ring atoms are carbon. Exemplary heteroaryl moieties include benzofuranyl, benzo[d]thiazolyl, benzo[d]thiazolium, isoquinolinyl, isoquinolinium, quinolinyl, quinolinium, thiophenyl, imidazolyl, imidazolium, oxazolyl, oxazolium, furanyl, thiazolyl, thiazolium, pyridinyl, pyridinium, furyl, thienyl, pyridyl, pyrrolyl, pyrrolidinium, indolyl, indolinium, and the like.
- The term “heterocyclo,” as used herein alone or as part of another group, denotes a saturated or unsaturated monovalent monocyclic group of 4 to 8 ring atoms in protonated or unprotonated form, in which one or two ring atoms are heteroatom(s), independently selected from N, O, and S, and the remaining ring atoms are carbon atoms. Additionally, the heterocyclic ring may be fused to a phenyl or heteroaryl ring, provided that the entire heterocyclic ring is not completely aromatic. Exemplary heterocyclo groups include the heteroaryl groups described above, pyrrolidino, pyrrolidinium, piperidino, piperidinium, morpholino, morpholinium, piperazino, piperazinium, and the like.
- The term “hydrocarbon” as used herein describes a compound or radical consisting exclusively of the elements carbon and hydrogen.
- The term “substituted” as in “substituted aryl,” “substituted alkyl,” and the like, means that in the group in question (i.e., the alkyl, aryl or other group that follows the term), at least one hydrogen atom bound to a carbon atom is replaced with one or more substituent groups such as hydroxy (—OH), alkylthio, phosphino, amido (—CON(RA)(RB), wherein RA and RB are independently hydrogen, alkyl, or aryl), amino (—N(RA)(RB), wherein RA and RB are independently hydrogen, alkyl, or aryl), halo (fluoro, chloro, bromo, or iodo), silyl, nitro (—NO2), an ether (—ORA wherein RA is alkyl or aryl), an ester (—OC(O)RA wherein RA is alkyl or aryl), keto (—C(O)RA wherein RA is alkyl or aryl), heterocyclo, and the like. When the term “substituted” introduces a list of possible substituted groups, it is intended that the term apply to every member of that group. That is, the phrase “optionally substituted alkyl or aryl” is to be interpreted as “optionally substituted alkyl or optionally substituted aryl.”
- As used herein “possible reaction sites” in the amine monomers are nitrogen atoms bonded to one or more hydrogen atoms.
- Having described the invention in detail, it will be apparent that modifications and variations are possible without departing from the scope of the invention defined in the appended claims.
- The following non-limiting examples are provided to further illustrate the present invention. The following assays were used for the in vitro and in vivo testing detailed in the examples below.
- Protocol 1: Conditions Mimicking the Lower Small Intestine (A Assay).
- Amine polymers were measured in conditions mimicking those found in the lower small intestine (Northfield, T C and McColl, I (1973) “Postprandial concentrations of free and conjugated bile salts down the length of the normal human small intestine”, Gut 14: 513-518, Borgstrom, B, et al. (1957) “Studies of intestinal digestion and absorption in the human”, J Clin Invest 36: 1521-1536.)
- The following test solution was prepared: 50 mM N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 50 mM sodium BES, 6.5 mM sodium phosphate, 0.93 mM sodium glycocholate, 0.93 mM sodium glycodeoxycholate, 150 mM sodium chloride, pH 7.0. The test solution was stored at −20° C. Before use the test solution was thawed in a 37° C. water bath, stirred vigorously on a stir plate for greater than 20 minutes, and filtered through a Nalgene 0.45 micron cellulose nitrate filter unit. This was found to provide reproducible results. Amine polymers to be analyzed were freeze-dried a minimum of 18 hours and were accurately dispensed into 16×100 mm borosilicate test tubes, with each tube containing between 23 and 28 mg of test sample. The precise weight was noted and the above solution was added using a 10 mL disposable pipette, so that the polymer concentration was 2.5 mg/mL. The tubes were covered with a sheet of Teflon, clamped and tumbled end-over-end (30-40 revolutions per minute) inside an atmospheric chamber at 37° C. for three hours. The polymers were recovered by centrifugation at 500×g for 10 minutes and the supernatants were sampled, filtered through a 96 well 0.45 micron Whatman Unifilter 800 by centrifugation at 1000×g for 10 minutes to remove any remaining particulates. Filtrates were transferred to either glass IC vials with rubber septa or 96 well polypropylene deep well sample plates.
- To determine the concentration of glycocholate (GC) and glycodeoxycholate (GDC) in the filtrate, 50 μL of the sample solution was injected onto a HPLC system, equipped with Phenomenex Luna C8 (2) column (100 Å, 5 μm, 50×2.00 mm), and a UV detector. The sample was analyzed using a gradient of water, 25 mM phosphate buffer (pH=3) and acetonitrile at a flow rate of 0.4 mL/min. The signal of GC and GDC was detected at a wavelength of 205 nm from the UV detector. Calibration solutions comprised of GC and GDC standards of different concentrations were also injected onto the same HPLC system. The calibration curve of each component was then constructed by plotting the peak area vs. concentration. Based on the peak area of the GC and GDC found in the sample and the corresponding calibration curve, the concentration of each component in the sample was calculated in mM.
- By comparing the equilibrium concentrations of glycocholate (GCeq) and glycodeoxycholate (GDCeq), in the presence of the polymer to their concentrations in test solution in the absence of the polymer, the amount of each component bound under these experimental conditions in mmoles/g polymer was calculated.
- In some cases, the concentration of phosphate was also determined by injection of 20 uL of filtrate onto strong anion exchange columns (Dionex AG11-HC 50×4 mm ID and Dionex AS11-HC 250×4 mm ID) using a Waters Alliance 2795 Separation Module equipped with a 6 column switching valve installed inside a column oven and a Dionex Conductivity Detector CD25 (with DS3 flow cell and ASRS Ultra 11 4 mm Suppressor). The mobile phase was 30 mM KOH buffer with a 1 mL/min flow rate and a run time of 15 minutes per sample. Phosphate standards of different concentrations were also injected onto the same system and the calibration curve was then constructed by plotting the peak area vs. concentration. Based on the peak area found in the sample and the corresponding calibration curve, the concentration of phosphate in the sample was calculated in mM.
- By comparing the equilibrium concentrations of phosphate (Peq) and in the presence of the polymer to their concentrations in test solution in the absence of the polymer, the amount of phosphate bound under these experimental conditions in mmoles/g polymer was calculated.
- Protocol 2: Conditions Mimicking the Upper Small Intestine (Assay B).
- Amine polymers were also measured in conditions mimicking those found in the upper small intestine after a meal (Fordtran, J S and Locklear, T W (1966) “Ionic constituents and osmolality of gastric and small-intestinal fluids after eating”, Am J Dig Dis 11: 503-521; Northfield, T C and McColl, I (1973) “Postprandial concentrations of free and conjugated bile salts down the length of the normal human small intestine”, Gut 14: 513-518; Evans, D F, et al. (1988) “Measurement of gastrointestinal pH profiles in normal ambulant human subjects”, Gut 29: 1035-1041). The bile salt binding performance of test polymers was evaluated at a polymer concentration of 2.5 mg/mL in the manner described in
Protocol 1 above, with the exception that the following test solution was used: 50 mM N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 50 mM sodium BES, 6.5 mM sodium phosphate, 4.6 mM sodium glycocholate, 4.6 mM sodium glycodeoxycholate, 1.2 mM oleyl glycerol, 9 mM oleic acid, 150 mM sodium chloride, pH 7.0. Freeze-dried polymer was precisely dispensed into the 16×100 mm borosilicate test tubes, with each tube containing between 28 and 33 mg of test sample. In certain cases, the concentration of polymer was adjusted from 2.5 mg/mL to 1 mg/mL. Otherwise the procedure was identical to that described inProtocol 1 above, except filtrates submitted for analytical analysis were only dispensed into glass IC vials. - To determine the concentration of glycocholate (GC), glycodeoxycholate (GDC), oleyl glycerol (OG) and oleic acid (OA) concentrations in filtrate samples, 20 μL was injected onto a HPLC system that was equipped with a Phenomenex Luna C8 (2) column (100 Å, 5 μm, 50×2.00 mm) and a UV detector. The sample was analyzed using a gradient of water, 25 mM phosphate buffer (pH=3) and acetonitrile at a flow rate of 0.4 mL/min. The signal of GC, GDC, OG and OA is detected at a wavelength of 205 nm from the UV detector. Calibration solutions comprised of GC, GDC, OG and OA standards of different concentrations were also injected onto the same HPLC system. The calibration curve of each component was then constructed by plotting the peak area vs. concentration. Based on the peak area of the GC, GDC, OG or OA found in the sample and the corresponding calibration curve, the concentration of each component in the sample is calculated in mM.
- By comparing the equilibrium concentrations of glycocholate (GCeq), glycodeoxycholate (GDCeq), oleyl glycerol (OGeq) and/or oleic acid (OAeq) in the presence of the polymer to their concentrations in test solution in the absence of the polymer, the amount of each component bound under these experimental conditions in mmoles/g polymer was calculated.
- Hamster Model. To collect in vivo data, Male Golden Syrian hamsters (8-9 weeks old) were obtained from Charles River Laboratories (Wilmington, Mass.). Upon arrival, the animals were placed on rodent diet Teklad 2018 (Madison, Wis.). Food and water were provided ad libitum throughout the course of the study. Animals were acclimated for at least seven days, and then randomized by body weight into groups of at least five animals each. All animals were then placed on a high-fat, high-sucrose western diet, D12079B (Research Diet, New Brunswick, N.J.) for three days before the study started. Amine polymers were blended into western diet at a dose of 0.5% to prepare the test diets. To initiate the study, all hamsters were moved into individual metabolic cages allowing the separation and collection of feces. Animals from the test groups were switched to the test diets, while animals from the untreated group were kept on western diet without added amine polymer. Food intake was measured for the next four consecutive days. For each hamster, feces from the last three days of the treatment period were collected, pooled, lyophilized, and then homogenized by grinding in a mortar and pestle. The feces samples were then extracted for fecal bile salt analysis.
- In some cases, a baseline treatment period was conducted where all groups of animals were placed in metabolic cages as described above and fed only on western diet without added test article. Feces were collected as described above and the effect of amine polymer on bile salt fecal excretion was determined by comparing baseline versus treatment periods. Otherwise, the effect of amine polymer on bile salt fecal excretion was determined by comparing untreated versus test groups.
- Hamster fecal bile salts were analyzed using a modification of the procedure reported by Porter and colleagues (Porter, J L. et al. 2003. Accurate enzymatic measurement of fecal bile salts in patients with malabsorption. J Lab Clin Med. 141:411-8). For each extraction, a 100 mg aliquot of dry feces was weighed into a 16×100 mm Pyrex test tube. Ethylene glycol (1 mL) with 0.7N NaOH was then added. The test tube was capped with a marble and heated at 190-200° C. for 2 h. After cooling, 1 mL of 20% NaCl and 0.2 mL 6N HCl were added. After brief mixing, 6 ml diethyl ether was added. The tube was capped, vortexed for 5 minutes, and then centrifuged at 1,000×g for 5 minutes. The diethyl ether phase was transferred into a 20 mL glass vial. Two additional extractions with 6 mL diethyl ether were performed and the extracts were pooled. The ether was completely evaporated under a stream of air. The residue was then dissolved in 3 mL methanol and bile salts (cholic acid, 3-OH-12-oxo-cholanic acid, chenodeoxycholic acid, deoxycholic acid, and lithocholic acid) were quantified by LC-MS.
- Synthesis of crosslinked N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine materials were conducted using parallel synthesis. A solution of N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C4 BTA) (40 wt. % of a N,N-dimethylformamide (DMF) solution) was dispensed into 40 mL glass vials. The crosslinking monomer of formula X-R1-X, wherein X was bromo and R1 was as listed in the table below, were added to each vial. Additional DMF and methanol (MeOH) were added resulting in a total solid content of 40 wt. % where the solvents are in at a ratio of 1:1 (by volume). The vials were capped and heated for 17 hours at 58° C. The resulting polymer gel was swollen and ground in MeOH, washed in MeOH (twice), ammonium hydroxide (10 vol. %, twice) then water (three times) and lyophilized until dry. Bile acid (BA) binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model as described above, and results are reported below.
- Synthesis of N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine. To a mixture of 1,4-diamino butane and acrylonitrile in dioxane was added 40% KOH solution under nitrogen. The reaction was stirred at room temperature over night and HPLC was used to monitor the reaction. After the completion of reaction, the mixture was diluted with tert-butyl methyl ether. The organic phase was washed with brine, then dried over anhydrous sodium sulfate. After concentration of the solution, 3,3′,3″,3′″-(butane-1,4-diylbis(azanetriyl))tetrapropanenitrile was obtained. A suspension of 3,3′,3″,3′″-(butane-1,4-diylbis(azanetriyl))tetrapropanenitrile in 1:1 methanol:water was placed in a Parr hydrogenation apparatus. To the mixture was charged wet Raney cobalt catalyst. The mixture was hydrogenated under 700 psi at 70° C. for 18 hours. After cooling to room temperature, the reaction was filtered through celite. The filtrate was concentrated to yield N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C4 BTA) as a pale yellow oil.
- N,N,N′,N′-tetrakis(3-aminopropyl)-1,8-octanediamine (C8 BTA), N,N,N′,N′-tetrakis(3-aminopropyl)-1,10-decanediamine (C10 BTA), and N,N,N′,N′-tetrakis(3-aminopropyl)-1,12-dodecanediamine (C12 BTA) were synthesized following same procedure.
-
BA BA BA BA binding Cross- Monomer:Cross- Cross- Binding binding Binding % Primary linking linking linking affinity capacity retention Bile Sam- monomer Monomer Monomer C4 BTA MeOH DMF A assay B assay Hamster Acids in Swelling ple # (R1) Molar Ratio (mg) (uL) (uL) (uL) (mmol/g) (mmol/g) (mmol/g) feces* (g/g) 1-A1 C8 alkylene 1:1.6 6705 5080 11126 11126 0.44 3.34 0.41 5.9 1.42 1-A2 C8 alkylene 1:2.2 6358 3503 9338 9338 0.50 3.29 0.79 1-A3 C10 alkylene 1:1.6 6868 4717 10947 10947 0.58 3.24 0.66 13.9 0.67 1-A4 C10 alkylene 1:2.2 6537 3265 9291 9291 0.65 2.95 0.52 25.0 0.60 1-A5 C10 alkylene 1:2.8 6083 2387 8045 8045 0.64 1.86 1.13 1-A6 C12 alkylene 1:1.6 7011 4403 10795 10795 0.68 3.25 0.77, 0.81 23.4, 20.0 0.41 1-B1 C12 alkylene 1:2.2 6694 3057 9250 9250 0.68 2.66 0.47 22.1 0.50 †average of 2 studies *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) - Synthesis of crosslinked N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine materials were conducted using parallel synthesis. A solution of N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (40 wt. % of a dimethyl sulfoxide (DMSO) solution) was dispensed into 40 mL glass vials. The bisacrylamide crosslinking monomer listed in the table below was added to each vial. Additional DMSO was added resulting in a total solid content of 40 wt. %. The vials were capped and heated for 17 hours at 58° C. The resulting polymer gel was swollen and ground in MeOH, washed in MeOH (twice), NaOH (0.5M once) then water (three times) and lyophilized until dry. Bile acid (BA) binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model as described above, and results are reported in the table below.
-
Monomer:Cross- Cross- Bisacrylamide linking linking Sam- Crosslinking Monomer Monomer C4 BTA DMSO ple # Monomer Molar Ratio (mg) (uL) (uL) 2-C3 N,N′-Octylene 1:2.2 1911 1135 5450 bis(acrylamide) 2-D2 N,N′-Decylene 1:1.6 1759 1293 5450 bis(acrylamide) BA BA BA BA Binding binding binding binding % Primary affinity capacity retention Bile Sam- A assay B assay Hamster Acids in Swelling ple # (mmol/g) (mmol/g) (mmol/g) feces* (gm/gm) 2-C3 0.60 2.97 0.39 21.5 2.00 2-D2 0.69 3.00 0.44 49.7 1.52 *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) - Synthesis of crosslinked N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine materials were conducted using parallel synthesis. A solution of N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (40 wt. % of a N,N-dimethylformamide (DMF) solution) was dispensed into 40 mL glass vials. Epichlorohydrin (ECH) was added to each vial. Additional DMF and methanol were added resulting in a total solid content of 40 wt. % where the solvents are in at a ratio of 1:1 (by volume). The vials were capped and heated for 17 hours at 58° C. The resulting polymer gel was swollen and ground in MeOH, washed in MeOH (twice), NaOH (0.5M once) then water (three times) and lyophilized until dry. Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model as described above, and results are reported in the table below.
-
Monomer:Cross- Cross- Cross- linking linking Sam- linking Monomer Monomer C4 BTA Methanol DMF ple # Monomer Molar Ratio (mg) (uL) (uL) (uL) 3-A1 ECH 1:1.6 39829 88720 72046 72046 BA Bile acid Bile acid Bile acid binding binding binding binding % Primary affinity capacity retention Bile Sam- A assay B assay Hamster Acids in Swelling ple # (mmol/g) (mmol/g) (mmol/g) feces* g/g 3-A1 0.34 3.15 0.12 4.7 52.06 *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) - Synthesis of crosslinked N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine materials were conducted using parallel synthesis. N,N,N′,N′-tetrakis(3-aminopropyl)-1,12-dodecanediamine was dispensed into a 40 mL glass vial. 1,3-bis(3-iodopropyl)-1H-imidazol-3-ium and N-methylpyrrolidone (NMP) was added to the vial. The vial was capped and heated for 17 hours at 58° C. The resulting polymer gel was swollen and ground in MeOH, washed in MeOH (twice), hydrochloric acid (1M, three times) then water (three times) and lyophilized until dry. Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model as described above, and results are reported in the table below.
-
Monomer:Cross- 1,3-bis(3-iodopropyl)-1H- linking imidazol-3-ium Sam- Monomer C12 BTA Crosslinking monomer NMP ple # Molar Ratio (mg) (mg) (uL) 4-B3 1:1.26 2080 3253 5666 BA Bile acid Bile acid Bile acid binding binding binding binding % Primary affinity capacity retention Bile Sam- A assay B assay Hamster Acids in Swelling ple # (mmol/g) (mmol/g) (mmol/g) feces* (g/g) 4-B3 0.51 2.99 0.48 18.5 11.45 *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) - A slurry of imidazole sodium salt (18.3 g, 0.2 mol) and 1-bromo-3-chloropropane (50 mL, 0.5 mol) in 200 mL of THF was stirred at room temperature overnight. The mixture was then refluxed for 8 hours and concentrated to dryness. Acetone (250 mL) was added to the residue, followed by sodium iodide (150 g, 1 mol). The slurry was stirred under refluxing overnight. Solvent was removed under reduced pressure. To the residue was added 300 mL of 10% methanol in dichloromethane. Solid was removed by filtration. The filtrate was concentrated and purified by chromatography (silica gel, 10-15% methanol in dichloromethane). 11.5 g of desired product was obtained as a brown oil. MS m/e (MH+), calcd 404.93, found 404.73. 1H NMR confirmed the structure.
- Synthesis of N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C4 BTA), N,N,N′,N′-tetrakis(3-aminopropyl)-1,10-decanediamine (C10 BTA) polymers materials were conducted using dispensing robots with liquid and powder dispensing capacities. C4 BTA or C10 BTA monomer was dispensed into 8 mL glass vials. Solutions of the crosslinking monomer of formula X-R1-X wherein X is halo such as chloro or bromo and R1 is a imidazolium hydrocarbon chain listed in the examples below. Crosslinkers were dispensed as 40 wt. % in dimethyl sulfoxide (DMSO). Solvent was added to each vial to make the final solid content concentration at 40 wt. %. Vials were equipped with magnetic stirrer, capped and heated for 17 hours at 70° C. Most vials contained a solid plug of polymer. The polymer was swollen and ground in dimethyl formamide (DMF), washed with aqueous hydrochloric acid (1 M), water, saturated solution sodium bicarbonate (NaHCO3) three times, water (two times) and lyophilized until dry.
-
BA binding Cross- BA binding % Primary monomer/cross- linking Capacity Affinity Retention Bile Sam- linker weight Monomer Weight DMSO B assay A assay Hamster Acids in ple # mole ratio Monomer (mg) (R1) (mg) (mg) (mmol/g) (mmol/g) (mmol/g) feces* 5-A1 1:1.6 C4 BTA 200.0 C10 bisimidazolium 879.7 1619.6 5-A2 1:2.2 C4 BTA 200.0 C10 bisimidazolium 1209.6 2114.4 2.59 0.59 6-A1 1:1 C4 BTA 200.0 C10 bisimidazolium 549.8 1124.7 2.68 0.58 6-A2 1:1.3 C4 BTA 200.0 C10 bisimidazolium 714.8 1372.1 2.57 0.50 6-A3 1:1.6 C4 BTA 200.0 C10 bisimidazolium 879.7 1619.6 2.82 0.54 7-A1 1:1.3 C4 BTA 1049.4 C10 bisimidazolium 3750.6 7200.0 2.71 0.57 7-A2 1:1.6 C4 BTA 1037.3 C10 bisimidazolium 4562.7 8400.0 2.91 0.56 0.48 12.1 8-A1 1:1 C4 BTA 200.0 C12 bisimidazolium 603.0 1084.0 2.82 0.58 8-A2 1:1.6 C4 BTA 200.0 C12 bisimidazolium 964.7 1572.4 2.69 0.66 8-B1 1:1 C10 BTA 200.0 C12 bisimidazolium 476.3 913.0 2.61 0.67 8-B2 1:1.6 C10 BTA 200.0 C12 bisimidazolium 762.1 1298.9 2.61 0.62 8-B3 1:1.6 C10 BTA 200.0 C12 bisimidazolium 762.1 1298.9 2.68 0.66 9-A1 1:1 C4 BTA 1494.5 C12 bisimidazolium 4505.0 8100.0 2.62 0.67 9-A2 1:1.6 C4 BTA 786.9 C12 bisimidazolium 3796.2 6187.3 2.62 0.66 0.44 10 9-B1 1:1 C10 BTA 1537.7 C12 bisimidazolium 3662.3 7020.0 2.70 0.68 9-B2 1:1.6 C10 BTA 838.9 C12 bisimidazolium 3197.0 5448.6 3.17 0.56 9-B3 1:1.6 C10 BTA 838.9 C12 bisimidazolium 3197.0 5448.6 2.7 0.63 0.47 16.4 10-A1 1:1.6 C4 BTA 1138.0 C12 core, C3 4062.0 7800.0 3.17 0.59 0.47 17.5 bisimidazolium 10-A2 1:1.6 C10 BTA 1361.3 C12 core, C3 3838.7 7800.0 3.12 0.58 0.47 27.5 bisimidazolium *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) - Synthesis of crosslinked N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine materials were conducted using parallel synthesis. A solution of N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (40 wt. % of a N,N-dimethylformamide (DMF) solution) was dispensed into 40 mL glass vials. 1,10-Dibromodecane (DBD), the crosslinking monomer and 1-(3-aminopropyl)imidazole (API), the comonomer, were added to each vial in the amounts described in the table below. Additional DMF and methanol were added resulting in a total solid content of 40 wt. % where the solvents were in at a ratio of 1:1 (by volume). The vials were capped and heated for 17 hours at 58° C. The resulting polymer gel was swollen and ground in MeOH, washed in MeOH (twice), NaOH (0.1M three times) then water (three times) and lyophilized until dry. Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model, and results are reported in the table below.
-
Monomer:Como- nomer:Cross- linking Sam- Monomer DBD C4 BTA API DMF methanol ple # Mole Ratio (mg) (uL) (uL) (uL) (uL) 11-D1 0.75:0.25:1.6 2588 1421 129 3426 3426 11-D2 0.5:0.5:1.6 3261 1119 405 3758 3758 11-D3 0.25:0.75:1.6 4406 605 876 4323 4323 BA BA BA BA binding binding binding binding % Primary affinity capacity retention Bile Sam- A assay B assay Hamster Acids in Swelling ple # (mmol/g) (mmol/g) (mmol/g) feces* g/g 11-D1 0.52 3.00 0.56 7.6 63.63 11-D2 0.56 2.92 0.62 10.4 49.36 11-D3 0.58 2.66 0.52 10.7 *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) - Synthesis of polymers with guanidine hydrochloride as a crosslinker consisted of three components: N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine monomer (C4 BTA), guanidine hydrochloride, and a comonomer. All the reactions were carried out using an appropriate size round bottom flask with a nitrogen inlet port and hot plates equipped with silicon oil baths.
- In a typical reaction, N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine monomer was dispensed into a round bottom flask with a nitrogen inlet port. Then guanidine hydrochloride and comonomer (if present) were added to the flask. The reaction flasks were capped using a rubber septum and nitrogen flow was introduced from the nitrogen inlet port. The reaction flask were then heated for 18 hours at 120° C. and then for 4 hours at 180° C. The polymer formed was swollen and ground in 1M hydrochloric acid solution and then washed with ethanol (two times), water, 3M sodium hydroxide (two times) and water (three times) and lyophilized until dry. Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below.
-
C4 Crosslinking C4 BTA:crosslinker:Comonomer BTA Crosslinker Sample # Monomer Comonomer (mol ratio) (g) (g) 12-B5 Guanidine None 1:2:0 20.00 12.07 HCl 13- A1 Guanidine 1,6- 1:1.56:1.56 3.49 1.64 HCl diamino- hexane 13- A2 Guanidine 1,8- 1:1.56:1.56 2.81 1.32 HCl diamino- octane 13- A3 Guanidine 1,10- 1:1.56:1.56 2.36 1.11 HCl diamino- decane 13- A4 Guanidine 1,12- 1:1.56:1.56 2.03 0.95 HCl diamino- dodecane 13- B1 Guanidine 1,12- 1:3.57:3.57 1.33 1.43 HCl diamino- dodecane BA binding BA binding BA binding BA binding % Primary Comonomer A assay B assay Hamster Bile Acids Swelling Sample # (g) (mmol/g) (mmol/g) (mmol/g) in feces* g/g 12-B5 0 0.48 3.39 0.43 20.9 13-A1 2.00 0.48 3.27 0.5 15.5 4.03 13-A2 2.00 0.54 3.2 0.495 20.8 2.76 13-A3 2.00 0.60 3.08 0.46 25.3 2.44 13-A4 2.00 0.65 3.21 0.595 22.2 2.41 13-B1 3.00 0.69 2.17 0.37 52.3 1.05 *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) - Synthesis of polymers with dihalobis piperidinium as crosslinkers consisted of two components: N,N,N′,N′-tetrakis(3-aminopropyl)-1,10-dacanediamine monomer (C10 BTA) or N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C4 BTA) and dihalobis piperidinium (TMBMP-DBD). The reactions were carried out using a 250 mL size round bottom flask with a nitrogen inlet port and hot plates equipped with silicon oil baths.
- In a typical reaction, a BTA monomer was dissolved in methanol to make a 50 wt. % solution and then dispensed into a round bottom flask. Then TMBMP-DBD or TMBMP-DBDD was added to the flask as a 50 wt. % solution in methanol. The reaction flasks were capped using a rubber septum and nitrogen flow was introduced from the nitrogen inlet port. The reaction flasks were then heated for 18 hours at 55° C. The polymers formed with C4 BTA were swollen and ground in methanol and washed with methanol (two times), 1M hydrochloric acid, and water (three times) and lyophilized until dry. The polymers formed with C10 BTA were swollen and ground in methanol and washed with methanol (two times), 0.5M hydrochloric acid, water, 0.5M sodium bicarbonate (two times) and water (three times) and lyophilized until dry. Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below.
-
Cross- Cross- Monomer:cross- linking Sam- Amine linking linker BTA CH3OH monomer ple # monomer Monomer (mol ratio) (g) (g) (g) 14-A1 C4 BTA TBMP-DBD 1:2 1.58 9.96 8.38 15-A1 C10 BTA TBMP-DBD 1:1.6 1.2 5.22 4.02 15-A2 C10 BTA TBMP-DBDD 1:1.6 1.2 5.49 4.29 BA Bile acid Bile acid Bile acid binding binding binding binding % Primary affinity capacity retention Bile Sam- A assay B assay Hamster Acids in Swelling ple # (mmol/g) (mmol/g) (mmol/g) feces* g/g 14-A1 0.55 2.73 0.37 14.0 7.6 15-A1 0.54 2.90 11.18 15-A2 0.66 2.79 0.53 18.8 1.83 *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) - Polymer synthesized with BTA and dihalobis piperidinium crosslinker were further modified by reacting with alkyl halides to attach a pendant alkyl ligand to the scaffold. In a typical reaction, polymer scaffold was first soaked in methanol in a 250 mL round bottom flask and then different amount of alkyl halide ligand (as listed in table below) was added to the flask. The reactions were carried out at 55° C. for 18 hours. The polymer were then washed with methanol (2 times), 1 M hydrochloric acid, 1 M sodium chloride (2 times), and water (3 times) and lyophilized until dry. Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below.
-
Polymer Polymer Sam- Polymer scaffold:Ligand scaffold Methanol Ligand ple # scaffold Ligand (mol ratio) (g) (g) (g) 16-A1 C4 BTA/ C10 alkyl 1:0.95 2.8 31.6 1.2 TMBMP/DBD 16-A2 C4 BTA/ C10 alkyl 1:1.75 2.2 27.69 1.8 TMBMP/DBD 16-A3 C4 BTA/ C10 alkyl 1:3.45 1.6 23.73 2.4 TMBMP/DBD BA binding BA BA BA Hamster binding binding binding % Primary affinity capacity retention Bile Sam- A assay B assay Hamster Acids in Swelling ple # (mmol/g) (mmol/g) (mmol/g) feces* g/g 16-A1 0.65 2.25 0.38 4.6 3.22 16-A2 0.62 2.11 2.29 16-A3 0.671 1.98 0.4 4.4 2.11 *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) - Into a round bottomed flask was weighed 60 g (0.20 moles) of dibromodecane and 20 mL of methanol. The flask was heated to 55° C. for 15-20 minutes. Then 10.0 g (0.041 mol) of 4,4′-Trimethylenebis(1-methylpiperidine) was added to the solution. The reaction mixture was allowed to stir for 12 hours and the reaction was stopped by the removal of heat and cooling to room temperature. The product was isolated by precipitation of the reaction solution into a solution of acetone:hexane 3:1 followed by filtration and washing with hexanes. The yield was 24.6 g 91% yield. The product was identified by 1H NMR and mass spec.
- A mixture of 11-bromoundecanol (31.65 g, 0.126 mol) and 4,4′-trimethylenebis(1-methylpiperidine) (5 g, 0.021 mol) in methanol (50 mL) was refluxed for 17 hours. Methanol was removed by rotary evaporation. To the residue was added toluene (100 mL) and the mixture was stirred at 50° C. for 2 hours. Solvent was removed by filtration. The solid was washed with toluene (100 mL) and ether (2×100 mL). After drying under high vacuum, 4,4′-(propane-1,3-diyl)bis(1-(11-hydroxyundecyl)-1-methylpiperidinium) was obtained as a white powder (15.5 g, 100%). MS m/e (M2+), calculated 290.3, found 290.5.
- 4,4′-(propane-1,3-diyl)bis(1-(11-hydroxyundecyl)-1-methylpiperidinium) (15.5 g, 0.21 mol) was placed in a pressure flask. Hydrobromic acid (50 mL, 48 wt. % in water) was added and the flask was tightened to seal. The reaction was stirred at 120° C. for 17 hours. The reaction mixture was azeotroped with THF and toluene to remove excess hydrobromic acid. The residue was dried in vacuum oven at 35° C. for 24 hours to give 17.27 g crude product as a light brown powder (94.9% yield).
- The crude product (4.02 g) was recrystallized in isopropanol (20 mL) to give 4,4′-(propane-1,3-diyl)bis(1-(11-bromoundecyl)-1-methylpiperidinium) as an off-white solid (3.11 g, 77.4% recovery). MS m/e (M2+), calculated 353.2, found 353.3.
- Synthesis of N,N,N′,N′-tetrakis(3-aminopropyl)-1,3-propanediamine, N,N,N′,N′-tetrakis (3-aminopropyl)-1,8-octaneanediamine, N,N,N′,N′-tetrakis(3-aminopropyl)-1,10-decanediamine and N,N,N′,N′-tetrakis (3-aminopropyl)-1,12-dodecanediamine polymers materials were conducted using dispensing robots with liquid and powder dispensing capacities. N,N,N′,N′-tetrakis(3-aminopropyl)-1,3-propanediamine or N,N,N′,N′-tetrakis (3-aminopropyl)-1, 8-octaneanediamine or N,N,N′,N′-tetrakis(3-aminopropyl)-1,10-decanediamine or N,N,N′,N′-tetrakis (3-aminopropyl)-1,12-dodecanediamine monomer was dispensed into 8 mL glass vials. Solutions of the crosslinking monomer of formula X-R1-X wherein X is halo such as chloro or bromo and R1 is a hydrocarbon chain listed in the examples below, 1,10-dibromodecane was dispensed at 40 wt. % in dimethyl sulfoxide (DMSO) and 1,12-dibromododecane was neat. Solvent was added to each vial to make the final solid content concentration at 40 wt %. Vials were equipped with magnetic stirrer, capped and heated for 17 hours at 60° C. Most vials contained a solid plug of polymer. The polymer was swollen and ground in dimethyl formamide (DMF), washed with aqueous hydrochloric acid (1 M), water, sodium hydroxide (0.01 M, three times), water (two times) and lyophilized until dry.
-
Bile acid Bile acid binding binding Capacity Affinity Retention % Primary Monomer:cosslinker Wt. Cross-linker wt DMSO B assay A assay Hamster Bile Acids Sample # mole ratio monomer (mg) (R1) (mg) (mg) (mmol/g) (mmol/g) (mmol/g) in feces* 17-A1 1:0.5 C8 BTA 300.0 C10 alkylene 120.8 631.2 17-A2 1:0.5 C10 BTA 300.0 C10 alkylene 112.3 618.5 17-A3 1:0.5 C12 BTA 300.0 C10 alkylene 105.0 607.5 17-B1 1:1 C8 BTA 300.0 C10 alkylene 241.6 812.4 3.33 17-B2 1:1 C10 BTA 300.0 C10 alkylene 224.7 787.0 3.22 17-B3 1:1 C12 BTA 300.0 C10 alkylene 210.0 764.9 3.32 17-C1 1:1.6 C8 BTA 300.0 C10 alkylene 386.6 1029.8 3.21 17-C2 1:1.6 C10 BTA 300.0 C10 alkylene 359.5 989.2 2.91 17-C3 1:1.6 C12 BTA 300.0 C10 alkylene 335.9 953.9 2.98 17-D1 1:2.2 C8 BTA 300.0 C10 alkylene 531.5 1247.3 2.93 17-D2 1:2.2 C10 BTA 300.0 C10 alkylene 494.3 1191.4 2.74 17-D3 1:2.2 C12 BTA 300.0 C10 alkylene 461.9 1142.9 2.61 18-A1 1:1.6 C10 BTA 6368.8 C10 alkylene 7631.2 21000.0 3.07 0.68 19-A1 1:1.6 C10 BTA 2911.5 C10 alkylene 3488.5 9600.0 3.15 0.68 0.49 25.1 19-A2 1:1.6 C12 BTA 3019.1 C10 alkylene 3380.9 9600.0 3.00 0.70 0.56 28.3 20-A2 1:1.6 C8 BTA 150.0 C10 alkylene 193.3 514.9 20-B2 1:2.2 C8 BTA 150.0 C10 alkylene 265.8 623.6 2.77 20-C2 1:2.8 C8 BTA 150.0 C10 alkylene 338.2 732.4 2.54 20-D2 1:3.4 C8 BTA 150.0 C10 alkylene 410.7 841.1 2.24 21-A1 1:1.6 C3 BTA 150.0 C10 alkylene 238.2 582.3 3.32 0.61 21-B1 1:2.2 C3 BTA 150.0 C10 alkylene 327.5 716.3 3.24 21-C1 1:2.8 C3 BTA 150.0 C10 alkylene 416.8 850.3 3.10 0.69 21-D1 1:3.4 C3 BTA 150.0 C10 alkylene 506.2 984.3 2.86 0.71 22-A1 1:1.6 C3 BTA 2923.5 C12 alkylene 5076.5 12000.0 3.03 0.68 0.64 26.2 *% Primary Bile Acids in feces as % of total measured: i e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) -
- Synthesis of N1,N1′-(1,3-phenylenebis(methylene))bis(N1-(3-aminopropyl)propane-1,3-diamine) (R3=1,3-phenylenedimethyl), N1,N1′-(1,4-phenylenebis(methylene))bis(N1-(3-aminopropyl)propane-1,3-diamine) (R3=1,4-phenylenedimethyl), N2,N2,N6,N6-tetrakis(3-aminopropyl)pyridine-2,6-dicarboxamide (R3=2,6-diformylpyridine), N1,N1,N6,N6-tetrakis(3-aminopropyl)adipamide (R3=1,6-dioxohexane-1,6-diyl), N1,N1,N4,N4tetrakis(3-aminopropyl)succinamide (R3=succinyl) and 1,3-bis(3-(bis(3-aminopropyl)amino)propyl)-1H-imidazol-3-ium (R3=3,3′-(1H-imidazole-3-ium-1,3-diyl)dipropyl) crosslinked materials were conducted using dispensing robots with liquid and powder dispensing capacities. The selected monomer was dispensed into 8 mL glass vials. Solutions of the crosslinking monomer of formula X-R1-X wherein X is halo such as chloro or bromo and R1 is a hydrocarbon chain as listed in the table below was dispensed as 40 wt. % in dimethyl sulfoxide (DMSO). Solvents and K2CO3 were added to each vial. The vials were equipped with magnetic stirrer, capped and heated for 17 hours at 60° C. Most vials contained a solid plug of polymer. The polymer was swollen and ground in methanol, washed with aqueous hydrochloric acid (1 M), water, sodium hydroxide (0.01 M, three times), water (two times) and lyophilized until dry.
-
BA binding % Mono- 1,10- BA binding Primary Cross- mer:cross- Dibromo Affinity Capacity Retention Bile Sample linking linker decane K2CO3 DMSO A assay B assay Hamster Acids in # monomer mole ratio Monomer R3 value wt (mg) (mg) (mg) (mg) (mmol/g) (mmol/g) (mmol/g) feces* 23-B1 C10 alkylene 1:0.5 1,3-phenylenedimethyl 400 102.9 568.6 754.3 0.672 2.7324 23-B2 C10 alkylene 1:1 1,3-phenylenedimethyl 400 205.8 568.6 908.6 0.6636 1.3948 23-C1 C10 alkylene 1:0.5 2,6-diformylpyridine 400 104.2 480 756.3 23-C2 C10 alkylene 1:1 2,6-diformylpyridine 400 208.4 480 912.7 0.6592 2.3176 23-D1 C10 alkylene 1:0.5 1,6-dioxohexane-1,6-diyl 400 115.8 426.6 773.7 23-D2 C10 alkylene 1:1 1,6-dioxohexane-1,6-diyl 400 231.5 426.6 947.3 0.6404 2.2948 24-A1 C10 alkylene 1:1.6 1,3-phenylenedimethyl 329.1 270.9 467.9 900 0.6586 1.3198 24-A2 C10 alkylene 1:1.6 2,6-diformylpyridine 327.2 272.8 392.7 900 0.6938 1.8654 24-A3 C10 alkylene 1:1.6 1,6-dioxohexane-1,6-diyl 311.5 288.5 332.2 900 0.6846 1.9758 25-A1 C10 alkylene 1:1.6 1,3-phenylenedimethyl 3949.4 3250.5 5614.3 10799.8 0.366 0.2862 25-A2 C10 alkylene 1:1.6 1,3-phenylenedimethyl 3926.3 3273.7 4711.9 10800 0.583 0.849 0.2 26.3 25-A3 C10 alkylene 1:1.6 1,6-dioxohexane-1,6-diyl 3983.9 3689.8 4248.7 11510.6 0.6502 1.495 0.25, 0.51 36.3, 29.2 26-A1 C10 alkylene 1:0.5 1,3-phenylenedimethyl 4600.6 1183.3 6540.1 8675.9 0.64905 2.7082 27-A1 C10 alkylene 1:0.5 1,3-phenylenedimethyl 2409.9 619.8 3425.8 4544.5 0.6652 2.6874 27-A2 C10 alkylene 1:1 2,6-diformylpyridine 2998.3 1562.4 3598.2 6841.1 0.5532 1.2818 28-A2 C10 alkylene 1:1 1,3-phenylenedimethyl 300 154.3 426.5 681.5 0.6668 2.8324 28-A3 C10 alkylene 1:0.5 1,3-phenylenedimethyl 300 231.5 426.5 797.2 0.6716 2.0856 29-A1 C10 alkylene 1:0.5 1,3-phenylenedimethyl 3943.4 1014.2 5605.8 7436.5 0.6628 2.1736 29-A2 C10 alkylene 1:1 1,3-phenylenedimethyl 2880.4 1481.7 4094.7 6543.2 0.67 1.8818 30-A1 C10 alkylene 1:0.8 3,3′-(1H-imidazole-3-ium- 300 108.2 373.6 612.2 0.573 2.889 1,3-diyl)dipropyl 30-A2 C10 alkylene 1:1.2 3,3′-(1H-imidazole-3-ium- 300 162.2 373.6 693.3 0.617 2.7334 1,3-diyl)dipropyl 31-A1 C10 alkylene 1:0.8 3,3′-(1H-imidazole-3-ium- 2001.4 721.5 2492.5 4084.5 0.6018 2.9138 1,3-diyl)dipropyl 31-A2 C10 alkylene 1:1.2 3,3′-(1H-imidazole-3-ium- 2001.4 1082.1 2492.5 4624.8 0.6374 2.4926 0.5 16.2 1,3-diyl)dipropyl 32-A1 C10 alkylene 1:0.8 3,3′-(1H-imidazole-3-ium- 4700 1694.4 5853.3 9591.6 0.638 2.3254 0.5 19.8 1,3-diyl)dipropyl 33-A1 C10 alkylene 1:0.8 Succinyl 400 195.83 450.99 795.1 0.62 2.86 33-A2 C10 alkylene 1:1.2 Succinyl 400 293.74 450.99 892.9 0.66 2.48 33-A3 C10 alkylene 1:1.6 Succinyl 400 391.66 450.99 990.7 0.66 1.78 33-A4 C10 alkylene 1:1.2 Succinyl 4000 2937.42 4509.85 8929.3 0.65 2.71 0.59 14.5 33-B1 C12 alkylene 1:0.8 Succinyl 400 214.14 450.99 813.4 0.68 1.83 33-B2 C12 alkylene 1:1.2 Succinyl 400 321.21 450.99 920.4 0.68 2.31 33-B3 C12 alkylene 1:1.6 Succinyl 400 428.28 450.99 1027.3 0.66 1.33 33-B4 C12 alkylene 1:1.2 Succinyl 4000 3212.11 4509.85 9203.7 0.68 1.95 0.39 25.0 *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) -
- Tert-butyl 3,3′-azanediylbis(propane-3,1-diyl)dicarbamate (14.0 g, 0.038 mol) was dissolved in 150 mL of acetonitrile. To the solution was added 1,3-bis(chloromethyl)benzene (3.34 g, 0.019 mol), followed by diisopropylethylamine (13.2 mL, 0.076 mol). The reaction was stirred at 60° C. for 20 hours. The solvent was removed and the residue was purified by flash chromatography (silica gel, 15% methanol in dichloromethane) to give 7.56 g (52%) of pure tert-butyl-3,3′,3″,3′″-(1,3-phenylenebis(methylene))bis(azanetriyl)tetrakis(propane-3,1-diyl)tetracarbamate as a brown oil. MS m/e (MH+), calculated 765.55, found 765.67.
- Tert-butyl 3,3′,3″,3′″-(1,3-phenylenebis(methylene))bis(azanetriyl)tetrakis-(propane-3,1-diyl)tetracarbamate (7.56 g, 0.099 mol) was dissolved in 40 mL of dichloromethane. To the solution was added trifluoroacetic acid (30.5 mL, 0.396 mol). The reaction was stirred at room temperature for 16 hours. Solvent was removed under reduced pressure and toluene (100 mL) was added to the residue to form a heteroazeotrope. After removal of toluene and remaining trifluoroacetic acid, a brown semi-solid was formed. To the residue was added 4N hydrochloric acid in dioxane (40 mL) and the mixture was stirred at room temperature for 30 minutes. A light brown solid formed. Ethyl ether (150 mL) was added to the mixture and the solid was filtered, washed with ethyl ether and dried under high vacuum to give 5.78 g N1,N1′-(1,3-phenylenebis(methylene))bis(N1-(3-aminopropyl)propane-1,3-diamine) as a hexahydrochloride salt in quantitative yield. MS m/e (MH+), calculated 365.33, found 365.39.
-
- A solution of tert-butyl 3,3′-azanediylbis(propane-3,1-diyl)dicarbamate (9.94 g, 0.03 mol) and diisopropylethyl amine (7.82 mL, 0.045 mol) in 200 mL of dichloromethane was cooled to 4° C. in an ice bath. Pyridine-2,6-dicarbonyl dichloride (3.06 g, 0.015 mol) was dissolved in 50 mL of dichloromethane and was added to the solution of tert-butyl 3,3′-azanediylbis(propane-3,1-diyl)dicarbamate dropwise. The internal temperature remained at or below 4° C. during the addition. After the addition, the reaction was warmed to room temperature and stirred for 3 hours. The reaction solution was washed with 1N HCl (2×150 mL), brine (150 mL), saturated NaHCO3 solution (150 mL), and brine (150 mL). The organic phase was dried over MgSO4 and concentrated. The crude product was passed through a silica gel plug (15% methanol in dichloromethane) to give 11.2 gram of tetra-Boc-protected N2,N2,N6,N6-tetrakis(3-aminopropyl)pyridine-2,6-dicarboxamide as a white solid (94%). MS m/e (MH+), calculated 794.50, found 794.71.
- To a solution of tetra-Boc-protected N2,N2,N6,N6-tetrakis(3-aminopropyl)pyridine-2,6-dicarboxamide (11.1 g, 0.014 mol) in 80 mL of dichloromethane was added trifluoroacetic acid (21.6 mL, 0.28 mol). The reaction was stirred at room temperature for 3 hours. Solvent was removed under reduced pressure and toluene (100 mL) was added to the residue to form a heteroazeotrope. Solvent and remaining trifluoroacetic acid were removed under reduced pressure. To the residue was added 4N HCl in dioxane (25 mL). The mixture was stirred at room temperature for 30 minutes and a white solid formed. Ethyl ether (150 mL) was added to the mixture and the solid was filtered, washed with ethyl ether and dried under high vacuum to give N2,N2,N6,N6-tetrakis(3-aminopropyl)pyridine-2,6-dicarboxamide as penta-hydrochloride salt in quantitative yield (8.02 g). MS m/e (MH+), calculated 394.29, found 394.3.
-
- The title compound was prepared using same procedure described above for N2,N2,N6,N6-tetrakis(3-aminopropyl)pyridine-2,6-dicarboxamide. After drying under high vacuum, 6.03 g of N1,N1,N6,N6-tetrakis(3-aminopropyl)adipamide tetra-hydrochloride salt was obtained as a white solid (78%). MS m/e (MH+), calculated 373.33, found 373.4.
-
- A solution of tert-butyl 3,3′-azanediylbis(propane-3,1-diyl)dicarbamate (15.0 g, 0.045 mol) and diisopropylethyl amine (8.6 mL, 0.0495 mol) in 200 mL of dichloromethane was cooled to 4° C. in ice bath. Succinyl chloride (2.68 mL, 0.0226 mol) was dissolved in 50 mL of dichloromethane and was added to the solution of tert-butyl 3,3′-azanediylbis(propane-3,1-diyl)dicarbamate dropwise. The internal temperature remained at or below 4° C. during the addition. After the addition, the reaction was warmed to room temperature and stirred for 2 hours. The reaction solution was washed with 1:1 mixture of 1N HCl and brine (2×150 mL), saturated NaHCO3 solution (200 mL), and brine (200 mL). Organic phase was dried over MgSO4 and concentrated. The crude product was purified on silica gel column (5-10% methanol in dichloromethane) to give 14.92 gram of t-Boc-protected N1,N1,N4,N4-tetrakis(3-aminopropyl)succinamide as a brown solid (88.6%).
- A solution of tetra-Boc-protected N1,N1,N4,N4-tetrakis(3-aminopropyl)succinamide (14.9 g, 0.02 mol) in 4N HCl in dioxane (100 mL, 0.4 mol) was stirred at room temperature overnight. Precipitate formed in the solution. Diethylether (100 mL) was added to the reaction mixture. The slurry was stirred at room temperature for 30 min. Solid was filtered under nitrogen blanket and washed with diethylether (3×100 mL). After removal of residue solvent, desired product was obtained in quantitative yield as a tetrahydrochloride salt. MS m/e (MH+), calculated 345.29, found 345.3.
-
- To a solution of 1,3-bis(3-iodopropyl)-1H-imidazol-3-ium iodide (5.02 g, 9.4 mmol) in 100 mL of acetonitrile was added tert-butyl 3,3′-azanediylbis(propane-3,1-diyl)dicarbamate (6.25 g, 18.8 mmol), followed by diisopropylethylamine (4.08 mL, 23.5 mmol). The reaction was stirred at 60° C. for 16 hours. Solvent was removed under reduced pressure. The crude product was purified by flash chromatography (silica gel, 15% methanol in dichloromethane containing 1% trimethylamine). 1,3-bis(3-(bis(3-(tert-butoxycarbonylamino)propyl)amino)propyl)-1H-imidazol-3-ium iodide was obtained as white solid (5.8 g, 66%). MS m/e (MH+), calculated 811.6, found 811.7.
- A mixture of 1,3-bis(3-(bis(3-(tert-butoxycarbonylamino)propyl)amino)propyl)-1H-imidazol-3-ium iodide (5.5 g, 5.8 mmol) in 4N HCl in dioxane (58.6 mL, 234 mmol) was stirred at room temperature overnight. Solvent was removed under reduced pressure. Toluene (3×100 mL) was added to form a heteroazeotrope. After removal of toluene and residue solvent, the desired product was obtained as a hexahydrochloride salt in quantitative yield. MS m/e (MH+), calculated 411.39, found 411.4.
- Synthesis of Bis imiazole-n-alkane. A solution of Na-imidazole (0.1 mol) (imidazole sodium derivative, Aldrich 197637, CAS 5587-42-8) in 100 mL THF was prepared. An appropriate amount of the dialkyl bromide was added and the mixture was stirred overnight at room temperature. The solids were filtered off and the filtrate was dried under vacuum. The product was purified by column chromatography using 500 g of silica and ethyl acetate. The resulting yield was 50-80%. The product was identified by 1H NMR and mass spec.
- Synthesis of 1-alkyl-3-(1-bromoalkyl) imidazolium bromide. Dibromoalkane (0.3 mol) was placed into a 3-necked flask that was fitted with an overhead stirrer. Acetone was added such that the resulting solution was 3 M. Alkyl imidazole (0.03 mol) was dissolved in acetone to result in a 2M solution. This was added to the flask and the reaction was stirred overnight at 45-50° C. The next day, the acetone was vacuumed off and the product was purified by column chromatography using 500 g of silica gel and 90:10 CH2Cl2:MeOH. The yield was in the range of 60-70% of materials that ranged from a clear oil to a white sold. Product was identified by 1H NMR and mass spec.
- Synthesis of polymer modified with 1,3-dialkylimidazolium bromide. The desired polyamine scaffold gel was dissolved in water and neutralized with an equimolar solution of NaOH. An appropriate amount of a solution of 1,3-dialkylimidazolium bromide in methanol was added to the polyamine solution. The mixture was heated to 75° C. for 24 hours. After cooling to room temperature the modified polyamine gel was washed by exposing the gel to a 2× methanol wash, 0.5 M HCl wash and 2× water washes. Each wash consisted of a process where the gel was stirred for 30 minutes, exposed to the washing solvent, centrifuged and the supernatant liquid was decanted off, and the wash solvent was added. After the final water wash, the gel was placed into a lyophilizer to remove the water. The gel was isolated as a white fluffy material.
- Synthesis of n-alkyl bisimidazole. Imidazole sodium derivative (27 g, 0.29 moles) and tetrabutyl ammonium hydrogen sulfate (2.2 g, 6 mmol) (both commercially available from Aldrich) was weighed into a 1 L, 3 necked flask. An overhead stirrer, a condenser with a feed of dry, inert atmosphere was fitted to the flask. The remaining neck was fitted with a rubber septa. Anhydrous THF (250 mL) was added to the flask and stirred for 1 hour at room temperature. An appropriate amount of alkyl dibromide (1, 12 dibromododecane, 16.g, 0.049 mol) in 50 mL THF was added. After stirring for 3-5 days and monitoring the progress with TLC, the solids were filtered off and the filtrate was dried under reduced pressure to generate an oil. The product was purified by adding CH2Cl2 and washing five times with water and then washing the organic layer with anhydrous magnesium sulfate. The purity was monitored by TLC (10% MeOH, 90% CH2Cl2), until no starting imidazole was present. The resulting yields were in the range of 80-90%. 1H NMR (CD3OD, 25° C., δ (ppm): 7.62 (s), 7.1, 6.90 (imidazole), 4.0 (tr), 1.8 (br), 1.25 (br, alkane). A similar synthesis procedure was used for 1,10-dibromodecane.
- Synthesis of bis(1-bromoalkyl imidazolium bromide) alkane. In a dry sealed round bottomed flask, an appropriate amount of dibromoalkane (dibromododecane 48.7 g, 0.14 mol) was taken and 49 g of acetone, 1 g of MeOH was added as solvent. To this, freshly prepared n-alkyl bisimidazole (10 g, 0.033 mol) was added dropwise. It was heated at 55° C. for 2-3 days. The product was isolated by precipitating the product. The reaction solution was allowed to cool to room temperature and then this was added slowly to a glass beaker containing 250 mL of hexanes being rapidly stirred. The product form a precipitate oil. The hexanes were removed and the precipitate was stirred/washed with the following solvents to remove excess dibromoalkane; ethylacetate and diethyl ether. The white precipitate was placed in a vacuum oven to remove excess organic solvent.
- The yields were in the range of 60%. 1H NMR (CD3OD, 25° C., δ (ppm): 9.1 (s), 7.7 (imidazolium), 4.21 (tr, —CH2-imidazolium), 3.4 (—CH2Br), 1.9 (br), 1.4 (br, alkane). A similar synthesis procedure was used to prepare all bisimidazolium alkylhalide crosslinkers e.g. bis imidazolium C10 crosslinker, bis imidazolium C12 crosslinker, bis imidazolium C12 core C3 crosslinker.
- Into a round bottomed flask was weighed 42.34 g (0.20 moles) of dibromopropane and 20 mL of methanol. The flask was heated to 55° C. for 15-20 minutes. Then 10.0 g (0.041 mol) of 4,4′-trimethylenebis(1-methylpiperidine) was added to the solution. The reaction mixture was allowed to stir for 12 hours and the reaction was stopped by the removal of heat and cooling to room temperature. The product was isolated by precipitation of the reaction solution into a solution of acetone:hexane 3:1 followed by filtration and washing with hexanes. The yield was 24.6 g (91% yield). The product was identified by 1H NMR and mass spectrometry.
- Synthesis of ligand-containing BTA polymers by the monomer approach was conducted in a 4×6 library format with 8 mL vials. N-alpha-(tert-butoxycarbonyl)-L-tryptophan N-succinimidyl ester (Boc-Trp-Osu) was obtained commercially (TCI America CAS 3392-11-8). The synthesis was conducted in a two step process.
- Step 1 (Recipe for BTA modified with ligand). A 75 wt. % solution of N,N,N′,N′-tetrakis(3-aminopropyl)-1,4-butanediamine (C4 BTA) in N-methylpyrrolidone (NMP) was dispensed into the vials, followed by a solution of ligand (20 wt. % in NMP). The vials were sealed and the mixture was stirred at 80° C., stirring at 500 RPM for 18 hours, then cooled to room temperature. Attachment of the ligand to C4 BTA was confirmed using MS. The amounts of the C4 BTA, NMP, and Boc-Trp-OSu use are listed in the table below.
- Step 2 (Crosslinking the modified BTA monomer). The C4 BTA-ligand mixture was subsequently treated with neat 1,10-dibromodecane (DBD) or epichlorohydrin (ECH). The reactions were sealed and heated at 80° C. for 18 hours with stirring at 500 RPM until the reaction mixture gelled. Samples that gelled were washed with methanol (2×), 1M NaOH solution, water (3×), then lyophilized dry. The amounts for the reactants are listed in the table below.
-
Recipe # C4 BTA NMP Boc-Trp-OSu 100-A1 911.14 1459.15 288.86 100-A2 734.37 2107.32 465.63 100-A3 529.07 2860.07 670.93 100-A4 339.34 3555.74 860.66 BA BA binding binding Amine:Cross- Ligand:Amine affinity capacity linker Mol Cross- A assay B assay Sample Amine Cross- Mol Ratio to 100- 100-A2 100-A3 100-A4 linker (mmol/ (mmol/ # Monomer Ligand linker Ratio BTA A1 (mg) (mg) (mg) (mg) (mg) g) g) 34-A1 BTA Boc-Trp-Osu ECH 1:2 1:0.25 650.435 0 0 0 130.28 0.47 2.95 34-A2 BTA Boc-Trp-Osu ECH 1:4 1:0.25 650.435 0 0 0 260.56 0.41 0.62 34-A3 BTA Boc-Trp-Osu ECH 1:6 1:0.25 650.435 0 0 0 390.85 0.37 0.68 34-A4 BTA Boc-Trp-Osu ECH 1:8 1:0.25 650.435 0 0 0 521.13 0.36 1.01 34-B1 BTA Boc-Trp-Osu ECH 1:2 1:0.5 0 0 0 0 104.69 0.44 2.42 34-B2 BTA Boc-Trp-Osu ECH 1:4 1:0.5 0 0 0 0 209.38 0.42 1.26 34-B3 BTA Boc-Trp-Osu ECH 1:6 1:0.5 0 806.535 0 0 314.06 0.38 1.23 34-B4 BTA Boc-Trp-Osu ECH 1:8 1:0.5 0 806.535 0 0 418.75 0.37 1.15 35-A1 BTA Boc-Trp-Osu DBD 1:1 1:0.5 0 806.535 0 0 211.27 0.57 3.20 35-A2 BTA Boc-Trp-Osu DBD 1:2 1:0.25 0 806.535 0 0 422.54 0.65 2.31 35-A3 BTA Boc-Trp-Osu DBD 1:3 1:0.25 0 0 0 0 633.81 0.55 1.06 35-A4 BTA Boc-Trp-Osu DBD 1:4 1:0.25 0 0 0 0 845.09 N/A 1.81 35-B1 BTA Boc-Trp-Osu DBD 1:1 1:0.5 0 0 1013.94 0 169.77 0.58 2.80 35-B2 BTA Boc-Trp-Osu DBD 1:2 1:0.5 0 0 1013.94 0 339.54 0.63 1.74 35-B3 BTA Boc-Trp-Osu DBD 1:3 1:0.5 0 0 1013.94 0 509.30 0.46 0.63 35-B4 BTA Boc-Trp-Osu DBD 1:4 1:0.5 0 0 1013.94 0 679.07 0.48 0.76 35-C1 BTA Boc-Trp-Osu DBD 1:1 1:1 0 167.56 0 0 125.25 N/A 1.12 35-C2 BTA Boc-Trp-Osu DBD 1:2 1:1 0 167.56 0 0 250.51 0.54 0.88 35-C3 BTA Boc-Trp-Osu DBD 1:3 1:1 0 167.56 0 1119.4693 375.76 0.54 0.83 *Boc-Trp-Osu is 2-(tert-butoxycarbonylamino)-3-1H-indol-3-yl)-1 oxopropanyl Animal samples prepared by the monomer approach follow. BA BA BA BA binding binding Amine:Cross- Ligand:Amine Cross- binding binding Hamster % Primary Swell- Sample linker Mol BTA Ligand NMP linker A assay B assay (mmol/ Bile Acids ing # Ligand Mol Ratio Ratio (mg) (mg) (uL) (mg) (mmol/g) (mmol/g) g) in feces* (g/g) 36-A1 Boc-Trp- Osu 1 0.25 3037.1 962.9 4731.4 2879.1 0.57 3.20 0.62 12.0 0.92 37-A1 Boc-Trp- Osu 1 0.25 5315 1685 1685 5038.4 0.58 3.28 0.51 17.7 0.80 38-B1 Trp ( De-Boc 1 0.25 3037.1 962.9 4731.4 2879.1 0.59 3.27 0.55 14.8 0.62 of 36-A1) 39-A1 Amphiphilic 0.33 0.25 2994.77 1005.2 18579.1 N/A 0.67 1.57 0.28 31.9 0.81 *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) - Preparation of de-Boc Trp animal sample (38-B1). Following the attachment of Boc-Trp-OSu ligand onto the polymer as described above, the polymer was treated with two additional washes of HCl in dioxane (4M). The polymer was then washed with water, 10 vol. % NH4OH (2×), and water (3×) before lyophilizing dry.
- The scaffold was prepared by mixing C4 BTA neat with a 50
wt. % 1,10-dibromodecane (DBD) in N-methylpyrrolidone (NMP). Additional NMP was added to give a total concentration of crosslinker and C4 BTA equal to 37.5 wt. %. The mixture was heated at 70° C. stirring at 400 RPM until the mixture formed a gel. The gel was continued to be heated for a total of 22 hours before cooling. The solid was ground in methanol, washed with methanol, 1M NaCl, MeOH, water (3×), then lyophilized dry to give tacky particles. - The scaffold was portioned out into a 4×6 library plate with 8 mL vials. To this was added a 20 wt. % solution of ligand (thiazolium) in NMP. The vials were filled with NMP to achieve a total volume of 2.5 mL. The mixture was stirred at 80° C. for 18 hours, stirring at 500 RPM. Reactions were cooled, washed with methanol, 1M NaOH, and water, then lyophilized dry. The amounts used for the reactions follow.
-
BTA- BA binding BA binding DBD affinity capacity Sample Amine Amine:Crosslinker Ligand:Amine Scaffold Ligand A assay B assay # Monomer Ligand Crosslinker Mol Ratio Mol Ratio (mg) (mg) NMP (uL) (mmol/g) (mmol/g) 40-A1 BTA None DBD 0.625 0 300 0 2380 0.60 3.29 40-A2 BTA Thiazolium DBD 0.625 0.04 300 5.78 2374.22 0.60 3.29 40-A3 BTA Thiazolium DBD 0.625 0.08 300 11.56 2368.44 0.61 3.27 40-A4 BTA Thiazolium DBD 0.625 0.12 300 17.33 2362.67 0.60 3.23 40-A5 BTA Thiazolium DBD 0.625 0.16 300 23.11 2356.89 0.60 3.21 40-A6 BTA Thiazolium DBD 0.625 0.2 300 28.89 2351.11 0.61 3.20 40-B1 BTA Thiazolium DBD 0.625 0.25 300 36.11 2343.89 0.60 3.23 40-B2 BTA Thiazolium DBD 0.625 0.3 300 43.33 2336.67 0.60 3.17 40-B3 BTA Thiazolium DBD 0.625 0.35 300 50.56 2329.44 0.61 3.22 40-B4 BTA Thiazolium DBD 0.625 0.4 300 57.78 2322.22 0.60 3.20 40-B5 BTA Thiazolium DBD 0.625 0.45 300 65.00 2315 0.59 3.12 40-B6 BTA Thiazolium DBD 0.625 0.5 300 72.22 2307.78 0.61 3.16
Animal samples prepared by the scaffold approach are listed below: -
BTA- Ligand:Amine DBD Amine:Crosslinker Mol Scaffold Ligand Solvent Sample # Ligand Solvent Mol Ratio Ratio (mg) (mg) (uL) 41-A2 Amphiphilic NMP 0.625 0.25 3000 399.4 28410.6 41-A1 Amphiphilic NMP 0.625 0.1 3000 159.8 28650.2 41-B2 Boc-Trp-Osu NMP 0.625 0.25 3000 377.3 28432.7 42-A1 Tryptamine NMP 0.625 0.25 3000 261.4 18548.6 43-A3 Thiazolium NMP 0.625 0.25 3000 358.1 18451.9 37-A3 Thiazolium NMP 0.625 0.5 3000 716.2 18093.8 44-B6 C10 Pyridinium NMP 0.625 0.25 3000 356.4 38453.6 43-A2 3-(2-Bromoethyl NMP 0.625 0.1 3000 84.2 18725.8 Indole) 44-A1 C3 thiophenium DMSO 0.625 0.25 3000 361 18449 44-A2 C3 thiophenium DMSO 0.625 0.5 3000 721.9 18088.1 45-A1 (3-Bromopropyl) DMSO 0.625 0.25 5000 408.77 17608.23 trimethylammonium bromide 45-A2 C3 methyl DMSO 0.625 0.25 5000 447.92 17569.08 imidazolium 45-A3 C3 pyrrolidinium DMSO 0.625 0.25 5000 435.44 17581.56 45-A4 C3 benz- DMSO 0.625 0.25 5000 527.87 17489.13 thiazolium 45-A5 C3 methyl DMSO 0.625 0.25 5000 620.35 17396.65 thiazolium BA binding BA binding BA binding Bile acid binding affinity capacity retention % Primary A assay B assay Hamster Bile Acids Swelling Sample # (mmol/g) (mmol/g) (mmol/g) in feces* (g/g) 41-A2 0.65 3.17 0.58 4.3 1.29 41-A1 0.64 3.25 0.62 5.7 1.00 41-B2 0.64 3.11 0.51 3.0 1.50 42-A1 0.62 3.25 0.60 8.1 0.64 43-A3 0.62 3.23 0.73, 0.42 6.4, 5.2 1.33 37-A3 0.59 2.99 0.35 6.4 8.30 44-B6 0.59 3.04 0.55 9.0 24.20 43-A2 0.62 3.25 0.67 6.1 N/A 44-A1 0.62 3.26 1.23 44-A2 0.63 3.16 0.75 45-A1 0.62 3.26 0.59 45-A2 0.62 3.27 0.56 45-A3 0.62 3.23 0.89 45-A4 0.62 3.23 0.40 45-A5 0.62 3.20 0.52 *% Primary Bile Acids in feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic acid) × 100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid) -
- The titled compound was prepared using same procedure described above. Thiazole (4 g, 0.047 mol) and diiodopropane (27.2 mL, 0.24 mol) were refluxed in acetonitrile (15 mL) for 5 hours, then stirring was continued at room temperature overnight. The white precipitate was removed by filtration. To the filtrate was added diethyl ether 100 mL. The mixture was cooled in refrigerator overnight. The solid was filtered and washed with acetonitrile (20 mL) then ether (3×30 mL). After drying under reduced pressure, 17 g (95%) of desired product was obtained as a yellow solid. MS m/e (MH+), calculated 253.95, found 254.0. 1H NMR confirmed the structure.
-
- To a solution of 2-methylthiazole (3.0 g, 0.03 mol) in acetonitrile (15 mL) was added diiodopropane (17.4 mL, 0.15 mol). The reaction was refluxed for 5 hours, then stirring was continued at room temperature overnight. White precipitate was removed by filtration. To the filtrate was added diethyl ether (100 mL). White crystals formed. The mixture was cooled in refrigerator overnight. The solid was filtered and washed with acetonitrile (20 mL) then ether (3×30 mL). After drying under reduced pressure, 8.41 g product was obtained as a white solid (71%). MS m/e (MH+), calculated 267.97, found 268.0. 1H NMR confirmed the structure.
-
- The titled compound was prepared using same procedure described above. Benzothiazole (22.5 mL, 0.2 mol) and 1,3-dibromopropane (102 mL, 1 mol) were refluxed for 48 hours to afford 35.5 g desired product as a yellow solid (69%). MS m/e (MH+), calculated 257.98, found 258.0. 1HNMR confirmed the structure.
-
- A mixture of tetrahydrothiophene (3.0 g, 0.034 mol) and diiodopropane (7.86 mL, 0.068 mol) in acetonitrile (3.4 mL) was stirred at 65° C. overnight. The solid was filtered and washed with acetonitrile (3×10 mL). After drying under high vacuum, the desired product was obtained as a white solid (6.13 g, 47%). MS m/e (MH+), calculated 256.99, found 257.0. 1H NMR confirmed the structure.
- To a vigorously stirring flask of 1,10-dibromodecane (337.2 mL; 1.5 mmol) was added pyridine in acetone (50 vol. %; 16.2 mL; 0.1 mmol) dropwise over 5 hours at 30° C. After the addition was complete, the mixture was heated to 45° C. for 18 hours. The reaction mixture was allowed to cool slightly and the resulting white precipitate was filtered over a Buchner funnel. The product was washed thoroughly with hexanes (3×100 mL) and vacuum dried. The product was identified by 1H NMR and mass spectrometry.
- A solution of Na-imidazole (0.1 mol) (imidazole sodium derivative, Aldrich 197637, CAS 5587-42-8) in 100 mL THF. An appropriate amount of the dialkyl bromide was added and the mixture was stirred overnight at room temperature. The solids were filtered off and the filtrate was dried under vacuum. The product was purified by column chromatography using 500 g of silica and ethyl acetate. The resulting yield was 50-80%. The product was identified by 1H NMR and mass spectrometry.
- Dibromoalkane (0.3 mol) was placed into a 3-necked flask that was fitted with an overhead stirrer. Acetone was added such that the resulting solution was 3 M. Methyl imidazole (0.03 mol) was dissolved in acetone to result in a 2M solution. This was added to the flask and the reaction was stirred overnight at 45-50° C. The next day, the acetone was vacuumed off and the product was purified by column chromatography using 500 g of silica gel and 90:10 CH2Cl2:MeOH. The yield was in the range of 60-70% of materials that ranged from a clear oil to a white sold. The product was identified by 1H NMR and mass spectrometry.
- Dibromoalkane (0.3 mol) was placed into a 3-necked flask that was fitted with an overhead stirrer. Acetone was added such that the resulting solution was 3M. A 1-methylpyrrolidine solution (0.03 mol) was dissolved in acetone to result in a 2M solution. This was added to the flask and the reaction was stirred overnight at 55° C. The isolation method depended on the form of the product, for example, when the product precipitated out of solution, the solid was filtered and washed with acetone and when the product was an oil, the acetone was vacuumed off and the product was purified either by column chromatography using 500 g of silica gel and CH2Cl2:MeOH. The yield was in the range of 60-70% of materials that ranged from a clear oil to a white sold. The product was identified by 1H NMR and mass spectrometry.
- The desired polyamine scaffold gel was dissolved in water and neutralized with an equimolar solution of NaOH. An appropriate amount of a solution of 1,3-dialkylimidazolium bromide in methanol was added to the polyamine solution. The mixture was heated to 75° C. for 24 hours. After cooling to room temperature the modified polyamine gel was washed by exposing the gel to a methanol wash (2×), 0.5 M HCl wash and water wash (2×). In each wash, the gel was stirred for 30 minutes, exposed to the washing solvent, and centrifuged; the supernatant liquid was decanted and the wash solvent was added to the gel. After the final water wash, the gel was placed into a lyophilizer to remove the water. The gel was isolated as a white fluffy material.
-
- Step A: 1. 4-(nonyloxy)benzoyl chloride. To a suspension of 4-(nonyloxy)benzoic acid (6.02 g, 0.0228 mol) in 100 mL of dichloromethane was added DMF (0.176 mL, 0.00228 mol), followed by thionyl chloride (2.5 mL, 0.0342 mol). The reaction was stirred at room temperature for 2 hours and became a clear solution. The solvent was removed under reduced pressure. The residue was dried under high vacuum overnight. The product (6.54 gram) was obtained as a brown oil which was used for next step directly.
- Step B: tert-butyl 2-(4-(nonyloxy)benzamido)ethylcarbamate. A solution of tert-butyl-2-aminoethylcarbamate (3.65 g, 0.0228 mol) and diisopropylethylamine (4.76 mL, 0.0274 mol) in 100 mL of dichloromethane was cooled to 4° C. in an ice bath. 4-(Nonyloxy)benzoyl chloride (6.54 g, 0.0228 mol) was dissolved in 50 mL of dichloromethane and was added to tert-butyl-2-aminoethylcarbamate solution dropwise. The internal temperature remained at or below 4° C. during the addition. After the addition, the reaction was warmed to room temperature and stirred for 2 hours. The mixture was washed with 1N HCl (2×150 mL), brine (150 mL), saturated NaHCO3 solution (150 mL), and brine (150 mL). Organic phase was dried over MgSO4 and concentrated. The crude product was passed through a silica gel plug (15% methanol in dichloromethane). The pure product (9.1 gram) was obtained as a white solid (98%).
- Step C: tert-butyl 2-(4-(nonyloxy)benzamido)ethylcarbamate. To a solution of tert-butyl-2-(4-(nonyloxy)benzamido)ethylcarbamate (9.1 g, 0.0224 mol) in 100 mL of dichloromethane was added trifluoroacetic acid (17.25 mL, 0.224 mol). The reaction was stirred at room temperature for 16 hours. Solvent was removed under reduced pressure. Toluene (100 mL) was added to the residue to form a heteroazeotrope. Solvent and remaining trifluoroacetic acid were removed under reduced pressure. The residue was dried under high vacuum until no further weight change (2 days). The product was obtained as a trifluoroacetate salt, which was used directly for next step.
- Step D: N-(2-(5-chloropentanamido)ethyl)-4-(nonyloxy)benzamide. A solution of tert-butyl-2-(4-(nonyloxy)benzamido)ethylcarbamate trifluoroacetate salt from previous step and diisopropylethylamine (11.7 mL, 0.0672 mol) in 150 mL of dichloromethane was cooled to 4° C. in an ice bath. 5-Chloro-valeroyl chloride (2.88 mL, 0.0224 mol) was dissolved in 50 mL of dichloromethane and was added to the above solution dropwise. The internal temperature remained at or below 4° C. during the addition. After the addition, the reaction was warmed to room temperature and stirred for 2 hours. It was then taken up with 150 mL of dichloromethane. The mixture was washed with 1N HCl (2×300 mL), brine (300 mL), saturated NaHCO3 solution (300 mL), and brine (300 mL). Organic phase was dried over MgSO4 and concentrated. The crude product was recrystallized in acetonitrile to give pure N-(2-(5-chloropentanamido)ethyl)-4-(nonyloxy)benzamide as a white solid (9.36 g, 98%). MS (EI) m/e (MNa+), calculated (for C23H37ClN2O3Na+) 447.24, found 447.21.
-
- A solution of 2-(1H-indol-3-yl)ethanamine (5.10 g, 0.032 mol) and diisopropylethyl amine (7.23 mL, 0.042 mol) in 100 mL of dichloromethane was cooled to 4° C. in ice bath. 5-Chloro-valeroyl chloride (4.2 mL, 0.32 mol) was dissolved in 50 mL of dichloromethane and was added to the solution of 2-(1H-indol-3-yl)ethanamine dropwise. The internal temperature remained at or below 4° C. during the addition. After the addition, the reaction was warmed to room temperature and stirred for 2 hours. The mixture was washed with 1N HCl (2×150 mL), brine (150 mL), saturated NaHCO3 solution (150 mL), and brine (150 mL). The organic phase was dried over MgSO4 and concentrated. The crude product was purified by flash chromatography (silica gel, 15% methanol in dichloromethane). Pure product (7.9 gram) was obtained as a yellow solid (89%). MS m/e (MH+), calculated 279.13, found 279.16. This synthesis can be used to make other amino acid-based ligands by substituting the appropriate amine reactant for 2-(1H-indol-3-yl)ethanamine (e.g., use of 3-methylbutan-1-amine to make a Leu-based ligand).
- Dibromodecane (12.10 g, 0.039 mol) was dispensed with methanol (13 mL) and N,N-dimethylformamide (13 mL) into a round bottom flask (100 mL) under nitrogen with a mechanical stirrer and reflux condenser. Diaminohexane (4.55 g, 0.039 mol) was added to the flask and the mixture was brought to reflux while stirring. After 35 minutes gelation occurred and mechanical stirring was stopped. The resulting gel was cured at 85° C. for 17 hours. The polymer formed was swollen and ground in water (two times, 80 mL), methanol (two times, 80 mL), water (two times, 80 mL), ethanol (once, 500 mL), water (once, 100 mL), HCl (1M, 80 mL) ethanol (500 mL) and water (100 mL) and lyophilized until dry.
-
Bile acid Bile acid Bile acid binding binding binding affinity capacity retention A assay B assay Hamster Sample # (mmol/g) (mmol/g) (mmol/g) 46-A1 0.52 2.60 6.22 4.6 - The synthesis of C12 BTA-DCP, C10 BTA-DCP, C8 BTA-DCP, C4 BTA-DCP beads were conducted in a Semi-Continuous Parallel Polymerization Reactor (SCPPR). C4 BTA, C8 BTA, C10 BTA, and C12 BTA monomers were dispensed into 11 mL glass tubes and cooled to 5° C. in an ice bath and water was added. Hydrochloric acid (HCl, 37 wt. % in water) was added slowly to this solution followed by mixing for 2 minutes. Dodecylbenzenesulfonic acid sodium salt (DDS) (molecular weight (MW) 348.48, 15 wt. % in water) and the
crosslinker 1,3-dichloropropanol (DCP) (MW 128.99) were added to the solution followed by mixing for 5 minutes. The organic layer of heptanes and Span 80 (MW 428.60, 15 wt. % in heptanes) was then added to the aqueous solution. The test tubes were loaded into the SCPPR, sealed, and pressurized to 70 pounds/square inch (psi) (4.83×105 Pa). The reaction was allowed to react at 75° C. with stirring (400 rpm) for 17 hours. The resulting solid polymer beads were then swollen in ethanol, washed with (1) aqueous HCl (1 M), (2) water, (3) NaOH (1M), (4) water (3×) and lyophilized until dry. Various synthesis experiments are detailed in the table below. -
Aqueous Layer Organic layer Monomer Solvent Acid Surfactant Crosslinker solvent Surfactant BTA BTA water HCl DDS DCP heptanes span 80 Polymer Sample # Core wt. (mg) (mg) (mg) (mg) (mg) (Mg) (mg) Product 47-A1 C10 400 949.2 0.0 6.8 218.9 1947.7 155.8 Beads 47-A2 C10 400 965.5 0.0 13.8 218.9 1981.2 158.5 Beads 47-A3 C10 400 982.5 0.0 21.1 218.9 2016.0 161.3 Beads 47-A4 C10 400 1000.0 0.0 28.6 218.9 2052.0 164.2 Gel 47-A5 C10 400 1035.6 36.4 7.4 218.9 2125.1 170.0 Beads 47-A6 C10 400 1053.5 36.4 15.0 218.9 2161.7 172.9 Beads 47-B1 C10 400 1071.9 36.4 23.0 218.9 2199.6 176.0 Beads 47-B2 C10 400 1091.1 36.4 31.2 218.9 2238.9 179.1 Beads 47-B3 C10 400 1363.9 36.4 18.2 218.9 2798.6 223.9 Gel 47-B4 C10 400 1053.5 36.4 15.0 218.9 2161.7 172.9 Beads 47-B5 C10 400 834.4 36.4 12.8 218.9 1712.1 137.0 Beads 47-B6 C10 400 671.4 36.4 11.2 218.9 1377.8 110.2 Gel 47-C1 C10 400 1122.1 72.9 8.0 218.9 2302.5 184.2 Beads 47-C2 C10 400 1141.4 72.9 16.3 218.9 2342.2 187.4 Gel 47-C3 C10 400 1161.4 72.9 24.9 218.9 2383.2 190.7 Beads 47-C4 C10 400 1182.2 72.9 33.8 218.9 2425.8 194.1 Beads 48-A1 C12 400 1047.7 34.1 15.0 120.3 2149.9 172.0 Beads 48-A2 C12 400 1047.7 34.1 15.0 180.5 2149.9 172.0 Beads 48-A3 C12 400 1047.7 34.1 15.0 240.7 2149.9 172.0 Beads 48-A4 C12 400 1047.7 34.1 15.0 300.9 2149.9 172.0 Beads 48-A5 C12 400 1047.7 34.1 15.0 204.6 2149.9 172.0 Beads 48-A6 C12 400 1047.7 34.1 15.0 204.6 2149.9 172.0 Beads 48-B1 C12 400 1047.7 34.1 15.0 204.6 2149.9 172.0 Beads 48-B2 C12 400 1047.7 34.1 15.0 204.6 2149.9 172.0 Gel 48-B3 C12 400 949.2 0.0 6.8 204.6 1947.7 155.8 Gel 48-B4 C12 400 965.5 0.0 13.8 204.6 1981.2 158.5 Gel 48-B5 C12 400 982.5 0.0 21.1 204.6 2016.0 161.3 Gel 48-B6 C12 400 1000.0 0.0 28.6 204.6 2052.0 164.2 Beads 48-C1 C12 400 1030.0 34.1 7.4 204.6 2113.5 169.1 Beads 48-C2 C12 400 1047.7 34.1 15.0 204.6 2149.9 172.0 Beads 48-C3 C12 400 1066.1 34.1 22.8 204.6 2187.6 175.0 Gel 48-C4 C12 400 1085.1 34.1 31.0 204.6 2226.7 178.1 Gel 48-C5 C12 400 1047.7 34.1 15.0 204.6 2149.9 10.7 Gel 48-C6 C12 400 1047.7 34.1 15.0 204.6 2149.9 50.2 Gel 48-D1 C12 400 1047.7 34.1 15.0 204.6 2149.9 89.6 Beads 48-D2 C12 400 1047.7 34.1 15.0 204.6 2149.9 129.0 Beads 48-D3 C12 400 1110.8 68.1 7.9 204.6 2279.3 182.3 Beads 48-D4 C12 400 1129.9 68.1 16.1 204.6 2318.6 185.5 Beads 48-D5 C12 400 1149.7 68.1 24.6 204.6 2359.3 188.7 Beads 48-D6 C12 400 1170.3 68.1 33.4 2401.4 192.1 204.6 Gel 49-A1 C4 400 1076.9 46.1 15.4 277.1 2209.7 176.8 gel/beads 49-A2 C4 400 1128.7 46.1 37.6 277.1 2316.2 185.3 gel/beads 49-A3 C4 400 1185.9 46.1 62.1 277.1 2433.5 194.7 Beads 49-A4 C4 400 1249.1 46.1 89.2 277.1 2563.2 205.1 Beads - A 250 mL 3-neck round bottom flask equipped with overhead stirrer, condenser, and thermometer was charged with C12 BTA (5.0 g, 11.66 mmol) and water (11.39 mL). The resulting mixture was stirred in an ice bath for 5 minutes. Hydrochloric acid (1.15 ml, 11.66 mmol, 37 wt. % in water) was added slowly over a 2 minute period. The mixture was stirred for an extra 2 minutes in the ice bath before removing it. DDS (1.24 mL, 15 wt. % in water) was then added to the above mixture and stirred for 2 minutes. 1,3-Dichloro-2-propanol (2.56 g, 19.83 mmol) was added. Heptanes (21.59 mL) and Span 80 solution (20.32 mL, 15 wt. % in heptanes) were then added. The final mixture was stirred at 220 rpm with an overhead stirrer and heated in oil bath at 75° C. The internal temperature of the reaction was at 70° C. After 3 hours, a Dean-Stark treatment was performed to remove the water using the azeotrope of heptanes and water (at 80° C.). The reaction was ended after the mixture temperature reached 100° C. or when all the water in the reaction mixture was collected.
- The reaction mixture was cooled to ambient temperature, stirring was stopped, and the organic layer was decanted. The beads were washed with 150 mL isopropyl alcohol, followed by one wash with HCl (150 ml, 1.0 M), one wash with water, two washes with NH4OH (150 mL, 10 wt. % in water), one wash saturated aqueous NaCl solution, and three washes with water. The beads were lyophilized for 48 hours. The final product was isolated in 80% yield (4.9 g). Various synthesis experiments are detailed below.
- Acid loading of sample 51-D1. The isolated dry bead prepared from 51-D1 (example 37) was placed into a flask. Using 1 M HCl solution in water, an appropriate amount of HCl was added to the bead such that the resulting beads contained 5, 10, 15 and 20 weight percent of chloride. The chloride content in the bead was later confirmed by elemental analysis and found to be 5, 9, 12, and 19 wt. % respectively. The sample ID's for these compounds were given 79-A1, 79-A2, 79-A3 and 79-A4 respectively.
-
Aqueous Layer Organic layer Monomer Solvent Acid Surfactant Crosslinker solvent Surfactant BTA BTA wt water HCl DDS DCP heptanes span 80 Polymer Sample # Core (mg) (mg) (mg) (mg) (mg) (Mg) (mg) Product 50-A1 C12 1600 4191 136 60 818 8600 688 beads 50-A2 C12 1600 4599 272 99 818 9437 755 beads 51-A1 C4 2000 5678 231 203 1385 11651 932 beads 51-B1 C8 2000 5300 196 76 1177 10877 870 beads 51-C1 C10 2000 5267 182 75 1094 10808 865 beads 51-D1 C12 2000 5239 170 75 1023 10750 860 beads 52-A1 C8 7460 19770 731 282 4390 40568 3245 beads 53-A1 C12 8250 21609 702 309 4219 44342 3547 beads 54-A1 C12 4312 11294 367 161 1427 23176 1854 beads 55-A1 C12 5000 13096 425 187 2106 26874 2150 beads 56-A1 C12 4312 11294 367 161 2595 23176 1854 beads 57-A1 C12 25000 65482 2128 935 12786 134369 10750 beads 58-A1 C12 5000 13096 426 187 3761 26874 2150 beads 59-A1 C4 5000 14731 577 737 3464 30227 2418 beads 60-A1 C12 10000 26193 851 374 5115 53748 4300 beads 61-A1 C12 5000 13096 426 187 2557 26874 2150 beads 62-A1 C12 5000 13096 426 187 2557 26874 2150 beads 63-A1 C12 4312 11294 367 161 1427 23176 1854 beads 64-A1 C12 5000 13096 425 187 2106 26874 2150 beads 65-A1 C12 4312 11294 367 161 2595 23176 1854 beads 66-A1 C12 10000 26193 851 374 5115 53748 4300 beads 67-A1 C12 5000 13096 426 187 1956 26874 2150 beads 68-A1 C12 5000 13096 426 187 2256 26874 2150 beads 69-A1 C12 5000 13096 426 187 2407 26874 2150 beads 70-A1 C12 25000 65480 2125 935 10530 134370 10750 beads 80-A1 C12 5000 13096 425 187 2557 26874 2150 beads 81-A2 C12 5000 13096 425 187 2106 26874 2150 beads
Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below. -
BA BA binding binding Phosphate capacity affinity BA binding % binding B Assay A Assay retention Primary B Assay Swelling BTA Data Data Hamster Bile Acid Data Swelling Library Core (mmol/g) (mmol/g) (mmol/g) in feces (mmol/g) (g/g) Tackiness* 50-A1 C12 3.34 0.64 0.50 10.9 0.65 2 50-A2 C12 3.33 0.64 0.43 12.8 0.97 2 51-A1 C4 3.19 0.37 0.15 10.5 5.98 0 51-B1 C8 3.28 0.45 0.33 3.5 0.99 0 51-C1 C10 3.26 0.54 0.40 5.7 0.27 1 51-D1 C12 3.32 0.64 0.34 8.5 0.38 2 52-A1 C8 3.24 0.46 0.24 2.5 0.26 1.15 0 53-A1 C12 3.18 0.66 0.36 6.5 0.69 2 54-A1 C12 3.25 0.65 0.35 14.8 0.28 2.16 2 55-A1 C12 3.27 0.67 0.52 17.3 0.23 0.39 2 56-A1 C12 3.01 0.66 0.34 20.4 0.08, 0.10 0.82 0 57-A1 C12 3.03 0.67 0.38 18.8, 16.4 0.07 0.41 1 58-A1 C12 2.87 0.67 0.32 25.9 0.07 0.50 0 59-A1 3.17 0.39 0.61 3.09 79-A1 C12 2.99 0.66 0.55 18.6 0.64 0 79-A2 C12 2.95 0.65 0.54 17.3 0.64 0 79-A3 C12 2.85 0.62 0.51 14.3 0.64 0 79-A4 C12 2.74 0.64 0.64 0 60-A1 C12 3.08 0.67 0.41 11.6 0.60 0 61-A1 C12 3.16 0.64 12.7 1.08 0 62-A1 C12 3.15 0.66 0.26 0 63-A1 C12 3.30 0.63 3.00 2 64-A1 C12 3.20 0.66 1.30 1 65-A1 C12 2.83 0.66 0.41 1 66-A1 C12 2.98 0.67 0.50 1 67-A1 C12 3.13 0.65 0.73 2 68-A1 C12 2.99 0.66 0.37 2 69-A1 C12 3.15 0.66 0.41 1 70-A1 C12 0.65 2 80-A1 C12 3.12 0.66 0.15 0.65 22 81-A2 C12 3.14 0.66 0.20 0.97 2 *tackiness number 0 = free flowing beads, 1 = slightly soft beads, 2 = slightly sticky beads, 3 = sticky and soft - The synthesis of C12 BTA-C12 core, C3 bisimidazolium, C10 BTA-C12 core, C3 bisimidazolium, and C4 BTA-C12 core, C3 bisimidazolium beads were conducted in a SCPPR. C4 BTA, C8 BTA, C10 BTA, and C12 BTA monomers were dispensed into 11 mL glass tubes and cooled to 5° C. in an ice bath and water was added. Hydrochloric acid (HCl, 37 wt. % in water) was added slowly to this solution followed by mixing for 2 minutes. DDS (15 wt. % in water) and a solution of the designated crosslinking monomer (40 wt. % in water) of formula X-R1-X (wherein X is halo such as chloro or bromo and R1 is C12 core/C3 bisimidazolium) were added. This solution was mixed for 5 minutes and the organic layer of heptanes and Span 80 (15 wt. % in heptanes) was added to the aqueous layer. The test tubes were loaded into the SCPPR, sealed, and pressurized to 70 psi. The reaction was run at 75° C. with stirring (400 rpm) for 17 hours. The solid polymer beads were then swollen in ethanol, washed with aqueous HCl (1 M), water (3×) and lyophilized until dry. Various synthesis experiments are detailed in the table below.
-
Aqueous Layer Monomer Crosslinker Organic layer BTA Solvent Acid Surfactant C12 core/C3 solvent Surfactant BTA wt water HCl DDS bisimidazolium heptanes span 80 Polymer Sample # Core (mg) (mg) (mg) (mg) (mg) (mg) (mg) Product 71-A1 C4 100 867 12 37 357 2600 208 Gel 71-A2 C4 100 867 12 37 357 2600 208 Gel 71-A3 C4 100 867 12 37 357 2600 208 Gel 71-A4 C4 100 867 12 37 357 2600 208 Gel 71-B1 C4 100 867 12 37 357 2600 208 Gel 71-B2 C4 100 867 12 37 357 2600 208 Gel 71-B3 C4 100 867 12 37 357 2600 208 Gel 71-B4 C4 100 867 12 37 357 2600 208 Gel 71-C1 C4 100 867 12 37 357 2600 208 Gel 71-C2 C4 100 995 12 42 424 2986 239 Gel 71-C3 C4 100 1124 12 48 491 3372 270 Gel 71-C4 C4 100 1253 12 53 558 3758 301 Gel 71-D1 C4 100 890 12 14 357 2670 214 Gel 71-D2 C4 100 872 12 32 357 2615 209 Gel 71-D3 C4 100 853 12 50 357 2560 205 Beads 71-D4 C4 100 835 12 69 357 2505 200 Gel 72-C1 C10 100 502 9 9 282 1507 15 Gel 72-C2 C10 100 619 9 10 282 1857 68 Gel 72-C3 C10 100 806 9 12 282 2419 153 Gel 72-C4 C10 100 1156 9 16 282 3468 312 Gel 72-D1 C10 100 960 9 0 282 2880 230 Gel 72-D2 C10 100 1057 9 40 282 3172 254 Beads 72-D3 C10 100 1177 9 88 282 3530 282 Gel 72-D4 C10 100 1326 9 149 282 3979 318 Gel 73-B1 C12 100 690 9 29 264 2071 166 Beads 73-B2 C12 100 690 9 29 264 2071 166 Beads 73-B3 C12 100 880 9 37 362 2640 211 Beads 73-B4 C12 100 880 9 37 362 2640 211 Beads 73-D1 C12 100 690 9 29 264 2071 166 Beads 73-D2 C12 100 690 9 29 264 2071 166 Beads 73-D3 C12 100 880 9 37 362 2640 211 Beads 73-D4 C12 100 880 9 37 362 2640 211 Beads - A 500 mL 3-neck round bottom flask equipped with overhead stirrer, condenser, and thermometer was charged with C12 BTA (5.0 g 11.66 mmol) and 5.67 mL water. The resulting mixture was stirred in an ice bath for 5 minutes. Hydrochloric acid (1.15 mL, 11.66 mmol, 37 wt. % in water) was added slowly over a two minute period. The mixture was stirred for an extra two minutes in the ice bath before removal. DDS (9.83 mL, 15 wt. % in water) was then added to the above mixture and stirred for two minutes. An organic phase of the crosslinking monomer (32.94 mL, 18.66 mmol, 40 wt. % in water) of formula X-R1-X (wherein X is halo such as chloro or bromo and R1 is C12 core, C3 bisimidazolium), heptanes (82.74 mL), and Span 80 solution (77.82 ml, 15 wt. % in heptanes) was added to the mixture. The final mixture was stirred at 220 rpm with an overhead stirrer and heated in oil bath at 75° C. The internal temperature of the reaction was at 70° C. After 3 hours, a Dean-Stark treatment was performed to remove the water using the azeotrope of heptanes and water at 80° C. This was achieved by increasing the temperature of the oil bath. The endpoint of the process was when the temperature of the mixture reached 100° C. or when all the water in the reaction mixture was collected.
- The reaction mixture was cooled to ambient temperature, stirring was stopped, and the organic layer was decanted. The beads were washed with 150 mL isopropyl alcohol, followed by one wash with HCl (150 mL, 1.0 M), one wash with water, one wash with saturated aqueous NaCl solution, and three washes with water. The beads were lyophilized for 48 hours. The final product was isolated in 80% yield (4.9 g).
-
Aqueous Layer Monomer Crosslinker Organic layer BTA Solvent Acid Surfactant C12 core/C3 solvent Surfactant BTA wt water HCl DDS bisimidazolium heptanes span 80 Polymer Sample # Core (mg) (mg) (mg) (mg) (mg) (mg) (mg) Product 82-D3 C4 100 853 11.53 50.3 356 2560 204.8 Bead 74-A1 C4 2000 17069 231 1006 7139 51207 4097 Beads 75-A1 C4 3000 25603 346 1509 10709 76810 6145 Beads 76-A1 C4 6000 51207 692 3019 21418 153620 12290 Beads 77-A1 C12 3794 26189 323 1118 10000 78566 6285 Beads 77-A2 C12 3794 26189 323 1118 10000 78566 6285 Beads 78-A1 C12 5000 34510 426 1474 13177 103529 8282 Beads
Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below. -
A In vivo % Primary BTA B Assay Assay binding Bile Acid Swelling Ligand Sample # Core (mmol/g) (mmol/g) (mmoles/g) in feces (g/g) Tackiness Grafted 77-A1 C12 2.74 0.62 0.49 9.6 32 0 77-A2 C12 2.83 0.62 0.44 12.4 25 1 75-A1 C4 3.06 0.54 0.34 3.7 25 1 - Sample 82-D3, described in example 39 was repeated on a larger scale (3 g of BTA C4 core was used) on the bench. The resultant beads were washed and described as above. To the resulting beads the following procedure was performed. N-methylpyrrolidone (NMP) was added to swell the C4 BTA crosslinked C12 core, C3 bisimidazolium beads in 11 mL glass tubes. The hydrophobizing agent (either 1,12-dibromododecane or 1-bromodecane) was added and the glass tubes were fitted with overhead stirrers, sealed, and purged with nitrogen. The post polymerization reaction was allowed to proceed at 75° C. for 18 hours. After cooling, the beads were diluted with ethanol and purified by washing with ethanol (2×), 1M HCl (2×), and water (3×). The beads were dried by lyophilization overnight.
-
1,12- 1- N- Sample dibromododecane bromodecane methylpyrrolidone # Beads (g) (g) (mL) 83-A1 1.00 1.00 4.50 83-A3 1.00 1.50 5.70 84-A1 1.00 1.00 4.50 84-A3 1.00 1.50 5.70
Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below. -
% Hamster Primary in vivo Bile B Assay A Assay binding Acid in Swelling Sample # (mmol/g) (mmol/g) (mmol/g) feces (g/g) 83-A1 2.94 0.60 10.1 83-A3 2.95 0.61 0.37 5.0 10.8 84-A1 2.99 0.61 47.4 84-A3 2.90 0.61 48.7 - A 1 L reactor equipped with overhead stirrer, condenser and thermocouple was charged with C4 BTA (7.24 g 22.9 mmol), water (56.0 mL), acetonitrile (27.2 mL), and DDS solution (23.9 mL, 15 wt. % in water). The mixture was stirred for 5 minutes. After a homogeneous solution was obtained, TMBMP-DBD (30.7 g, 36.6 mmol) was added. The resulting mixture was stirred for an extra 5 minutes before the addition of heptanes (182.9 mL) and Span 80 solution (172.0 mL, 15 wt. % in heptanes). The final mixture was stirred at 150 rpm with an overhead stirrer. The external oil was ramped to 75° C. in 1 hour. The internal temperature of the reaction was at 72-75° C. After 16 hours, a Dean-Stark treatment was performed to remove the acetonitrile and water at 80° C. This was achieved by increasing the temperature of the oil bath to 95° C. The end point of the process end point was when the temperature of the mixture reached 95° C. or when all the water in the reaction mixture was collected.
- The reaction mixture was cooled to ambient temperature, stirring was stopped, and the organic layer was removed by vacuum. The beads were washed with 500 mL ethanol twice and collected by filtration. The beads were vacuum dried for 24 hours before the post polymerization. The final product was isolated in a 67% yield (25 g).
- Post polymerization, a further reaction with halogenated hydrophobic ligand, was conducted using parallel synthesis. NMP and dry beads obtained from previous procedure were placed into a 12 mL test tube. Halogenated hydrophobic ligand solution (20 wt. % in NMP) was then added. The amount of each component was summarized in the table below. The mixture was stirred at 400 rpms with an overhead stirrer for 5 minutes before applying heat to 75° C. for 16 hour. The resulting beads were washed with NMP twice, ethanol twice, 0.5M HCl solution for three times, saturated NaCl solution, and water for three times followed by drying under vacuum.
-
Monomer:Crosslinking Hydrophobic Monomer:hydrophobic beads ligand NMP Sample # Hydrophobic ligand ligand Ratio (mg) (mg) (mg) 85-A1 1,12- 1:1.6:0.5 1000 99 4396 dibromododecane 85-B1 1,12- 1:1.6:1.5 1000 297 5187 dibromododecane 86-A1 1-bromododecane 1:1.6:0.5 1000 75 4300 86-B1 1-bromododecane 1:1.6:1.5 1000 225 4902 87-B1 1,12- 1:1.6:1.5 1000 216 4865 dichlorododecane 88-A1 1-Chlorooctane 1:1.6:1 1000 90 4359 88-B1 1-Chlorooctane 1:1.6:3 1000 269 5076
Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below. -
BA BA BA binding binding binding % Monomer:Crosslinking affinity capacity retention Primary Sample Hydrophobic Monomer:hydrophobic A assay B assay Hamster Bile Acid Swelling # ligand ligand Ratio (mmol/g) (mmol/g) (mmol/g) in feces (g/g) 85-A1 1,12- 1:1.6:0.5 0.58 2.7 8 dibromododecane 85-B1 1,12- 1:1.6:1.5 0.6 2.6 0.46 10.7 6 dibromododecane 86-A1 1-bromododecane 1:1.6:0.5 0.59 2.72 43 86-B1 1-bromododecane 1:1.6:1.5 0.63 2.56 0.48 8.3 39 87-B1 1,12- 1:1.6:1.5 0.59 2.61 0.38 5.9 7 dichlorododecane 88-A1 1-Chlorooctane 1:1.6:1 0.55 2.45 31 88-B1 1-Chlorooctane 1:1.6:3 0.57 2.61 0.38 4.8 25 - Synthesis of C4 BTA with TMBMP-DBUD was conducted using parallel synthesis. TMBMP-DBUD (438 mg) was dispensed into a 12 mL glass tube followed by addition of water (1,514 mg) and C4 BTA (100 mg). After mixing C4 BTA with TMBMP-DBUD, DDS (179 mg, 15 wt. % in water) was added. After that, the organic phase of heptane (2,733 mg) and Span 80 solution (2,667 mg, 15 wt. % in heptane) was added. The reaction mixture was stirred with an overhead stirrer at 400 rpm. The vial was capped and heated for 17 hours at 75° C.
- A 250 mL 3-neck round flask equipped with overhead stirrer, condenser and thermometer was charged with C12 BTA (1.63 g, 3.8 mmol) and water (14.4 mL). The resulting mixture was stirred in an ice bath for 5 minutes and hydrochloric acid (374 uL, 3.8 mmol, 37 wt. % in water) was added slowly. After the ice bath was removed, dodecylbenzenesulfonic acid sodium salt (2.77 mL, 15 wt. % in water) was then added to the above mixture and stirred for 2 minutes, followed by the addition of 4,4′-(propane-1,3-diyl)bis(1-(10-bromodecyl)-1-methylpiperidinium) (5.09 g, 6.01 mmol) was added. Heptanes (40.8 mL) and Span 80 solution (38.3 mL, 15 wt. % in heptanes) were then added respectively. The final mixture was stirred at 170 rpm with an overhead stirrer and heated in oil bath at 75° C. The internal temperature of the reaction was 75° C. After 16 hours, a Dean-Stark treatment was performed to remove the water using the azeotrope of heptanes and water (at 80° C.); achieved by increasing the temperature of the oil bath to 95° C. The end point of the process was when the temperature of the mixture reached 100° C. or when all the water in the reaction mixture was collected.
- The reaction mixture was cooled to ambient temperature, stirring was stopped, and the organic layer was decanted. The beads were washed with two washes with ethanol, two washes with 0.5 M HCl solution, one wash with saturated aqueous NaCl solution, and two washes with water. The beads were vacuum-dried for 48 hours.
-
BA BA binding binding BA binding % Monomer:Crosslinking affinity capacity retention Primary Monomer A assay B assay Hamster Bile Acid Swelling Sample # Ratio (mmol/g) (mmol/g) (mmol/g) in feces (g/g) 89-A1 1:1.6 0.58 2.72 0.28 3.7 33 - An Argonaut Advantage Series 3400 Process Chemistry workstation equipped with over head stirrer, reflux condenser, nitrogen inlet port, and Julabo FP88 refrigeration unit was used to prepare prepolymer solution. To the 250 mL reaction flask, 50 g (166.63 mmol) of 1, 10-dibromodecane and 50 g ethanol were added. The mixture was heated to 50° C. at 300 rpm to make sure that 1,10-dibromodecane was completely dissolved in ethanol. In a separate 100 mL beaker, 32.965 g (104.14 mmol) of C4 BTA and 32.96 g of ethanol were added to make a 50 wt. % solution of C4 BTA in ethanol. This solution was then added to the 250 mL reaction flask containing 50 wt. % 1,10-dibromodecane solution in ethanol. The reaction was allowed to heat at 50° C. for 90 minutes. The reaction viscosity increased over the time but no gelation occurred. The reaction was cooled for 5 minutes using refrigeration unit. Then hydrochloric acid solution (30.37 mL of 37 wt. % aqueous hydrochloric acid in 65.9 mL deionized water) was added to the reaction mixture to quench the reaction. The reaction mixture was allowed to cool down to room temperature and then ethanol was removed by a rotary evaporator operated at room temperature. The resulting prepolymer solution was then filtered to remove any unreacted 1,10-dibromodecane. The solution was then stored in a 250 mL pyrex glass bottle with cap before next utilization. The percent solid content of the solution was determined by thermogravimetric analysis and was found to be 58 wt. % of prepolymer in water.
- Bead synthesis was performed in a 250 mL Argonaut Advantage Series 3400 Process Chemistry workstation equipped with an over head stirrer, a reflux condenser, a nitrogen inlet port, and a Julabo FP88 refrigeration unit. Mineral oil was used as a continuous phase with 10 wt. % Span 80 as a surfactant. To the reactor, 30 g (21.5 mmol) of prepolymer solution (58 wt. % in water) was added. The reaction flask was stirred at 300 rpm and was heated to 50° C. Then 6.98 mL (27.925 mmol) of 4M sodium hydroxide, prepared previously, was added to the reaction flask and allowed to mix for 1 minute. The stirring was stopped and 101.17 mL of mineral oil solution containing 10 wt. % Span 80 was added to the reaction mixture. The stirring was resumed at 300 rpm, the reaction temperature was increased to 60° C. and the reaction was allowed to continue for 17 hours under inert nitrogen atmosphere. The reaction was cooled to room temperature with the help of refrigeration unit. The reaction content was then transferred to a filter frit to remove the excess continuous and discrete phases. Beads thus formed were then washed with 100 mL hexane (2 times), 100 mL ethanol (2 times), 100 mL aqueous hydrochloric acid solution (0.5M), 100 mL 10 vol. % aqueous ammonium hydroxide solution (2 times) and finally 100 mL deionized water (3 times). The beads were then vacuum dried for 48 hours to remove water. The final product weight was 5.2 gm.
- Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below.
-
BA BA BA Binding Binding Binding affinity capacity retention % Primary A assay B assay Hamster Bile Acid Swelling Sample # (mmol/g) (mmol/g) (mmol/g) in feces (g/g) 90-A2 0.647 3.23 0.45 15.8 0.38 - A 40 mL vial equipped with magnetic stirrer was charged with N,N,N′,N′-(3-aminopropyl)-diaminododecane (4.0 g, 9.3 mmole) and water (4.7 mL). The mixture was stirred for 5 minutes; 2-methyl-1,3-bis(oxiran-2-ylmethyl)-1H-imidazol-3-ium (3.0 g, 13.1 mmole) was then added. The vial was heated in an oil bath at 70° C. with stirring for 17 hours. A slightly turbid hard gel was obtained. The gel was ground with an ultrasonic mixer for 30 minutes in methanol and then washed with methanol twice, 0.5 M hydrochloric acid once, and water three times.
-
Monomer/ Crosslinker Sample # Monomer Crosslinker ratio 91-A1 Mon 4 Xlin 2 1:4 91-A2 Mon 4 Xlin 2 1:7 - Mon4: N,N,N′,N′-(3-aminopropyl)-diaminododecane
Xlin2: 2-methyl-1,3-bis(oxiran-2-ylmethyl)-1H-imidazol-3-ium having the structure: - Bile acid binding capacity, affinity, and retention for each resulting polymer were determined via the A assay, B assay and hamster model and results are reported in the table below.
-
Bile acid binding Bile acid binding Bile acid capacity affinity retention B assay A assay Hamster Swelling Sample # (mmol/g) (mmol/g) (mmol/g) (g/g) 91-A1 3.07 0.58 0.40 10.68 91-A2 2.98 0.61 0.43 6.1 - A 500 mL three-neck flask equipped with overhead stirrer, condenser was charged with tris(3-aminopropylamine) (3.37 g, 17.9 mmole), water (29.5 mL), acetonitrile (20.3 mL), and dodecylbenzenesulfonic acid sodium salt solution (12.2 mL, 15 wt. % in water). The mixture was stirred for 5 minutes. After homogeneous solution was obtained, TMBMP-DBD (18.00 g, 21.4 mmol) was added. The resulting mixture was stirred for an extra 5 minutes before the addition of heptanes (95.7 mL) and sorbitan oleate (Span 80) solution (90.0 mL, 15 wt. % in heptanes). The final mixture was stirred at ˜160 rpm with an overhead stirrer. The external oil was ramped to 75° C. in 1 hour. After 16 hours, a Dean-Stark treatment was performed to remove the acetonitrile and water at 80° C. This was achieved by increasing the temperature of the oil bath to 105° C. The process end point was identified by the temperature of the mixture reaching 95° C. or until all the water in the reaction mixture was collected.
- The reaction mixture was allowed to cool to ambient temperature, stirring was stopped and the organic layer was removed by vacuum. The beads were washed with 500 mL 2-propanl twice before collecting by filtration. The beads were vacuum-dried for 24 hours before the post polymerization. Final product isolated was 15.5 g (70% yield).
- A 250 mL three-neck flask equipped with overhead stirrer, condenser was charged with tris(3-aminopropylamine) (1.35 g, 7.17 mmole), water (14.5 mL), acetonitrile (9.93 mL), and dodecylbenzenesulfonic acid sodium salt solution (5.93 mL, 15 wt. % in water). The mixture was stirred for 5 minutes. After homogeneous solution was obtained, TMBMP-DBD (9.00 g, 10.7 mmol) was added. The resulting mixture was stirred for an extra 5 minutes before the addition of heptanes (46.8 mL) and sorbitan oleate (Span 80) solution (44.0 mL, 15 wt. % in heptanes). The final mixture was stirred at 150-200 rpm with an overhead stirrer. The external oil was ramped to 75° C. in 1 hour. After 16 hours, a Dean-Stark treatment was performed to remove the acetonitrile and water at 80° C. This was achieved by increasing the temperature of the oil bath to 105° C. The process end point was identified by the temperature of the mixture reaching 95° C. or until all the water in the reaction mixture was collected.
- The reaction mixture was allowed to cool to ambient temperature, stirring was stopped and the organic layer was removed by vacuum. The beads were washed with 500 mL 2-propanol twice, saturated sodium carbonate solution twice, saturated sodium chloride twice, and water twice before collecting by filtration. The beads were vacuum-dried for 24 hours before the post polymerization. Final product isolated was 10 g.
- A 150 mL three-neck flask equipped with overhead stirrer, condenser was charged with tris(3-aminopropylamine) (0.63 g 3.35 mmole), water (8.86 mL), acetonitrile (6.05 mL), and dodecylbenzenesulfonic acid sodium salt solution (3.56 mL, 15 wt. % in water). The mixture was stirred for 5 minutes. After homogeneous solution was obtained, TMBMP-DBD (5.60 g, 6.68 mmol) was added. The resulting mixture was stirred for an extra 5 minutes before the addition of heptanes (28.5 mL) and sorbitan oleate (Span 80) solution (26.8 mL, 15 wt. % in heptanes). The final mixture was stirred at ˜180 rpm with an overhead stirrer. The external oil was ramped to 75° C. in 1 hour. After 16 hours, a Dean-Stark treatment was performed to remove the acetonitrile and water at 80° C. This was achieved by increasing the temperature of the oil bath to 105° C. The process end point was identified by the temperature of the mixture reaching 95° C. or until all the water in the reaction mixture was collected.
- The reaction mixture was allowed to cool to ambient temperature, stirring was stopped and the organic layer was removed by vacuum. The beads were washed with hexane twice, ethanol twice, 0.5M HCl solution three times, saturated NaCl solution once, and water three times. The beads were then vacuum-dried for 24 hours.
- Post polymerization, a further reaction with halogenated hydrophobic ligand, was conducted using parallel synthesis. NMP or 2-propanol and dry beads obtained from Examples 46-48 above were placed into a 12 mL test tube. Halogenated hydrophobic ligand solution (20 wt. % in NMP) was then added. The amount of each component was summarized in the table below. The mixture was stirred at 400 rpm with an overhead stirrer for 5 minutes before applying heat to 75° C. for 16 hours. The resulting beads were washed with NMP twice, ethanol twice, 0.5M HCl solution three times, saturated NaCl solution once, and water three times followed by drying under vacuum.
-
Halogenated Monomer:Crosslinking Hydrophobic Hydrophobic Monomer:hydrophobic beads ligand NMP 2-propanol Sample # ligand ligand Ratio (mg) (mg) (mg) (mg) 92-A1 1,12-dibromo- 1:1.2:0.5 900 124 4094 NA dodecane 92-B1 1,12-dibromo- 1:1.2:1.5 900 371 5083 NA dodecane 93-A1 1,12-dibromo- 1:1.5:0.5 1000 113 4454 NA dodecane 94-A1 1,12-dibromo- 1:1.2:1.0 1000 275 5099 NA dodecane 95-A1 1,12-dibromo- 1:1.2:0.5 1000 137 549 4000 dodecane 95-B1 1,12-dibromo- 1:1.2:1.0 1000 275 1099 4000 dodecane 95-C1 1,12-dibromo- 1:1.2:1.5 1000 412 1648 4000 dodecane 96-A1 1,12-dibromo- 1:1.5:0.5 1000 139 4556 NA dodecane 96-B1 1,12-dibromo- 1:1.5:1.0 1000 278 5113 NA dodecane Bile acid Bile acid Bile acid Monomer:Crosslinking binding binding binding Halogenated Monomer:hydrophobic affinity capacity retention Sample Hydrophobic ligand A assay B assay Hamster Swelling # ligand Ratio (mmol/g) (mmol/g) (mmol/g) (g/g) 97-A1 NA 1:1.5:0 0.48 2.31 0.23 79 98-A1 NA 1:2.0:0 0.5 2.67 85 92-A1 1,12-dibromo- 1:1.2:0.5 0.53 2.46 18 dodecane 92-B1 1,12-dibromo- 1:1.2:1.5 0.56 2.57 0.34 14 dodecane 93-A1 1,12-dibromo- 1:1.5:0.5 0.57 2.56 0.38 16 dodecane 94-A1 1,12-dibromo- 1:1.2:1.0 0.59 2.58 0.34 15 dodecane 95-A1 1,12-dibromo- 1:1.2:0.5 0.55 2.69 46 dodecane 95-B1 1,12-dibromo- 1:1.2:1.0 0.57 2.70 49 dodecane 95-C1 1,12-dibromo- 1:1.2:1.5 0.57 2.64 50 dodecane 96-A1 1,12-dibromo- 1:1.5:0.5 0.59 2.55 0.36 11 dodecane 96-B1 1,12-dibromo- 1:1.5:1.0 0.62 2.51 0.38 6 dodecane - A 500 mL 3-neck flask equipped with overhead stirrer, condenser, thermometer and an oil bath was charged with N, N, N, N tetrakis (3-aminopropyl) 1, 12 diaminododecane (20.0 g, 46.65 mmole) and water (47.84 mL). The resulting mixture was stirred in an ice-bath for 5 minutes. Hydrochloric acid, 5.06 mL (51.31 mmole, 37 wt % in water), was added slowly over a 10 minute period. The mixture was stirred for an extra 10 minutes in the ice bath before removal. The organic layer was then charged to the reactor as heptane (83.69 mL) followed by sorbitan oleate (Span 80) solution (78.71 ml, 15 wt. % in the heptane). The final mixture was stirred at 200 rpm with an overhead stirrer. The internal temperature of the reaction was raised to 70° C. before starting the addition of 1,3 dichloro-2-propanol (8.42 g, 65.31 mmole) slowly over two hours. Heating then continued for 17 hours. Dean-Stark treatment was subsequently performed to remove the water using the azeotrope of heptane and water (at 80° C.). This was achieved by increasing the temperature of the circulating oil bath to 100° C. for 3 hours and then to 110° C. The process end point was identified by the temperature of the mixture reaching 98° C. or until all the water initially added into the reaction mixture was collected. The reaction mixture was allowed to cool to ambient temperature, stirring was stopped and the organic layer was decanted off
-
Sample 99 was subsequently washed to remove excess solvents and impurities as outlined in the table below. The beads were further exposed to HCl to reach a final content of 10.04 wt. % chloride by elemental analysis. -
Solvent:beads Time Solvent ratio (gm:gm) (mins) Toluene 6:1 20 Methanol 6:1 20 Methanol 6:1 20 Methanol 6:1 20 0.5M Hydrochloric Acid 6:1 20 0.5M Hydrochloric Acid 6:1 20 Water Excess - Flush until pH 4-5 2M Sodium Hydroxide 6:1 20 2M Sodium Hydroxide 6:1 20 Water Excess - Flush until pH 6-7 Methanol 6:1 20 Toluene 6:1 20 Methanol 6:1 20 Water 4L - flush on the filter - Bile acid binding capacity, affinity, and retention for
Sample 99 were determined via the A assay, B assay and hamster model and results are reported in the table below, along with swelling ratio and bead size. -
Test Method Result Malvern Bead Size d(0.5) = 102.8 um Swelling 1.2-1.6 g/g B Assay 3.18 mmol/g A Assay 0.65 mmol/g Hamster 0.43 mmol/g - Additional Polymers Tested.
- Five additional polymers known to bind bile acids were tested as comparator substances. Polymer lots and methods of purification are noted in the table below.
-
Polymer Source Lot # Purification Cholestyramine Sigma C4650 045K0658 None (CT) Colesevelam Pharmacy KB004434 Purification of API (CV) from tablets Colestipol (CP) Pharmacy 84RAC None Sevelamer (SV) Pharmacy 8-16-08 Purification of API from tablets Colestimide Pharmacy KB04438 Purification of API (CM) from tablets - Preparation of the BES Buffer.
- A simple buffer was made consisting of 100 mM BES (N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid) and 150 mM NaCl at a final pH of 7.0 in 4 L batches. Briefly, 42.65 g of BES (acid), 47.04 g of BES (Na-salt) and 35.06 g of NaCl were dissolved in MilliQ pure water. The volume was adjusted to 4 L and the pH was noted.
- Preparation of the Binding Matrices.
- On the day preceding the binding assay, a single bile acid was added to 300 ml of BES buffer to a concentration of 20 mM. The solution was allowed to mix 3-6 hours and then subsequently diluted in a series of two fold dilutions. The final dilution set, therefore, contained matrices at 0, 0.31, 0.62, 1.25, 2.5, 5, 10, and 20 mM bile acid. The bile acid and the amount weighed into the BES buffer are listed in the table below.
-
Bile Acid Abbreviation Amount added (g) Cholate CA 2.58 Glycocholate GC 2.925 Taurocholate TC 3.226 Glycodeoxycholate GDC 2.829 Taurodeoxycholate TDC 3.13 - Assay Methods.
- Polymer samples were dispensed in duplicate into 16×100 mm glass tubes, with each tube containing accurately weighed 8 to 12 mg of dried sample. Binding matrices as described above were dispensed into the sample tubes to give a final concentration of 1 mg test sample per mL of buffer. Control tubes with buffer only were also prepared. The samples were incubated at 37° C. for three hours to reach bile acid binding equilibrium while rotating on a rotisserie platform. Following incubation, the samples were centrifuged at 500×g for 30 minutes to pellet the bile acid binding polymer. The supernatant was collected and transferred to a 0.45 micron Whatman 96-well uniplate to remove small particles prior to analysis. The filtrate was used to determine bile acid concentration as described below. Samples were diluted with BES buffer as needed for a final anticipated concentration of less than 2 mM.
- Analytical Methods.
- To determine the concentration of bile acid in the isotherm sample, 50 μL of the sample solution was injected onto a HPLC system equipped with Phenomenex Luna C5 column (100 Å, 5 μm, 50×2.00 mm) and a UV detector. The sample was analyzed using a gradient of 15 mM aqueous phosphate buffer (pH=3) and acetonitrile at a flow rate of 0.4 mL/min. The signal of the bile acid was detected at a wavelength of 205 nm from the UV detector. Calibration solutions comprised of the bile acid standards of different concentrations were also injected onto the same HPLC system. The calibration curve of the bile acid was then constructed by plotting the peak area vs. concentration. Based on the peak area of the bile acid peak found in the sample chromatogram and its calibration curve, the concentration of the bile acid in the sample was calculated.
- Data Analysis.
- Binding capacity was calculated as (Cstart−Ceq)/1, where Cstart (mM) is the starting concentration of bile acid in the binding matrix, Ceq (mM) is the concentration of bile acid remaining in the sample at equilibrium after exposure to polymer, and 1 corresponds to the concentration of the bile acid binder (mg/ml). The units for the bound bile acid (e.g., TDC Bnd) and the unbound bile acid (e.g., TDC Unbd) are mmol bile acid/g binder. All assays were run in duplicate with values reported as an average, +/−SD.
-
TDC GDC TC GC CA Start TDC TDC Start GDC GDC Start TC TC Start GC GC Start CA CA Binder (mM) Bnd Unbd (mM) Bnd Unbd (mM) Bnd Unbd (mM) Bnd Unbd (mM) Bnd Unbd CT 18.94 3.26 15.68 18.57 3.05 15.53 20.42 3.29 17.14 18.17 1.80 16.37 19.63 2.85 16.78 CT 9.50 3.11 6.38 9.08 2.85 6.23 10.34 2.98 7.35 9.27 1.47 7.81 10.18 2.10 8.08 CT 4.94 3.16 1.78 4.65 2.78 1.87 5.22 2.09 3.13 4.73 0.97 3.76 5.61 1.79 3.82 CT 2.56 2.20 0.36 2.36 1.75 0.60 2.64 1.07 1.57 2.42 0.60 1.82 2.68 0.91 1.78 CT 1.20 1.07 0.13 1.14 0.90 0.24 1.27 0.59 0.68 1.16 0.37 0.79 1.22 0.43 0.79 CT 0.61 0.55 0.06 0.57 0.46 0.11 0.64 0.32 0.32 0.59 0.20 0.39 0.63 0.24 0.39 CT 0.31 0.28 0.03 0.29 0.23 0.06 0.32 0.17 0.16 0.30 0.10 0.20 0.31 0.11 0.20 CT 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 CV 18.94 4.45 14.50 18.57 4.16 14.41 20.42 4.44 15.98 18.17 3.62 14.55 19.63 4.84 14.80 CV 9.50 4.15 5.34 9.08 4.08 5.00 10.34 4.06 6.28 9.27 2.95 6.32 10.18 4.01 6.17 CV 4.94 4.17 0.78 4.65 3.77 0.88 5.22 2.80 2.41 4.73 1.96 2.77 5.61 3.10 2.50 CV 2.56 2.40 0.16 2.36 2.12 0.24 2.64 1.42 1.22 2.42 1.13 1.29 2.68 1.61 1.07 CV 1.20 1.12 0.083 1.14 1.05 0.097 1.27 0.80 0.472 1.16 0.67 0.494 1.22 0.84 0.380 CV 0.61 0.58 0.029 0.57 0.53 0.038 0.64 0.50 0.133 0.59 0.44 0.156 0.63 0.53 0.101 CV 0.31 0.308 0.000 0.29 0.288 0.000 0.32 0.324 0.000 0.30 0.261 0.037 0.31 0.313 0.000 CV 0.00 0.00 0.000 0.00 0.00 0.000 0.00 0.00 0.000 0.00 0.00 0.000 0.00 0.00 0.000 CP 18.94 5.367 13.577 18.57 5.702 12.869 20.42 4.632 15.791 18.17 4.159 14.011 19.63 5.040 14.593 CP 9.50 5.098 4.397 9.08 5.025 4.056 10.34 3.874 6.462 9.27 3.183 6.092 10.18 3.976 6.203 CP 4.94 4.340 0.604 4.65 3.989 0.658 5.22 1.992 3.226 4.73 1.587 3.146 5.61 2.370 3.237 CP 2.56 2.246 0.313 2.36 2.002 0.355 2.64 0.378 2.260 2.42 0.238 2.182 2.68 0.492 2.191 CP 1.20 0.893 0.309 1.14 0.819 0.324 1.27 0.029 1.243 1.16 0.026 1.138 1.22 0.012 1.205 CP 0.61 0.327 0.282 0.57 0.261 0.309 0.64 0.007 0.630 0.59 0.012 0.578 0.63 0.013 0.619 CP 0.31 0.049 0.258 0.29 0.022 0.266 0.32 0.007 0.317 0.30 0.005 0.293 0.31 0.011 0.324 CP 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 SV 18.94 7.748 11.196 18.57 7.523 11.049 20.42 8.831 11.593 18.17 7.781 10.390 19.63 8.169 11.464 SV 9.50 7.648 1.848 9.08 7.297 1.784 10.34 6.714 3.622 9.27 5.722 3.553 10.18 6.505 3.675 SV 4.94 4.769 0.175 4.65 4.489 0.157 5.22 3.480 1.738 4.73 3.033 1.700 5.61 2.970 2.637 SV 2.56 2.411 0.147 2.36 2.215 0.142 2.64 1.030 1.608 2.42 0.939 1.481 2.68 1.018 1.665 SV 1.20 1.059 0.144 1.14 1.004 0.139 1.27 0.110 1.163 1.16 0.100 1.065 1.22 0.062 1.156 SV 0.61 0.466 0.143 0.57 0.435 0.135 0.64 0.029 0.608 0.59 0.029 0.562 0.63 0.032 0.600 SV 0.31 0.173 0.135 0.29 0.160 0.129 0.32 0.016 0.307 0.30 0.012 0.287 0.31 0.001 0.312 SV 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 S 99 18.94 7.181 11.763 18.57 7.022 11.549 20.42 6.626 13.797 18.17 5.559 12.611 19.63 7.338 12.295 S 99 9.50 6.867 2.628 9.08 6.880 2.201 10.34 5.537 4.799 9.27 4.674 4.601 10.18 5.843 4.337 S 99 4.94 4.729 0.216 4.65 4.445 0.202 5.22 3.563 1.655 4.73 3.168 1.565 5.61 4.432 1.175 S 99 2.56 2.478 0.081 2.36 2.283 0.074 2.64 1.890 0.748 2.42 1.679 0.741 2.68 2.106 0.577 S 99 1.20 1.144 0.058 1.14 1.090 0.052 1.27 0.831 0.441 1.16 0.734 0.430 1.22 0.888 0.329 S 99 0.61 0.564 0.045 0.57 0.531 0.039 0.64 0.374 0.263 0.59 0.334 0.256 0.63 0.425 0.207 S 99 0.31 0.274 0.034 0.29 0.260 0.028 0.32 0.171 0.153 0.30 0.148 0.151 0.31 0.186 0.127 S 99 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 CM 18.94 5.391 13.552 18.57 5.225 13.346 20.42 4.941 15.482 19.63 4.663 14.969 CM 9.50 5.068 4.427 9.08 4.798 4.283 10.34 4.194 6.141 10.18 3.281 6.898 CM 4.94 4.376 0.569 4.65 3.858 0.789 5.22 2.120 3.097 5.61 1.567 4.040 CM 2.56 2.250 0.309 2.36 1.819 0.538 2.64 0.306 2.332 2.68 0.375 2.309 CM 1.20 0.905 0.297 1.14 0.675 0.467 1.27 0.029 1.244 1.22 0.007 1.210 CM 0.61 0.324 0.285 0.57 0.127 0.443 0.64 0.008 0.630 0.63 0.014 0.618 CM 0.31 0.043 0.265 0.29 0.009 0.280 0.32 0.004 0.320 0.31 −0.009 0.322 CM 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 - Data was graphically represented in an isotherm format in which Bound Bile Acid (mmol bile acid/g polymer) was plotted vs Unbound Bile Acid (mmol bile acid/g polymer). (
FIGS. 1 and 2 ). Unbound Bile Acid is calculated as Ceq (mM)/1 mg/ml polymer. Bound Bile Acid is calculated as Cstart−Ceq/1 mg/ml polymer. - In view of the above, it will be seen that the several objects of the invention are achieved and other advantageous results attained. As various changes could be made in the above polymers, pharmaceutical compositions, and methods of treatment without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawing[s] shall be interpreted as illustrative and not in a limiting sense.
Claims (155)
1. An amine polymer comprising repeat units derived from polymerization of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1.1, and the amine polymer has a binding affinity for bile acids of at least 0.46 mmol/g when measured using an in vitro A assay.
2. An amine polymer comprising the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer, wherein units of the polymer have the structure of formula 1
wherein
R10 is derived from the crosslinking monomer and is C2 to C16 alkylene, —NH—C(NH)—NH—, —NH—C(NH2 +)—NH—, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy;
R30 is derived from the amine monomer and is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, a cycloalkyl, an aryl, or a heterocyclo functional group;
each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and
at least one of R10 or R30 is a hydrophobic group having a calculated log P (c Log P) of greater than 4.
3. An amine polymer comprising the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the structure of formula 1
wherein
R10 is derived from the crosslinking monomer and is C2 to C16 alkylene, —NH—C(NH)—NH—, —NH—C(NH2 +)—NH—, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy;
R30 is derived from the amine monomer and is C2 to C6 alkylene;
each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and
R10 is a hydrophobic group having a calculated log P (c Log P) of greater than 4.
4. An amine polymer comprising the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the structure of formula 1
wherein
R10 is derived from the crosslinking monomer and is C8 to C16 alkylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
R30 is derived from the amine monomer and is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and
each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group.
5. An amine polymer comprising the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer wherein units of the polymer have the structure of formula 1
wherein
R10 is derived from the crosslinking monomer and is C2 to C6 alkylene, or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy;
R30 is derived from the amine monomer and is C8 to C16 alkylene, arylene, diformylheterocyclo, or C8 to C16 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and
each R20 is independently C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group.
6. The amine polymer of any one of claims 2 to 5 wherein the polymer comprises primary and secondary amine atoms in a calculated ratio in the range of from 1:1 to about 1:5.
7. The amine polymer of any one of claims 2 to 6 wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1.1.
8. The amine polymer of any one of claims 2 to 7 having a binding affinity for bile acids of at least 0.46 mmol/g when measured using an in vitro A assay.
9. An amine polymer comprising the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites,
said polymer being insoluble in water,
at least some of said amine secondary nitrogen atoms being part of a crosslinked polymer network,
the crosslinking monomer is a compound having the formula X-R1-X, wherein each X is independently a leaving group, and R1 is C8 to C16 alkylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, and the calculated log P (c Log P) of the crosslinking monomer is greater than 4.
10. An amine polymer comprising the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites,
said polymer being insoluble in water,
at least some of said amine secondary nitrogen atoms being part of a crosslinked polymer network,
the amine monomer having at least one segment that is a C8 to C16 alkylene, arylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, and a calculated log P (c Log P) of the at least one segment of the amine monomer is greater than 4, and
the crosslinking monomer is a compound having the formula X-R1-X, wherein each X is independently a leaving group, and R1 is C2 to C6 alkylene, or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
11. The polymer of claim 9 wherein the crosslinking monomer is X-R1-X wherein each X is independently a leaving group, and R1 is C8 to C16 alkylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with a heterocyclo functional group.
12. The polymer of claim 10 wherein the crosslinking monomer is X-R1-X wherein each X is independently a leaving group, and R1 is C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
13. An amine polymer comprising repeat units derived from polymerization of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer having two or three possible reaction sites, wherein the molar ratio of the amine monomer to the crosslinking monomer is in the range of from 1:3 to about 1:1.1, and wherein:
said polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and
said polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using a B assay.
14. An amine polymer comprising units of the polymer having nodes of positive charge separated by aliphatic segments, wherein the nodes of positive charge have a charge density of at least 19.0 mEq/g and a molecular weight of at least 200.0 g/mol and at least one aliphatic segment is bonded to each node of positive charge, the at least one aliphatic segment having a calculated log P (c Log P) greater than 4 and wherein each of the nodes of positive charge does not contain an aliphatic segment having a calculated log P (c Log P) greater than 4.
15. An amine polymer comprising units of the polymer having nodes of positive charge separated by aliphatic segments, wherein the nodes of positive charge have a charge density greater than 17.3 mEq/g and the structure of formula A
wherein each R20 is independently C3 to C8 alkylene or C3 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group;
and wherein at least one aliphatic segment is bonded to each node of positive charge, each aliphatic segment having a calculated log P (c Log P) greater than 4.
16. The amine polymer of claim 14 or 15 , wherein the at least one aliphatic segment is a C8 to C16 alkylene, or C8 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
17. The amine polymer of any one of claims 14 to 16 , wherein said polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and said polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using the B assay.
18. The amine polymer of claim 17 , wherein said polymer binds phosphate in vitro in an amount of less than 0.2 mmol/gram of polymer when measured using the B assay.
19. The amine polymer of any one of claims 15 to 18 wherein each of the nodes of positive charge does not contain an aliphatic segment having a calculated log P (c Log P) greater than 4.
20. An amine polymer comprising units of the polymer having the structure of formula 1
wherein
R10 is C2 to C16 alkylene, arylene, —NH—C(NH)—NH—, —NH—C(NH2 +)—NH—, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, a cycloalkyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy;
R30 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and
each R20 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group;
said polymer binds phosphate in vitro in an amount of less than 0.3 mmol/gram of polymer when measured using a B assay; and
said polymer binds bile acids with an in vitro capacity of greater than about 3 mmol/gram of polymer when measured using a B assay.
21. The amine polymer of claim 20 wherein the amine polymer comprises the reaction product of an amine monomer having six, seven or eight possible reaction sites and a crosslinking monomer and R10 is derived from the crosslinking monomer and R30 is derived from the amine monomer.
22. The amine polymer of claim 20 wherein the amine polymer binds phosphate in vitro in an amount of less than 0.2 mmol/gram of polymer when measured using a B assay.
23. The amine polymer of any of claims 1 to 22 wherein the calculated Log P is greater than 4.5.
24. The amine polymer of any of claims 1 to 22 wherein the calculated Log P is greater than 5.
25. The amine polymer of any of claims 1 to 22 wherein the calculated Log P is greater than 5.5.
26. The amine polymer of any of claims 1 to 22 wherein the calculated Log P is greater than 6.
27. An amine polymer comprising repeat units derived from polymerization of an amine monomer and a crosslinking monomer, wherein the amine monomer is an amine of formula 2 having the structure:
wherein each R2 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with at least one amide functional group, and R3 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and
the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, R1 is C8 to C16 alkylene, or C5 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
28. The amine polymer of any one of claims 1 to 26 wherein the amine monomer is an amine of formula 2 having the structure:
wherein each R2 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group, and R3 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
29. The amine polymer of any one of claims 1 to 26 wherein the amine monomer is an amine of formula 2 having the structure:
wherein each R2 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group, and R3 is C8 to C16 alkylene, arylene, diformylheterocyclo, or C8 to C16 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
and the crosslinking monomer is a compound having the formula X-R1-X, wherein each X is independently a leaving group, R1 is C2 to C6 alkylene or C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
30. The amine polymer of claim 28 wherein the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, R1 is C8 to C16 alkylene, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with one or two phenyl, piperidinium or imidazolium functional groups.
31. The amine polymer of claim 30 wherein the C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with one or two phenyl, piperidinium or imidazolium functional groups is p-xylene, 1,3-bis(m-haloCmalkyl)-1H-imidazol-3-ium, 4,4′-(Cxalkane-Lx-diyl)bis(1-(m-haloCmalkyl)-1-methylpiperidinium), or 1-(q-haloCqalkyl)-3-(m-(3-(p-haloCpalkyl)-1H-imidazol-3-ium-1-yl)Cmalkyl)-1H-imidazol-3-ium, wherein m is an integer from 2 to 14, p is an integer from 2 to 14, q is an integer from 2 to 14, and x is an integer from 2 to 8.
32. The amine polymer of claim 28 wherein the crosslinking monomer is guanidine, a compound having the formula X-R1-X wherein R1 is C8 to C16 alkylene, or a combination thereof, and the amine polymer comprises a comonomer, the comonomer being Cmalkane-1,m-diyldiamine, alkylenedicycloalkanamine, (m-aminoCmalkyl)heterocycle, 3-(m-aminoCmalkyl)-1H-imidazol-3-ium, or a combination thereof, wherein m is an integer from 2 to 16, and each X is independently a leaving group.
33. The amine polymer of claim 29 wherein the crosslinking monomer is a compound having the formula X-R1-X wherein R1 is C2 to C6 alkylene, and the amine polymer comprises a comonomer, the comonomer being Cmalkane-1,m-diyldiamine, alkylenedicycloalkanamine, (m-aminoCmalkyl)heterocycle, 3-(m-aminoCmalkyl)-1H-imidazol-3-ium, or a combination thereof, wherein m is an integer from 2 to 16, and each X is independently a leaving group.
34. The amine polymer of claim 29 wherein R3 is octylene, decylene, undecylene, or dodecylene.
35. The amine polymer of claim 29 wherein the polymer comprises a comonomer, the comonomer being hexane-1,6-diyldiamine, heptane-1,7-diylamine, octane-1,8-diyldiamine, nonane-1,9-diylamine, decane-1,10-diyldiamine, undecane-1,11-diylamine, dodecane-1,12-diyldiamine, 4,4′-methylenedicyclohexanamine, 3-(3-aminopropyl)-1H-imidazol-3-ium, or a combination thereof.
36. The amine polymer of claim 28 wherein R3 is ethylene, propylene, butylene, pentylene, hexylene, heptylene, octylene, decylene, undecylene, dodecylene, 1,4-phenylenedimethyl, 1,6-dioxohexane-1,6-diyl, 1,4-dioxobutane-1,4-diyl or 2,6-diformylpyridine.
37. The amine polymer of claim 1 wherein the amine monomer is an amine of formula 3 having the structure:
wherein each R21 is independently C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with at least one sulfur atom, and R31 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and
the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, and R1 is C2 to C16 alkylene, arylene, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
38. The amine polymer of claim 37 wherein each R21 is m-sulfidoCmalkyl, m is an integer from 1 to 6 and R31 is C3 to C8 alkylene.
39. An amine polymer comprising repeat units derived from polymerization of an amine monomer of formula 2 and a crosslinking monomer, wherein the amine monomer of formula 2 has the structure:
wherein each R2 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide functional group; and R3 is C2 to C12 alkylene, arylene, diformylheterocyclo, or C2 to C12 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group; and a portion of the nitrogen atoms of the amine polymer are substituted with a ligand selected from aminoalkyl, aryl, arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo, heterocycloalkyl, (trialkylammonio)alkyl, 2-(protected amino)-m-(heterocyclo)-1-oxoCmalkyl, 2-(protected amino)-1-oxoCmalkyl, 2-(protected amino)-3-methyl-1-oxoCmalkyl, 2-(protected amino)-4-methyl-1-oxoCmalkyl, 2-(protected amino)-1-oxo-m-arylCmalkyl, 2-(protected amino)-m-(alkylthio)-1-oxoCmalkyl, 2-(protected amino)-m-(aryl)-1-oxoCmalkyl, 2-(protected amino)-m-carboxy-1-oxoCmalkyl, 2-(protected amino)-m-guanidino-1-oxoCmalkyl, 2-(protected amino)-(m-1)-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-mercapto-1-oxoCmalkyl, m-(alkylamino)-m-oxoCmalkyl, m-(alkylheterocyclo)Cmalkyl, m-amino-2-(protected amino)-1-oxoCmalkyl, m-amino-2-(protected amino)-1,m-dioxoCmalkyl, m-(x-aminoCxalkyl)heterocycloCmalkyl, (m-1)-amino-m-(heterocyclo)-1-oxoCmalkyl, m-(arylalkylamino)-m-oxoCmalkyl, m-(x-(alkylthio)Cxalkylamino)-m-oxoCmalkyl, m-(x-aminoCxalkylamino)-m-oxoCmalkyl, m-(x-amino-x-oxoCxalkylamino)-m-oxoCmalkyl, m-(x-carboxyCxalkylamino)-m-oxoCmalkyl, m-(heterocycloalkylamino)-m-oxoCmalkyl, m-(x-hydroxyCxalkylamino)-m-oxoCmalkyl, m-((x-1)-hydroxyCxalkylamino)-m-oxoCmalkyl, m-(x-mercaptoCxalkylamino)-m-oxoCmalkyl, m-(x-trialkylammonioCxalkyl)heterocycloCmalkyl, m-(x-(2-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, m-(x-(3-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, m-(x-(4-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, a ligand of formula 4
*-R46-R47-R48 (4)
*-R46-R47-R48 (4)
or a combination thereof, wherein R46 is C6 to C16 alkylene, R47 is 1,y-bis(1-methylpiperidin-4-yl)Cyalkylene, R48 is C6 to C16 alkyl, m is an integer from 3 to 12, x is an integer from 1 to 12, y is an integer from 1 to 14, and z is an integer from 1 to 16.
40. The amine polymer of any one of claims 1 to 38 wherein a portion of the nitrogen atoms of the amine polymer are substituted with a ligand selected from alkyl, aminoalkyl, aryl, arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo, heterocycloalkyl, (trialkylammonio)alkyl, 2-(protected amino)-m-(heterocyclo)-1-oxoCmalkyl, 2-(protected amino)-1-oxoCmalkyl, 2-(protected amino)-3-methyl-1-oxoCmalkyl, 2-(protected amino)-4-methyl-1-oxoCmalkyl, 2-(protected amino)-1-oxo-m-arylCmalkyl, 2-(protected amino)-m-(alkylthio)-1-oxoCmalkyl, 2-(protected amino)-m-(aryl)-1-oxoCmalkyl, 2-(protected amino)-m-carboxy-1-oxoCmalkyl, 2-(protected amino)-m-guanidino-1-oxoCmalkyl, 2-(protected amino)-(m-1)-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-mercapto-1-oxoCmalkyl, m-(alkylamino)-m-oxoCmalkyl, m-(alkylheterocyclo)Cmalkyl, m-amino-2-(protected amino)-1-oxoCmalkyl, m-amino-2-(protected amino)-1,m-dioxoCmalkyl, m-(x-aminoCxalkyl)heterocycloCmalkyl, (m-1)-amino-m-(heterocyclo)-1-oxoCmalkyl, m-(arylalkylamino)-m-oxoCmalkyl, m-(x-(alkylthio)Cxalkylamino)-m-oxoCmalkyl, m-(x-aminoCxalkylamino)-m-oxoCmalkyl, m-(x-amino-x-oxoCxalkylamino)-m-oxoCmalkyl, m-(x-carboxyCxalkylamino)-m-oxoCmalkyl, m-(heterocycloalkylamino)-m-oxoCmalkyl, m-(x-hydroxyCxalkylamino)-m-oxoCmalkyl, m-((x-1)-hydroxyCxalkylamino)-m-oxoCmalkyl, m-(x-mercaptoCxalkylamino)-m-oxoCmalkyl, m-(x-trialkylammonioCxalkyl)heterocycloCmalkyl, m-(x-(2-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, m-(x-(3-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, m-(x-(4-(alkoxy)benzamido)Cxalkylamino)-m-oxoCmalkyl, a ligand of formula 4
*-R46-R47-R48 (4)
*-R46-R47-R48 (4)
or a combination thereof, wherein R46 is C6 to C16 alkylene, R47 is 1,y-bis(1-methylpiperidin-4-yl)Cyalkylene, R48 is C6 to C16 alkyl, m is an integer from 3 to 12, x is an integer from 1 to 12, y is an integer from 1 to 14, and z is an integer from 1 to 16.
41. The amine polymer of claim 39 or 40 wherein the ligand is arylalkyl selected from naphthalen-2-ylalkyl or naphthalen-1-ylalkyl; heterocycloalkyl selected from m-(1-methylpyrrolidinium-1-yl)Cmalkyl, m-(2-(1H-indol-3-yl)ethylamino)-m-oxoCmalkyl, m-(2-methylthiazol-3-ium-3-yl)Cmalkyl, m-(benzo[d]thiazol-3-ium-3-yl)Cmalkyl, m-(pyridinium-1-yl)Cmalkyl, m-(tetrahydro-1H-thiophenium-1-yl)Cmalkyl, z-(1,2-dialkyl-1H-imidazol-3-ium-3-yl)Czalkyl, m-(2,3-dialkyl-1H-imidazol-3-ium-1-yl)Cmalkyl, z-(1-alkyl-1H-imidazol-3-ium-3-yl)Czalkyl, m-(3-alkyl-1H-imidazol-3-ium-1-yl)Cmalkyl, or z-(thiazol-3-ium-3-yl)Czalkyl; 2-(protected amino)-m-(heterocyclo)-1-oxoCmalkyl selected from 2-(protected amino)-m-(1H-indol-3-yl)-1-oxoCm-alkyl or 2-(protected amino)-m-(1H-imidazol-4-yl)-1-oxoCmalkyl; 2-(protected amino)-1-oxo-m-phenylCmalkyl; 2-(protected amino)-m-(hydroxyphenyl)-1-oxoCmalkyl; m-(alkylheterocyclo)Cmalkyl selected from m-(3-alkyl-1H-imidazol-3-ium-1-yl)Cmalkyl, m-(1-alkyl-1H-imidazol-3-ium-3-yl)Cmalkyl, m-(1-alkyl-2-methyl-1H-imidazol-3-ium-3-yl)Cmalkyl, or m-(3-alkyl-2-methyl-1H-imidazol-3-ium-1-yl)Cmalkyl; m-(x-aminoCxalkyl)heterocycloCmalkyl selected from m-(3-(x-aminoCxalkyl)-1H-imidazol-3-ium-1-yl)Cmalkyl or m-(1-(x-aminoCxalkyl)-1H-imidazol-3-ium-3-yl) Cmalkyl; (m-1)-amino-m-(1H-indol-2-yl)-1-oxoCmalkyl; m-(arylalkylamino)-m-oxoCmalkyl selected from m-(hydroxyphenalkylamino)-m-oxoCmalkyl or m-(phenalkylamino)-m-oxo-Cmalkyl; m-(x-(heterocyclo)Cxalkyl)heterocycloCmalkyl selected from m-(1-(x-(1-methyl-1H-imidazol-3-ium-3-yl)Cxalkyl)-1H-imidazol-3-ium-3-yl) Cmalkyl, m-(1-(x-(3-methyl-1H-imidazol-3-ium-1-yl)Cxalkyl)-1H-imidazol-3-ium-3-yl) Cmalkyl, m-(3-(x-(1-methyl-1H-imidazol-3-ium-3-yl)Cxalkyl)-1H-imidazol-3-ium-1-yl) Cmalkyl, or m-(3-(x-(3-methyl-1H-imidazol-3-ium-1-yl)Cxalkyl)-1H-imidazol-3-ium-1-yl) Cmalkyl; m-(x-(1H-imidazol-4-yl)Cxalkylamino)-m-oxoCmalkyl; or m-(x-trialkylammonioCxalkyl)heterocycloCmalkyl selected from m-(3-(x-trialkylammonio)Cxalkyl)-1H-imidazol-3-ium-1-yl)Cmalkyl or m-(1-(x-trialkylammonio)Cxalkyl)-1H-imidazol-3-ium-3-yl)Cmalkyl wherein m is an integer from 3 to 12, x is an integer from 1 to 12, and z is an integer from 1 to 16.
42. The amine polymer of claim 39 or 40 wherein the ligand is 2-(protected amino)-m-(heterocyclo)-1-oxoCmalkyl, m-amino-2-(protected amino)-1,m-dioxoCmalkyl, m-amino-2-(protected amino)-1-oxoCmalkyl, 2-(protected amino)-1-oxoCmalkyl, 2-(protected amino)-m-(alkylthio)-1-oxoCmalkyl, 2-(protected amino)-m-(hydroxyphenyl)-1-oxoCmalkyl, 2-(protected amino)-1-oxo-m-phenylCmalkyl, 2-(protected amino)-m-(1H-imidazol-4-yl)-1-oxoCmalkyl, 2-(protected amino)-m-carboxy-1-oxoCmalkyl, 2-(protected amino)-3-methyl-1-oxoCmalkyl, 2-(protected amino)-4-methyl-1-oxoCmalkyl, 2-(protected amino)-m-mercapto-1-oxoCmalkyl, 2-(protected amino)-(m-1)-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-hydroxy-1-oxoCmalkyl, 2-(protected amino)-m-guanidino-1-oxoCmalkyl, m-(x-(alkylthio)Cxalkylamino)-m-oxoCmalkyl, m-(hydroxyphenalkylamino)-m-oxoCmalkyl, m-oxo-m-(phenalkylamino)Cmalkyl, m-(x-(1H-imidazol-4-yl)Cxalkylamino)-m-oxoCmalkyl, m-(x-carboxyCxalkylamino)-m-oxoCmalkyl, m-(alkylamino)-m-oxoCmalkyl, m-(x-mercaptoCxalkylamino)-m-oxoCmalkyl, m-((x-1)-hydroxyCxalkylamino)-m-oxoCmalkyl, m-(x-hydroxyCxalkylamino)-m-oxoCmalkyl, m-(x-aminoCxalkylamino)-m-oxoCmalkyl, or m-(x-amino-x-oxoCxalkylamino)-m-oxoCmalkyl, wherein m is an integer from 3 to 12, and x is an integer from 1 to 12.
43. The amine polymer of claim 39 or 40 wherein the ligand is 2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-1-oxopropyl, 5-(2-(4-(nonyloxy)benzamido)ethylamino)-5-oxopentyl, (4,5-dihydro-1H-imidazolyl, 10-(pyridinium-1-yl)decyl, 2-(1H-indol-3-yl)ethyl, 5-(2-(1H-indol-3-yl)ethylamino)-5-oxopentyl, 2-amino-3-(1H-indol-2-yl)-1-oxopropyl, 3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl, 10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl, 10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl, 3-(thiazol-3-ium-3-yl)propyl, 3-aminopropyl, 3-cyclohexylpropyl, 3-phenylpropyl, 3-(trimethylammonio)propyl, 3-(1-methylpyrrolidinium-1-yl)propyl, 3-(2-methylthiazol-3-ium-3-yl)propyl, 3-(benzo[d]thiazol-3-ium-3-yl)propyl, 3-(tetrahydro-1H-thiophenium-1-yl)propyl, 3-(3-methyl-1H-imidazol-3-ium-1-yl)propyl, 3-(1-methyl-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(3-aminopropyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(3-aminopropyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-decyl-1H-imidazol-3-ium-1-yl)propyl, 3-(1-decyl-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(1-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-1-yl)propyl, 4-(3-decyl-1H-imidazol-3-ium-1-yl)butyl, 4-(1-decyl-1H-imidazol-3-ium-3-yl)butyl, 10-(1-decyl-2-methyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-decyl-2-methyl-1H-imidazol-3-ium-1-yl)decyl, 3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl, 3-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)propyl, 10-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)decyl, 10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl, 10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-methyl-1H-imidazol-3-ium-1-yl)decyl, 10-(1-butyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-butyl-1H-imidazol-3-ium-1-yl)decyl, 10-(pyridinium-1-yl)decyl, 10-(1-methylpyrrolidinium-1-yl)decyl, naphthalen-2-ylmethyl, naphthalen-1-ylmethyl, 4-amino-2-(tert-butoxycarbonylamino)-1,4-dioxobutyl, 2-(tert-butoxycarbonylamino)-1-oxoethyl, 2-(tert-butoxycarbonylamino)-4-(methylthio)-1-oxobutyl, 5-(3-(methylthio)propylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)-1-oxopropyl, 5-(4-hydroxyphenethylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-1-oxo-3-phenylpropyl, 5-oxo-5-(phenethylamino)pentyl, 2-(tert-butoxycarbonylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl, 5-(2-(1H-imidazol-4-yl)ethylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-3-carboxy-1-oxopropyl, 5-(2-carboxyethylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-3-methyl-1-oxobutyl, 5-(isobutylamino)-5-oxopentyl,(3R)-2-(tert-butoxycarbonylamino)-3-methyl-1-oxopentyl,(R)-5-(2-methylbutylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-3-mercapto-1-oxopropyl, 5-(2-mercaptoethylamino)-5-oxopentyl,(3R)-2-(tert-butoxycarbonylamino)-3-hydroxy-1-oxobutyl,(R)-5-(2-hydroxypropylamino)-5-oxopentyl, 6-amino-2-(tert-butoxycarbonylamino)-1-oxohexyl, 5-(5-aminopentylamino)-5-oxopentyl, 5-amino-2-(tert-butoxycarbonylamino)-1,5-dioxopentyl, 5-(4-amino-4-oxobutylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-5-guanidino-1-oxopentyl, 5-(4-guanidinobutylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-3-hydroxy-1-oxopropyl, 5-(2-hydroxyethylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-4-methyl-1-oxopentyl, 5-(isopentylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-4-carboxy-1-oxobutyl, 5-(3-carboxypropylamino)-5-oxopentyl, 2-(tert-butoxycarbonylamino)-1-oxopropyl, 5-(ethylamino)-5-oxopentyl, a ligand of formula 4
*-R46-R47-R48 (4)
*-R46-R47-R48 (4)
or a combination thereof, wherein R46 is decylene, R47 is 1,3-bis(1-methylpiperidin-4-yl)propane, and R48 is decyl.
44. The amine polymer of claim 39 or 40 wherein the ligand is 2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-1-oxopropyl, 5-(2-(4-(nonyloxy)benzamido)ethylamino)-5-oxopentyl, (4,5-dihydro-1H-imidazolyl, 10-(pyridinium-1-yl)decyl, 2-(1H-indol-3-yl)ethyl, 5-(2-(1H-indol-3-yl)ethylamino)-5-oxopentyl, 2-amino-3-(1H-indol-2-yl)-1-oxopropyl, 3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl, 10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl, 10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl, 3-(thiazol-3-ium-3-yl)propyl, 3-aminopropyl, 3-cyclohexylpropyl, 3-phenylpropyl, 3-(trimethylammonio)propyl, 3-(1-methylpyrrolidinium-1-yl)propyl, 3-(2-methylthiazol-3-ium-3-yl)propyl, 3-(benzo[d]thiazol-3-ium-3-yl)propyl, 3-(tetrahydro-1H-thiophenium-1-yl)propyl, 3-(3-methyl-1H-imidazol-3-ium-1-yl)propyl, 3-(1-methyl-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(3-aminopropyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(3-aminopropyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-decyl-1H-imidazol-3-ium-1-yl)propyl, 3-(1-decyl-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-1-yl)propyl, 3-(1-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(1-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-3-yl)propyl, 3-(3-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-1-yl)propyl, 4-(3-decyl-1H-imidazol-3-ium-1-yl)butyl, 4-(1-decyl-1H-imidazol-3-ium-3-yl)butyl, 10-(1-decyl-2-methyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-decyl-2-methyl-1H-imidazol-3-ium-1-yl)decyl, 3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl, 3-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)propyl, 10-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)decyl, 10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl, 10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-methyl-1H-imidazol-3-ium-1-yl)decyl, 10-(1-butyl-1H-imidazol-3-ium-3-yl)decyl, 10-(3-butyl-1H-imidazol-3-ium-1-yl)decyl, 10-(pyridinium-1-yl)decyl, 10-(1-methylpyrrolidinium-1-yl)decyl, naphthalen-2-ylmethyl, naphthalen-1-ylmethyl, a ligand of formula 4
*-R46-R47-R48 (4)
*-R46-R47-R48 (4)
or a combination thereof, wherein R46 is decylene, R47 is 1,3-bis(1-methylpiperidin-4-yl)propane, and R48 is decyl.
45. The amine polymer of any one of claims 39 to 42 wherein the protecting group is independently —C(O)OR49, —C(O)R50, wherein R49 is alkyl or aryl, and R50 is amino, hydrogen, alkyl, or haloalkyl.
46. The amine polymer of claim 39 wherein the crosslinking monomer is guanidine, a guanidinium salt, a compound having the formula X-R1-X, or a combination thereof, wherein each X is independently a leaving group, and R1 is C2 to C16 alkylene, arylene, dimethylbiphenyl, or C2 to C50 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
47. The amine polymer of any one of claims 39 to 46 comprising about 5 mole % to about 60 mole % ligand based on the moles of amine monomer.
48. The amine polymer of any one of claims 39 to 46 comprising about 5 mole % to about 50 mole % ligand based on the moles of amine monomer.
49. The amine polymer of any one of claims 39 to 46 comprising about 10 mole % to about 30 mole % ligand based on the moles of amine monomer.
50. The amine polymer of any one of claims 9 to 12 , 27 , and 29 to 49 wherein X is halo, epoxy, diaziridino or a combination thereof.
51. The amine polymer of any one of claims 29 to 50 wherein R1 is C8 to C14 alkylene.
52. The amine polymer of claim 51 wherein R1 is decylene or dodecylene.
53. The amine polymer of any one of claims 2 , 5 to 8 , 10 , 20 -26 , 29 , 37 , 38 , 40 to 45 , and 47 to 50 wherein R1 or R10 is C2 to C6 alkylene wherein one or more of the —CH2— groups of the alkylene group is substituted with hydroxy.
54. The amine polymer of claim 53 wherein R1 or R10 is —CH2—CH(OH)—CH2—.
55. The amine polymer of any one of claims 29 to 54 wherein R3 or R30 is C3 to C12 alkylene.
56. The amine polymer of claim 55 wherein R3 or R30 is butylene.
57. The amine polymer of claim 55 wherein R3 or R30 is decylene.
58. The amine polymer of any one of claims 2 , 4 to 8 , 20 to 36 and 39 to 54 wherein R3 or R30 is dodecylene.
59. The amine polymer of any one of claims 2 to 8 , 20 to 36 and 39 to 58 wherein each R2 or R20 is independently C2 to C6 alkylene.
60. The amine polymer of claim 59 wherein each R2 or R20 is independently C2 to C4 alkylene.
61. The amine polymer of claim 60 wherein each R2 or R20 is propylene.
62. The amine polymer of any one of claims 1 to 61 having an in vivo binding capacity at least 25% greater than colesevelam hydrochloride when measured at a dosage of 0.5% in male Golden Syrian hamsters fed a Western diet.
63. The amine polymer of claim 62 wherein the in vivo binding capacity is at least 50% greater than colesevelam hydrochloride.
64. The amine polymer of claim 62 wherein the in vivo binding capacity is at least 75% greater than colesevelam hydrochloride.
65. The amine polymer of claim 62 wherein the in vivo binding capacity is at least 100% greater than colesevelam hydrochloride.
66. The amine polymer of any one of claims 1 to 65 wherein the binding affinity for bile acids is at least about 0.46 mmol/g when measured using an in vitro A assay.
67. The amine polymer of any one of claims 1 to 65 wherein the binding affinity for bile acids is at least about 0.55 mmol/g when measured using an in vitro A assay.
68. The amine polymer of any one of claims 1 to 65 wherein the binding affinity for bile acids is at least about 0.60 mmol/g when measured using an in vitro A assay.
69. The amine polymer of any one of claims 1 to 65 wherein the binding affinity for bile acids is at least about 0.65 mmol/g when measured using an in vitro A assay.
70. The amine polymer of any one of claims 1 to 69 having a binding capacity at least 25% greater than colesevelam hydrochloride when measured using an in vitro B assay.
71. The amine polymer of claim 70 wherein the in vitro binding capacity is at least 50% greater than colesevelam hydrochloride when measured using an in vitro B assay.
72. The amine polymer of claim 70 wherein the in vivo binding capacity is at least 75% greater than colesevelam hydrochloride when measured using an in vitro B assay.
73. The amine polymer of claim 70 wherein the in vivo binding capacity is at least 100% greater than colesevelam hydrochloride when measured using an in vitro B assay.
74. The amine polymer of any one of claims 1 to 73 , wherein, in an in vivo measurement, on average there are at least 11% primary bile acids in the feces.
75. The amine polymer of any one of claims 1 to 73 , wherein, in an in vivo measurement, on average there are at least 15% primary bile acids in the feces.
76. The amine polymer of any one of claims 1 to 75 wherein the binding capacity for bile acids is at least about 2.22 mmol/g when measured using the B assay.
77. The amine polymer of any one of claims 1 to 76 wherein the concentration of bound taurocholic acid is greater than 1.5 mmol/g polymer and the concentration of unbound taurocholic acid is less than 1.0 mmol/g polymer when the polymer is placed in a buffer solution having a 2.5 mM taurocholic acid concentration at 37° C. and the concentration of bound taurocholic acid is greater than 5.0 mmol/g polymer and the concentration of unbound taurocholic acid is greater than 4.0 mmol/g polymer when the polymer is placed in a buffer solution having a taurocholic acid concentration of at least 10 mM at 37° C.
78. The amine polymer of any one of claims 1 to 76 wherein the concentration of bound glycodeoxycholate is greater than 1.0 mmol/g polymer and the concentration of unbound glycodeoxycholate is less than 0.1 mmol/g polymer when the polymer is placed in a buffer solution having a 1.25 mM glycodeoxycholate concentration at 37° C. and the concentration of bound glycodeoxycholate is greater than 6.0 mmol/g polymer and the concentration of unbound glycodeoxycholate is greater than 2.0 mmol/g polymer when the polymer is placed in a buffer solution having a glycodeoxycholate concentration of at least 10 mM at 37° C.
79. An amine polymer useful as a bile acid sequestrant, wherein, in a buffer solution at 37° C. containing less than 2.6 mM taurocholic acid, the amine polymer binds more of the acid than sevelamer and in a buffer solution at 37° C. containing more than 5.0 mM taurocholic acid the amine polymer binds more of the acid than colesevelam.
80. The amine polymer of claim 79 having the structure of any one of claims 1 to 75 .
81. The amine polymer of claim 80 wherein the amine polymer is derived from the polymerization of an amine monomer and a crosslinking monomer wherein the amine monomer comprises N,N,N′,N′-tetrakis(3-aminopropyl)-1,12-diaminododecane and the crosslinking monomer comprises 1,3-dichloropropanol.
82. The amine polymer of any one of claims 1 to 81 having a swelling ratio of from about 1 to about 10.
83. The amine polymer of claim 82 wherein the swelling ratio of from about 2 to about 6.
84. The amine polymer of claim 83 wherein the swelling ratio of from about 2 to about 4.
85. The amine polymer of any one of claims 1 to 84 wherein the polymer is a particle having a mean diameter from about 50 microns to about 100 microns.
86. The amine polymer of claim 85 wherein the particle is a bead.
87. The amine polymer of claim 86 wherein the bead is a substantially spherical bead.
88. A pharmaceutical composition comprising the amine polymer of any one of claims 1 to 87 and a pharmaceutically acceptable excipient.
89. A method of reducing serum LDL-cholesterol in an animal subject comprising administering an effective amount of an amine polymer of any one of claims 1 to 87 or a pharmaceutical composition of claim 88 to an animal subject in need thereof.
90. A method of treating diabetes in an animal subject comprising administering an effective amount of an amine polymer of any one of claims 1 to 87 or a pharmaceutical composition of claim 88 to an animal subject in need thereof.
91. A method of treating Alzheimer's disease, non-alcoholic steatohepatitis, pruritus, IBS-D, or idiopathic bile acid malabsorption in an animal subject comprising administering an effective amount of an amine polymer of any one of claims 1 to 87 or a pharmaceutical composition of claim 88 to an animal subject in need thereof.
92. A method of removing bile salts from an animal subject comprising administering an effective amount of an amine polymer of any one of claims 1 to 87 or a pharmaceutical composition of claim 88 to an animal subject in need thereof.
93. The method of any one of claims 89 to 92 further comprising administering an agent that treats dyslipidemia to an animal subject.
94. The method of claim 93 wherein the agent that treats dyslipidemia is a hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor, a fibrate, a cholesterol absorption inhibitor, niacin (i.e. nicotinic acid or derivatives thereof), a phytosterol, an intestinal lipase inhibitor, an intestinal or secreted phospholipase A2 inhibitor, inhibitors of the synthesis or normal activity of Apo-B100, agonists of the synthesis or normal activity of ApoA, or any agent that modulates cholesterol absorption or metabolism, or a combination thereof to the animal subject.
95. The method of claim 93 or 94 wherein the amine polymer and the agent that treats dyslipidemia, or the combination thereof are administered to the animal subject at the same time.
96. The method of claim 93 or 94 wherein the amine polymer and the agent that treats dyslipidemia, or the combination thereof are sequentially administered to the animal subject.
97. The method of any one of claims 94 to 96 wherein the agent that treats dyslipidemia is a HMG CoA reductase inhibitor, the HMG CoA reductase inhibitor comprising a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and a combination thereof.
98. The method of any one of claims 94 to 96 wherein the agent that treats dyslipidemia is a fibrate, the fibrate comprising benzafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate, or a combination thereof.
99. The method of any one of claims 94 to 96 wherein agent that treats dyslipidemia is a cholesterol absorption inhibitor, the cholesterol absorption inhibitor comprising ezetimibe.
100. The method of any one of claims 89 to 99 wherein mean serum LDL is decreased by at least 15% after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events.
101. The method of claim 100 wherein mean serum LDL is decreased by at least 20% after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events.
102. The method of claim 100 wherein mean serum LDL is decreased by at least 25% after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events.
103. The method of claim 100 wherein mean serum LDL is decreased by at least 30% after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events.
104. The method of any one of claims 89 to 99 wherein mean serum LDL is decreased by at least 15% after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a daily dose of 6.0 g/day.
105. The method of claim 104 wherein mean serum LDL is decreased by at least 20% after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a dose of 6.0 g/day or less.
106. The method of claim 104 wherein mean serum LDL is decreased by at least 25% after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a dose of 6.0 g/day or less.
107. The method of claim 104 wherein mean serum LDL is decreased by at least 30% after 2, 4, 12, 26, 52 or more weeks of treatment with the amine polymer at a dose of 6.0 g/day or less.
108. The method of any one of claims 89 to 107 wherein the animal subject has primary hyperlipidemia or coronary heart disease.
109. A method of improving glycemic control in an animal subject with Type II diabetes mellitus comprising administering an effective amount of an amine polymer of any one of claims 1 to 87 or a pharmaceutical composition of claim 88 to the animal subject.
110. The method of any one of claims 89 to 109 further comprising administration of an agent that treats diabetes to the animal subject.
111. The method of claim 110 wherein the amine polymer, the agent that treats diabetes, or the combination thereof are administered to the animal subject at the same time.
112. The method of claim 107 wherein the amine polymer, the agent that treats diabetes, or the combination thereof are sequentially administered to the animal subject.
113. The method of any one of claims 110 to 112 wherein the agent that treats diabetes is a sulfonylurea, a biguanide, a glitazone, a thiazolidinedione, an activator of peroxisome proliferator-activated receptors (PPARs), an alpha-glucosidase inhibitor, a potassium channel antagonist, an aldose reductase inhibitor, a glucagon antagonist, a retinoid X receptor (RXR) antagonist, a farnesoid X receptor (FXR) agonist, a FXR antagonist, glucagon-like peptide-1 (GLP-1), a GLP-1 analog, a dipeptidyl peptidase IV (DPP-IV) inhibitor, amylin, an amylin analog, an SGLT2 inhibitor, insulin, an insulin secretagogue, a thyroid hormone, a thyroid hormone analog or a combination thereof.
114. The method of claim 113 wherein the agent that treats diabetes is a biguanide, wherein the biguanidine is metformin, buformin, phenformin, or a combination thereof.
115. The method of claim 113 wherein the agent that treats diabetes is a thiazolidinedione, wherein the thiazolidinedione is pioglitazone, rivoglitazone, rosiglitazone, troglitazone, or a combination thereof.
116. The method of claim 114 wherein the agent that treats diabetes is a sulfonylurea, wherein the sulfonylurea is acetohexamide, chlorpropamide, tolbutamide, tolazamide, glipizide, gliclazide, glibenclamide, gliquidone, glyclopyramide, glimepiride, or a combination thereof.
117. The method of claim 113 wherein the agent that treats diabetes is a DPP-IV inhibitor, wherein the DPP-IV inhibitor is alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin, or a combination thereof.
118. The method of claim 113 wherein the agent that treats diabetes is a GLP-1 analog, wherein the GLP-1 analog is exenatide, liraglutide, albiglutide, or a combination thereof.
119. The method of any one of claims 109 to 118 wherein glycated hemoglobin (HbA1c) is decreased by at least 0.5% after 18 weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events.
120. The method of any one of claims 109 to 118 wherein fasting plasma glucose is decreased by at least 14 mg/dL (0.8 mmol/L) after 18 weeks of treatment with the amine polymer at a daily dose at which the subject experiences no severe gastrointestinal adverse events.
121. The method of any one of claims 109 to 118 wherein glycated hemoglobin (HbA1c) is decreased by at least 0.5% after 18 weeks of treatment with the amine polymer at a dose of 6.0 g/day or less.
122. The method of any one of claims 109 to 118 wherein fasting plasma glucose is decreased by at least 14 mg/dL (0.8 mmol/L) after 18 weeks of treatment with the amine polymer at a dose of 6.0 g/day or less.
123. The method of any one of claims 89 to 122 wherein the animal subject is a human.
124. The method of any one of claims 89 to 123 wherein less than four unit doses of the amine polymer are administered per day.
125. The method of any one of claims 89 to 123 wherein less than three unit doses of the amine polymer are administered per day.
126. The method of any one of claims 89 to 123 wherein the amine polymer is administered once per day.
127. The method of any one of claims 89 to 126 wherein the amine polymer is administered in the form of a chewable or mouth-disintegrating tablet, a liquid, a powder, a powder contained within a sachet, a soft gelatin capsule, or a hard gelatin capsule.
128. The method of any one of claims 89 to 127 wherein a daily amount of the polymer administered once per day or twice per day has a bile acid binding capacity of at least 75% of the same daily amount of the same polymer administered three times per day.
129. The method of claim 128 wherein a daily amount of the polymer administered once per day or twice per day has a bile acid binding capacity of at least 85% of the same daily amount of the same polymer or the same composition administered three times per day.
130. The method of claim 128 wherein a daily amount of the polymer administered once per day or twice per day has a bile acid binding capacity of at least 95% of the same daily amount of the same polymer or the same composition administered three times per day.
131. The method of any one of claims 89 to 130 wherein less than 25% of subjects taking the polymer once per day or twice per day experience mild or moderate gastrointestinal adverse events.
132. The method of any one of claims 89 to 131 wherein the polymer or composition administered once a day or twice a day have about substantially the same tolerability as the same polymer or the same composition of the same daily amount administered three times a day.
133. The method of any one of claims 128 to 132 wherein the daily amount is at least 2 grams of polymer.
134. The method of claim 133 wherein the daily amount is at least 4 grams of polymer.
135. The method of claim 133 wherein the daily amount is at least 6 grams of polymer.
136. The method of any one of claims 128 to 135 wherein the sediment yield stress of the polymer is less than 4000 Pa.
137. The method of claim 136 wherein the sediment yield stress of the polymer is less than 3000 Pa.
138. The method of claim 136 wherein the sediment yield stress of the polymer is less than 2500 Pa.
139. The method of any one of claims 128 to 138 wherein a mass of the polymer particles formed by hydration and sedimentation of the polymer has a viscosity of less than about 2,500,000 Pa·s, the viscosity being measured at a shear rate of 0.01 sec−1.
140. The method of claim 139 wherein the sedimented mass of particles has a viscosity of less than 2,000,000 Pa·s.
141. The method of claim 139 wherein the sedimented mass of particles has a viscosity of less than 1,500,000 Pa·s.
142. The method of claim 139 wherein the sedimented mass of particles has a viscosity of less than 1,000,000 Pa·s.
143. The method of claim 139 wherein the sedimented mass of particles has a viscosity of less than 500,000 Pa·s.
144. The method of any one of claims 136 to 143 wherein the polymer particles in dry form have a compressibility index of less than about 30, wherein the compressibility index is defined as 100*(TD−BD)/TD, and BD and TD are the bulk density and tap density, respectively.
145. The method of claim 144 wherein the compressibility index is less than about 25.
146. The method of claim 144 wherein the compressibility index is less than about 20.
147. The method of claim 144 wherein the compressibility index is less than about 15.
148. The method of claim 144 wherein the compressibility index is less than about 10.
149. A process for preparing the amine polymers of any one of claims 1 to 87 comprising contacting the amine monomer with the crosslinking monomer.
150. An amine of formula 6 having the structure:
wherein each R25 is independently C2 to C8 alkylene or C2 to C8 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with at least one amide functional group, and R35 is C8 to C16 alkylene, or C8 to C16 alkylene wherein one or more of the —CH2— groups of the alkylene group is replaced with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional group.
151. The amine of claim 150 wherein each R25 is independently C3 to C6 alkylene.
152. The amine of claim 150 wherein each R25 is propylene.
153. The amine of any one of claims 150 to 152 wherein R35 is C10 to C14 alkylene.
154. The amine of claim 153 wherein R35 is decylene.
155. The amine of claim 153 wherein R35 is dodecylene.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/601,291 US20170258825A1 (en) | 2010-02-24 | 2017-05-22 | Amine polymers for use as bile acid sequestrants |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30782210P | 2010-02-24 | 2010-02-24 | |
US30782010P | 2010-02-24 | 2010-02-24 | |
US37368210P | 2010-08-13 | 2010-08-13 | |
PCT/US2011/026106 WO2011106548A1 (en) | 2010-02-24 | 2011-02-24 | Amine polymers for use as bile acid sequestrants |
US201413581148A | 2014-08-20 | 2014-08-20 | |
US15/601,291 US20170258825A1 (en) | 2010-02-24 | 2017-05-22 | Amine polymers for use as bile acid sequestrants |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/581,148 Continuation US9655920B2 (en) | 2010-02-24 | 2011-02-24 | Amine polymers for use as bile acid sequestrants |
PCT/US2011/026106 Continuation WO2011106548A1 (en) | 2010-02-24 | 2011-02-24 | Amine polymers for use as bile acid sequestrants |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170258825A1 true US20170258825A1 (en) | 2017-09-14 |
Family
ID=43901141
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/581,148 Active 2034-08-23 US9655920B2 (en) | 2010-02-24 | 2011-02-24 | Amine polymers for use as bile acid sequestrants |
US15/601,291 Abandoned US20170258825A1 (en) | 2010-02-24 | 2017-05-22 | Amine polymers for use as bile acid sequestrants |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/581,148 Active 2034-08-23 US9655920B2 (en) | 2010-02-24 | 2011-02-24 | Amine polymers for use as bile acid sequestrants |
Country Status (14)
Country | Link |
---|---|
US (2) | US9655920B2 (en) |
EP (1) | EP2539389B1 (en) |
JP (3) | JP6258586B2 (en) |
KR (1) | KR101822608B1 (en) |
CN (2) | CN107266681A (en) |
AU (2) | AU2011220748B2 (en) |
BR (1) | BR112012021446A2 (en) |
CA (1) | CA2790901C (en) |
DE (1) | DE112011100657T5 (en) |
ES (1) | ES2661079T3 (en) |
GB (1) | GB2490855A (en) |
MX (1) | MX348821B (en) |
RU (2) | RU2017106587A (en) |
WO (1) | WO2011106548A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9181364B2 (en) | 2010-02-24 | 2015-11-10 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
US20150239824A1 (en) * | 2012-08-24 | 2015-08-27 | Universite De Strasbourg | Branched or macrocyclic polyamines and uses thereof |
WO2014163883A2 (en) * | 2013-03-13 | 2014-10-09 | Elevance Renewable Sciences | Natural oil derivatives including primary amine functional groups |
CN111671767B (en) * | 2013-06-05 | 2024-03-08 | 特里赛达公司 | Proton-binding polymers for oral administration |
MA41202A (en) | 2014-12-18 | 2017-10-24 | Genzyme Corp | CROSS-LINKED POLYDIALLYMINE COPOLYMERS FOR THE TREATMENT OF TYPE 2 DIABETES |
PE20180034A1 (en) | 2015-04-07 | 2018-01-09 | Intercept Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPIES |
CN105111089B (en) * | 2015-09-07 | 2017-05-10 | 南京华威医药科技开发有限公司 | Bixalomer intermediate |
CN106176800B (en) * | 2016-07-11 | 2019-12-06 | 韩源平 | Pharmaceutical application of polycation resin |
GB201809627D0 (en) * | 2018-06-12 | 2018-07-25 | Biorelevant Com Ltd | Methods for preparing buffer solutions suitable for in vitro drug dissolution testing, drug solubility testing and/or drug profiling |
KR20220065812A (en) | 2019-09-20 | 2022-05-20 | 글라이센드, 인코포레이티드 | Substituted Phenyl Boronic Acid Containing Polymers and Methods of Use |
WO2024040380A1 (en) * | 2022-08-22 | 2024-02-29 | 中美华世通生物医药科技(武汉)股份有限公司 | Ammonium salt polymer, method for preparing same, and use thereof as bile acid chelating agent |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7335795B2 (en) * | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
JPH066667A (en) | 1992-06-22 | 1994-01-14 | Canon Inc | Camera-shake detector and correction device therefor |
DE59307535D1 (en) | 1992-07-22 | 1997-11-20 | Hoechst Ag | Polyvinylamine derivatives which have hydrophilic centers, processes for their preparation and the use of the compounds as medicaments, active substance carriers and food additives |
ATE146193T1 (en) | 1992-07-22 | 1996-12-15 | Hoechst Ag | CROSS-LINKED, NITROGEN-CONTAINING VINYL COPOLYMERS, METHOD FOR THE PRODUCTION THEREOF AND THE USE OF THESE COMPOUNDS |
AU672824B2 (en) | 1992-08-20 | 1996-10-17 | E.I. Du Pont De Nemours And Company | Crosslinked polymeric ammonium salts |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5414068A (en) | 1994-01-24 | 1995-05-09 | Rohm And Haas Company | Crosslinked anion exchange particles and method for producing the particles |
TW474813B (en) * | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
US6383500B1 (en) | 1996-06-27 | 2002-05-07 | Washington University | Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications |
US6083497A (en) * | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
US7425579B2 (en) * | 1998-04-21 | 2008-09-16 | Universite Laval | Methods for inhibiting activity of polyamine transporters |
US6294163B1 (en) | 1998-10-02 | 2001-09-25 | Geltex Pharmaceuticals, Inc. | Polymers containing guanidinium groups as bile acid sequestrants |
AU2374800A (en) * | 1998-12-23 | 2000-07-31 | Geltex Pharmaceuticals, Inc. | Amine condensation polymer bile acid sequestrants |
US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
CA2551528A1 (en) | 2003-12-31 | 2005-07-21 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
JP2008531751A (en) * | 2004-10-13 | 2008-08-14 | イリプサ, インコーポレイテッド | Cross-linked amine polymer |
EP2511274A3 (en) * | 2005-01-21 | 2013-01-02 | Basf Se | Polyamine derivative |
EP2016114A2 (en) | 2006-05-05 | 2009-01-21 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
BRPI0715053A2 (en) | 2006-07-18 | 2013-03-19 | Genzyme Corp | pharmaceutical composition, method for treating diseases, and polymer |
JP2010504285A (en) | 2006-09-01 | 2010-02-12 | ゲンズイメ コーポレーション | Dendrimer composition |
EP2120972A1 (en) | 2006-12-14 | 2009-11-25 | Genzyme Corporation | Amido-amine polymer compositions |
EP2114376A1 (en) * | 2007-02-23 | 2009-11-11 | Genzyme Corporation | Amine polymer compositions |
US20100166696A1 (en) | 2007-04-27 | 2010-07-01 | Dhal Pradeep K | Amido-amine dendrimer compositions |
WO2009023544A2 (en) * | 2007-08-10 | 2009-02-19 | Ilypsa, Inc. | Dosage unit anion-exchange polymer pharmaceutical compositions |
JP5332520B2 (en) * | 2007-11-07 | 2013-11-06 | アステラス製薬株式会社 | Pharmaceutical tablets |
WO2009097127A1 (en) | 2008-01-31 | 2009-08-06 | Genzyme Corporation | Pharmaceutical compositions |
WO2009122400A1 (en) | 2008-03-31 | 2009-10-08 | Semorex Inc. | Phosphate binding polymers |
WO2009158625A2 (en) * | 2008-06-26 | 2009-12-30 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders |
US9181364B2 (en) | 2010-02-24 | 2015-11-10 | Relypsa, Inc. | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
EP2538947B1 (en) | 2010-02-24 | 2016-08-17 | Relypsa, Inc. | Polyimidazoles for use as bile acid sequestrants |
-
2011
- 2011-02-24 CN CN201710479049.3A patent/CN107266681A/en active Pending
- 2011-02-24 EP EP11706453.5A patent/EP2539389B1/en not_active Not-in-force
- 2011-02-24 ES ES11706453.5T patent/ES2661079T3/en active Active
- 2011-02-24 MX MX2012009783A patent/MX348821B/en active IP Right Grant
- 2011-02-24 BR BR112012021446A patent/BR112012021446A2/en not_active Application Discontinuation
- 2011-02-24 KR KR1020127024557A patent/KR101822608B1/en active IP Right Grant
- 2011-02-24 GB GB1216820.9A patent/GB2490855A/en not_active Withdrawn
- 2011-02-24 AU AU2011220748A patent/AU2011220748B2/en not_active Ceased
- 2011-02-24 RU RU2017106587A patent/RU2017106587A/en not_active Application Discontinuation
- 2011-02-24 CA CA2790901A patent/CA2790901C/en not_active Expired - Fee Related
- 2011-02-24 JP JP2012555155A patent/JP6258586B2/en not_active Expired - Fee Related
- 2011-02-24 RU RU2012140432A patent/RU2612795C2/en active
- 2011-02-24 WO PCT/US2011/026106 patent/WO2011106548A1/en active Application Filing
- 2011-02-24 CN CN201180019265.0A patent/CN102906159B/en not_active Expired - Fee Related
- 2011-02-24 DE DE112011100657T patent/DE112011100657T5/en not_active Withdrawn
- 2011-02-24 US US13/581,148 patent/US9655920B2/en active Active
-
2016
- 2016-02-04 AU AU2016200700A patent/AU2016200700B2/en not_active Ceased
- 2016-03-24 JP JP2016059918A patent/JP2016130320A/en active Pending
-
2017
- 2017-05-22 US US15/601,291 patent/US20170258825A1/en not_active Abandoned
- 2017-07-21 JP JP2017141886A patent/JP6622760B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7335795B2 (en) * | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
US11813283B2 (en) | 2018-08-13 | 2023-11-14 | Viscera Labs, Inc. | Therapeutic composition and methods |
Also Published As
Publication number | Publication date |
---|---|
RU2012140432A (en) | 2014-03-27 |
JP2013520563A (en) | 2013-06-06 |
EP2539389A1 (en) | 2013-01-02 |
AU2016200700B2 (en) | 2017-08-17 |
RU2612795C2 (en) | 2017-03-13 |
RU2017106587A (en) | 2019-01-21 |
CN102906159B (en) | 2017-09-26 |
KR101822608B1 (en) | 2018-01-29 |
BR112012021446A2 (en) | 2016-05-31 |
DE112011100657T5 (en) | 2013-02-28 |
CN102906159A (en) | 2013-01-30 |
JP6622760B2 (en) | 2019-12-18 |
AU2011220748A1 (en) | 2012-09-20 |
ES2661079T3 (en) | 2018-03-27 |
AU2016200700A1 (en) | 2016-02-25 |
GB2490855A (en) | 2012-11-14 |
GB201216820D0 (en) | 2012-11-07 |
CA2790901C (en) | 2018-05-01 |
CA2790901A1 (en) | 2011-09-01 |
AU2011220748B2 (en) | 2015-11-05 |
JP2017190464A (en) | 2017-10-19 |
US9655920B2 (en) | 2017-05-23 |
WO2011106548A1 (en) | 2011-09-01 |
JP2016130320A (en) | 2016-07-21 |
EP2539389B1 (en) | 2017-12-20 |
JP6258586B2 (en) | 2018-01-10 |
CN107266681A (en) | 2017-10-20 |
US20140356316A1 (en) | 2014-12-04 |
KR20120130227A (en) | 2012-11-29 |
MX2012009783A (en) | 2012-11-21 |
MX348821B (en) | 2017-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170258825A1 (en) | Amine polymers for use as bile acid sequestrants | |
US10272103B2 (en) | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | |
AU2017201276B2 (en) | Polyimidazoles for use as bile acid sequestrants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: RELYPSA, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CONNOR, ERIC;BIYANI, KALPESH;HECKER, SCOTT;AND OTHERS;SIGNING DATES FROM 20100902 TO 20120822;REEL/FRAME:042457/0001 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |